<SEC-DOCUMENT>0001171843-21-002976.txt : 20210430
<SEC-HEADER>0001171843-21-002976.hdr.sgml : 20210430
<ACCEPTANCE-DATETIME>20210430162519
ACCESSION NUMBER:		0001171843-21-002976
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20210616
FILED AS OF DATE:		20210430
DATE AS OF CHANGE:		20210430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		21878475

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>def14a_042921.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: Black 4.5pt double; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>SCHEDULE 14A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Proxy Statement
Pursuant to<BR> Section 14(a) of the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">Filed by the Registrant &#9746;</TD>
    <TD STYLE="text-align: right; width: 50%">Filed by a Party other than the Registrant &#9744;</TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: justify">Check the appropriate box:</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: justify">&#9744;</TD>
    <TD STYLE="width: 97%; text-align: justify">Preliminary Proxy Statement</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&#9746;</TD>
    <TD STYLE="text-align: justify">Definitive Proxy Statement</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify">Definitive Additional Materials</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify">Soliciting Material Pursuant to &sect;240.14a-12</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="logo.jpg" ALT="" STYLE="height: 56px; width: 300px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>ANIKA THERAPEUTICS,
INC.</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 8pt"><I>(Name of Registrant as Specified in Its Charter)</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: justify">Payment of Filing Fee (Check the appropriate box):</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&#9746;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">No fee required.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify">(1)</TD>
    <TD STYLE="vertical-align: top; width: 92%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of each class of securities to which transaction
        applies:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(2)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate number of securities to which transaction
        applies:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(3)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Per unit price or other underlying value of transaction
        computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(4)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proposed maximum aggregate value of transaction:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(5)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total fee paid:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">Fee paid previously with preliminary materials.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and
        identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or
        the Form or Schedule and the date of its filing.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(1)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount Previously Paid:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(2)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Form, Schedule or Registration Statement No.:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(3)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filing Party:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(4)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date Filed:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: Red"><IMG SRC="logo.jpg" ALT="" STYLE="height: 56px; width: 300px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 30, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Fellow Stockholder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is my pleasure to invite you to attend the
Annual Meeting of Stockholders of Anika Therapeutics, Inc. to be held on June&nbsp;16, 2021, at 9:00 a.m., Eastern time. This year&rsquo;s
Annual Meeting will be a &ldquo;virtual meeting&rdquo; conducted via live audio webcast, consistent with last year&rsquo;s practice and
with prudent planning in light of the public health risks attributable to the COVID-19 pandemic. Each holder of common stock as of 5&nbsp;p.m.,
Eastern time, on the record date of April 20, 2021 will be able to participate in the Annual Meeting by accessing a live webcast at <I>virtualshareholdermeeting.com/ANIK2021</I>
and entering the control number included on the holder&rsquo;s Notice of Internet Availability of Proxy Materials or proxy card. Stockholders
will also be able to vote their shares and submit questions via the Internet during the meeting by participating in the webcast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the Annual Meeting stockholders will be
asked to elect two Class I directors, to approve an amendment to our 2017 Omnibus Incentive Plan, to approve our 2021 Employee Stock Purchase
Plan, and to ratify the appointment of Deloitte &amp; Touche LLP as our independent auditor for 2021. We will also be asking stockholders
to approve, by an advisory vote, our 2020 executive compensation as disclosed in the Proxy Statement for the Annual Meeting (a &ldquo;say-on-pay&rdquo;
vote). Each of these matters is important, and we urge you to vote in favor of the election of each of the director nominees, the approval
of our 2017 Omnibus Incentive Plan amendment and our 2021 Employee Stock Purchase Plan, the ratification of the appointment of our independent
auditor, and the approval on an advisory basis of our 2020 executive compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are furnishing proxy materials to our stockholders
over the Internet. This process expedites the delivery of proxy materials to our stockholders, lowers our costs, and reduces the environmental
impact of the Annual Meeting. Today we are sending to each of our stockholders a Notice of Internet Availability of Proxy Materials containing
instructions on how to access our Proxy Statement for the Annual Meeting and our 2020 Annual Report to Stockholders, as well as how to
vote via proxy either by telephone or over the Internet. Other stockholders will receive copies of the Proxy Statement, a proxy card and
the 2020 Annual Report by mail or e-mail. If you received a Notice of Internet Availability of Proxy Materials by mail and would like
to receive a printed copy of our proxy materials, you may request those materials by following the instructions included in your Notice
of Internet Availability of Proxy Material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is important that you vote your shares of common
stock virtually or by proxy, regardless of the number of shares you own. You will find the instructions for voting on your Notice of Internet
Availability of Proxy Materials and proxy card. We appreciate your prompt attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors invites you to participate
in the Annual Meeting where Anika will address appropriate general questions about the business as time allows. Thank you for your support,
and we look forward to joining you at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red"><IMG SRC="blanchard_sig.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cheryl R. Blanchard, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #365F91"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #365F91"><FONT STYLE="font-size: 14pt"><B>NOTICE
OF ANNUAL MEETING OF STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors of Anika Therapeutics,&nbsp;Inc.,
a Delaware corporation (&ldquo;Anika&quot;), is soliciting proxies for use at Anika&rsquo;s 2021&nbsp;Annual Meeting of Stockholders being
held on Wednesday, June 16, 2021, at 9:00&nbsp;a.m., Eastern time (the &ldquo;Annual Meeting&rdquo;). You are receiving the enclosed proxy
statement because you were a holder of Anika&rsquo;s common stock as of 5&nbsp;p.m., Eastern time, on the record date of April 20, 2021
and therefore are entitled to vote at the Annual Meeting. You may participate in the Annual Meeting, including casting votes and asking
questions, by accessing a live webcast at <I>virtualshareholdermeeting.com/ANIK2021</I> and entering the control number included on the
Notice of Internet Availability of Proxy Materials or proxy card. Online check-in to the Annual Meeting will begin at 8:45 a.m., Eastern
time, and stockholders are encouraged to allow ample time to log in to the meeting webcast and test their computer and audio system. There
will be no physical location for the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Annual Meeting the following matters will
be considered:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">1.</TD>
    <TD STYLE="text-align: justify">election of two Class&nbsp;I directors;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">2.</TD>
    <TD STYLE="text-align: justify">amendment of Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">3.</TD>
    <TD STYLE="text-align: justify">approval of Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">4.</TD>
    <TD STYLE="text-align: justify">ratification of appointment of Deloitte &amp; Touche LLP as Anika&rsquo;s independent auditor for 2021;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">5.</TD>
    <TD STYLE="text-align: justify">advisory &ldquo;say-on-pay&rdquo; vote on executive compensation; and</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">6.</TD>
    <TD STYLE="text-align: justify">any other matters that properly come before the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of common stock is entitled to one
vote for each director position and other proposal. In accordance with rules of the Securities and Exchange Commission, we are providing
stockholders with access to proxy materials on the Internet, instead of mailing printed copies. We are mailing to stockholders, commencing
on or about April 30, 2021, a Notice of Internet Availability of Proxy Materials to provide:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">directions for accessing and reviewing the proxy materials on the Internet and submitting a proxy over the
        Internet or by telephone;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">instructions for requesting copies of proxy materials in printed form or by email at no charge; and</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">a control number for use in submitting proxies and accessing the Annual Meeting webcast.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other stockholders will receive copies of the
Proxy Statement, a proxy card and the 2020 Annual Report by mail or e-mail. If you received a Notice of Internet Availability of Proxy
Materials by mail and would like to receive a printed copy of our proxy materials, you may request those materials by following the instructions
included in the Notice of Internet Availability of Proxy Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Your
vote is important.</B></FONT> Whether or not you plan to participate in the Annual Meeting, please complete and return your proxy card
or vote by telephone or via the Internet by following the instructions on the Notice of Internet Availability of Proxy Materials. Returning
a proxy card or otherwise submitting your proxy does not deprive you of your right to access the Annual Meeting and vote during the webcast
at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anika will maintain a list of stockholders of
record as of the record date at Anika&rsquo;s corporate headquarters, 32 Wiggins Avenue, Bedford, Massachusetts, for a period beginning
ten days prior to the Annual Meeting and ending at the close of the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: justify">By Order of the Board of Directors,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><IMG SRC="colleran.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">David Colleran</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><I>Executive Vice President, General Counsel and Secretary</I></TD></TR>
    <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Bedford, Massachusetts </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">April 30, 2021</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="5" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border: Black 1.5pt solid; width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Important Notice Regarding Availability of
        Proxy Materials for Annual Meeting on June 16, 2021:</I></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Notice of Annual Meeting of Stockholders, Proxy
        Statement and 2020 Annual Report to Stockholders are available at <I>https://ir.anikatherapeutics.com/annual-meeting</I>.</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: Red"><IMG SRC="logo.jpg" ALT="" STYLE="height: 56px; width: 300px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">32 Wiggins Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Bedford, Massachusetts 01730</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt">Proxy
Statement dated April 30, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #365F91"><FONT STYLE="font-size: 14pt"><B>2021
Annual Meeting of Stockholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; line-height:20pt">Anika Therapeutics, Inc., a
Delaware corporation, is furnishing this Proxy Statement and the related proxy materials in connection with the solicitation by its Board
of Directors of proxies to be voted at its 2021 Annual Meeting of Stockholders and any postponements or adjournments thereof. Anika Therapeutics,
Inc. is providing these materials to the holders of record of its common stock as of the close of business on April 20, 2021 and is first
making available or mailing the materials on or about April 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="color: #365F91; font-weight: bold; text-align: left">The Annual Meeting is scheduled to be held as follows:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="color: #365F91; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%; color: #365F91; font-weight: bold; font-style: italic">Date</TD>
    <TD STYLE="width: 1%; color: #365F91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="width: 59%; color: rgb(54,95,145); font-weight: bold">Wednesday, June 16, 2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="color: #365F91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: #365F91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: rgb(54,95,145); font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="color: #365F91; font-weight: bold; font-style: italic">Time</TD>
    <TD STYLE="color: #365F91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: rgb(54,95,145); font-weight: bold; text-align: left">9:00 a.m., Eastern time</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="color: #365F91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: #365F91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: rgb(54,95,145); font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Meeting Webcast Address</TD>
    <TD STYLE="color: #365F91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: rgb(54,95,145); font-weight: bold">virtualshareholdermeeting.com/ANIK2021</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91"><B>Your
vote is important.</B></FONT> Please see the detailed information that follows.</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt; color: #365F91"><B><I>Table
of Contents</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021
    Proxy Summary</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif">Questions
    and Answers about the Annual Meeting</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proposal
    1: Election of Directors</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif">Information
    Regarding Directors</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">Governance
    of the Company</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">Board&rsquo;s
    Role in Risk Oversight</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif">Board&rsquo;s
    Increased Involvement due to COVID-19 and Executive Team Changes</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif">Board
    Leadership Structure</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif">Corporate
    Governance and Board Matters</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif">Board
    Committees</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif">Board
    Membership Qualifications and Procedures</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif">25</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif">Communications
    with Directors</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif">26</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif">Code
    of Business Conduct and Ethics</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif">27</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitment
    to Compliance</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif">27</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif">Corporate
    Social Responsibility &ndash; Environmental Sustainability, Social, and Governance Matters</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif">27</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif">Human
    Capital Management</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif">28</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director
    Overboarding Guidelines</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prohibition
    on Employee, Officer, and Director Hedging and Pledging</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif">Majority
    Voting in Uncontested Director Elections Policy</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transactions
    with Related Persons and Conflict of Interest Policy</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif">31</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial
    Ownership of Common Stock</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif">32</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif">Executive
    Officers</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif">35</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif">Compensation
    Discussion and Analysis</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif">36</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif">Executive
    Summary</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif">36</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif">Compensation
    Philosophy</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif">38</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif">Key
    Compensation Policies and Practices</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif">39</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020
    Compensation Decisions</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif">42</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_028"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    Compensation Matters</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_028"><FONT STYLE="font-family: Times New Roman, Times, Serif">47</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_029"><FONT STYLE="font-family: Times New Roman, Times, Serif">Compensation
    Committee Report</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_029"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_030"><FONT STYLE="font-family: Times New Roman, Times, Serif">Executive
    and Director Compensation</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_030"><FONT STYLE="font-family: Times New Roman, Times, Serif">52</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_031"><FONT STYLE="font-family: Times New Roman, Times, Serif">Summary
    Compensation Table</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_031"><FONT STYLE="font-family: Times New Roman, Times, Serif">52</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_032"><FONT STYLE="font-family: Times New Roman, Times, Serif">Grants
    of Plan-Based Awards in 2020</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_032"><FONT STYLE="font-family: Times New Roman, Times, Serif">53</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_033"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    Equity Awards at December&nbsp;31, 2020</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_033"><FONT STYLE="font-family: Times New Roman, Times, Serif">55</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_034"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020
    Option Exercises and Stock Vested</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_034"><FONT STYLE="font-family: Times New Roman, Times, Serif">56</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_035"><FONT STYLE="font-family: Times New Roman, Times, Serif">Potential
    Payments Upon Termination or Change in Control</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_035"><FONT STYLE="font-family: Times New Roman, Times, Serif">57</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_036"><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO
    Pay Ratio</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_036"><FONT STYLE="font-family: Times New Roman, Times, Serif">58</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_037"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director
    Compensation</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_037"><FONT STYLE="font-family: Times New Roman, Times, Serif">59</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_038"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director
    and Executive Officer Stock Retention Guidelines</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_038"><FONT STYLE="font-family: Times New Roman, Times, Serif">60</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_039"><FONT STYLE="font-family: Times New Roman, Times, Serif">Compensation
    Committee Interlocks and Insider Participation</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_039"><FONT STYLE="font-family: Times New Roman, Times, Serif">61</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><A HREF="#a_040"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
    Compensation Plan Information</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_040"><FONT STYLE="font-family: Times New Roman, Times, Serif">61</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_041"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proposal
    2: Amendment of 2017 Omnibus Incentive Plan</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_041"><FONT STYLE="font-family: Times New Roman, Times, Serif">62</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_042"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proposal
    3: Approval of 2021 Employee Stock Purchase Plan</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_042"><FONT STYLE="font-family: Times New Roman, Times, Serif">71</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_043"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit
    Committee Report</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_043"><FONT STYLE="font-family: Times New Roman, Times, Serif">77</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_044"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proposal
    4: Ratification of Appointment of Independent Auditor for 2021</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_044"><FONT STYLE="font-family: Times New Roman, Times, Serif">79</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_045"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proposal
    5: Advisory Vote on Executive Compensation</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_045"><FONT STYLE="font-family: Times New Roman, Times, Serif">80</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_046"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    Matters</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_046"><FONT STYLE="font-family: Times New Roman, Times, Serif">83</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_047"><FONT STYLE="font-family: Times New Roman, Times, Serif">Solicitation
    Expenses</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_047"><FONT STYLE="font-family: Times New Roman, Times, Serif">83</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_048"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholder
    Proposals</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_048"><FONT STYLE="font-family: Times New Roman, Times, Serif">83</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_049"><FONT STYLE="font-family: Times New Roman, Times, Serif">Householding</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_049"><FONT STYLE="font-family: Times New Roman, Times, Serif">84</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_050"><FONT STYLE="font-family: Times New Roman, Times, Serif">Appendix
    A</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_050"><FONT STYLE="font-family: Times New Roman, Times, Serif">A-1</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_051"><FONT STYLE="font-family: Times New Roman, Times, Serif">Appendix
    B</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_051"><FONT STYLE="font-family: Times New Roman, Times, Serif">B-1</FONT></A></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Calibri Light">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><A HREF="#a_052"><FONT STYLE="font-family: Times New Roman, Times, Serif">Appendix
    C</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0in"><A HREF="#a_052"><FONT STYLE="font-family: Times New Roman, Times, Serif">C-1</FONT></A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">References in this
Proxy Statement to &ldquo;Anika,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company&rdquo; and similar references
refer to Anika Therapeutics, Inc. and its subsidiaries, unless the context requires otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">Anika, Anika Therapeutics,
Arthrosurface, Parcus Medical, WristMotion, Hyalofast, and Cingal are our registered trademarks. For convenience, these registered trademarks
appear in this Proxy Statement without &reg; symbols, but that practice does not mean we will not assert, to the fullest extent under
applicable law, our rights to the registered trademarks. This Proxy Statement also contains trademarks and service marks that are the
property of other companies, including certain trademarks licensed to us.</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_001"></A>2021
Proxy Summary</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights information contained
elsewhere in this Proxy Statement. This summary does not contain all of the information that you should consider, and you should read
the entire Proxy Statement carefully before voting. </I></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Annual
Meeting of Stockholders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 20%; text-align: justify">Time&nbsp;and&nbsp;Date&#9;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 78%; text-align: justify">9:00 a.m., Eastern time, on June 16, 2021</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="color: black">Meeting Webcast Address&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><I>virtualshareholdermeeting.com/ANIK2021</I> &mdash;To join, a stockholder will
        need the control number located on the stockholder&rsquo;s Notice of Internet Availability of Proxy Materials or proxy card</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">Record Date&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">5:00 p.m., Eastern time, on April 20, 2021</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="color: black">Voting&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: black">Stockholders will be entitled to one vote at the Annual Meeting for each outstanding
        share of common stock they hold of record as of the record date</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">Outstanding Common Stock&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">14,366,686 shares as of the record date</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Annual
Meeting Agenda</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>Proposal</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 69%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>Board Recommendation</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.15pt; text-indent: -0.15pt; text-align: center"><FONT STYLE="color: black">1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; text-indent: -12.25pt; text-align: justify"><FONT STYLE="color: black">Election of
        two Class I directors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><B>FOR
        each nominee</B></FONT></TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; padding-left: 0.15pt; text-indent: -0.15pt; text-align: center"><FONT STYLE="color: black">2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; text-indent: -12.25pt; text-align: justify"><FONT STYLE="color: black">Amendment of
        2017 Omnibus Incentive Plan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><B>FOR</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.15pt; text-indent: -0.15pt; text-align: center"><FONT STYLE="color: black">3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; text-indent: -12.25pt; text-align: justify">Approval of 2021 Employee Stock Purchase
        Plan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FOR</B></FONT></TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; padding-left: 0.15pt; text-indent: -0.15pt; text-align: center"><FONT STYLE="color: black">4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; text-indent: -12.25pt; text-align: justify"><FONT STYLE="color: black">Ratification
        of independent auditor for 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><B>FOR</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.15pt; text-indent: -0.15pt; text-align: center">5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; text-indent: -12.25pt; text-align: justify">Advisory &ldquo;say-on-pay&rdquo; vote</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FOR</B></FONT></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">How
to Vote Prior to the Annual Meeting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>By mailing your proxy card</B></P> </TD>
    <TD STYLE="border-top: Black 1pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>By telephone</B></P> </TD>
    <TD STYLE="border-top: Black 1pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>By Internet</B></P> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-left: Black 1pt solid"><IMG SRC="envelope.jpg" ALT=""></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><IMG SRC="phone.jpg" ALT=""></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: Black 1pt solid"><IMG SRC="laptop.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">Cast your ballot,
        sign your proxy card and <BR> send by free post</FONT></P></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">Dial toll-free 24/7</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">1-800-690-6903</FONT></P></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">Visit 24/7</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">www.proxyvote.com</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><I>Mark, sign and
        date your proxy card and return it in the postage-paid envelope included in your proxy materials. Your proxy&nbsp;card must arrive by
        June 15, 2021.</I></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><I>Use a touch-tone
        telephone to transmit your voting instructions at any time up to 11:59&nbsp;p.m., ET, on June 15, 2021. Follow the instructions on your
        Notice of Internet Delivery of Proxy Materials or proxy card.</I></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><I>Use the Internet
        to transmit your voting instructions at any time up to 11:59 p.m., ET, on June 15, 2021. Follow the instructions on your Notice of Internet
        Delivery of Proxy Materials or proxy card.</I></FONT></P></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Proposal
1: Election of Two Class I Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stephen O. Richard and Jeffery S. Thompson serve
as Class&nbsp;I Directors, with terms of office expiring at this year&rsquo;s Annual Meeting. Messrs. Richard and Thompson are the Board&rsquo;s
nominees for election to the Board at the Annual Meeting. Each Class&nbsp;I Director will be elected to hold office until the 2024 Annual
Meeting and until his successor is duly elected and qualified. Dr. Joseph L. Bower is currently a Class I director who has announced his
intention to retire and will not stand for re-election at the Annual Meeting. Anika is very thankful to Dr. Bower for his 28 years of
thoughtful leadership and service to Anika.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #365F91">
    <TD STYLE="white-space: nowrap; width: 17%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: white"><B>Director
        Nominees</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: white"><B>Age</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 7%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: white"><FONT STYLE="font-size: 7pt"><B>Director</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: white"><FONT STYLE="font-size: 7pt"><B>Since</B></FONT></P></TD>
    <TD STYLE="white-space: nowrap; width: 28%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: white"><B>Occupation</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: white"><B>Experience
        /<BR> Qualifications</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: white"><B>Independent</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; color: white"><B>Board
        Roles</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-left: 4.5pt; text-indent: -4.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Stephen
        O. Richard</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt">58</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt">2020</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Senior Vice President, Chief Risk Officer and Chief Audit Executive of Becton, Dickinson
        and Company</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.65pt; text-align: justify; text-indent: -8.65pt"><FONT STYLE="font-size: 8pt; color: #365F91">&bull;</FONT><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;Executive
        Leadership</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.65pt; text-align: justify; text-indent: -8.65pt"><FONT STYLE="font-size: 8pt; color: #365F91">&bull;</FONT><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;Accounting
        Expertise</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.65pt; text-align: justify; text-indent: -8.65pt"><FONT STYLE="font-size: 8pt; color: #365F91">&bull;</FONT><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;Industry
        Experience</FONT></P></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt">Yes</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt">Member of <BR> Audit&nbsp;Committee</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="white-space: nowrap; padding-left: 4.5pt; text-indent: -4.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Jeffery
        S. Thompson</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt">55</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Operating Partner, HealthEdge Investment Partners, LLC</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.65pt; text-align: left; text-indent: -8.65pt"><FONT STYLE="font-size: 8pt; color: #365F91">&bull;</FONT><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;Board
        and Executive Leadership</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.65pt; text-align: justify; text-indent: -8.65pt"><FONT STYLE="font-size: 8pt; color: #365F91">&bull;</FONT><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;Industry
        Experience</FONT></P></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt">Yes</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt">Chair of the Board</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify; text-indent: -1.8in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 20%; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Board Recommendation:</TD>
    <TD STYLE="width: 1%; color: #365F91">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left">The Board of Directors recommends a vote &ldquo;FOR&rdquo; the reelection of each of Mr.&nbsp;Richard
        and Mr. Thompson.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; color: #365F91; font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD>
    <TD STYLE="color: #365F91">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; white-space: nowrap; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Vote Required
        for Approval:</TD>
    <TD STYLE="color: #365F91">&nbsp;</TD>
    <TD STYLE="text-align: left">Affirmative vote of a majority of the shares of common stock that are voting in the election of directors, meaning
        that, to be elected, the shares voted &ldquo;FOR&rdquo; a nominee must exceed the number of shares voted &ldquo;AGAINST&rdquo; that nominee.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; white-space: nowrap; color: #365F91; font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD>
    <TD STYLE="color: #365F91">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Under our Majority Voting in Uncontested Director Elections Policy, if a director receives a greater number of
        votes &ldquo;against&rdquo; than &ldquo;for&rdquo; his election, such director shall promptly offer his resignation for consideration
        by the Governance and Nominating Committee. Please see the section captioned &ldquo;Majority Voting in Uncontested Director Elections
        Policy&rdquo; for more details on this policy and its impact on the election of director nominees.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Abstentions and Broker non-votes will have no effect on the outcome of this proposal because they are not counted
        as &ldquo;votes cast.&rdquo;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><B>Board Representation</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #003E64"><B>DIVERSITY</B></P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #003E64"><B>INDEPENDENCE</B></P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #003E64"><B>TENURE</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3 of our 7 continuing directors and director nominees
        voluntarily self-identify as having a diverse identity (gender, race/ethnicity, or LGBTQ+).</P></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6 of our 7 continuing directors and director nominees
        qualify as independent under NASDAQ standards and SEC regulations.</P></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tenure of our continuing directors and director
        nominees (average 5.5 years) reflects a balance of experience and fresh perspective.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><IMG SRC="p3a.jpg" ALT="" STYLE="height: 200px; width: 200px"></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><IMG SRC="p3b.jpg" ALT="" STYLE="height: 200px; width: 200px"></P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><IMG SRC="p3c.jpg" ALT="" STYLE="height: 200px; width: 200px"></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><B>Director Skills and
Experience </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors is committed to maintaining
a diverse and inclusive membership with varying experience, characteristics, and expertise that complement our business strategy. The
matrix below provides a summary of certain key skills and experience of our continuing directors and director nominees. Our directors,
individually and as a group, possess numerous skills and experience that are highly relevant as we expand our business into new product
lines and treatment areas. Our directors are strategic thinkers with high expectations for our performance and are attuned to the demands
of proper Board oversight and good governance practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="3" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: middle; background-color: #C8D7EA">
    <TD STYLE="border-top: black 1pt solid; font-weight: bold; border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: justify; width: 36%">Director</TD>
    <TD STYLE="font-weight: bold; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; border-left-color: black; border-left-width: 1pt; width: 9%">Blanchard</TD>
    <TD STYLE="font-weight: bold; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; border-left-color: black; border-left-width: 1pt; width: 10%">Henneman</TD>
    <TD STYLE="font-weight: bold; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; border-left-color: black; border-left-width: 1pt; width: 9%">Land</TD>
    <TD STYLE="font-weight: bold; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; border-left-color: black; border-left-width: 1pt; width: 9%">Larsen</TD>
    <TD STYLE="font-weight: bold; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; border-left-color: black; border-left-width: 1pt; width: 9%">Richard</TD>
    <TD STYLE="font-weight: bold; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; border-left-color: black; border-left-width: 1pt; width: 9%">Thompson</TD>
    <TD STYLE="font-weight: bold; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; border-left-color: black; border-left-width: 1pt; width: 9%">Vogt</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-right: Black 1pt solid; font-weight: bold; border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: justify; border-top-color: black; border-top-width: 1pt">Age</TD>
    <TD COLSPAN="7" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Our directors range in age from
        55 to 76</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: #C8D7EA">
    <TD STYLE="border-right: Black 1pt solid; font-weight: bold; border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: justify">Skills
        and Experience</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; border-top-color: black; border-top-width: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; border-top-color: black; border-top-width: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; border-top-color: black; border-top-width: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; border-top-color: black; border-top-width: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; border-top-color: black; border-top-width: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; border-top-color: black; border-top-width: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: #C8D7EA">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left; border-top-color: black; border-top-width: 1pt">CEO/CFO
        Experience</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; text-align: center; border-top-color: black; border-top-width: 1pt; border-left-color: black; border-left-width: 1pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-top-color: black; border-top-width: 1pt; border-left-color: #F2F2F2; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="text-align: center; border-top-color: black; border-top-width: 1pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; border-left: #EEECE1 0.5pt solid; text-align: center; border-top-color: black; border-top-width: 1pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-top-color: black; border-top-width: 1pt; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="text-align: center; border-top-color: black; border-top-width: 1pt; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; border-left: #EEECE1 0.5pt solid; text-align: center; border-top-color: black; border-top-width: 1pt">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">Medical Devices/Pharmaceutical</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: #C8D7EA">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">Manufacturing</TD>
    <TD STYLE="text-align: center; border-left-color: black; border-left-width: 1pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; border-left: #EEECE1 0.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&nbsp;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; text-align: center; border-left-color: #F2F2F2; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; text-align: center">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">R&amp;D/Innovation</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-left: #F2F2F2 0.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-left: #F2F2F2 0.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; text-align: center; border-left-color: #F2F2F2; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; text-align: center">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: #C8D7EA">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">Regulatory</TD>
    <TD STYLE="text-align: center; border-left-color: black; border-left-width: 1pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; border-left: #EEECE1 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; border-left: #EEECE1 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&nbsp;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; border-left: #DDD9C4 0.5pt solid; text-align: center">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">Financial Oversight/Accounting</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; border-bottom: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; text-align: center; border-left-color: #F2F2F2; border-left-width: 0.5pt">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: #C8D7EA">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">Human Capital Management</TD>
    <TD STYLE="text-align: center; border-left-color: black; border-left-width: 1pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; border-left: #EEECE1 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-top-color: #F2F2F2; border-top-width: 0.5pt; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; border-left: #DDD9C4 0.5pt solid; text-align: center">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">Commercialization/Marketing</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; text-align: center; border-left-color: #F2F2F2; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: #C8D7EA">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">Public Company Governance/Corporate Responsibility</TD>
    <TD STYLE="text-align: center; border-left-color: black; border-left-width: 1pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; border-left: #EEECE1 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; border-left: #EEECE1 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; text-align: center">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">M&amp;A/Business Development</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; border-bottom: #F2F2F2 0.5pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-right: #F2F2F2 0.5pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: #C8D7EA">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-left: Black 1pt solid; text-align: left">International/Global Business</TD>
    <TD STYLE="text-align: center; border-left-color: black; border-left-width: 1pt">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; border-left: #EEECE1 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; border-left: #EEECE1 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: #EEECE1 0.5pt solid; text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="text-align: center; border-left-color: #EEECE1; border-left-width: 0.5pt">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; border-left: #DDD9C4 0.5pt solid; text-align: center">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-right: Black 1pt solid; padding-left: -10pt; border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: left">Other Public Company
        Experience</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: #F2F2F2 0.5pt solid; text-align: center">&bull;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red"><B></B></P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Additional Board Governance
Practices</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 18%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #003E64"><B><I>Elections:</I></B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 60%; text-align: left">Voting Standard</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: left">Majority<SUP>(1)</SUP></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Resignation Policy</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Mandatory Retirement Age or Tenure</TD>
    <TD>&nbsp;</TD>
    <TD>No</TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #003E64"><B><I>Chair:</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Separate Chair of the Board and CEO</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Independent Chair of the Board</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Robust Responsibilities and Duties Assigned to Independent Chair</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #003E64"><B><I>Meetings:</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Number of Board Meetings Held in 2020</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">23</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">All Directors Attended More than 90% of Board Meetings in 2020</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Independent Directors Meet without Management Present</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Number of Standing Committee Meetings Held in 2020</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">28</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">All Members Attended more than 90% of Committee Meetings in 2020</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #003E64"><B><I>Director
        Status:</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">All Directors in compliance with our Overboarding Guidelines</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Material Related-Party Transactions with Directors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">None</TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Standing Board Committee Membership Independence</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">100%</TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Board Oversight of Company Strategy and Risk</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">All Directors in Compliance with Hedging and Pledging Prohibitions</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">All Directors in Compliance with Stock Ownership Guidelines</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Yes</TD></TR>
  <TR>
    <TD ROWSPAN="2" STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #003E64"><B><I>Stockholder
        Rights:</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Dual Class Common Stock</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">No</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Poison Pill</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">No</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Cumulative Voting</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">No</TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1)</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: #003E64">P</FONT><FONT STYLE="font-size: 8pt">lurality
        carve out for contested elections</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Proposal
2: Amendment of 2017 Omnibus Incentive Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors has approved the amendment,
subject to stockholder approval, of our 2017 Omnibus Incentive Plan (as amended June 16, 2020) to increase the number of shares of common
stock reserved by 1,100,000, from 3,500,000 to 4,600,000. As of April&nbsp;20, 2021, a total of 758,748 shares of common stock remained
available for grant under the plan. The 1,100,000 shares requested reflects our estimate of the number of shares we will grant under the
plan after giving effect to the proposed amendment over the course of the next year based on our current share price, recent burn rate
history, and new-hire and annual grant practices. Additionally, the Board approved an amendment, subject to stockholder approval, to allow
all shares authorized under the plan to be granted as incentive stock options. Please see the complete amendment attached hereto as <I>Appendix
A</I>. No other provisions of the plan are proposed to be amended. The following table recaps key provisions of the plan, after giving
effect to the proposed amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #365F91">
    <TD STYLE="vertical-align: top; white-space: nowrap; width: 20%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Key
        Provision</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 78%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Summary
        Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; white-space: nowrap; text-align: left">Shares reserved</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">Up to 1,858,748 shares of common stock, representing approximately 12.9% of the fully
        diluted common stock outstanding as of April 20, 2021, would be available for grant, subject to adjustment by the plan administrator as
        set forth in the plan.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; white-space: nowrap; text-align: left">Multiple award types</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">Various types of awards may be granted as compensation tools to motivate our workforce,
        including incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards,
        and other types of share and cash-based awards.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; white-space: nowrap; text-align: left">Minimum vesting requirements</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Awards
        must have a vesting period of at least 1 year, except that:</P>
        <DIV STYLE="float: left; width: 1%"> &bull;</DIV>
        <DIV STYLE="float: right; width: 98%">up to 5% of the share pool can be granted without such minimum vesting period; and</div><br clear="all">
        <DIV STYLE="float: left; width: 1%">&bull;</DIV>
        <DIV STYLE="float: right; width: 98%">awards may be accelerated due to a participant&rsquo;s, retirement, death, disability or a change
        in control of Anika, if such term was included in the award agreement.</div><br clear="all"></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; white-space: nowrap; text-align: left">Maximum award terms</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">Awards may have terms of up to 10 years.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; white-space: nowrap; text-align: left">Director limits</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">The plan specifies annual limits on the value of awards that may be granted to non-employee
        directors.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; white-space: nowrap; text-align: left">No repricing</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">Awards may not be repriced without stockholder approval.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; white-space: nowrap; text-align: left">No transferability</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">Awards generally may not be transferred, except by will or laws of descent and distribution.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify; text-indent: -1.8in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; white-space: nowrap; width: 20%; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Board
        Recommendation:</TD>
    <TD STYLE="width: 1%; color: #365F91">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left">The Board recommends a vote &ldquo;FOR&rdquo; the amendment of our 2017 Omnibus Incentive Plan.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; white-space: nowrap; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Vote Required
        for Approval:</TD>
    <TD STYLE="color: #365F91">&nbsp;</TD>
    <TD STYLE="text-align: left">Affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions
        and broker non-votes will not be treated as votes cast and will have no impact on the proposal.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify; text-indent: -1.8in">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify"></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Proposal
3: Approval of 2021 Employee Stock Purchase Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors has approved the adoption,
subject to stockholder approval, of the 2021 Employee Stock Purchase Plan, or ESPP. Please see the complete text of the ESPP attached
hereto as <I>Appendix B</I>. The following table recaps key provisions of the ESPP:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #365F91">
    <TD STYLE="vertical-align: top; width: 20%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Key
        ESPP Provision</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 78%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Summary
        Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">Shares reserved</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">A total of 200,000 shares of common stock would be reserved, subject to adjustment by
        the ESPP plan administrator as set forth in the ESPP.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">Eligible participants</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">Except as otherwise determined by the ESPP plan administrator, all employees employed
        for at least one month prior to the start date of an offering period would be eligible to participate for that offering period.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">Offering periods</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">Except as otherwise determined by the ESPP plan administrator, offering periods would
        extend for six months commencing on November 15, 2021 and on each May 15 and November 15 thereafter.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">Limitations</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">Except as otherwise determined by the ESPP plan administrator, participants would be
        granted an option to purchase a maximum of 800&nbsp;shares of common stock for an offering period, subject to adjustment by the ESPP plan
        administrator as more fully set forth in <I>Appendix B</I>. No participant could be granted an option to purchase shares to accrue at
        a rate that exceeds $25,000 of fair market value of common stock for each calendar year the option is outstanding. Except as otherwise
        determined by the ESPP plan administrator, a participant&rsquo;s payroll deductions in connection with purchases under the ESPP could
        not be less than 1% or more than 15% of the participant&rsquo;s compensation.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">Option price</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">The exercise price of an option for an offering period would equal 85% of the lesser
        of (a)&nbsp;the fair market value of common stock on the start date of the offering period and (b)&nbsp;the fair market value of common
        stock on the exercise date. The ESPP plan administrator may increase, but not decrease, the exercise price.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; text-align: left">Transferability</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">Options generally could not be transferred, except by will or laws of descent and distribution.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">Termination</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 1.55pt; text-align: justify">The ESPP would terminate on June 16, 2031 (the tenth anniversary of its approval by
        stockholders), unless terminated earlier in accordance with its terms.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify; text-indent: -1.8in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; white-space: nowrap; width: 20%; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Board
        Recommendation:</TD>
    <TD STYLE="width: 1%; color: #365F91">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left">The Board recommends a vote &ldquo;FOR&rdquo; the approval of the 2021 Employee Stock Purchase Plan.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; white-space: nowrap; color: #365F91; font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD>
    <TD STYLE="color: #365F91">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; vertical-align: top; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Vote Required
        for Approval:</TD>
    <TD STYLE="color: #365F91">&nbsp;</TD>
    <TD STYLE="text-align: left">Affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions
        and broker non-votes will not be treated as votes cast and will have no impact on the proposal.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify; text-indent: -1.8in">&nbsp;</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Proposal
4: Ratification of Independent Auditor for 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee has approved the retention
of Deloitte &amp; Touche LLP as our independent auditor with respect to our consolidated financial statements as of, and for the year
ending, December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify; text-indent: -1.8in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; white-space: nowrap; width: 20%; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Board
        Recommendation:</TD>
    <TD STYLE="width: 1%; color: #365F91; font-style: italic">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left">The Board of Directors recommends a vote &ldquo;FOR&rdquo; the ratification of
        Deloitte &amp; Touche LLP as our independent auditor for 2021.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; white-space: nowrap; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Vote Required
        for Approval:</TD>
    <TD STYLE="color: #365F91; font-style: italic">&nbsp;</TD>
    <TD STYLE="text-align: left">Affirmative vote of the holders of a majority of the shares of common stock that are voting
        on the matter. Abstentions will not count as votes cast and will have no effect on the vote. Because this proposal is considered a routine
        matter, discretionary votes by brokers will be counted.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify; text-indent: -1.8in">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Proposal
5: Advisory &ldquo;Say-on-Pay&rdquo; Vote</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The overall objective of our executive compensation
policy is to attract and retain highly qualified executive officers and to motivate those officers to provide superior performance for
the benefit of our company and stockholders.</P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><B>2020 Executive Total
Compensation Mix</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The charts below show the annual total direct
compensation (actual base salary, grant date fair value of equity incentive compensation granted in 2020, and actual cash bonuses received
for the 2020 fiscal year) for our CEO and our other named executive officers for 2020. Of total direct compensation, 95% of our CEO&rsquo;s
and, on average, 77% of our other named executive officers&rsquo; compensation was variable, either because it was subject to performance
goals, the fluctuations of our stock price or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="p8.jpg" ALT="" STYLE="height: 205px; width: 600px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #365F91">
    <TD STYLE="width: 20%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Compensation
        Element</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 38%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Description
        </B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 38%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Objectives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Base salary</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Fixed cash compensation</div><br clear="all"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Provide appropriate level of fixed compensation based on role, responsibility, performance and competitive
        market practices</div><br clear="all"></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="text-align: justify">Cash bonuses</TD>
    <TD>&nbsp;</TD>
    <TD>
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Annual cash award based on performance of company and individual</div><br clear="all">
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Prorated in the year of hire if employment begins before October 1</div><br clear="all">
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Overall cash bonus capped at 200% of the target payout</div><br clear="all"></TD>
    <TD>&nbsp;</TD>
    <TD>
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Reward the achievement of financial results, organizational development, business and technical
        development, individual goals and contribution to building stockholder value</div><br clear="all">
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Encourage retention based on achievement of near-term goals consistent with long-term strategy</div><br clear="all"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Equity-based grants</TD>
    <TD>&nbsp;</TD>
    <TD>
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Grants of equity awards, including restricted stock unit awards and stock options, under our equity
        plan</div><br clear="all">
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Includes performance-based and time-vesting equity awards</div><br clear="all"></TD>
    <TD>&nbsp;</TD>
    <TD>
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Align interests of our executive officers with those of our stockholders in terms of value generation</div><br clear="all">
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Provide executive officers with opportunity to be compensated based on common stock price appreciation</div><br clear="all">
        <DIV STYLE="float: left; width: 2%">&bull;</DIV>
        <DIV STYLE="float: right; width: 97%">Encourage retention through long-term value creation</div><br clear="all"></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table provides information concerning
the compensation paid for 2020 to our named executive officers, as determined in accordance with SEC rules and explained further below
in this proxy statement, including the Compensation Discussion and Analysis and the executive compensation tables:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Name
    and Principal Position</FONT></TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; white-space: nowrap; color: white; font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Salary
    ($) </FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Bonus
</FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock
    Awards <BR>
($)</FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option
    Awards <BR>
($) </FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">All
    Other <BR>
Compensation <BR>
($) </FONT></TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Total
    ($)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="width: 23%; text-align: left">Cheryl R. Blanchard, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: center">2020</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">548,077</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">458,510</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">5,335,439</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">3,659,450</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">27,958</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">10,029,434</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">President and Chief</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Michael L. Levitz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">173,077</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">73,601</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">799,971</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">799,993</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,318</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,857,960</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">EVP, Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">and Treasurer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>David Colleran</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">344,077</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">143,931</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">645,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">553,445</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,263</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,705,616</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>EVP, General Counsel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>and Secretary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Thomas Finnerty</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">353,505</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">143,169</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">626,367</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,746</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,143,787</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">EVP, Human Resources</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">James Loerop</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">381,563</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">171,703</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">464,449</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,156</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,039,871</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">EVP, Business Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">and Strategic Planning</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; background-color: white">Joseph G. Darling</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: center; background-color: white">2020</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">80,752</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">208,001</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">$</TD><TD STYLE="text-align: right; background-color: white">288,753</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; background-color: white">President and Chief</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: center; background-color: white">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: right; background-color: white">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; background-color: white">Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: center; background-color: white">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: right; background-color: white">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>Sylvia Cheung</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">294,252</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">924,637</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">89,644</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,308,534</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>Chief Financial Officer, Treasurer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>and Assistant Secretary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify; text-indent: -1.8in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 20%; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Board
        Recommendation:</TD>
    <TD STYLE="width: 1%; color: #365F91">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left">The Board of Directors recommends a vote &ldquo;FOR&rdquo;&nbsp;the approval of named executive officer
        compensation for the 2020 fiscal year as set forth in this Proxy Statement.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; vertical-align: top; color: #365F91; font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD>
    <TD STYLE="color: #365F91">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; vertical-align: top; color: #365F91; font-weight: bold; font-style: italic; text-align: left">Vote Required
        for Approval:</TD>
    <TD STYLE="color: #365F91">&nbsp;</TD>
    <TD STYLE="text-align: left">Affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions
        and broker non-votes will not be treated as votes cast and will have no impact on the proposal. This vote is not binding on us, but will
        be given due consideration by the Compensation Committee and the Board.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8in; text-align: justify; text-indent: -1.8in">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Participation
in the Virtual Annual Meeting</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors considers the appropriate
format of our annual meeting of stockholders on an annual basis. This year, in light of the COVID-19 pandemic, the Board again chose a
virtual meeting format for the Annual Meeting in response to public health and travel concerns and in an effort to facilitate stockholder
attendance and participation by enabling stockholders to participate fully, and equally, from any location around the world, at no cost.
The virtual meeting format will allow our stockholders to engage with us at the Annual Meeting from any geographic location, using any
convenient internet connected devices, including smart phones and tablets, and laptop or desktop computers. The virtual meeting format
also will allow stockholders to maintain their own personal safety in light of the public health risks attributable to the COVID-19 pandemic.
The virtual format allows stockholders to submit questions during the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The live audio webcast of the Annual Meeting will
be available for listening by the general public, but participation in the Annual Meeting, including voting shares and submitting questions,
will be limited to stockholders. To ensure they can participate, stockholders and proxyholders should visit <I>virtualshareholdermeeting.com/ANIK2021</I>
and enter the control number included on their Notice of Internet Availability of Proxy Materials or proxy card. If you wish to participate
in the meeting and your shares are held in street name, you must obtain, from the broker, bank or other organization that holds your shares,
the information required, including a control number, in order for you to be able to participate in, and vote at, the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stockholders can vote their shares and submit
questions via the Internet during the Annual Meeting by accessing the annual meeting website at <I>virtualshareholdermeeting.com/ANIK2021</I>.
We will answer any timely submitted and relevant questions on a matter to be voted on at the Annual Meeting before voting is closed on
the matter. Following adjournment of the formal business of the Annual Meeting, we will address appropriate general questions from stockholders
regarding Anika as time allows. Questions relating to stockholder proposals or Anika may be submitted in the field provided in the web
portal at or before the time the questions are to be discussed. If we receive substantially similar questions, we may group those questions
together and provide a single response to avoid repetition. Additional information regarding the submission of questions during the Annual
Meeting can be found in our 2021 Annual Meeting of Stockholders Rules of Conduct and Procedure, a copy of which is attached hereto as
<I>Appendix C</I>. Any material changes or updates to the 2021 Rules of Conduct and Procedure will be posted on our website and disclosed
in a periodic report filed with the SEC on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Online check-in to the Annual Meeting webcast
will begin at 8:45 a.m., Eastern time, and you should allow ample time to log in to the meeting webcast and test your computer audio system.
During online check-in and continuing through the length of the Annual Meeting, we will have technicians standing by to assist you with
any technical difficulties you may have accessing the virtual meeting. If you encounter any difficulties accessing the virtual meeting
during the check-in or meeting time, please call the technical support number that will be posted on the Virtual Shareholder Meeting log
in page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have designed our virtual format to enhance,
rather than constrain, stockholder access, participation and communication. For example, stockholders will be able to communicate with
us during the Annual Meeting so they can ask questions. An audio replay of the Annual Meeting will be made publicly available at <I>https://ir.anikatherapeutics.com/financial-information/annual-reports
</I>until our 2022 annual meeting of stockholders. This audio replay will include each stockholder question addressed during the Annual
Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are utilizing technology from Broadridge Financial
Solutions, Inc., or Broadridge, the leading virtual meeting solution. The Broadridge platform is expected to accommodate most, if not
all, stockholders. Both we and Broadridge will test the platform technology before going &ldquo;live&rdquo; for the Annual Meeting.</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_002"></A>Questions
and Answers about the Annual Meeting</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>When and where will the Annual Meeting be held?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">This year the Annual Meeting of Stockholders of Anika Therapeutics, Inc., which we refer to throughout this
        Proxy Statement as the Annual Meeting, will be held exclusively by webcast at <I>virtualshareholdermeeting.com/ANIK2021</I> on Tuesday,
        June 16, 2021, beginning at 9:00 a.m., Eastern time. We encourage you to access the Annual Meeting webcast prior to the start time.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B><I>Q:</I></B></TD>
    <TD STYLE="text-align: justify"><B><I>Who may join the Annual Meeting?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A</B>:</TD>
    <TD STYLE="text-align: justify">The live audio webcast of the Annual Meeting will be available for listening by the general public, but participation
        in the Annual Meeting, including voting shares and submitting questions, will be limited to stockholders. To ensure they can participate,
        stockholders and proxyholders should visit <I>virtualshareholdermeeting.com/ANIK2021</I> and enter the control number included on their
        Notice of Internet Availability of Proxy Materials or proxy card.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Online check-in to the Annual Meeting
webcast will begin at 8:45 a.m., Eastern time. We encourage you to allow ample time to log in to the meeting webcast and test your computer
audio system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>What materials have been prepared for stockholders in connection with the Annual Meeting?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">We are furnishing stockholders of record with access to, or copies of, the following proxy materials:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">our 2020 Annual Report to Stockholders, which includes our audited consolidated financial statements;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">this Proxy Statement for the 2021 Annual Meeting, which also includes a Notice of Annual Meeting of Stockholders;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">for most stockholders, a Notice of Internet Availability of Proxy Materials; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">for other stockholders who are receiving printed copies of the 2020 Annual Report and Proxy Statement by mail,
        a proxy card for the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">These materials were first made available
on the Internet or mailed to stockholders on or about April&nbsp;30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>Why was I mailed a Notice of Internet Availability of Proxy Materials rather than a printed set of proxy
        materials?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">In accordance with rules and regulations adopted by the Securities and Exchange Commission or SEC, we are
        furnishing the proxy materials to most stockholders by providing access via the Internet, instead of mailing printed copies. This e-proxy
        process expedites our stockholders&rsquo; receipt of proxy materials, lowers our costs, and reduces the environmental impact of the Annual
        Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Notice of Internet Availability
of Proxy Materials tells you how to access and review the proxy materials on the Internet and how to vote on the Internet. The Notice
also provides instructions you may follow to request paper or e-mailed copies of our proxy materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>Are the proxy materials available via the Internet?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">You can access and review the proxy materials for the Annual Meeting at <I>https://ir.anikatherapeutics.com/
        annual-meeting</I> or <I>proxyvote.com</I>. In order to submit your proxies or access the Annual Meeting webcast, however, you will need
        to refer to the Notice of Internet Availability of Proxy Materials or proxy card to obtain your control number and other personal information
        needed to vote by proxy or virtually<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>. </I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>What is a proxy?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">Because it is important that as many stockholders as possible be represented at the Annual Meeting, the Board
        of Directors asks that you review this Proxy Statement carefully and then vote by following the instructions set forth on the Notice of
        Internet Availability of Proxy Materials or proxy card. In voting prior to the Annual Meeting, you will deliver your proxy to Cheryl R.
        Blanchard, Ph.D., David Colleran, and Michael L. Levitz, which means you will authorize each of Dr.&nbsp;Blanchard and Messrs. Colleran
        and Levitz to vote your shares at the Annual Meeting in the way you instruct. All shares represented by valid proxies will be voted in
        accordance with the stockholder&rsquo;s specific instructions. Please see the section captioned &ldquo;Executive Officers&rdquo; for the
        titles and roles of Dr. Blanchard and Messrs. Colleran and Levitz with our company.</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>What matters will the stockholders vote on at the Annual Meeting?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="width: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify">Proposal 1.&#9;Election of two Class I director nominees: Stephen O. Richard and Jeffery S. Thompson.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">Proposal 2.<B>&#9;</B>Amendment of our 2017 Omnibus Incentive Plan.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">Proposal 3.<B>&#9;</B>Approval of our 2021 Employee Stock Purchase Plan.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">Proposal 4.&#9;Ratification of the appointment of our independent auditor for 2021.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">Proposal 5.&#9;Approval, as an advisory vote, of 2020 executive compensation as disclosed in this Proxy Statement.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>Who can vote at the Annual Meeting?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">Stockholders of record of common stock at the close of business on April&nbsp;20, 2021, the record date, will
        be entitled to vote at the Annual Meeting. A total of 14,366,686 shares of common stock were outstanding as of the record date. Each share
        outstanding on the record date will be entitled to one vote on each proposal.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>What is a stockholder of record?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">A stockholder of record is a stockholder whose ownership of our common stock is reflected directly on the
        books and records of our transfer agent, American Stock Transfer &amp; Trust Co.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>What does it mean for a broker or other nominee to hold shares in &ldquo;street name&rdquo;?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">If you beneficially own shares held in an account with a broker, bank, or similar organization, that organization
        is the stockholder of record and is considered to hold those shares in &ldquo;street name.&rdquo;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">An organization that holds your beneficially
owned shares in street name will vote in accordance with the instructions you provide. If you do not provide the organization with specific
voting instructions with respect to a proposal, under the rules of the NASDAQ Stock Market, Inc., or NASDAQ, the organization&rsquo;s
authority to vote your shares will depend upon whether the proposal is considered a &ldquo;routine&rdquo; or non-routine matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">The organization generally may vote your beneficially owned shares on routine items for which you have not
        provided voting instructions to the organization. The only routine matter expected to be voted on at the Annual Meeting is the ratification
        of the appointment of our independent auditor for 2021 (Proposal&nbsp;4).</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify">The organization generally may not vote on non-routine matters, including Proposals 1, 2, 3, and 5. Instead,
        it will inform the inspector of election that it does not have the authority to vote on those matters. This is referred to as a &ldquo;broker
        non-vote.&rdquo;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For the purpose of determining a quorum,
we will treat as present at the Annual Meeting any proxies that are voted on any of the five proposals to be acted upon by the stockholders,
including abstentions or proxies containing broker non-votes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>How do I vote my shares if I do not attend the Annual Meeting?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify"><B><I>If you are a stockholder of record,</I></B> you may vote prior to the Annual Meeting as follows:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><I><U>Via the Internet</U></I>: You may vote via the Internet at <I>www.proxyvote.com</I>, in accordance with
        the voting instructions printed on the Notice of Internet Availability of Proxy Materials and the proxy card. Internet voting is available
        24 hours a day until 11:59 p.m., Eastern time, on June 15, 2021. You will be given the opportunity to confirm that your instructions have
        been recorded properly. If you vote via the Internet, you do not need to return a proxy card.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><I><U>By Telephone</U></I>: If you receive a proxy card by mail, you may vote by calling 1-800-690-6903 and
        following the instructions provided on the telephone line. Telephone voting is available 24&nbsp;hours a day until 11:59&nbsp;p.m., Eastern
        time, on June 15, 2021. Easy-to-follow voice prompts allow you to vote your shares and confirm that your instructions have been recorded
        properly. If you vote by telephone, you do not need to return a proxy card.</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><I><U>By Mail</U></I>: If you receive a proxy card by mail, you may vote by returning the dated and signed
        proxy card in the postage-paid return envelope provided with the proxy card. Your proxy card must arrive by June 15, 2021.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>If you hold shares in street name,</I></B>
you may vote by following the voting instructions provided by your bank, broker, or other nominee. In general, you may vote prior to the
Annual Meeting as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><I><U>Via the Internet</U></I>: You may vote at <I>www.proxyvote.com</I>, in accordance with the voting instructions
        printed on the Notice of Internet Availability of Proxy Materials and the proxy card. Internet voting is available 24 hours a day until
        11:59 p.m., Eastern time, on June 15, 2021. You will be given the opportunity to confirm that your instructions have been recorded properly.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><I><U>By Telephone</U></I>: If you receive a proxy card by mail, you may vote by calling 1-800-690-6903 and
        following the instructions provided on the telephone line. Telephone voting is available 24&nbsp;hours a day until 11:59&nbsp;p.m., Eastern
        time, on June 15, 2021. Easy-to-follow voice prompts allow you to vote your shares and confirm that your instructions have been recorded
        properly.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify"><I><U>By Mail</U></I>: You may vote by returning a completed and signed proxy card in accordance with instructions
        provided by your bank, broker, or other nominee. Your proxy card must arrive by June 15, 2021.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For your information, voting via the
Internet is the least expensive to us, followed by telephone voting, with voting by mail being the most expensive. Also, you may help
us to save the expense of a second mailing if you vote promptly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B><I>Q:</I></B></TD>
    <TD STYLE="text-align: justify"><B><I>Can I vote at the Annual Meeting?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">If you are a stockholder of record, you may vote virtually at the Annual Meeting, whether or not you previously
        voted. If your shares are held in street name, you must obtain a written proxy, executed in your favor, from the stockholder of record
        to be able to vote at the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B><I>Q:</I></B></TD>
    <TD STYLE="text-align: justify"><B><I>Can I ask questions at the Annual Meeting?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">A:</TD>
    <TD STYLE="text-align: justify">You may submit questions via the Internet during the Annual Meeting by participating in the webcast at <I>virtualshareholdermeeting.com/ANIK2021</I>.
        We will answer any timely submitted questions on a matter to be voted on at the Annual Meeting before voting is closed on the matter.
        Following adjournment of the formal business of the Annual Meeting, we will address appropriate general questions from stockholders regarding
        Anika in the order in which the questions are received as time allows. Questions relating to the stockholder proposals or Anika may be
        submitted in the field provided in the web portal at or before the time the questions are to be discussed. If we receive substantially
        similar questions, we may group those questions together and provide a single response to avoid repetition. Additional information regarding
        the submission of questions during the Annual Meeting can be found in our 2021 Annual Meeting of Stockholders Rules of Conduct and Procedure,
        attached hereto as <I>Appendix C</I> and available at <I>https://ir.anikatherapeutics.com/annual-meeting</I>.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B><I>Q:</I></B></TD>
    <TD STYLE="text-align: justify"><B><I>Why is the Annual Meeting being conducted as a virtual meeting?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">A:</TD>
    <TD STYLE="text-align: justify">The Board considers the appropriate format of our annual meeting of stockholders on an annual basis. This
        year, as in 2020, the Board chose a virtual meeting format for the Annual Meeting in an effort to facilitate stockholder attendance and
        participation in light of the COVID-19 pandemic by enabling stockholders to participate fully, and equally, from any location around the
        world, at no cost. The virtual meeting format will allow our stockholders to engage with us at the Annual Meeting from any geographic
        location, using any convenient internet-connected devices, including smart phones and tablets, and laptop or desktop computers. The virtual
        meeting format also will allow stockholder to maintain their own personal safety in light of the public health risks attributable to the
        COVID-19 pandemic.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The virtual format allows stockholders
to submit questions during the meeting. We are utilizing technology from Broadridge Financial Solutions, Inc., or Broadridge, the leading
virtual meeting solution. The Broadridge platform is expected to accommodate most, if not all, stockholders. Both we and Broadridge will
test the platform technology before going &ldquo;live&rdquo; for the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B><I>Q:</I></B></TD>
    <TD STYLE="text-align: justify"><B><I>If I am unable to participate in the live audio webcast of the Annual Meeting, may I listen at a later
        date?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">A:</TD>
    <TD STYLE="text-align: justify">An audio replay of the Annual Meeting will be posted and publicly available at <I>https://ir.anikatherapeutics.com/financial-information/annual-reports</I>
        following the Annual Meeting and will remain publicly available until our next annual meeting of stockholders in 2022. This audio replay
        will cover the entire Annual Meeting, including each stockholder question addressed during the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>May I change my vote or revoke my proxy?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">If you are a stockholder of record, you may later change or revoke your proxy at any time before it is exercised
        by:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify">voting via the Internet or telephone at a later time;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify">submitting a completed and signed proxy card with a later date; or</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify">voting via the Internet at the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If you are a beneficial owner of shares
held in street name, you should contact your bank, broker, or other nominee for instructions as to whether, and how, you can change or
revoke your proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>What happens if I do not give specific voting instructions?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">If you are a stockholder of record and you return a proxy card without giving specific voting instructions,
        the proxy holders will vote your shares in the manner recommended by the Board on all five proposals presented in this Proxy Statement
        and as they may determine in their discretion on any other matters properly presented for a vote at the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If you are a beneficial owner of shares
held in street name and do not provide specific voting instructions to the broker, bank, or other organization that is the stockholder
of record of your shares, the organization generally may not vote on some proposals. Instead, the organization will inform the inspector
of election that it does not have the authority to vote on the specific matter. As a result, beneficial owners of shares held in street
name that do not provide specific voting instructions may not have an effect on the outcome of certain proposals. See &ldquo;Q. <I>What
does it mean for a broker or other nominee to hold shares in &lsquo;street name&rsquo;?</I>&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B><I>Q:</I></B></TD>
    <TD STYLE="text-align: justify"><B><I>What should I do if, during check-in or the meeting, I have technical difficulties or trouble accessing
        the virtual meeting website?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">A:</TD>
    <TD STYLE="text-align: justify">Online check-in to the Annual Meeting webcast will begin at 8:45 a.m., Eastern time. You should allow ample
        time to log in to the meeting webcast and test your computer audio system. During online check-in and continuing through the length of
        the Annual Meeting, we will have technicians standing by to assist you with any technical difficulties you may have accessing the Annual
        Meeting. If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical
        support number that will be posted on the Virtual Shareholder Meeting log in page.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #365F91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>Q:</B></TD>
    <TD STYLE="text-align: justify"><B><I>What if other matters are presented at the Annual Meeting?</I></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">If a stockholder of record provides a proxy by voting in any manner described in this Proxy Statement, the
        proxy holders will have the discretion to vote on any matters, other than the five proposals presented in this Proxy Statement, that are
        properly presented for consideration at the Annual Meeting. We do not know of any other matters to be presented for consideration at the
        Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_003"></A>Proposal
1: Election of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our company is managed under the oversight of
the Board of Directors, which is led by an independent chair.&nbsp;The directors utilize their deep experience in business and science
&ndash; including biotech, pharmaceuticals, and medical devices &ndash; as well as their diverse backgrounds to provide management with
guidance and oversight in delivering innovative therapies to meet the needs of clinicians and the patients that they treat, and in executing
on our strategy for value creation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board sets high standards for management and
employees tied to our core values of principled and ethical behavior, and we apply those same standards to the Board, undertaking regular
and rigorous reviews of the directors&rsquo; performance both collectively and individually.&nbsp;This is evidenced in our ongoing approach
to Board refreshment, having added four of our current eight directors in the past three years.&nbsp;The current mix of longer-serving
and recently added directors provides an appropriate balance of perspectives as the Board holds management accountable for delivering
long-term value and keeping the interests of our stockholders and stakeholders, including clinicians and their patients, employees and
business partners, at the center of our priorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board is currently comprised of eight directors
and is divided into three classes: Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Each class of directors serves for a three-year term,
with one class of directors being elected by our stockholders at each annual meeting. Stephen Richard and Jeffery Thompson serve as Class&nbsp;I
Directors, with terms of office expiring at the year&rsquo;s Annual Meeting. Joseph Bower, who currently serves as a Class I director,
will not stand for re-election at this year&rsquo;s Annual Meeting. Cheryl Blanchard, Raymond Land and Glenn Larsen serve as Class&nbsp;II
Directors, with terms of office expiring at the 2022 Annual Meeting. Susan Vogt and John Henneman serve as Class&nbsp;III Directors, with
terms of office expiring at the 2023 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Richard and Thompson are the Board&rsquo;s
nominees for election to the Board at the Annual Meeting. Each Class&nbsp;I Director will be elected to hold office until the 2024 Annual
Meeting and until his successor is duly elected and qualified. Unless otherwise instructed, the persons named in the accompanying proxy
will vote, as permitted by our bylaws, to elect Messrs. Richard and Thompson as the Class&nbsp;I Directors. If either Mr. Richard or Mr.
Thompson becomes unavailable or declines to serve, the persons acting under the accompanying proxy may vote the proxy for the election
of a substitute in their discretion. The Board has no reason to believe that either Mr. Richard or Mr. Thompson will be unable or unwilling
to serve if elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no arrangements or understandings between
any nominee and any other person pursuant to which the nominee was selected.&nbsp;</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Annual Meeting, the election of a director
requires the affirmative vote of a majority of the shares of common stock that are voting in the election of directors, meaning that,
to be elected, the shares voted &ldquo;FOR&rdquo; a nominee must exceed the number of shares voted &ldquo;AGAINST&rdquo; that nominee.
Abstentions and Broker non-votes will not be treated as votes cast and will have no impact on the proposal. Under our Majority Voting
in Uncontested Director Elections Policy, if a director receives a greater number of votes &ldquo;against&rdquo; than &ldquo;for&rdquo;
election, the director must promptly offer the director&rsquo;s resignation for consideration by the Governance and Nominating Committee.
Please see the section captioned &ldquo;Majority Voting in Uncontested Director Elections Policy&rdquo; for more details on this policy
and its impact on the election of director nominees.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Board
Recommendation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
A VOTE &ldquo;FOR&rdquo; THE ELECTION OF EACH OF STEPHEN O. RICHARD AND JEFFERY S. THOMPSON, THE DIRECTOR NOMINEES.</B></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_004"></A>Information
Regarding Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the name of our
current directors, and includes the nominees for re-election as directors at the Annual Meeting, together with their ages (as of the record
date) and the years in which they became a director. As noted elsewhere, Dr. Bower will not stand for re-election at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 40%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="color: white"><B>Director
        Name</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 20%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="color: white"><B>Age</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 20%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="color: white"><B>Director Since</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; width: 20%"><FONT STYLE="color: white"><B>Term Expires</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><B><I>Class I Directors</I></B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; padding-left: 0.15in; text-align: justify">Joseph L Bower</TD>
    <TD STYLE="text-align: center">82</TD>
    <TD STYLE="text-align: center">1993</TD>
    <TD STYLE="text-align: center">2021</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.15in; text-align: justify">Stephen O. Richard</TD>
    <TD STYLE="text-align: center">58</TD>
    <TD STYLE="text-align: center">2020</TD>
    <TD STYLE="text-align: center">2021</TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; padding-left: 0.15in; text-align: justify">Jeffery S. Thompson</TD>
    <TD STYLE="text-align: center">55</TD>
    <TD STYLE="text-align: center">2011</TD>
    <TD STYLE="text-align: center">2021</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><B><I>Class II Directors</I></B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; padding-left: 0.15in; text-align: justify">Cheryl R. Blanchard Ph.D.</TD>
    <TD STYLE="text-align: center">56</TD>
    <TD STYLE="text-align: center">2018</TD>
    <TD STYLE="text-align: center">2022</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.15in; text-align: justify">Raymond J. Land</TD>
    <TD STYLE="text-align: center">76</TD>
    <TD STYLE="text-align: center">2006</TD>
    <TD STYLE="text-align: center">2022</TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; padding-left: 0.15in; text-align: justify">Glenn R. Larsen, Ph.D.</TD>
    <TD STYLE="text-align: center">66</TD>
    <TD STYLE="text-align: center">2015</TD>
    <TD STYLE="text-align: center">2022</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><B><I>Class III Directors</I></B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; padding-left: 0.15in; text-align: justify">John B. Henneman III</TD>
    <TD STYLE="text-align: center">59</TD>
    <TD STYLE="text-align: center">2020</TD>
    <TD STYLE="text-align: center">2023</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-left: 0.15in; text-align: justify">Susan N. Vogt</TD>
    <TD STYLE="text-align: center">67</TD>
    <TD STYLE="text-align: center">2018</TD>
    <TD STYLE="text-align: center">2023</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="float: left; width: 48%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>
        Cheryl R. Blanchard, Ph.D.</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="blanchard.jpg" ALT=""></TD>
    <TD STYLE="width: 5%"></TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">Anika Board Service:</P>
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenure:
        2.5 years</P></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: rgb(200,215,234); width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>PRESIDENT
        and CEO</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 56</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="text-align: left; vertical-align: middle">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="vertical-align: top; width: 9.35pt; text-align: left"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director since August 2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">President and Chief Executive Officer of Anika since April 2020, and Interim Chief Executive Officer of Anika
        from February 2020 through April 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Principal at Blanchard Consulting, LLC, a provider of scientific, regulatory, and business strategy consulting
        services to medical device companies and private equity clients, from 2012 to 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">President and Chief Executive Officer of Microchips Biotech, Inc., a venture-backed biotechnology company
        developing regenerative medicine and drug delivery products, from 2014 until its sale to Dar&eacute; Bioscience, Inc. in November 2019</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Various offices, including Senior Vice President, Chief Scientific Officer, and general manager of Zimmer
        Biologics, of Zimmer, Inc., a medical device company focused on musculoskeletal products, from 2000 to 2012</TD></TR>
  </TABLE> </DIV>

<DIV STYLE="float: right; width: 48%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>John
        B. Henneman, III</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="henneman.jpg" ALT=""></TD>
    <TD STYLE="width: 5%"></TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anika Board Service:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Tenure: 0.5 years</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Committees:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -8.65pt"><FONT STYLE="color: #365F91">&cir; </FONT>Compensation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -8.65pt"><FONT STYLE="color: #365F91">&cir;</FONT>
        Governance and Nominating</P> </TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: rgb(200,215,234); width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 59</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director since September 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Senior Advisor to Prettybrook Partners, a private equity firm investing in medical technology and healthcare
        services companies, since May 2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Consultant to SparkMed Advisors LLC, a provider of consulting and other services to start-up medical device
        and biotechnology companies, since January 2019</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation, a public biotechnology
        company, from October 2014 to July 2018 and Chief Administrative Officer of NewLink from July 2018 through his retirement in November
        2018</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Various offices of Integra LifeSciences Holdings Corp., a medical devices company, from 1998 to 2014, including
        Chief Financial Officer from 2007 to 2014 and earlier as General Counsel and Chief Administrative Officer</TD></TR>
  </TABLE> </div><br clear="all">

<DIV STYLE="float: left; width: 48%">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Other Public Company Board
Service</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Dar&eacute; Bioscience, Inc. (NASDAQ: DARE), a clinical-stage biopharmaceutical company committed to the advancement
        of innovative products for women's health, since November 2019</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on products for psychiatric
        disorders, from February 2019 to June 2020</TD></TR>
  </TABLE></DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Other Public Company Board
Service</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Aprea Therapeutics Inc. (NASDAQ:APRE), a biotechnology company focused on novel cancer therapeutics, since
        August 2019 (lead independent director since September 2020)</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">R1 RCM, Inc. (NASDAQ:RCM), a provider of revenue cycle management services to healthcare providers, since
        February 2016</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">SeaSpine Holdings Corporation (NASDAQ:SPNE), a spinal implant and orthobiologics company, since July 2015</TD></TR>
  </TABLE></div><br clear="all">

<DIV STYLE="float: left; width: 48%">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Ph.D. and M.S. in Materials Science and Engineering from the University of Texas-Austin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">B.S. in Ceramic Engineering from Alfred University</TD></TR>
  </TABLE></div>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Education </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">J.D. from University of Michigan Law School</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">A.B. in Politics from Princeton University</TD></TR>
  </TABLE></div><br clear="all">

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Strong scientific background in biologics and regenerative medicine Industry</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Extensive experience in management, including as a CEO, business development and developing and commercializing
        medical device and regenerative medicine and drug delivery products at multiple companies in the life science industry</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Significant experience in innovative research and product development</TD></TR>
  </TABLE></div>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">More than 25 years of senior management experience in the medical technology and biotechnology industries</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Significant experience in serving on boards of directors, including boards of publicly held life science companies</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Extensive experience in the areas of finance, financial accounting, business transactions, law, and mergers
        and acquisitions</TD></TR>
  </TABLE></div><br clear="all">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<DIV STYLE="float: left; width: 48%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>Raymond
        J. Land</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="land.jpg" ALT=""></TD>
    <TD STYLE="width: 5%"></TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anika Board Service:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Tenure: 15 years</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Committees:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -8.65pt"><FONT STYLE="color: #365F91">&#9675;</FONT>
        Audit (Chair, Financial Expert)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -8.65pt"><FONT STYLE="color: #365F91">&#9675;</FONT>
        Compensation</P>
        </TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: rgb(200,215,234); width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 76</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director since January 2006</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Retired Certified Public Accountant</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Interim Chief Financial Officer of BioAmber Inc., a developer of chemicals from renewable feedstocks, for
        three months during 2017</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Senior Vice President and Chief Financial Officer of Clarient, Inc., an advanced molecular diagnostics company,
        from 2008 until his retirement in 2010</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc., a venture capital firm,
        from 2007 to 2008</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Executive Vice President and Chief Financial Officer of Medcenter Solutions, Inc., a pharmaceutical marketing
        company, during 2006</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Senior Vice President and Chief Financial Officer of Orchid Cellmark, a DNA testing company, from 2005 to
        2006</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Senior Vice President and Chief Financial Officer of Genencor International, Inc., a biotechnology company
        focusing on bioproducts and healthcare, from 1997 until its acquisition in 2005</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Other Public Company Board
Service</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">BioAmber Inc. (OTC:BIOAQ), a developer of chemicals from renewable feedstocks, from 2011 and chairman from
        2012 through July 2018</TD></TR>
  </TABLE></div>

<DIV STYLE="float: right; width: 48%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>Glenn
        R. Larsen, Ph.D.</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="larsen.jpg" ALT=""></TD>
    <TD STYLE="width: 5%"></TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anika Board Service</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Tenure: 6 years</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Committees:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -8.65pt"><FONT STYLE="color: #365F91">&#9675; </FONT>Compensation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -8.65pt"><FONT STYLE="color: #365F91">&#9675;</FONT>
        Governance and Nominating</P> </TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: rgb(200,215,234); width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 67</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director since February 2015</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT>Chairman, President, Chief Executive Officer and co-founder of Aquinnah Pharmaceuticals, Inc., a pharmaceutical
        company focused on the development of treatments for ALS, Alzheimer&rsquo;s and other neurodegenerative diseases, since February 2014</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT>Chairman, President, and Chief Executive Officer of 180 Therapeutics L.P., a clinical stage musculoskeletal
        drug development company, from 2013 until its merger with NASDAQ-listed 180 LifeSciences in 2020.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT>Chief Scientific Officer and Executive Vice President of Research and Development of SpringLeaf Therapeutics,
        Inc., a producer of combination drug delivery devices, from 2010 to 2013</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT>Chief Operating Officer, Executive Vice President of Research and Development and director of Hydra
        Biosciences, Inc., a biopharmaceutical company focused on developing pain therapeutic drugs, from 2003 to 2010</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT>Series of drug discovery and development leadership positions, including Vice President Musculoskeletal
        Sciences, at Wyeth (now Pfizer)/Genetics Institute, where he directed Wyeth&rsquo;s second-largest therapeutic area with responsibility
        for Enbrel, an anti-TNF therapeutic for arthritic pain with multi-billion dollar annual sales, and the development of Infuse Bone Graft,
        the 1<SUP>st</SUP> regenerative biologic medicine approved for numerous orthopedic bone regeneration indications</FONT></TD></TR>
  </TABLE></div><br clear="all">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Education </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">B.S. in accounting and finance from Temple University</TD></TR>
  </TABLE></div>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Ph.D. in Biochemistry from Stony Brook University</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">P.M.D. from Harvard University</TD></TR>
  </TABLE></div><br clear="all">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Education, training and experience in accounting and finance, including as Certified Public Accountant</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">More than 35 years of experience as chief financial officer and other senior accounting and finance roles
        at multiple companies, including several in the life science industry</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Transactional experience in merger and acquisitions and financings</TD></TR>
  </TABLE></DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Strong scientific background in pharmaceuticals, biotech, orthopedics, pain management <FONT STYLE="background-color: white">and</FONT>
        regenerative medicine</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Extensive experience in management, product development <FONT STYLE="background-color: white">and</FONT> business
        development at multiple companies in the life science industry</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Significant experience in innovative research and product development and commercial development</TD></TR>
  </TABLE></div><br clear="all">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<DIV STYLE="float: left; width: 48%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>Stephen
        O. Richard</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="richard.jpg" ALT=""></TD>
    <TD STYLE="width: 5%"></TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anika Board Service</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Tenure: 0.5 years</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Committees:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -8.65pt"><FONT STYLE="color: #365F91">&#9675; </FONT>Audit
        (Financial Expert)</P> </TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: rgb(200,215,234); width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 58</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director since September 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Senior Vice President, Chief Risk Officer since May 2019 and Chief Audit Executive since 2016 of Becton, Dickinson
        and Company, a medical technology company</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Various offices in the areas of finance, operations and business development of the National Basketball Association
        organization from 1998 to 2016, including Senior Vice President, Business Development and Global Operations of NBA Properties, Inc. from
        2013 to 2016, Chief Financial Officer of NBA China from 2010 to 2013 and Interim Chief Executive Officer of NBA China from 2010 to 2011</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Earlier in his career, Mr.&nbsp;Richard served as, among other positions, Regional Audit Director, U.S. Consumer
        Businesses at Citigroup Inc., District Manager, Financial Planning and Analysis at AT&amp;T Corporation, and Senior Manager at Deloitte
        &amp; Touche LLP</TD></TR>
  </TABLE></div>

<DIV STYLE="float: right; width: 48%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>Jeffery
        S. Thompson</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="thompson.jpg" ALT=""></TD>
    <TD STYLE="width: 5%"></TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anika Board Service</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Tenure: 10 years</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.65pt; text-align: justify; text-indent: -8.65pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Chair of the Board</P> </TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: rgb(200,215,234); width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 55</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director since January 2011</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Partner with HealthEdge Investment Partners, LLC, or HealthEdge, a private equity firm providing strategic
        capital exclusively to the healthcare industry, since 2008, where he sits on the investment team and serves as a director for numerous
        HealthEdge affiliated companies, including ITRACs, Legacy Xspire Holdings, LifeSync and Westone</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Previously, Chairman, Chief Executive Officer and President of Advanced Bio-Technologies, Inc. and Enaltus
        LLC, both HealthEdge portfolio company specializing in skincare solutions sold to consumers and direct to physicians from 2008 to 2017</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Non-executive director of Sinclair Pharma, plc, a publicly traded international aesthetic dermatology company
        from September 2014 until its acquisition by China Grand in November 2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director of Stiefel Laboratories, Inc., an independent pharmaceutical company specializing in dermatology,
        and President of Glades Pharmaceuticals, both of which were sold to GlaxoSmithKline in 2008</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Earlier in his career, Mr.&nbsp;Thompson held sales and business management positions at Bausch &amp; Lomb
        Pharmaceuticals and SmithKline Beecham</TD></TR>
  </TABLE></div><br clear="all">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">M.B.A. in Finance from Columbia Business School.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: white">B.S. in </FONT>Accounting from Northeastern University</TD></TR>
  </TABLE></DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Education</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: white">B.S. in General Science from University of Pittsburgh</FONT></TD></TR>
  </TABLE></div><br clear="all">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Education, training and experience in accounting and finance, reflected
        in status as a Certified Public Accountant, multiple senior accounting roles and the Chairman of the Committee on Governance, Risk and
        Compliance of Financial Executives International, an association of financial executives serving public and private companies</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Significant senior management experience, including in the medical technology industry</TD></TR>
  </TABLE></DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Extensive experience serving on boards of directors of numerous life
        sciences, biotechnology, and healthcare services companies</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Significant experience as chief executive officer of life sciences and
        healthcare services companies</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: white">More than a decade of experience advising HealthEdge portfolio and other
        life science companies on business development strategies and transactions</font></TD></TR>
  </TABLE></div><br clear="all">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="float: left; width: 48%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>Susan
        N. Vogt</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="vogt.jpg" ALT=""></TD>
    <TD STYLE="width: 5%"></TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anika Board Service:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Tenure: 2.5 years</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: left; text-indent: -8.65pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4372B9">&nbsp;&nbsp;
        </FONT>Committees:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -8.65pt"><FONT STYLE="color: #365F91">&#9675;</FONT>
        Audit (Financial Expert)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -8.65pt"><FONT STYLE="color: #365F91">&#9675;</FONT>
        Governance and Nominating (Chair)</P> </TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: rgb(200,215,234); width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 67</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director since October 2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Chief Executive Officer and President of Aushon Biosystems, Inc., a developer of a multiplex immunoassay platform,
        from 2013 until its acquisition in January 2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Chief Executive Officer, President, and a director of SeraCare Life Sciences, Inc., a NASDAQ-listed life sciences
        developer of products facilitating human diagnostics and therapeutics, from 2006 to 2011</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Former director of Andor Technology (LSE:AND) from 2010 to 2013</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">From 1981 to 2005, various management and officer positions at Millipore Corporation (now part of MilliporeSigma,
        the life science business of Merck KGaA), an NYSE-listed developer of technologies for life science research, drug development and manufacturing
        for the biotechnology and pharmaceutical industries, including, among other leadership roles, President of the Biopharmaceutical Division,
        Vice President and General Manager of the Laboratory Water Division, Vice President and General Manager of the Analytical Products Division.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Other Public Company Board
Service</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Sharps Compliance, Inc. (NASDAQ: SMED) a leading full-service national provider of comprehensive waste management
        services, including medical, pharmaceutical, and hazardous, since October 2019</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Charlotte&rsquo;s Web Holdings, Inc. (TSX: CWEB) a leading provider of CBD wellness products, since September
        2020</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">M.B.A. from Boston University, concentration in Finance</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">A.B. in Art History from Brown University</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">More than thirty-five years of experience in the global life science research, pharmaceutical, biotech and
        clinical diagnostics industries</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 9.35pt"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Proven record of driving operational efficiency and productivity, successfully scaling commercial operations,
        enhancing profitability by streamlining, restructuring and consolidating operations, and delivering sustained revenue and cash flow growth
        at multiple companies</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Deep understanding of finance and accounting as a result of her education, financial-based roles during her
        career and serving on audit committees of several companies</TD></TR>
  </TABLE></div><br clear="all">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><FONT STYLE="font-size: 14pt">Governance
of the Company</FONT></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><A NAME="a_006"></A><FONT STYLE="font-size: 12pt">Board&rsquo;s
Role in Risk Oversight</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The role of the Board of Directors in our risk
oversight process includes receiving reports from management and the Chairs of Board committees on areas of material risk to our company,
including operational, financial, commercial, legal, regulatory, strategic, and reputational risks. The Board has delegated primary responsibility
to the Audit Committee to review these reports and discuss with management the process by which management assesses and manages our risk
exposure, risk management, and risk mitigation strategies. The Audit Committee also works with other committees to assess areas of risk
under the particular purview of those committees. When the Audit Committee receives a report from management or another committee, the
Chair of the Audit Committee reviews the report and then summarizes the review results in a presentation to the full Board. This enables
the Board and its committees to coordinate the risk oversight role to ensure that all directors receive all significant risk-related information.
The Board also administers its risk oversight function through the required approval by the Board (or a committee of the Board) of significant
transactions and other material decisions and through regular periodic reports from our independent registered public accounting firm
and other outside consultants regarding various areas of potential risk, including, among others, those relating to our internal controls
and financial reporting. In addition, as part of its charter, the Audit Committee discusses with management and our independent registered
public accounting firm significant risks and exposures, as well as the steps management has taken to minimize those risks.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_007"></A>Board&rsquo;s
Increased Involvement due to COVID-19 and Executive Team Changes</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2020, the Board made it a priority to oversee
and support the company&rsquo;s management and thereby manage risk following the onset of the COVID-19 pandemic. The COVID-19 pandemic
impacted not just our employees and our traditional operations, but also significantly impacted our business as many of the medical procedures
in which our products are used were either cancelled or delayed due to global quarantine orders or other shut-downs of healthcare facilities.
The Board&rsquo;s oversight and frequent involvement with management during 2020 was especially important in light of our acquisitions
of Parcus Medical and Arthrosurface early in the year and the changes in our executive management team throughout the year, including
the appointment of Dr. Cheryl Blanchard as our President and Chief Executive Officer following the unexpected passing of Joseph Darling
in January 2020. The Board&rsquo;s increased involvement took the form of additional meetings with the executive management team held
on a more frequent basis than was its historical practice, including bi-weekly meetings for a number of months during the spring, to review
and discuss steps that management was taking to support employee health and safety and to review business progress reports, bi-weekly
financial updates and projections, and other strategic responses to the COVID-19 pandemic.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_008"></A>Board
Leadership Structure</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jeffery Thompson has served as the Chair of the
Board since September 2020. Separating the roles of Chair and Chief Executive Officer allows our Chief Executive Officer to focus on the
strategic management of our day-to-day business, while allowing the Chair to focus on leading the Board of Directors in its fundamental
role of providing advice to, and independently overseeing, management. The Board recognizes the time, effort, and energy that the Chief
Executive Officer is required to devote to the position in the current business environment, as well as the commitment required to serve
as our Chair, particularly as the Board&rsquo;s oversight responsibilities continue to grow. The Board believes that having separate positions,
with an independent, non-executive director serving as the Chair, is the appropriate leadership structure for our company at this time
and allows the Board to fulfill its role with appropriate independence.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_009"></A>Corporate
Governance and Board Matters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors annually reviews the independence
of all non-employee directors. In April 2020, the Board established categorical standards consistent with the corporate governance standards
of Nasdaq to assist the Board in making determinations of the independence of Board members. A copy of our Standards for Director Independence,
which was adopted by the Board in April 2020, is available on the investor relations portion of our website at <I>https://ir.anikatherapeutics.com/corporate-governance</I>.
These categorical standards require that, to be independent, a director may not have a material relationship with our company. Even if
a director meets all categorical standards for independence, the Board reviews other relationships with Anika in order to conclude that
each independent director has no material relationship with Anika either directly or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has determined that each of its members,
including the director nominees, but excluding our President and Chief Executive Officer Cheryl R. Blanchard, is &ldquo;independent&rdquo;
within the meaning of the director independence standards of NASDAQ and the SEC. The Board based these determinations primarily on a review
of the responses of each director to questions regarding employment and compensation history, affiliations, and family and other relationships,
and on other relevant discussions with the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Independent directors meet regularly in executive
sessions without management participation. The executive sessions generally occur in connection with regularly scheduled meetings of the
Board and committees of the Board, and at other times the independent directors deem appropriate. The executive sessions are chaired either
by the Chair of the Board or by the chair of the Board committee having jurisdiction over the particular subject matter to be discussed
at the particular meeting or portion of a meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board reviews matters related to our corporate
governance annually at a regularly scheduled meeting of the Board. This includes an evaluation of our bylaws, committee charters, diversity
programs, corporate social responsibility initiatives, and other matters related to our governance. During this review, the Board assesses
input from management and outside consultants to discern whether any actions should be taken on any of these topics. Furthermore, the
Board conducts periodic evaluations that focus on the effectiveness of the Board as a whole and of its committees. Board members complete
a detailed questionnaire that provides for quantitative rankings in key areas and seeks subjective comments in each of those areas. In
addition, members of each Board committee complete a detailed questionnaire to evaluate how well their committee is operating and to make
suggestions for improvement. The evaluation process is managed by the Chair of the Governance and Nominating Committee, with advice from
outside counsel. Outside counsel may conduct separate, confidential interviews with some or all of the directors to follow-up on responses
and comments reflected in the questionnaires to the extent it is determined helpful or necessary. An anonymized summary of the principal
findings from the evaluation process is prepared by outside counsel and is used as the basis for self-assessment discussions by the Board
and its committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board met 23 times during 2020. No director
attended less than 90% of the total number of Board meetings during the director&rsquo;s term. As described elsewhere in this Proxy Statement,
the Board made it a priority to oversee and support the executive management team following the onset of the COVID-19 pandemic, including
through bi-weekly meetings with key executive members for a number of months during the spring. The Board placed great importance on taking
this approach in light of our ongoing company transformation following our early 2020 acquisitions of Parcus Medical and Arthrosurface
and the changes in our management team, including the appointment of Dr. Cheryl Blanchard as President and Chief Executive Officer. In
these meetings, the Board focused on key business updates, regular financial updates, including monitoring our liquidity and cash position,
and providing support to the management team to ensure an appropriate and well-measured response to the COVID-19 pandemic. The key goal,
which we believe was achieved, was to support employee health and safety, while avoiding significant operational disruptions to the business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Annual Meetings of Stockholders are generally
held to coincide with one of the Board&rsquo;s regular quarterly meetings. Although we have no formal policy requiring attendance, directors
are encouraged to attend Annual Meetings of Stockholders. Each of the then-serving or nominated directors attended the 2020 Annual Meeting.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_010"></A>Board
Committees</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors currently has three standing
committees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify">Audit Committee;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify">Compensation Committee; and</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify">Governance and Nominating Committee.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The membership of each standing committees was
as follows as of April 20, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #365F91">
    <TD ROWSPAN="2" STYLE="white-space: nowrap; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Director</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; white-space: nowrap; border-bottom: White 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Committee</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="white-space: nowrap; border-top: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Independent
        Under <BR> SEC Rules</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="white-space: nowrap; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Financial
        Expert <BR> Under SEC Rules</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #365F91">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Audit</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Compensation</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Governance
        and <BR> Nominating</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 25%; text-align: justify">Joseph L. Bower</TD>
    <TD STYLE="vertical-align: bottom; width: 15%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 15%; text-align: center">Chair</TD>
    <TD STYLE="vertical-align: bottom; width: 15%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 15%; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; text-align: justify">John B. Henneman III</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">Raymond J. Land</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Chair</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; text-align: justify">Glenn R. Larsen</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">Stephen O. Richard</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; text-align: justify">Jeffery S. Thompson</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">Susan N. Vogt</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Chair</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #365F91">&#10003;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has adopted a written charter for each
standing committee, which is reviewed yearly by that committee. You can find these charters on the investor relations portion of our website
at <I>https://ir.anikatherapeutics.com/corporate-governance</I>. The information contained on the website is not incorporated by reference
in, or considered to be a part of, this Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Audit Committee</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>Role and Key Responsibilities</B></FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="4" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify; width: 97%">Overseeing accounting and financial reporting processes</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Overseeing audits of our financial statements and internal controls</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Taking, or recommending that the Board of Directors take, appropriate action to oversee the qualifications,
        independence and performance of our independent registered public accounting firm</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Leading the review of our risk management processes and exposure to risk</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Preparing an Audit Committee report, as required by the SEC, for inclusion in our annual Proxy Statement</TD>
        </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Selecting, retaining, overseeing, and, when appropriate, terminating our independent registered public accounting
        firm</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Conferring with the independent registered public accounting firm and reporting to the Board regarding the
        scope, method, and result of the audit of our books and records</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Reviewing and discussing proposed earnings press releases and financial information and guidance proposed
        to be provided to investors</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Establishing, overseeing and periodically reviewing procedures for complaints regarding accounting or auditing
        matters</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Establishing and monitoring a policy relative to non-audit services provided by the independent registered
        public accounting firm in order to ensure the firm&rsquo;s independence</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee held 5 meetings in 2020. No
member attended less than 90% of the total number of Audit Committee meetings held while the member served on the Audit Committee. The
Audit Committee holds separate sessions of its meetings, outside the presence of management, with our independent auditor in conjunction
with each regularly scheduled Audit Committee meeting in which the independent auditor participates. During 2020, the Audit Committee
met privately with our management and held executive sessions with only non-employee directors in attendance as appropriate. No director
is eligible to serve on the Audit Committee if that director simultaneously serves on the audit committees of four or more other public
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current members of the Audit Committee are
Raymond Land, who serves as Chair, Stephen Richard and Susan Vogt. The Board has determined that each member is independent, as defined
for purposes of the SEC and NASDAQ, is financially literate, and has the requisite financial sophistication to serve on the Audit Committee.
The Board has also determined that each member qualifies under SEC rules as an &ldquo;audit committee financial expert,&rdquo; which designation
is an SEC disclosure requirement related to their experience and understanding of certain accounting and auditing matters. The designation
does not impose upon any of the three members any duties, obligations, or liabilities that are greater than those otherwise imposed on
them as members of the Audit Committee and the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Committee</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="width: 100%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>Role and Key Responsibilities</B></FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="4" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify; width: 97%">Managing our overall compensation philosophy, structure, policies, processes, procedures, and
        programs</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive
        Officer and other executive officers</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Reviewing the performance of and determining the compensation of the Chief Executive Officer</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Reviewing the performance of and determining, with the advice and assistance of the Chief Executive Officer,
        the compensation of our executive officers other than the Chief Executive Officer</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Annually reviewing and recommending to the Board of Directors compensation for non-employee directors</TD>
        </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Overseeing our overall compensation programs, including the granting of awards under our omnibus incentive
        plan</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Preparing a report on executive compensation for inclusion in our annual Proxy Statement</TD> </TR>
    <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Reviewing, discussing with management and any compensation consultant, and recommending the inclusion of disclosures under
&ldquo;Compensation Discussion and Analysis&rdquo; in our Proxy Statement</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Periodically conducting a risk assessment to evaluate whether forms of pay encourage unnecessary or excessive
        risk taking and assisting the Audit Committee in assessing and managing potential risks created by our compensation practices, policies
        and programs</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Reviewing, approving, recommending to the Board for approval, and considering the results of stockholder advisory
        &ldquo;say-on-pay&rdquo; and &ldquo;say-on-frequency&rdquo; votes and reviewing and recommending to the Board whether to submit a stockholder
        advisory vote on certain acquisition-related compensation arrangements</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Appointing, retaining, compensating, terminating, and overseeing the work of any compensation consultant or
        other compensation adviser, as well as considering the independence of any compensation consultant or other compensation adviser</TD>
        </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee held 16 meetings in
2020. No member attended less than 90% of the total number of Compensation Committee meetings held while the member served on the Compensation
Committee. During 2020, the Compensation Committee held executive sessions with only non-employee directors in attendance as appropriate,
including when evaluating the performance of Dr. Cheryl Blanchard. In 2020, the number of Compensation Committee meetings exceeded historical
practice, largely in response to changes to our executive management team and the COVID-19 pandemic. The Compensation Committee was engaged
in significant discussions, including with its independent compensation consultant, regarding the compensation of Dr. Blanchard in relation
to her appointments as our interim Chief Executive Officer, and then as our President and Chief Executive Officer, as well as that of
David Colleran and Michael Levitz in relation to their appointments to our executive management team. In addition, the Compensation Committee
met multiple times to monitor and discuss the impact of the COVID-19 pandemic and its impact on our organization, especially in light
of the cancellation or delay of many clinical procedures and the impacts of the pandemic and global quarantine orders were having on the
company&rsquo;s clinical trials, to ensure that there continued to be strong engagement and appropriate incentivization for our employee
base. The Compensation Committee also used these meetings, in certain cases, to send messages to the company&rsquo;s employees through
the executive management team in support of their engagement and efforts to continue to design, manufacture, support, market, and sell
our medical products in spite of the difficult environment created by COVID-19, and to provide assurances and comfort around our compensation
program and plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current members of the Compensation Committee
are Joseph Bower, who serves as Chair, John Henneman, Raymond Land, and Glenn Larsen. The Board has determined that each current member
of the Compensation Committee is independent, as defined in the listing standards of NASDAQ.</P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Governance and Nominating
Committee</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="width: 100%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>Role and Key Responsibilities</B></FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="4" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify; width: 97%">Recommending to the Board of Directors the criteria for Board and committee membership</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Identifying, evaluating, and recommending nominees to stand for election as directors at each Annual Meeting
        of Stockholders, including incumbent directors and candidates recommended by stockholders</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Developing succession plans for the Board, the Chief Executive Officer and other executives</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Coordinating performance evaluations of the Board and its standing committees</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Recommending to the Board assignments of directors to each Board committee and monitoring compliance with
        Board and committee membership criteria</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Overseeing and administering Board education programs</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify">Overseeing corporate governance affairs of the Board and our company</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Governance and Nominating Committee held 7
meetings in 2020. No member attended less than 90% of the total number of Governance and Nominating Committee meetings held while the
member served on the Governance and Nominating Committee. During 2020, the Governance and Nominating Committee held executive sessions
with only non-employee directors in attendance as appropriate. In 2020, the Governance and Nominating committee focused on the creation
and oversight of the process to replace our Chief Executive Officer following the passing of Mr. Darling, as well as the activities required
to identify, recruit, and onboard our new directors, Mr. Henneman and Mr. Richard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current members of the Governance and Nominating
Committee are John Henneman, Glenn Larsen, and Susan Vogt, who serves as Chair. The Board has determined that each current member of the
Governance and Nominating Committee is independent, as defined in the listing standards of NASDAQ.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_011"></A>Board
Membership Qualifications and Procedures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When considering candidates for director, the
Governance and Nominating Committee takes into account a number of factors, including the following minimum qualifications: the nominee
(a) shall have the highest personal and professional integrity, (b) shall have demonstrated exceptional ability and judgment, and (c)
shall be most effective, in conjunction with the other members of the Board of Directors, in collectively serving the long-term interests
of the stockholders. In addition, the Governance and Nominating Committee will take into consideration such other factors as it deems
appropriate, including any direct experience in the biotechnology, pharmaceutical, medical device, and/or life sciences industries, or
in the markets in which we operate. The Governance and Nominating Committee may also consider, among other things, the skills of the candidate,
his or her availability, the candidate&rsquo;s depth and breadth of experience or other background characteristics, and his or her independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the considerations above, the Board
strongly believes that diversity is an important component of a successful and effective board of directors and good corporate governance,
including diversity of background, skills, experience, gender, race, and ethnicity. The Governance and Nominating Committee, guided by
its charter, assesses and considers the diversity of the Board prior to nominating candidates and seeks to identify director candidates
who will enhance the Board&rsquo;s overall diversity. The Governance and Nominating Committee and the Board select candidates on the basis
of qualifications and experience without discriminating on the basis of race, color, national origin, gender, sex, sexual preference,
or religion. Accordingly, it is the practice of the Governance and Nominating Committee to include, and we request that the search firms
we engage include, women and minority or underrepresented candidates in any pool from which the Governance and Nominating Committee selects
director candidates. We believe that our current Board members collectively reflect diverse knowledge, expertise, and experience in the
disciplines that impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bylaws include a procedure that stockholders
must follow to nominate a person for election as a director at an annual meeting of stockholders. The bylaws require that timely notice
of the nomination in proper written form, including all required information as specified in the bylaws, be mailed to the Governance and
Nominating Committee in care of our Chief Executive Officer, Anika Therapeutics,&nbsp;Inc., 32 Wiggins Avenue, Bedford, Massachusetts
01730. A copy of our bylaws can be viewed on the investor relations portion of our website at <I>https://ir.anikatherapeutics.com/corporate-governance.</I>
The Governance and Nominating Committee will consider director nominees recommended by stockholders in accordance with the Anika Therapeutics,
Inc. Policy and Procedures for Stockholder Nominations to the Board adopted by the Governance and Nominating Committee and approved by
the Board in April 2020, a copy of which is available on the investor relations portion of our website at <I>https://ir.anikatherapeutics.com/corporate-governance</I>.
Recommendations should be submitted to our Secretary in writing at Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts
01730, along with additional required information about the nominee and the stockholder making the recommendation. Information on qualifications
for nominations to the Board and procedures for stockholder nominations to the Board is included below under &ldquo;Proposal 1. Election
of Directors&mdash;Board Membership Qualifications and Procedures&rdquo; and &ldquo;Stockholder Proposals.&rdquo; The Governance and Nominating
Committee may solicit recommendations for candidates for directors from non-management directors, the Chief Executive Officer, other executive
officers, third-party search firms, and such other sources as it deems appropriate, including stockholders. The Governance and Nominating
Committee will review and evaluate the qualifications of all such proposed candidates in the same manner and without regard to the source
of the recommendation.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_012"></A>Communications
with Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors seek input from a wide variety of
sources to inform their work, including from stockholders.&nbsp;The Board of Directors welcomes stockholder input via voting,&nbsp;via
participating in our Annual Meetings of Stockholders, via our stockholder engagement program, and, more formally, via mail. If you wish
to communicate with any of our directors or the Board as a group, you may do so by writing to the individual director or to the Board,
in care of our Chief Executive Officer, Anika Therapeutics,&nbsp;Inc., 32&nbsp;Wiggins Avenue, Bedford, Massachusetts 01730. We recommend
that all correspondence be sent via certified U.S. mail, return receipt requested. All correspondence received by the Chief Executive
Officer will be forwarded promptly to the appropriate addressee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_013"></A>Code
of Business Conduct and Ethics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is our policy that all of our officers, directors,
and employees worldwide conduct our business in an honest and ethical manner and in compliance with all applicable laws and regulations.
The Board of Directors has adopted the Anika Therapeutics,&nbsp;Inc. Code of Business Conduct and Ethics to clarify, disseminate, and
enforce this policy. The Code of Business Conduct and Ethics applies to all of our officers, directors, and employees worldwide, including
our Chief Executive Officer and Chief Financial Officer. The Code of Business Conduct and Ethics can be viewed on the investor relations
portion of our website at <I>https://ir.anikatherapeutics.com/corporate-governance</I>. Please note that the information contained on
the website is not incorporated by reference in, or considered to be part of, this Proxy Statement.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_014"></A>Commitment
to Compliance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are committed to maintaining a strong culture
of compliance across our entire organization. We believe that a workplace with a culture of &ldquo;do the right thing,&rdquo; guided by
high standards and comprehensive policies, is the bedrock of our success as a healthcare company and our ability to deliver life-changing
solutions to the customers we serve and all of the patients they treat around the world. As part of setting this culture and maintaining
a strong tone at the top, the following quote from our President and Chief Executive Officer, Dr. Blanchard, is included in our strategic
plan as presented to the Board and at the beginning of each individual and annual compliance training session:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><I>&ldquo;At Anika, a commitment to ethics and
quality, as realized and demonstrated through personal integrity and accountability, forms the basis for everything we do and forges the
path to all that we can achieve. These foundational tenets of our company are non-negotiable and do not take a day off.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in 2020, in conjunction with the
acquisitions of Parcus Medical and Arthrosurface and the expansion of our commercial infrastructure in the United States, and with the
support of the Board, we substantially expanded our company-wide Compliance Program focused on healthcare fraud and abuse, anti-kickback,
and foreign corrupt practices act regulations, among others, and instituted more robust processes to ensure that appropriate controls
are in place for compliance with these laws and regulations.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_015"></A>Corporate
Social Responsibility &ndash; Environmental Sustainability, Social, and Governance Matters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are committed to good corporate citizenship
and to creating a sustainable and diverse workplace, while ensuring we operate with the highest standards of quality, ethics, and corporate
governance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain a global Health, Safety, and Environment
(HSE) policy to make good on our commitment to the health and safety of our employees and the protection of the environment. Key principles
of this policy include, among others, maintaining a goal of zero workplace injuries or accidents, proactively integrating HSE considerations
into all business activities, and minimizing the environmental impact of our operations. We have a broad range of environmental practices
focused on reducing our consumption of energy, water, and natural resources and minimizing our production of waste. We have implemented
material recycling, ozone depleting substance, heat recovery, and efficient lighting programs to better our environmental footprint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the COVID-19 pandemic, we immediately
implemented a cross-functional COVID-19 task force to provide senior leadership with guidance and recommendations to ensure an appropriate
response to the pandemic and promote health and safety for our employees worldwide. We established strict safety policies and protocols,
and we regularly update our employees with respect to any changes. We transitioned much of our administrative workforce to work remotely
to protect the health of those who must be onsite to perform their jobs, including our manufacturing staff, and we have adjusted attendance
policies to encourage those who may be ill to stay home. We have provided an abundance of personal protective equipment and cleaning supplies,
including sending a COVID-19 care package including multiple masks, face shields, hand sanitizer, and other personal protective equipment
to all of our employees to support them and their families when there were shortages of certain of these items. We require masks to be
worn in our facilities and initially prohibited all non-essential domestic and international travel for all employees, though we have
relaxed that restriction for certain personnel as travel carriers have developed additional safety protocols and vaccinations have become
more prevalent. We have also provided general information updates and support for our employees to ensure that they have resources and
information to protect their health and that of those around them, including their families and co-workers. In conjunction with certain
of our partners, we also donated personal protection equipment and other supplies to frontline healthcare workers as part of our COVID-19
response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are dedicated to attracting and retaining highly
talented people, fostering a diverse and inclusive workforce, and providing a safe and healthy work environment for our employees. We
have a strong employee wellness program that includes both on- and off-site activities aimed at keeping our employees active. We collaborate
with multiple charitable organizations and educational institutions to ensure that we give back to the communities that support us, including
through grants to universities and other charitable organizations. For additional information about how we view and support our workforce,
please see the following section, <I>Human Capital Management</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are dedicated to strong governance practices
as can be seen through the recent changes we have made to the Board of Directors and its diversity, as well our commitment to appropriate
risk management strategies and corporate policies, as are described in more detail throughout this Proxy Statement. Our commitments to
diversity and sustainability are designed to make us a best-in-class business with efficient processes and operations, and we believe
that these values can also be key drivers of our company&rsquo;s success and growth, and increase stockholder return over the long-term.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_016"></A>Human
Capital Management</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that a diverse, talented, and inclusive
workplace is a central aspect to our culture and increases employee engagement, innovation, operational excellence, and overall individual
and company performance. In turn, this culture and drive for performance helps us attract and retain qualified employees and key talent.
Our culture is centered around our fundamental values of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="3" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>People</I>: We engage and invest in each other in a community that values diversity and inclusion.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Innovation</I>: We are agile and entrepreneurial in developing and delivering meaningful solutions to our
        healthcare stakeholders within our target markets.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Quality</I>: We strive for the highest quality and compliance in everything we do.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Teamwork</I>: We operate with mutual respect and trust and are collaborative as we grow together.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Integrity</I>: We live up to our promises and do the right thing, every day.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Accountability</I>: We are empowered and accountable to deliver results and value to all of our stakeholders.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B></B></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="p31.jpg" ALT="" STYLE="height: 437px; width: 700px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We substantially increased our employee base in
2020 with the acquisitions of Parcus Medical and Arthrosurface as well as our hiring of additional people to support our expanded operations,
and we expect to continue to add employees in 2021 and beyond as we grow and transform our business. Our Compensation Committee and executive
management team are focused on attracting and retaining top industry talent and key employees, and we offer market competitive total rewards
packages consisting of base salary, a potential cash bonus based on individual and company performance, and a comprehensive benefits package
to all employees. We also provide equity-based compensation to a large segment of our employee population based on various criteria, including
their level within the company, to ensure that our employees contribute to our strategic objectives and that their compensation is aligned
with the best interests of our stockholders. Ongoing employee development is a key component of our overall business strategy. To facilitate
this, we support our employees&rsquo; development through individualized development plans, mentoring, coaching, group training, conference
attendance, financial support, including tuition reimbursement for qualified programs, and access to a broad-based learning management
platform for self-directed learning and improvement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In early 2021, to coincide with our annual equity
granting cycle, our Compensation Committee determined to make the &ldquo;One Anika Grant,&rdquo; a unique, one-time grant of stock options
to all employees below the level of Vice President. The message from Dr. Blanchard accompanying this grant praised the efforts of all
of our employees in integrating our acquired companies and the work that had been done to build collaborative relationships throughout
the organization. The message also relayed the company&rsquo;s belief regarding the importance of each employee having the opportunity
to be a stockholder of the company with the potential to see appreciating value as the result of shared success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors and executive management
team believe that employees understanding how their work contributes to our overall strategy and performance is key to our success. In
order to communicate with respect to these important topics in ways that are engaging and accessible to our team, we utilize a variety
of channels, including quarterly company-wide town hall meetings with presentations by members of senior management, regular email updates
from our chief executive officer and other key members of the executive team, and employee engagement surveys.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in 2020, Dr. Blanchard, with the
support of the Board of Directors, signed the Massachusetts Biotechnology Council &ldquo;CEO Pledge for a More Equitable and Inclusive
Life Sciences Industry.&rdquo; The signers of this pledge &ldquo;recognize that racial inequity exists in [the life sciences] industry
and in [life sciences] companies, and [they] must take responsibility to fix that injustice through comprehensive equity, diversity, and
inclusion initiatives that are broad in scope, specific in action, and measurable in results.&rdquo; The full text of the pledge can be
found at: https://www.massbio.org/initiatives/equity-diversity-and-inclusion/open-letter/. Both the development of plans to fulfill the
equity, diversity, and inclusion goals of the CEO pledge and the continued discussion and implementation of plans to address the feedback
received in the 2020 employee engagement survey are corporate goals for this coming year and have been shared and agreed upon with the
Board of Directors.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><A NAME="a_017"></A><FONT STYLE="font-size: 12pt">Director
Overboarding Guidelines</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors recognizes that its members
benefit from service on the boards of other companies and it encourages such service. The Board also believes, however, that it is critical
that directors are able to dedicate sufficient time to their service on the Board. The Board adopted our Commitment to the Board; Service
on Other Boards; Change in Status Guidelines on March 17, 2021. Pursuant to these guidelines, unless the Board determines that such service
would not impair the ability of a director to effectively serve on the Board or the Audit Committee of the Board:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">no director who serves as the chief executive officer of any public company, including Anika, may serve on
        the boards of directors of more than three public companies, including Anika.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">no other director may serve on the board of directors of more than five public companies, including Anika;
        and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">no member of the Audit Committee should serve simultaneously on the audit committees of more than four public
        companies, including Anika.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors must notify the Chair of the Governance
and Nominating Committee and our Corporate Secretary before accepting a seat on the board of directors of, or any assignment to the audit
committee of, another public company so that the potential for conflicts or other factors compromising the director&rsquo;s ability to
perform his or her duties may be fully assessed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_018"></A>Prohibition
on Employee, Officer, and Director Hedging and Pledging</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is our policy that all employees and directors,
as well as their family members, must not hedge or pledge any Anika securities they hold directly. An exception to this prohibition may
be granted where a person wishes to pledge Anika securities as collateral for a loan, upon approval by our Chief Financial Officer, if
certain other conditions are met. The prohibition on hedging is included in our Insider Trading Policy, which was implemented by the Board
of Directors on December 20, 2016, as amended on July 16, 2020, and as subsequently amended on March 17, 2021. A copy of our Insider Trading
Policy is available on our website and can be viewed on the investor relations portion of our website at <I>https://ir.anikatherapeutics.com/corporate-governance</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_019"></A>Majority
Voting in Uncontested Director Elections Policy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 8, 2015, the Board of Directors adopted
our &ldquo;Majority Voting in Uncontested Director Elections Policy.&rdquo; An uncontested election occurs when the number of director
nominees is equal to the number of Board positions to be filled through election and proxies are being solicited for such election of
directors solely by our company. Pursuant to our policy in such an election, if a director receives a greater number of votes &ldquo;against&rdquo;
than &ldquo;for&rdquo; his or her election, such director shall promptly offer his or her resignation for consideration by the Governance
and Nominating Committee. The Governance and Nominating Committee shall then consider all of the relevant facts and circumstances and
recommend to the Board whether or not to accept such offer of resignation. The final decision of whether or not to accept such resignation
shall be made by the Board, and, if required or determined by the Board to be desirable, we shall appropriately disclose the decision
of the Board along with the rationale for such decision.</P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_020"></A>Transactions
with Related Persons and Conflict of Interest Policy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is our policy that all employees and directors,
as well as their family members, must avoid any activity that is, or has the appearance of, conflicting with our business interests. This
policy is included in our Code of Business Conduct and Ethics, and it is supplemented by our Conflict of Interest Policy, which was implemented
by the Board of Directors on October 6, 2015, and can be viewed on the investor relations portion of our website at <I>https://ir.anikatherapeutics.com/corporate-governance</I>.
Both the Code of Business Conduct and Ethics and the Conflict of Interest Policy are reviewed at least every three years, or more often
as necessary or advisable. Among other things, this policy requires each director and officer to provide to the Chair of the Board (or
to the Chief Executive Officer, if such transaction involves the Chair of the Board) written notice of any potential related party transaction,
defined by our policy to mirror the definition of Item 404 of Regulation S-K under the Securities Exchange Act of 1934, or the Exchange
Act, (with the exception that our policy includes a monetary threshold of $100,000 as opposed to the threshold of $120,000 set by Item
404 of Regulation S-K under the Exchange Act). Any such notice must include all information requested by the Chair of the Board (or the
Chief Executive Officer). Upon receiving all relevant information, the disinterested members of the Board may approve the transaction
if they determine that the transaction is in the best interests of, and fair to, Anika, may require modifications to the transaction to
make it acceptable for approval, or may reject it. The Board may also establish guidelines for ongoing management of a specific related
party transaction. The policy requires continuing related party transactions to be reviewed on at least an annual basis. Additionally,
the policy requires all of our executives and directors to complete a director and officer questionnaire in connection with each of our
annual proxy statements, which asks them to disclose family relationships and other related party transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From January 1, 2020 through April&nbsp;30, 2021,
we had no reportable related party transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_021"></A>Beneficial
Ownership of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the beneficial
ownership of common stock as of April&nbsp;20, 2021, by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify">&#9679;</TD>
    <TD STYLE="width: 96%; text-align: justify">each director who served during 2020 or 2021;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">each of the current Named Executive Officers named in the Summary Compensation Table set forth under &ldquo;Executive
        Compensation&rdquo;;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">each other person who is known by us to beneficially own 5% or more of our common stock; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">current directors and executive officers as a group.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock owned by
each person is determined under the rules of the SEC. Under these rules, beneficial ownership includes any shares as to which the individual
has sole or shared voting power or investment power and any shares that the individual has the right to acquire by June&nbsp;19, 2021
(sixty days after April 20, 2021) through the conversion of a security or other right. Unless otherwise indicated, each person has sole
investment and voting power, or shares such power with a family member, with respect to the shares set forth in the following table. The
inclusion in this table of any shares deemed beneficially owned does not constitute an admission of beneficial ownership of those shares
for any other purpose. As of April 20, 2021, there were 14,366,686 shares of common stock outstanding. Shares not outstanding, but deemed
beneficially owned by virtue of the right of a person to acquire those shares, are treated as outstanding only for purposes of determining
the number and percent of shares of common stock owned by such person or group. Unless otherwise noted below, the address of each person
listed on the table is in care of Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="background-color: #1F497D">
    <TD STYLE="color: white; font-weight: bold; vertical-align: bottom; border-bottom: Black 0.5pt solid">Beneficial Owner</TD>
    <TD STYLE="color: white; font-weight: bold; vertical-align: bottom; border-bottom: Black 0.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="color: white; font-weight: bold; vertical-align: bottom; border-bottom: Black 0.5pt solid; text-align: center">Amount
        and Nature <BR> of Beneficial <BR> Ownership</TD>
    <TD COLSPAN="2" STYLE="color: white; font-weight: bold; vertical-align: bottom; border-bottom: Black 0.5pt solid; text-align: center">Percentage
        of <BR> Common Stock <BR> Outstanding</TD></TR>
  <TR>
    <TD STYLE="font-weight: bold; font-style: italic; vertical-align: bottom; width: 48%">Directors and Named Executive officers<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700">:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 13%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 12%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 13%">&nbsp;</TD>
    <TD STYLE="width: 12%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 20pt">Joseph L. Bower</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">19,117</TD>
    <TD>&nbsp;<SUP>(1)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 20pt; background-color: white">John B. Henneman, III</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: right; background-color: white">3,103</TD>
    <TD>&nbsp;<SUP>(2)</SUP></TD>
    <TD STYLE="text-align: right; background-color: white">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 20pt">Raymond J. Land</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">9,953</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 20pt">Glenn R. Larsen, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">11,697</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 20pt">Stephen O. Richard</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3,103</TD>
    <TD>&nbsp;<SUP>(3)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt">Jeffery S. Thompson</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10,949</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 20pt">Susan N. Vogt</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">11,652</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 20pt">Cheryl R. Blanchard, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">69,357</TD>
    <TD>&nbsp;<SUP>(4)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 20pt">David Colleran</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,500</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 20pt">Michael L. Levitz</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;<SUP>(5)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;-&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 20pt">Thomas Finnerty</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">11,701</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 20pt">James Loerop</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3,323</TD>
    <TD>&nbsp;<SUP>(6)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 20pt; vertical-align: middle; background-color: white">Current directors and executive officers as a group
        (12 persons)</TD>
    <TD STYLE="vertical-align: bottom; background-color: white">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; background-color: white">156,455</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;<SUP>(7)</SUP></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">1.09%</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="font-weight: bold; font-style: italic">5% and Above Stockholders:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 40pt; text-align: left">BlackRock, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: #95B3D7">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">55 East 52nd Street</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">New York, NY 10055</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,250,290</TD>
    <TD>&nbsp;<SUP>(8)</SUP></TD>
    <TD STYLE="text-align: right">15.80%</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD COLSPAN="3" STYLE="padding-left: 40pt; vertical-align: middle; text-align: left">Kayne Anderson Rudnick Investment Management LLC</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">1800 Avenue of the Stars, 2nd Floor</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">Los Angeles, CA 90067</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,546,263</TD>
    <TD>&nbsp;<SUP>(9)</SUP></TD>
    <TD STYLE="text-align: right">10.88%</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 40pt; vertical-align: middle; text-align: left">Ameriprise Financial, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: #95B3D7">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">145 Ameriprise Financial Center</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">Minneapolis, MN 55474</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,004,108</TD>
    <TD>&nbsp;<SUP>(10)</SUP></TD>
    <TD STYLE="text-align: right">7.07%</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding-left: 40pt; vertical-align: middle; text-align: left">The Vanguard Group</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">100 Vanguard Blvd.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">Malvern, PA 19355</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">934,282</TD>
    <TD>&nbsp;<SUP>(11)</SUP></TD>
    <TD STYLE="text-align: right">6.57%</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 40pt; vertical-align: middle; text-align: left">Dimensional Fund Advisors LP</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: #95B3D7">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">6300 Bee Cave Road, Building One</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">Austin, TX 78746</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">884,116</TD>
    <TD>&nbsp;<SUP>(12)</SUP></TD>
    <TD STYLE="text-align: right">6.20%</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 40pt; vertical-align: middle; text-align: left">State Street Corporation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">State Street Financial Center</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">One Lincoln Street</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">Boston, MA 02111</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">820,746</TD>
    <TD>&nbsp;<SUP>(13)</SUP></TD>
    <TD STYLE="text-align: right">5.77%</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 40pt; vertical-align: middle; text-align: left">Renaissance Technologies LLC</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: #95B3D7">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">800 Third Avenue</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">New York, NY, 10022</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">809,117</TD>
    <TD>&nbsp;<SUP>(14)</SUP></TD>
    <TD STYLE="text-align: right">5.69%</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 40pt; vertical-align: middle; text-align: left">Avidity Partners Management LP</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">2828 N Harwood Street, Suite 1220</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="color: red; vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 60pt; vertical-align: middle; text-align: left">Dallas, TX 75201</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">731,000</TD>
    <TD>&nbsp;<SUP>(15)</SUP></TD>
    <TD STYLE="text-align: right">5.10%</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">* Indicates less than 1%</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-size: 8pt">(1)</FONT></TD>
    <TD STYLE="width: 96%; text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 2,000 shares owned by Dr. Bower's spouse.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 3,103 shares subject to restricted stock units vesting within
        sixty days of April 20, 2021.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 3,103 shares subject to restricted stock units vesting within
        sixty days of April 20, 2021.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 34,879 shares subject to stock options that are exercisable
        within sixty days of April 20, 2021 and 24,575 shares of restricted stock units expected to vest within 60 days of April 20, 2021.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Levitz joined our company on August 10, 2020, and he does not currently beneficially
        own any shares of our common stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 1,567 deferred stock units that vested on February 25, 2021
        and to be settled in a lump sum within 60 days of the anniversary of &quot;separation from service&quot; as that term is defined in Section
        409A of the Internal Revenue Code.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 34,879 shares subject to stock options that are exercisable
        within sixty days of April 20, 2021 and 30,781 shares of restricted stock units expected to vest within 60 days of April 20, 2021.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule 13G filed with the SEC
        on behalf of BlackRock, Inc. on January 25, 2021. BlackRock, Inc. has sole voting power with respect to 2,225,545 shares and sole dispositive
        power with respect to 2,250,290 shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule 13G filed with the SEC
        on behalf of Kayne Anderson Rudnick Investment Management LLC on February 11, 2021. Kayne Anderson Rudnick Investment Management LLC has
        sole voting power with respect to 1,110,920 shares, shared voting power with respect to 435,343 shares, sole dispositive power with respect
        to 1,110,920 shares, and shared dispositive power with respect to 435,343 shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on Schedule 13G filed with the SEC on behalf
        of Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Wanger Asset Management,
        LLC, on February 12, 2021. Ameriprise Financial, Inc. beneficially owns 1,004,108 shares of shares, has shared voting power with respect
        to 1,003,580 shares, and shared dispositive power with respect to 1,004,108 shares. Columbia Management Investment Advisers, LLC beneficially
        owns 1,003,590 shares, has shared voting power with respect to 1,003,580 shares, and shared dispositive power with respect to 1,003,590
        shares. Columbia Wanger Asset Management, LLC beneficially owns 932,719 shares, has shared voting power with respect to 932,719 shares,
        and shared dispositive power with respect to 932,719 shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(11)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule 13G filed with the SEC
        on behalf of The Vanguard Group on February 10, 2021. The Vanguard Group has shared voting power with respect to 14,356 shares, sole dispositive
        power with respect to 910,086 shares, and shared dispositive power with respect to 24,196 shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(12)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule 13G filed with the SEC
        on behalf of Dimensional Fund Advisors LP on February 12, 2021. Dimensional Fund Advisors LP has sole voting power with respect to 835,206
        shares and sole dispositive power with respect to 884,116 shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(13)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule 13G filed with the SEC
        on behalf of State Street Corporation on February 5, 2021.&nbsp;&nbsp;State Street Corporation has shared voting power with respect to
        758,662 shares and shared dispositive power with respect to 820,746 shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(14)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on Schedule 13G filed with the SEC on behalf
        of Renaissance Technologies LLC on February 10, 2021.&nbsp;&nbsp;Renaissance Technologies LLC has sole voting power with respect to 809,117
        shares and sole dispositive power with respect to 809,117 shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(15)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on Schedule 13G filed with the SEC on behalf
        of Avidity Partners Management LP on February 16, 2021.&nbsp;&nbsp;Avidity Partners Management LP has shared voting power with respect
        to 731,000 shares and shared dispositive power with respect to 731,000 shares.</FONT></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_022"></A>Executive
Officers</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors elects our executive officers
annually at a regular meeting held immediately preceding an Annual Meeting of Stockholders. The Board also elects executive officers throughout
the year as such individuals are hired by us. Executive officers hold office until the next Annual Meeting of Stockholders or until their
successors are duly elected and qualified, unless they sooner resign or are removed from office. There are no family relationships between
any of our directors (including director nominees) or executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table lists our executive officers
and their offices and ages, all as April&nbsp;30, 2021. It is currently expected that each of these officers will be re-appointed to their
current offices by the Board immediately preceding the Annual Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="width: 27%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 67%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Position</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Age</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0.15pt; text-align: left">Cheryl R. Blanchard, Ph.D.&#9;</TD>
    <TD STYLE="text-indent: 0.15pt; text-align: justify">President and Chief Executive Officer </TD>
    <TD STYLE="text-indent: 0.15pt; text-align: center">56</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-indent: 0.15pt; text-align: left">Michael L. Levitz&#9;</TD>
    <TD STYLE="text-indent: 0.15pt; text-align: justify">Executive Vice President, Chief Financial Officer and Treasurer</TD>
    <TD STYLE="text-indent: 0.15pt; text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0.15pt; text-align: left">David Colleran&#9;</TD>
    <TD STYLE="text-indent: 0.15pt; text-align: justify">Executive Vice President, General Counsel and Secretary</TD>
    <TD STYLE="text-indent: 0.15pt; text-align: center">49</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-indent: 0.15pt; text-align: left">Thomas Finnerty&#9;</TD>
    <TD STYLE="text-indent: 0.15pt; text-align: justify">Executive Vice President, Human Resources</TD>
    <TD STYLE="text-indent: 0.15pt; text-align: center">63</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: 0.15pt; text-align: left">James Loerop&#9;</TD>
    <TD STYLE="text-indent: 0.15pt; text-align: justify">Executive Vice President, Business Development and Strategic Planning</TD>
    <TD STYLE="text-indent: 0.15pt; text-align: center">57</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dr. Blanchard&rsquo;s</I> biography is included
above in the section titled &ldquo;Proposal 1: Election of Directors &ndash; Information Regarding the Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Michael L. Levitz</I> was appointed Executive
Vice President, Chief Financial Officer and Treasurer in August 2020. Mr.&nbsp;Levitz served as the Senior Vice President, Chief Financial
Officer and Treasurer of Insulet Corporation, a publicly traded, global medical device and drug delivery company, from 2015 to May 2019.
From 2009 to 2015, Mr. Levitz was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation, a global provider
of medical guidance, diagnostic imaging, and threat detection equipment. Previously, during his seven years with Hologic, Inc. and Cytyc
Corporation (which merged with Hologic), Mr. Levitz served in various capacities including Vice President and Corporate Controller. Mr.
Levitz began his career in the high technology audit practice at Arthur Andersen LLP. Mr. Levitz earned his Bachelor of Arts in Business
Economics, with emphasis in Accounting, from the University of California Santa Barbara and is a certified public accountant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>David Colleran</I> was appointed Executive
Vice President, General Counsel and Secretary in March 2020. Most recently, Mr. Colleran served as Senior Vice President, General Counsel,
Secretary and Chief Compliance Officer at Insulet Corporation, a publicly traded, global medical device and drug delivery company, from
July 2015 through March 2019. Prior to that, from 2010 to 2015, he held the role of Vice President and General Counsel of the Medical
Supplies segment, and from 2006 to 2010, he held the role of Associate General Counsel, both at Covidien, a global manufacturer of medical
devices and supplies acquired by Medtronic in 2015. Prior to that, he was Corporate Counsel at Ocean Spray Cranberries. Mr. Colleran began
his career as a corporate attorney at the law firm Choate, Hall &amp; Stewart. Mr. Colleran holds a B.A. in Political Science from Boston
College and a J.D. from Boston College Law School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Thomas Finnerty</I> was appointed Chief Human
Resource Officer in October 2017, and his title was changed to Executive Vice President, Human Resources in July 2019 to align with our
corporate convention. From June 2017 to October 2017, Mr. Finnerty served as a human resources consultant to our company. Prior to his
work with Anika, Mr. Finnerty served as the Senior Vice President of Human Resources at Smith &amp; Nephew, a leading portfolio medical
technology company manufacturing products for global distribution, from 1999 through April 2016, where he was responsible for delivering
value-added programs, processes, and leadership in global human capital management. Mr. Finnerty has also held human resources positions
at Novartis/Chiron Diagnostics and the Foxboro Company. Mr. Finnerty holds a B.S. in business from the University of Massachusetts Dartmouth
and an M.B.A. from Babson College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>James Loerop</I> was appointed Executive Vice
President, Business Development and Strategic Planning in July 2019. Most recently, Mr. Loerop served as Chief Corporate Development Officer
for Lupin Pharmaceuticals from September 2017 to July 2019, where he was a member of the company&rsquo;s Executive Leadership Team and
was responsible for global business development and corporate development activities. Prior to his work with Lupin, Mr. Loerop held senior
leadership roles at various companies in the pharmaceutical and life sciences industry, including at Alexion Pharmaceuticals as Senior
Vice President of Global Business Development from April 2015 to September 2017, GlaxoSmithKline as Vice President of North America Business
Development from September 2010 to April 2015, and Stiefel Laboratories as Senior Vice President of Global Corporate Development, prior
to GSK&rsquo;s acquisition of Stiefel. Mr. Loerop holds a B.S. in Marketing from Western Michigan University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_023"></A>Compensation
Discussion and Analysis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This section describes and analyzes the material
elements of the 2020 compensation for our named executive officers, or NEOs, determined in accordance with SEC rules, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #365F91">
    <TD STYLE="width: 37%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 63%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Title
        (as of December 31, 2020)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>&nbsp;Cheryl R. Blanchard, Ph.D.*</B></TD>
    <TD STYLE="text-align: left">President and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><B>&nbsp;Michael L. Levitz</B></TD>
    <TD STYLE="text-align: left">EVP, Chief Financial Officer, and Treasurer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>&nbsp;David Colleran</B></TD>
    <TD STYLE="text-align: left">EVP, General Counsel, and Secretary </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><B>&nbsp;Thomas Finnerty</B></TD>
    <TD STYLE="text-align: left">EVP, Human Resources</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>&nbsp;James Loerop</B></TD>
    <TD STYLE="text-align: left">EVP, Business Development and Strategic Planning</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><B>&nbsp;Joseph G. Darling**</B></TD>
    <TD STYLE="text-align: left">Former President and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>&nbsp;Sylvia Cheung***</B></TD>
    <TD STYLE="text-align: left">Former Chief Financial Officer, Treasurer, and Assistant Secretary</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0; text-align: right"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 8pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Dr. Blanchard was appointed as our interim Chief Executive Officer on February
        10, 2020 and as our President and Chief Executive Officer on April 26, 2020.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0; text-align: right"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 8pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Darling unexpectedly passed away on January 29, 2020.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0; text-align: right"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 8pt">***</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Ms. Cheung resigned from her role as our Chief Financial Officer, Treasurer,
        and Assistant Secretary as of August 10, 2020.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have divided this discussion into five parts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">1.</TD>
    <TD>Executive Summary</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">2.</TD>
    <TD>Compensation Philosophy</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">3.</TD>
    <TD>Key Compensation Policies and Practices</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">4.</TD>
    <TD>2020 Compensation Decisions</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">5.</TD>
    <TD>Other Compensation Matters</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_024"></A>Executive
Summary</FONT></P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Our Fiscal Year 2020 Business
Performance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fiscal Year 2020 was a transformative year for
Anika, as we completed our acquisitions of Parcus Medical, LLC, or Parcus Medical, and Arthrosurface, Inc., or Arthrosurface. These acquisitions
in early 2020 expanded our overall technology portfolio and product pipeline, significantly enhanced our global footprint and commercial
infrastructure, diversified our revenue streams in faster growing segments, and grew our overall market opportunity from the over $1 billion
global osteoarthritis, or OA, pain management market to the over $8 billion joint preservation market (which includes the faster growing
sports medicine and bone preserving extremities segments). Following these acquisitions, we successfully managed our business through
the COVID-19 pandemic to prioritize the health and safety of our employees while continuing to deliver high-quality products and support
for our customers and their patients with no significant operational interruptions. We also delivered other important accomplishments
in talent acquisition, commercial organization integration, and new product launches. These achievements in a year of tremendous change
and challenges have positioned us to meet our previously-stated growth targets of doubling overall revenue by 2024 (over fiscal year 2019
results) and expanding profitability with double-digit adjusted EBITDA growth<SUP>1</SUP>, thus creating significant value for our customers,
their patients, and our stockholders. In 2020, specific accomplishments included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><SUP>1</SUP> Adjusted
EBITDA is a Non-GAAP financial measure. Please see pages 35-37 in the section captioned &ldquo;<I>Non-GAAP Financial Measures</I>&rdquo;
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 5, 2021 for the reconciliation
to Net Income prepared in accordance with GAAP.</FONT></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>completing the acquisitions of Parcus Medical and Arthrosurface, accelerating our revenue diversification and expansion beyond our historic
        $1 billion global OA pain management market to the over $8 billion joint preservation market;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>completing the integration of our U.S. and international commercial organizations, through which we enhanced our own direct selling capabilities
        in the U.S. and fortified our large network of domestic and international distributors;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>navigating Anika through the COVID-19 pandemic without any significant operational disruption or reduction in workforce;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>strengthening our senior leadership team and board of directors through the addition of seven senior leaders and two new board members,
        bringing deep industry experience and complementary skill sets to our team;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>launching several new joint preservation products and receiving 510(k) clearance for our WristMotion Total Arthroplasty System in the
        United States; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>initiating enrollment in our pilot clinical study for Cingal and resuming enrollment in our clinical trial for Hyalofast to support U.S.
        approval, while continuing to sell these products in over 30 markets internationally.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to these operational efforts, our
financial highlights for 2020 included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>total revenue of $130.5 million, up 14% as compared to 2019;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>product gross margin of 53%, including a 13 point negative impact due to acquisition-related expenses;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>$13.1 million of cash flows from operations despite a reported net loss of $24 million, which included the impact of acquisition-related
        expenses and non-cash adjustments;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>cash, cash equivalents and investments totaling $98.3 million as of December 31, 2020; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">repayment in full of the $50 million drawn from our credit facility in April 2020 out of precaution at the
        onset of the COVID-19 pandemic in the United States.</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Compensation
Decisions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described more fully below, we made compensation
decisions for our NEOs for 2020 that were generally linked to our performance. In particular, the Compensation Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">paid the NEOs annual cash bonuses, generally at 90% of target (subject to proration for NEOs hired in 2020),
        based on the company&rsquo;s business performance results above, including the strong stewardship of the company through the unprecedented
        circumstances associated with the COVID-19 pandemic, and a review of each NEO&rsquo;s individual accomplishments;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">other than Dr. Blanchard, granted the NEOs restricted stock unit awards in early 2020, or on their hire date,
        split evenly (based on target achievement) between time-vesting awards and performance-based awards with multi-year targets (excepting
        certain adjustments for NEOs as described more fully below);</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">granted Dr. Blanchard time-vesting restricted stock units upon her appointment as interim Chief Executive
        Officer in February 2020 and, upon her subsequent appointment as President and Chief Executive Officer in April 2020, granted her (1)
        time-vesting restricted stock units, (2) performance-based restricted stock units, (3) time-vesting stock options, and (4) performance-based
        stock options that vest based on the company&rsquo;s total shareholder return relative to a comparison group of companies as described
        more fully below that, in their totality and assuming target performance, are split nearly evenly between time-vesting and performance-based
        awards and represent an appropriate starting equity package in comparison to chief executive officers at peer group companies;</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">granted Mr. Colleran and Mr. Levitz, who joined the company in March and August 2020, respectively, additional
        time-vesting stock option awards covering 35,000 and 57,145 shares of common stock, respectively, as an inducement to join the company;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">continued to utilize a multi-year performance period for new performance-based restricted stock unit grants
        and, as described above, implemented a relative metric based on total shareholder return for the vesting of our President and Chief Executive
        Officer&rsquo;s new-hire performance-based stock option grant; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">implemented changes to our 2020 NEO compensation programs to address the feedback that we received from stockholder
        outreach in 2019 and 2020.</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Stockholder Outreach</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our say-on-pay vote last year, approximately
98% of the votes were cast in favor of our NEO compensation for 2019. We were pleased with the improved results as compared to the prior
two years when 84% and 80% of the votes were cast in favor, respectively. We routinely speak with many of our large and small stockholders
and solicit feedback on our executive compensation program to understand issues and concerns pertinent to our investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management spoke to stockholders that we believe
owned or represented over 80% of our outstanding shares during both 2019 and 2020. Some general themes from these conversations have been
that our investors would like to understand how we align performance and compensation through enhanced narrative disclosure, including
specific metrics considered by us in our short- and long-term incentive compensation, would like more clarity around the vesting of equity
awards, including in the context of a change in control of the company, and appreciate the more equitable split of time-based and performance-based
grants under our equity programs beginning in 2019. They would also like to ensure that relative metrics and multi-year targets continue
to be included in performance-based grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have implemented changes to our 2020 and 2021
compensation programs to address the feedback that we received, including maintaining an even split between time-based and performance-based
equity grants (excluding new hire stock option grants provided to induce key employees to join the company and certain adjustments for
our other NEOs), implementing multi-year performance periods for each performance metric included in performance-based grants, and, as
described above, utilizing a relative metric based on total shareholder return in our President and Chief Executive Officer&rsquo;s new-hire
performance-based stock option grant. We always appreciate the feedback that we receive from our stockholders, and we have, and will continue
to, consider this feedback and enhance our compensation program and disclosure around it, including in the following discussion.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_025"></A>Compensation
Philosophy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee oversees our overall
compensation program and approves our compensation policies. The overriding goal of our compensation program is to drive long-term high
performance and increase stockholder value through our pay programs and corporate culture. As a result, the Compensation Committee incorporates
performance into many aspects of our compensation program, including pay levels, incentive payouts, and pay opportunities. Corporate and
individual goals are set through our yearly budgeting and strategic planning processes and these goals are ultimately reviewed and approved
by the Board prior to, or at the beginning of, each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee, utilizing both the
structure of our compensation program and its discretion, as appropriate, structures our executive compensation program to reward our
NEOs when their performance exceeds stated goals. A significant portion of each NEO&rsquo;s incentive compensation is weighted towards
the leadership team&rsquo;s achievement against targeted goals (rather than individual performance), so that if we meet or exceed our
goals, the team earns awards at or above target levels. Conversely, if the team fails to meet the minimum thresholds, they will not be
awarded the targeted components of the performance-based compensation.</P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a general matter, the Compensation Committee
uses compensation data from the annual compensation study of competitive peer companies to inform its decisions about overall compensation
opportunities and specific compensation elements. Additionally, the Compensation Committee uses multiple reference points when establishing
targeted compensation levels, and it does not benchmark specific elements or total compensation to any specific level or percentile relative
to peer companies or the broader market. Rather than rely on a specific formula-based model, the Compensation Committee applies judgment
and discretion in establishing targeted pay levels, taking into account not only competitive market data, but also factors such as company,
business, and individual performance, scope of responsibility, critical needs and skill sets, leadership potential, and succession planning.
The Compensation Committee believes that retaining this discretion gives the Compensation Committee the ability to more accurately reflect
factors and individual contributions that cannot be absolutely quantified. The Compensation Committee also considers the company&rsquo;s
primary physical location near Boston, Massachusetts, the high level of competition for life sciences employees in that area, and the
need to remain competitive with the compensation offered by other life sciences companies to ensure the successful recruitment and retention
of top performing executives and employees. We have designed our compensation program to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="3" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">motivate and reward our executives to achieve or exceed our financial and operating performance objectives;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">propel our business forward through a focus on operational excellence and execution of our business strategy;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">link each NEO&rsquo;s compensation with specific business objectives;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">align each NEO&rsquo;s compensation with the interests of long-term stockholders by tying a significant portion
        of total compensation opportunity to the value of our stock;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">reinforce accountability and cooperation by tying a significant portion of total NEO compensation to overall
        company performance;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">attract and retain talented leaders who can drive and implement our growth and operational excellence strategies;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">reward individual performance and accomplishments; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">keep the compensation packages competitive with those of our peers and other companies with whom we compete
        for talent.</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_026"></A>Key
Compensation Policies and Practices</FONT></P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Key Features</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that our executive compensation program
includes key features that align the performance and objectives of the NEOs and the company with the interests of our stockholders and
does not include features that misalign NEO and company objectives with stockholder interests. During 2020, we arranged our compensation
program in accordance with the practices set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<DIV STYLE="float: left; width: 50%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="width: 100%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>What
        We Do</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="3" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt; width: 97%">Align a significant portion of NEO compensation with our performance</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Allocate a significant portion of NEO compensation with stockholders&rsquo; interests
        through long-term incentives, including grants of performance-based awards in 2020 with exclusively multi-year performance metrics and
        3-year cliff vesting</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Balance our equity grants to NEOs evenly between time-vesting and performance-based awards
        (excepting certain new-hire awards of time-vesting stock options and certain adjustments for other NEOs as described more fully below)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Include a relative total shareholder return performance measure in the new-hire grant
        of performance-based stock options to our President and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Balance short-term and long-term incentives</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Require NEOs to own significant amounts of stock through robust stock ownership guidelines
        (see page 60 of this Proxy Statement)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Include minimum vesting requirements for equity awards in our equity compensation plan,
        subject to certain exceptions</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Incorporate double-trigger vesting upon a change in control for all equity awards to NEOs
        in 2019 and beyond</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Cap annual cash bonus payouts at 2x target</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Utilize an independent compensation consultant annually to assist our assessment of our
        compensation program</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; color: #365F91">&uuml;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 9.35pt">Solicit say-on-pay votes annually</TD></TR>
  </TABLE></DIV>

<DIV STYLE="float: right; width: 50%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="border-right: Black 1pt solid; width: 100%; border-top: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>What
        We Don&rsquo;t Do</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="3" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; color: #365F91">&Auml;</FONT></TD>
    <TD STYLE="text-align: left; width: 97%">No automatic or guaranteed annual salary increases</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Symbol; color: #365F91">&Auml;</FONT></TD>
    <TD STYLE="text-align: left">No guaranteed short- or long-term incentive awards</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Symbol; color: #365F91">&Auml;</FONT></TD>
    <TD STYLE="text-align: left">No repricing of stock options or SARs without stockholder approval</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Symbol; color: #365F91">&Auml;</FONT></TD>
    <TD STYLE="text-align: left">No hedging/pledging of our stock per our Insider Trading Policy</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Symbol; color: #365F91">&Auml;</FONT></TD>
    <TD STYLE="text-align: left">No &ldquo;golden parachute&rdquo; excise tax gross-ups</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Symbol; color: #365F91">&Auml;</FONT></TD>
    <TD STYLE="text-align: left">No granting of stock options or SARs at a per share exercise price less than fair market value on the grant date</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Symbol; color: #365F91">&Auml;</FONT></TD>
    <TD STYLE="text-align: left">No pension or other special benefits</TD></TR>
  </TABLE></div><br clear="all">

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Key Performance Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In setting the compensation for our executive
officers, the Compensation Committee relies primarily on our overall financial performance and an assessment of each individual&rsquo;s
performance and contribution to the achievement of our goals. The Compensation Committee seeks to align the metrics it uses in evaluating
our executive compensation with the metrics that we use to evaluate our performance more generally, including those metrics that we publicly
disclose. Financial performance measures form the majority of the criteria for performance-based equity awards, and the Compensation Committee
balances financial and individual performance (as set forth below) in making decisions on annual cash bonus payments. In 2020, decisions
on annual cash bonus payments also included as a key component the Compensation Committee&rsquo;s consideration of the role the NEOs played
in guiding the company through the challenges of the COVID-19 pandemic with no significant operational disruption. Typical achievement
measures considered by the Compensation Committee include, but may not be limited to, the following:</P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="float: left; width: 50%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; width: 100%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: white"><B>Company
        Financial Performance</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="3" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%">Revenue growth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Adjusted EBITDA (as previously described)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Vitality index (i.e., revenue from new products as a percentage of total revenue)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Net income and adjusted net income (as publicly discussed by us)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Adjusted EBITDA margin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Gross margin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Cash flow</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Share price performance</TD> </TR>
  </TABLE>
</div>
<DIV STYLE="float: right; width: 50%">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="border-right: Black 1pt solid; width: 100%; border-top: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: white"><B>Individual
        Performance</B></FONT></TD> </TR>
  </TABLE>


<TABLE CELLPADDING="3" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%">Product family or geographic revenue growth</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Strategic transactions</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Significant integration and infrastructure implementation</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>New product launches in key geographies (especially the United States)</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Achievement of regulatory approvals for new products or line extensions</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Clinical trial achievements or completions</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Key employee recruitment or retention</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Completion of strategic projects that drive current or future company growth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Contributions towards expanding or strengthening the company&rsquo;s intellectual property portfolio</TD></TR>
  </TABLE></div><br clear="all">


<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Peer Group and Role of
Compensation Consultant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the company and individual performance
metrics set forth above, the Compensation Committee weighs other quantitative factors, such as general compensation trends, in making
compensation decisions. In this regard, the Compensation Committee periodically reviews surveys of executive compensation and information
concerning compensation at similarly situated companies. In 2020, as in prior years, the Compensation Committee engaged the Radford advisory
team of the Rewards Solution practice at Aon, or Radford, to provide executive compensation consulting services to the Compensation Committee,
to assist the Compensation Committee in selecting an appropriate peer group for compensation comparisons, and to perform an executive
compensation review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee, with the assistance
of Radford, has performed this analysis each year from 2015 through 2020, and currently intends to continue the practice of performing
this analysis yearly. In completing its analysis for 2020, the Compensation Committee reviewed competitive data compiled by Radford from
a peer group comprised of 18 companies in related businesses at similar stages of development and of similar size in terms of market capitalization
and employee population. The Compensation Committee also reviewed market data from the&nbsp;2019 Radford Global Life Sciences Executive
Survey (the &ldquo;Radford Survey&rdquo;) covering 65 public biopharmaceutical and medical device companies.&nbsp;The Compensation Committee
uses competitive compensation data from these peer company and industry reviews to inform its decisions about overall compensation opportunities
and specific compensation elements. Additionally, the Compensation Committee uses multiple reference points when establishing targeted
compensation levels. The Compensation Committee does not benchmark specific compensation elements or total compensation to any specific
level or percentile relative to the peer companies or the broader United States market. Rather than rely on a specific formula-based model,
the Compensation Committee applies judgment and discretion in establishing targeted pay levels, considering not only competitive market
data, but also factors such as company, business, and individual performance, scope of responsibility, critical needs and skill sets,
leadership potential, and succession planning. The Compensation Committee believes that retaining this discretion gives the Compensation
Committee the ability to more accurately reflect factors and individual contributions that cannot be absolutely quantified. The Compensation
Committee also considers the company&rsquo;s primary physical location near Boston, Massachusetts, the high level of competition for life
sciences employees in that area, and the need to remain competitive with the compensation offered by other life sciences companies to
ensure the successful recruitment and retention of top performing executives and employees.</P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With Radford&rsquo;s assistance, we review and
adjust our Peer Group annually to ensure that the industry data we review is relevant to our current and near-term future activities and
goals. We believe that the adjustments we made to our 2020 Peer Group are appropriate to better reflect changes in our company over time,
based on our history of strong financial performance, growing product pipeline, commercial strategies, and change in our Global Industrial
Classification System (GICS) Code from 35101020 (Health Care Supplies) to 35201010 (Biotechnology). Given this dynamic, we felt it appropriate
to blend biopharmaceutical companies with medical device companies in a ratio of approximately 2/3 to 1/3, as we did in 2019. The following
is the composition of the peer group utilized for 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #365F91">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>Peer Group Companies</B></FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="color: #365F91"><I><U>Biopharmaceutical Companies</U></I></FONT></TD>
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="color: #365F91"><I><U>Medical Device Companies</U></I></FONT></TD>
    <TD STYLE="background-color: White; width: 20%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">AMAG Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: justify">AtriCure, Inc.</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avid Biosciences, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Halozyme Therapeutics, Inc.</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Atrion Corporation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Axogen, Inc.</P></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">MacroGenics, Inc.</TD>
    <TD STYLE="text-align: justify">Cryolife, Inc.</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Momenta Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: justify">Glaukos Corporation</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Omeros Corporation</TD>
    <TD STYLE="text-align: justify">Orthofix, Inc.</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Portola Pharmaceutics, Inc.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Radius Health, Inc.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Retrophin, Inc.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Spectrum Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Vanda Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Vericel Corporation</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With Radford&rsquo;s assistance, we have further
refined the peer group for our 2021 compensation program to build on some of the changes we made to the group from 2019 to 2020. The 2021
peers were selected to provide a reasonable set of comparable companies in terms of commercial products, market value, headcount, and
revenue. We believe the adjustments were appropriate to continue to reflect changes in our company&rsquo;s direction and commercial strategies.
The 2021 peer group is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #365F91">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>Peer Group Companies</B></FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="color: #365F91"><I><U>Biopharmaceutical Companies</U></I></FONT></TD>
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="color: #365F91"><I><U>Medical Device Companies</U></I></FONT></TD>
    <TD STYLE="background-color: White; width: 20%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">AMAG Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: justify">AtriCure, Inc.</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avid Biosciences, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collegium Pharmaceutical, Inc.</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Atrion Corporation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Axogen, Inc.</P></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Flexion Therapeutics, Inc.</TD>
    <TD STYLE="text-align: justify">Cryolife, Inc.</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">MacroGenics, Inc.</TD>
    <TD STYLE="text-align: justify">Glaukos Corporation</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Momenta Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: justify">Orthofix, Inc.</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Omeros Corporation</TD>
    <TD STYLE="text-align: justify">SurModics, Inc. </TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Organogenesis, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Radius Health, Inc.</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Retrophin, Inc.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Spectrum Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Vanda Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Vericel Corporation</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_027"></A>2020
Compensation Decisions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our 2020 NEO compensation was made up of three
key components:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">base salary;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">discretionary annual bonuses; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">equity-based long-term incentive awards, generally in the form of time- and performance-based stock options
        and restricted stock units.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aside from Dr. Blanchard, each of the NEOs is
an at-will employee with terms of employment documented on the company&rsquo;s standard form of offer letter. For additional detailed
information regarding the compensation of Dr. Blanchard resulting from her employment agreement with the company, please see the section
captioned &ldquo;<I>Other Compensation Matters &ndash; The Death of Mr. Darling and the Appointment of Dr. Blanchard</I>.&rdquo;</P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Base Salary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first principal component of compensation
for our executive officers is base salary, which is generally paid to our NEOs to recognize fulfillment of their job responsibilities.
Base salaries for our NEOs are subject to annual review by the Compensation Committee. For this purpose, the Compensation Committee considers
a number of factors, including the individual&rsquo;s level of responsibility, experience, and performance, including both past company
performance and individual performance in accordance with the metrics previously discussed. The Compensation Committee also considers
market practices as described above, taking into account any contractual obligations.&nbsp;Salaries are reviewed and determined at the
discretion of the Compensation Committee on an annual basis, and there is no guaranteed year-over-year increase to any of the NEOs&rsquo;
salaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For 2020, base salaries and compensation increases,
as applicable, for the NEOs are set forth below. Dr. Blanchard, Mr. Levitz, and Mr. Colleran were hired by the company in 2020, and their
2020 salaries reflect the annualized salaries approved by the Compensation Committee at the time of their hire (in the case of Dr. Blanchard,
her appointment as President and Chief Executive Officer on April 26, 2020). Mr. Finnerty received a 3.5% salary increase, which was largely
in line with the rest of the company, while Mr. Loerop received a more modest increase because we hired him mid-way through 2019. Mr.
Darling and Ms. Cheung received comparatively larger salary increases to reflect competitive market practices for their positions and
their 2019 performance, including with respect to the Parcus Medical and Arthrosurface acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the annualized salary reflected
below, Dr. Blanchard received compensation at an annualized rate of $600,000 during the term of her employment as the company&rsquo;s
interim Chief Executive Officer, which resulted in base salary payments of $115,385.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>2020 Base Salary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #365F91">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Name</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: white"><B>2019 Salary</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>2020 Salary</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: white"><B>% Change</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 25%"><FONT STYLE="color: black"><B>&nbsp;Cheryl R. Blanchard, Ph.D.</B></FONT></TD>
    <TD STYLE="text-align: right; width: 14%"><FONT STYLE="color: black">n/a</FONT></TD>
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 25%">$625,000</TD>
    <TD STYLE="padding-left: 0.6in; text-indent: -0.25in; text-align: right; width: 14%">n/a</TD>
    <TD STYLE="width: 11%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Michael L. Levitz</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">n/a</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">$450,000</FONT></TD>
    <TD STYLE="padding-left: 0.6in; text-indent: -0.25in; text-align: right"><FONT STYLE="color: black">n/a</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;David Colleran</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">n/a</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">$420,000</FONT></TD>
    <TD STYLE="padding-left: 0.6in; text-indent: -0.25in; text-align: right"><FONT STYLE="color: black">n/a</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Thomas Finnerty</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">$341,550</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">$353,505</FONT></TD>
    <TD STYLE="padding-left: 0.6in; text-indent: -0.25in; text-align: right"><FONT STYLE="color: black">3.5%</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;James Loerop</B></FONT></TD>
    <TD STYLE="text-align: right">$375,000</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$381,563</TD>
    <TD STYLE="padding-left: 0.6in; text-indent: -0.25in; text-align: right">1.8%</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Joseph G. Darling</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">$599,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">$650,000</FONT></TD>
    <TD STYLE="padding-left: 0.6in; text-indent: -0.25in; text-align: right"><FONT STYLE="color: black">8.4%</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Sylvia Cheung</B></FONT></TD>
    <TD STYLE="text-align: right">$392,094</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$427,383</TD>
    <TD STYLE="padding-left: 0.6in; text-indent: -0.25in; text-align: right">9.0%</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual Cash Bonus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second principal component of our compensation
policy for executive officers consists of cash bonuses, which are generally paid to our NEOs to motivate attainment of our near-term goals
that are consistent with our long-term strategic plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each NEO has a target annual bonus amount established
by the Compensation Committee at the beginning of each year that is expressed as a percentage of the NEO&rsquo;s base salary. In 2020,
these targets were unchanged from the targets from the prior year for individuals in similar positions. The Compensation Committee establishes
the target bonus amounts consistent with the compensation philosophy described above, including consideration of market practices, and
to provide, in its view, an appropriate balance between fixed (salary) and variable (bonus) cash compensation. The 2020 target bonus amounts
for the NEOs were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B></B></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>2020 Annual Cash Bonus Targets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #365F91">
    <TD STYLE="width: 44%; text-indent: 48.75pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>% of
        Salary</B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Amount
        at Target</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Cheryl R. Blanchard, Ph.D.*</B></FONT></TD>
    <TD STYLE="text-align: center">85%</TD>
    <TD STYLE="text-align: center">$531,250</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Michael L. Levitz*</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">45%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">$202,500</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;David Colleran*</B></FONT></TD>
    <TD STYLE="text-align: center">45%</TD>
    <TD STYLE="text-align: center">$189,000</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Thomas Finnerty</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">45%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">$159,077</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;James Loerop</B></FONT></TD>
    <TD STYLE="text-align: center">45%</TD>
    <TD STYLE="text-align: center">$171,703</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Joseph G. Darling</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">85%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">$552,500</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Sylvia Cheung</B></FONT></TD>
    <TD STYLE="text-align: center">45%</TD>
    <TD STYLE="text-align: center">$192,322</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 8pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">For Dr. Blanchard, Mr. Levitz, and Mr. Colleran, each of their new-hire employment
        documentation provided that any bonus paid for 2020 would be prorated based on their dates of hire (in the case of Dr. Blanchard, her
        appointment as President and Chief Executive Officer on April 26, 2020).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actual bonus amounts awarded are not formulaic
and depend on the Compensation Committee&rsquo;s assessment of both our business and individual NEO performance after the completion of
each year. The Compensation Committee considers our financial performance in accordance with metrics previously discussed, our overall
operational performance, and our contribution to increasing stockholder value at its discretion to determine an appropriate level of baseline
cash bonus compensation for our NEOs. Once the Compensation Committee has established this baseline, it considers the applicable individual
performance with respect to individual goals and contribution to overall company performance in its discretion to adjust each individual
NEO&rsquo;s cash bonus award. See &ldquo;Key Performance Factors&rdquo; above regarding the key financial and individual performance factors
considered. Historically, cash bonuses for the most recently completed year are awarded contemporaneously with annual compensation reviews
for that year. Bonuses are generally prorated in the year of hire, provided that this requirement may be waived to induce top talent to
join the organization in certain circumstances. The Compensation Committee may also, in certain circumstances, grant cash bonuses for
executive retention purposes, taking into account, among other things, general industry practices, special performance bonuses in exceptional
circumstances, and any contractual obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the completion of the 2020 fiscal year,
the Compensation Committee, with the assistance of the Chief Executive Officer, reviewed our performance, as well as the individual performance
of each executive officer (other than her own performance). The accomplishments set forth in the Executive Summary section titled &ldquo;<I>Our
Fiscal Year 2020 Business Performance</I>&rdquo; were considered in this review. For the year, the Compensation Committee determined that
we made strong overall business progress transforming our organization and integrating our acquisitions, especially in light of the challenges
presented by the COVID-19 pandemic. While the COVID-19 pandemic, in conjunction with the impact of purchase accounting, had a major impact
on the financial results delivered by the organization, especially as compared to prior years, the company delivered on the significant
strategic and operational achievements set forth in the section captioned &ldquo;<I>Our Fiscal Year 2020 Business Performance</I>&rdquo;
above, including completing the acquisitions of Parcus Medical and Arthrosurface. In addition, the company completed the integration of
the commercial organizations across the entire company, launched seven new products, built out the company&rsquo;s management team and
board of directors with nine new additions, and guided the company through the COVID-19 pandemic with no significant operational disruption
or reductions in workforce. These achievements transformed the company and set the stage for execution of the company&rsquo;s strategic
plan and delivery of value to all of its stakeholders over the coming years. As a result, the Compensation Committee, using its informed
judgment in considering the company&rsquo;s performance in relation to its 2020 corporate objectives, including in light of macroeconomic
business factors such as the COVID-19 pandemic, and without any pre-established formulas or target levels, set a cash bonus payment baseline
of 90% of the target for each NEO, subject to adjustment based on individual performance achievement with respect to individual goals
and contribution to overall company performance. The Compensation Committee recognized the role that Mr. Loerop played in leading the
company through the acquisitions of Parcus Medical and Arthrosurface, and the initial integration activities thereafter, and awarded him
100% of his target bonus. Overall, each NEO had a strong performance during the year and significantly contributed to the company&rsquo;s
growth and business and financial highlights outlined above. The bonus targets based on annualized salary and final, individual actual
bonus amounts paid are included in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the 2020 annual bonus amounts reflected
below, Dr. Blanchard received a cash retention bonus of $127,500 to recognize her service as the company&rsquo;s interim Chief Executive
Officer in accordance with the terms of a letter agreement executed between her and the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>2020 Cash Bonus Decisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #365F91">
    <TD STYLE="width: 28%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 24%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Bonus
        Target</B></FONT></TD>
    <TD STYLE="width: 24%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>% Achieved</B></FONT></TD>
    <TD STYLE="width: 24%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Bonus
        Paid</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Cheryl R. Blanchard, Ph.D.*</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">$531,250</TD>
    <TD STYLE="vertical-align: top; text-align: right">90%</TD>
    <TD STYLE="text-align: right">$331,010</TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Michael L. Levitz*</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="color: black">$202,500</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="color: black">90%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">$73,601</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="color: black"><B>&nbsp;David Colleran*</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">$189,000</TD>
    <TD STYLE="vertical-align: top; text-align: right">90%</TD>
    <TD STYLE="text-align: right">$143,931</TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Thomas Finnerty</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="color: black">$159,077</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="color: black">90%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">$143,169</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="color: black"><B>&nbsp;James Loerop**</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">$171,703</TD>
    <TD STYLE="vertical-align: top; text-align: right">100%</TD>
    <TD STYLE="text-align: right">$171,703</TD></TR>
  <TR STYLE="background-color: #C6D9F1">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Joseph G. Darling***</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="color: black">$552,500</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="color: black">n/a</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">n/a</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="color: black"><B>&nbsp;Sylvia Cheung***</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">$192,322</TD>
    <TD STYLE="vertical-align: top; text-align: right">n/a</TD>
    <TD STYLE="text-align: right">n/a</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 8pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">For Dr. Blanchard, Mr. Levitz, and Mr. Colleran, each of the bonuses paid for
        2020 were prorated based on their dates of hire (in the case of Dr. Blanchard, her appointment as our President and Chief Executive Officer
        on April 26, 2020).</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 8pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Loerop received 100% of target due to achievement of additional business
        development and transactional goals, as further described in the &ldquo;Annual Cash Bonus&rdquo; section above.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 8pt">***</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Neither Mr. Darling nor Ms. Cheung were eligible for 2020 bonus payments as their
        employment with the company ceased during 2020.</FONT></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Equity-Based Grants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The third principal component of our compensation
policy for executive officers consists of grants under our equity incentive plan, which are generally provided to our NEOs to align their
goals and objectives with the interests of our stockholders, to motivate attainment of our long-term strategic vision, and for retention
purposes. Under our equity compensation plan, NEOs may be granted stock options or other forms of equity awards, including stock appreciation
rights, restricted stock awards and units, and performance-based equity awards. Equity awards are approved at a regularly-scheduled Compensation
Committee meeting, generally during the first quarter of each year given the meeting&rsquo;s proximity to the beginning of the performance
period for performance-based awards, and generally granted effective on the third full business day following our announcement of financial
and business results for the completed prior fiscal year. During 2019, we implemented a deferred stock program that allows our directors
and executives, at their discretion, to defer settlement of restricted stock unit awards granted to them in 2020 and thereafter. We implemented
this program to remain competitive with market practices and to encourage our NEO&rsquo;s to hold shares of our common stock, thereby
aligning their long-term incentives with those of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also note that we are seeking shareholder approval
to make an additional 1,100,000 shares available for issuance under our equity incentive plan. As discussed further in Proposal 2, as
we refine our strategic objectives and initiatives and position our company for future growth, we are seeking shareholder approval for
an amount of additional shares equivalent to our estimate of the number of shares we would grant over the course of the next year based
on our current share price, recent burn rate history, and new-hire and annual grant practices to ensure that we are able to appropriately
recruit, retain, and motivate our employees over the next year. Furthermore, in connection with this approval and our business strategy,
we will review our compensation strategy as a whole, including the appropriate goals and metrics under our performance-based awards to
drive long-term shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount and form of equity-based grants each
year are determined by the Compensation Committee using the compensation philosophy described above, including its informed judgment,
and taking into account company performance, competitive market practices, past and expected individual performance achievements, past
and expected contributions to overall company performance, and the need to attract and retain talented executives who can drive and implement
our growth and operational excellence strategies. For the last several years, the Compensation Committee has increasingly used performance-based
equity awards to align the interests of our NEOs with those of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2020, Dr. Blanchard was granted equity awards
that, in their totality and assuming target achievement, are split nearly evenly between time-vesting and performance-based awards and
represent an appropriate starting equity package in comparison to chief executive officers of comparable companies, and are intended to
begin to align Dr. Blanchard&rsquo;s equity ownership with that of chief executive officers of comparable companies. As a result, the
value of Dr. Blanchard&rsquo;s 2020 equity awards is larger than the value of equity awards that we expect to grant to her in near-term
future years. Mr. Levitz and Mr. Colleran were granted restricted stock units evenly split between time-vesting and performance-based
awards, as well as a new hire grant of time-vesting stock options as an additional inducement to join the company, in line with our past
practices. Ms. Cheung, Mr. Finnerty, and Mr. Loerop were each granted restricted stock units split between time-vesting and performance-based
awards using an even split as a baseline. In the case of Ms. Cheung and Mr. Finnerty, this split was adjusted towards a slightly greater
amount of time-vesting restricted stock units to ensure market competitiveness and to account for prior granting history, expected future
performance, and retention concerns. In the case of Mr. Loerop, his award was adjusted to a slightly greater amount of performance-based
restricted stock units as a result of his hire around the midpoint of 2019 and the equity award he received in connection with his hire.
For 2020, the Compensation Committee awarded the NEOs a balanced mix of time-vesting and performance-based restricted stock units and
stock options as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>2020 Restricted Stock Unit Grants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="vertical-align: bottom; width: 33%; text-indent: 39.75pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 35%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: -5.75pt; color: white"><FONT STYLE="font-size: 8pt"><B>Time-Vesting
        RSUs</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: -5.75pt; color: white"><FONT STYLE="font-size: 8pt"><B>(#
        of shares)</B></FONT></P></TD>
    <TD STYLE="width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: white"><FONT STYLE="font-size: 8pt"><B>Performance-Based
        RSUs</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: white"><FONT STYLE="font-size: 8pt"><B>(#
        of shares at target)</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;Cheryl R. Blanchard, Ph.D.*</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">77,957</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">80,620</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;Michael L. Levitz</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">11,577</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">11,577</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;David Colleran</B></FONT></TD>
    <TD STYLE="text-align: right">7,500</TD>
    <TD STYLE="text-align: right">7,500</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;Thomas Finnerty</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">8,500</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">6,200</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;James Loerop</B></FONT></TD>
    <TD STYLE="text-align: right">4,700</TD>
    <TD STYLE="text-align: right">6,200</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;Joseph G. Darling**</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">n/a</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">n/a</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;Sylvia Cheung</B></FONT></TD>
    <TD STYLE="text-align: right">11,700</TD>
    <TD STYLE="text-align: right">10,000</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 8pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Dr. Blanchard received 4,231 time-vesting restricted stock units upon her appointment
        as interim Chief Executive Officer on February 10, 2020 and the balance of her awards upon her appointment as our President and Chief
        Executive Officer on April 26, 2020.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 8pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Darling was not granted any equity awards in 2020 due to his passing in January
        2020.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>2020 Stock Option Grants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="vertical-align: bottom; width: 33%; text-indent: 39.75pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 35%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: -5.75pt; color: white"><FONT STYLE="font-size: 8pt"><B>Time-Vesting
        Stock Options</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: -5.75pt; color: white"><FONT STYLE="font-size: 8pt"><B>(New
        Hire Grants)</B></FONT></P></TD>
    <TD STYLE="width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: white"><FONT STYLE="font-size: 8pt"><B>Performance-Based
        Stock Options</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: white"><FONT STYLE="font-size: 8pt"><B>(#
        of shares at target)</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;Cheryl R. Blanchard, Ph.D.</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">104,638</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">104,638</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;Michael L. Levitz</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">57,145</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">n/a</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="color: black"><B>&nbsp;David Colleran</B></FONT></TD>
    <TD STYLE="text-align: right">35,000</TD>
    <TD STYLE="text-align: right">n/a</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #4F81BD"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>2020 Time-Based Restricted Stock
Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The restricted stock units were granted under our
2017 Omnibus Incentive Plan, or the Plan. Except for the award to Dr. Blanchard associated with her appointment as interim Chief Executive
Officer, each award vests in three equal annual installments beginning one year from the effective date of grant. Dr. Blanchard&rsquo;s
award associated with her appointment as interim Chief Executive Officer vested on April 26, 2020 in accordance with the terms of a letter
agreement executed between her and the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>2020 Performance-Based Restricted
Stock Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The performance-based restricted stock units, or
PSUs, were approved at a target level, but will be earned based upon the achievement of three performance metrics. The performance metrics
for each NEO are identical. In order for the awards to vest and for the NEOs to receive the vested shares that are earned based on performance,
the PSUs generally require continued employment through the date on which performance is measured against the stated metrics, which will
occur after our independent public accounting firm renders its opinion on our fiscal year 2022 financial results. The first performance
metric accounts for 60% of the target award level and relates to certain financial milestones associated with our newly-acquired businesses
and their contributions to our consolidated results. The second metric accounts for 20% of the target award level and is linked to enrollment
progress and certain clinical trial milestones. The third metric accounts for 20% of the target award level and is associated with certain
new product regulatory milestones. The maximum possible payout under the 2020 PSUs is 150% of the target shares set forth in the table
above. We generally do not disclose forward-looking goals for our multi-year incentive programs, because we do not provide forward-looking
guidance to our investors with respect to multi-year periods, and the forward-looking multi-year goals contain competitively sensitive
information. We will disclose multi-year performance goals in our regular programs in full after the close of the performance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>2020 Stock Option Grants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #4F81BD"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The time-vesting stock options were granted in accordance
with our Plan, and each award vests in three equal annual installments beginning one year from the effective date of grant. The performance-based
stock options granted to Dr. Blanchard are eligible to vest as to 150% of the target shares reported in the table based on the company&rsquo;s
total shareholder return relative to a comparison group of companies set forth in Dr. Blanchard&rsquo;s employment agreement through December
31, 2022.&#9; The comparison group of companies excludes Anika and includes (1) the Global Industry Classification Standard (GICS) 3520
(Pharmaceuticals, Biotechnology &amp; Life Sciences) companies in the Russell 2000 Value Index determined as of April 26, 2020, (2) the
GICS 3510 (Health Care Equipment) companies in the Russell 2000 Value Index as of April 26, 2020, and (3) to the extent not otherwise
included, Amag Pharmaceuticals, Inc., Avid Biosciences, Inc., Vericel Corporation, Conformis, Inc., Axogen, Inc., CyroLife, Inc., and
Glaukos Corporation.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_028"></A>Other
Compensation Matters</FONT></P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Employment and Executive
Retention Agreements Effective at December 31, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Blanchard entered into an employment agreement
with us (more fully described in the section captioned &ldquo;<I>The Death of Mr. Darling and the Appointment of Dr. Blanchard</I>&rdquo;)
and we entered into executive retention agreements with each of the other NEOs. While the NEOs remain employed at-will, these agreements
are intended to provide market-level severance compensation to be competitive with our peer group of comparable companies and to promote
retention. We believe that these agreements are fair to the executives and to our stockholders because they provide relatively modest
severance in exchange for the restrictive covenants that help protect our company. These restrictive covenants include standard non-competition,
non-solicitation, non-disparagement, and confidentiality restrictions. The agreements are discussed in connection with the Potential Payments
Upon Termination or Change in Control table on page 57 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each agreement provides for severance benefits
that may be triggered by an involuntary termination of employment by us without &ldquo;cause&rdquo; or by the executive for &ldquo;good
reason&rdquo; (as defined in each agreement), or a qualifying termination. The level of severance benefits depends on whether the involuntary
termination occurs during or outside of a change in control protected period that runs from three months before until 12 months after
a change in control (as defined in each agreement). In addition, the agreements provide for full vesting of outstanding equity awards
upon a qualifying termination occurring during the period from three months before until 12 months after a change in control for awards
granted after January 29, 2019. Equity awards granted prior to January 29, 2019 will continue to vest in full upon the occurrence of a
change in control in accordance with the award terms. Except as described in this paragraph and for certain equity grants made to Dr.
Blanchard upon her appointment as our President and Chief Executive Officer, none of the equity grants made to our NEOs provide for accelerated
vesting upon termination of their employment by us without &ldquo;cause&rdquo; or by the executive for &ldquo;good reason.&rdquo; If &ldquo;golden
parachute&rdquo; excise taxes would be triggered by payments due in connection with termination during a change in control protected period,
the agreements provide for a cut-back in the payments to avoid the excise tax, if the cut-back would result in a greater after-tax benefit
to the executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes of these agreements, &ldquo;cause&rdquo;
is generally defined, subject to slight variation, as (a) neglect of duties, (b) willful misconduct or gross negligence, (c) embezzlement,
fraud or violation of company policies, (d) disclosure of a trade secret or other confidential information, (e) conviction of a felony
associated with financial impropriety, (f) failure to perform in a material respect without proper cause, or (g) willful failure to cooperate
with a bona fide internal or external investigation. &ldquo;Good reason&rdquo; is generally defined as (a) a material diminution in responsibilities,
(b) a material diminution in compensation (except as part of an across-the-board diminution to all executive employees), (c) a material
change to the geographic location where the executive is expected to provide services, or (d) material breach of the agreement by the
company. &ldquo;Change in control&rdquo; is generally defined as (a) a person becoming the beneficial owner of more than 50% of the company&rsquo;s
voting securities (except as a result of an acquisition of securities directly from the company), (b) a majority of the members of the
board being replaced in a twelve month period or at two consecutive annual stockholder meetings, whichever is longer, or (c) an acquisition
of control of the company or substantially all of its assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes the cash and health benefits
(i.e., company payment of premiums under the company&rsquo;s health plans) severance provided to the NEOs as of December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #365F91">
    <TD STYLE="width: 31%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Trigger</B></FONT></TD>
    <TD STYLE="width: 21%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Type
        of Severance</B></FONT></TD>
    <TD STYLE="width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Dr. Blanchard</B></FONT></TD>
    <TD STYLE="width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: white"><B>Other
        NEOs</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="padding-left: 4.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Termination without cause or with good reason,
        not in connection with a change in control</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cash severance</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">18 months&rsquo; salary</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">12 months&rsquo; salary</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Health benefits</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">18 months at active employee rates</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">12 months at active employee rates</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD ROWSPAN="2" STYLE="padding-left: 4.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Termination without cause or with good reason,
        within 3 months before or 12 months after a change in control</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cash severance</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2x the sum of 12 months&rsquo; salary plus target bonus</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">12 months&rsquo; salary plus target bonus</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Health benefits</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">18 months at active employee rates</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">12 months at active employee rates</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in accordance with the terms of Dr.
Blanchard&rsquo;s employment agreement, if Dr. Blanchard&rsquo;s employment is terminated &ldquo;without cause&rdquo; or Dr. Blanchard
terminates her employment with us for &ldquo;good reason&rdquo; not due to disability prior to December 31, 2021, she would be entitled
to pro rata vesting of the time-vesting restricted stock unit grant and the time-vesting stock option grant awarded to her on April 26,
2020 in conjunction with the commencement of her employment as President and Chief Executive Officer.</P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">The Death of Mr. Darling
and the Appointment of Dr. Blanchard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Darling unexpectedly passed away on January
29, 2020. At the time of his passing, the Compensation Committee had previously determined that Mr. Darling&rsquo;s base salary would
be increased to $650,000 for fiscal year 2020. Mr. Darling&rsquo;s bonus and salary through January 29, 2020 were paid to his estate.
In 2020, the company also paid $100,000 to Mr. Darling&rsquo;s estate for the housing allowance contained in his employment agreement
and continued to pay the company portion of COBRA premiums at the active employee rate under our health plans for Mr. Darling&rsquo;s
family. In accordance with the terms of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended, and Mr. Darling&rsquo;s
employment agreement with us, all of Mr. Darling&rsquo;s unvested stock option, restricted stock, and restricted stock unit awards were
forfeited as of the date of his passing. Vested, but unexercised, stock options remained exercisable for one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following Mr. Darling&rsquo;s passing, the Board
of Directors briefly activated an interim Office of the President to provide leadership and oversight of day-to-day affairs before appointing
Dr. Blanchard as our interim Chief Executive Officer, effective February 10, 2020, pursuant to the terms of a letter agreement executed
between her and the company. Dr. Blanchard was later appointed our President and Chief Executive Officer effective April 26, 2020. In
connection with Dr. Blanchard&rsquo;s transition to President and Chief Executive Officer, we and Dr. Blanchard entered into an employment
agreement effective as of April 23, 2020 (the &ldquo;Agreement&rdquo;). The Agreement has an initial term of April 26, 2020 through December
31, 2021, which automatically renews for successive 1-year periods unless either party elects nonrenewal in accordance with the Agreement.
The Agreement provides for an annual base salary of $625,000 and a target annual bonus opportunity equal to 85% percent of annual base
salary. In addition, the Agreement provides for the following equity awards: (i) a time-based restricted stock unit grant covering 73,726
shares, eligible to vest in equal annual installments over three years; (ii) a performance-based restricted stock unit grant covering
80,620 shares at target, eligible to vest up to 150% of the target shares on February 25, 2023 pursuant to our 2020 performance measures
(as described above) for performance-based restricted stock units; (iii) a time-based stock option grant covering 104,638 shares, eligible
to vest in equal annual installments over three years; and (iv) a performance-based stock option grant covering 104,638 shares at target,
eligible to vest up to 150% of the target shares based on our total shareholder return relative to a comparison group of companies set
forth in the Agreement through December 31, 2022. In each case, vesting generally requires Dr. Blanchard&rsquo;s continued employment
through the relevant vesting date. The Agreement provides for (i) reimbursement of reasonable business expenses, (ii) the payment of up
to $10,000 in legal fees incurred by Dr. Blanchard in connection with the Agreement, (iii) participation in our benefit plans, and (iv)
30 paid vacation days per year. Under the Agreement, if Dr. Blanchard&rsquo;s employment is terminated due to death, disability (as defined
in the Agreement), by us without &ldquo;cause&rdquo; (as defined in the Agreement and including our nonrenewal of the term of the Agreement),
or by Dr. Blanchard for &ldquo;good reason&rdquo; (as defined in the Agreement), Dr. Blanchard would become entitled to (i) 18 months
of base salary, (ii) continued payment of company premiums under our benefit plans for 18 months and (iii) if such termination is not
due to disability and occurs prior to December 31, 2021, pro rata vesting of the time-based restricted stock unit grant and the time-based
option grant described above. Notwithstanding the foregoing, if such a termination without cause or for good reason occurs within 3 months
prior to or 12 months after a change in control (as defined in the Agreement), Dr. Blanchard would become entitled to (i) 2 times the
sum of her base salary and her target annual bonus, (ii) continued payment of company premiums under our benefit plans for 18 months and
(iii) vesting of her equity awards. The performance-based restricted stock unit grant and each other award with a performance metric-based
vesting condition (other than a total stockholder return-based vesting condition) would vest based on the greater of assumed target performance
or actual performance measured through the date of termination. For the total stockholder return-based option grant (and any other award
with a total stockholder return-based vesting condition), the applicable performance period would be shortened to end as of immediately
prior to the change in control and performance would be measured at such time. Any such severance benefits under the Agreement are contingent
on Dr. Blanchard entering into and not revoking a general release of claims in favor of our company, our affiliates, and our service providers.
Finally, the Agreement contains customary covenants related to non-competition and non-solicitation for 12 months following termination
of employment, as well as customary covenants related to confidentiality, inventions and intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the Agreement, the company entered
into a letter agreement with Dr. Blanchard in connection with her appointment as our interim Chief Executive Officer under which she was
employed at will and the company (i) paid her base salary compensation at an annualized rate of $600,000, which resulted in base salary
payments of $115,385, (ii) paid her a cash retention bonus of $127,500, (iii) provided additional monthly payments of $3,448.28 in lieu
of her participation in the company&rsquo;s health plans, (iv) granted her 4,231 restricted stock units on February 25, 2020, and (v)
provided for the payment of up to $3,000 in legal fees incurred by Dr. Blanchard in connection with the letter agreement. The letter agreement
was executed on February 25, 2020 and covered the period from her appointment as interim Chief Executive Officer on February 10, 2020
through her appointment as our President and Chief Executive Officer on April 26, 2020.</P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Other Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NEOs are eligible to participate in our health
and welfare programs, 401(k) plan, and other benefit programs on the same basis as other employees.</P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Deductibility of Executive
Compensation and Accounting Considerations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;162(m) of the Internal Revenue Code
generally limits our annual corporate tax deduction for compensation paid to each of our &ldquo;covered employees&rdquo; to $1&nbsp;million.
&ldquo;Covered employees&rdquo; include anyone who served as chief executive officer or chief financial officer during any part of a year
and the next three most highly compensated named executive officers for that year. In addition, once a person is considered a &ldquo;covered
employee,&rdquo; that person remains a covered employee in all subsequent years (including after the person leaves our service or changes
roles). The American Rescue Plan Act of 2021 updated Section&nbsp;162(m) of the Internal Revenue Code, effective in 2026, to expand the
number of &ldquo;covered employees&rdquo; subject to the $1 million deduction limit to include the next five highest compensated employees
of the company; however this new group of employees will not retain the perpetual &ldquo;covered employee&rdquo; status and will be determined
annually. Consequently, we generally will not be entitled to a U.S. tax deduction for compensation paid in any year to our named executive
officers and our other &ldquo;covered employees&rdquo; in excess of $1&nbsp;million. While considering tax deductibility as only one of
several considerations in determining compensation, we believe that the tax deduction limitation should not compromise our ability to
structure compensation programs that provide benefits to the Company that outweigh the potential benefit of a tax deduction and, therefore,
may approve compensation that is not deductible for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We follow the Financial Accounting Standard Board&rsquo;s
Accounting Standards Codification Topic 718 for our stock-based compensation awards, which requires us to measure the compensation expense
for all share-based awards based on the grant date &ldquo;fair value&rdquo; of these awards. This calculation is performed for accounting
purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient of the awards
may realize no value from their awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not provided or committed to provide any
NEO with a gross-up or other reimbursement for tax amounts the executive might pay pursuant to Section 280G or Section 409A of the Internal
Revenue Code. Section&nbsp;280G and related sections of the Internal Revenue Code provide that an executive officer and certain persons
who hold significant stockholder interests and certain other service providers could be subject to significant additional taxes if they
receive payments or benefits in connection with a change in control that exceeds certain limits, and that we or our successor could lose
a deduction on the amounts subject to the additional tax. Section 409A of the Internal Revenue Code also imposes additional significant
taxes on the individual in the event that an executive officer, director or service provider of certain types receives &ldquo;deferred
compensation&rdquo; that does not meet the requirements of Section 409A of the Internal Revenue Code.</P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Role of Management in Determining
Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee, which is comprised
entirely of independent directors, is responsible for establishing and implementing our executive compensation philosophy and for ensuring
that the total compensation paid to our NEOs and other executives is fair, competitive and motivates high performance. The Compensation
Committee is solely responsible for compensation decisions regarding our CEO. When making compensation recommendations for NEOs other
than the CEO, the Compensation Committee expects to seek and consider the advice and counsel of the CEO, given her direct day-to-day working
relationship with those executives. Taking this feedback into consideration, the Compensation Committee will engage in discussions and
make final determinations related to compensation paid to the NEOs.</P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Risk Considerations in
Our Compensation Programs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee believes that risks
arising from our policies and practices for compensating employees are not reasonably likely to have a material adverse effect on our
company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Compensation Clawback </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All awards, amounts or benefits received or outstanding
under the Plan by the NEOs are subject to clawback, cancellation, recoupment, rescission, payback, reduction or other similar action in
accordance with the terms of any clawback or similar policy or any applicable law related to such actions, as may be in effect from time
to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Prohibition on Hedging, Pledging,
and Short Sales</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Insider Trading Policy prohibits the NEOs
from hedging or pledging of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Stock Retention Guidelines</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our stock retention guidelines generally require
each NEO to beneficially own certain amounts of our common stock. Generally, these guidelines require the Chief Executive Officer to beneficially
own, at a minimum, either (a) 50,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common
stock having a market value equal to three times the amount of his or her base salary. They require any other NEO to beneficially own,
at a minimum, either (a) 10,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common stock
having a market value equal to the amount of his or her base salary. Any individual initially elected as an executive officer has five
years to achieve compliance.&nbsp;Each NEO is currently in compliance or within the five-year grace period. See the section captioned
&ldquo;<I>Director and Executive Officer Stock Retention Guidelines</I>&rdquo; elsewhere in this Proxy Statement for additional information.</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_029"></A>Compensation
Committee Report</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee of the Board of Directors
of Anika Therapeutics,&nbsp;Inc. has reviewed and discussed with the management of Anika Therapeutics, Inc. the section entitled &ldquo;Compensation
Discussion and Analysis&rdquo; contained in this Proxy Statement. Based on its review and discussions with management, the Compensation
Committee recommended to the Board that the section entitled &ldquo;Compensation Discussion and Analysis&rdquo; be included in this Proxy
Statement for the 2021 Annual Meeting of Stockholders. This report is submitted by the following independent directors who comprise the
Compensation Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: center">Joseph L. Bower, Chair</TD>
    <TD STYLE="width: 23%; text-align: center">John B. Henneman, III</TD>
    <TD STYLE="width: 29%; text-align: center">Raymond J. Land</TD>
    <TD STYLE="width: 23%; text-align: center">Glenn R. Larsen</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE FOREGOING REPORT SHOULD NOT BE DEEMED INCORPORATED
BY REFERENCE INTO ANY FILING UNDER THE SECURITIES ACT OF 1933 OR UNDER THE SECURITIES EXCHANGE ACT OF 1934 BY ANY GENERAL STATEMENT INCORPORATING
BY REFERENCE THIS PROXY STATEMENT, EXCEPT TO THE EXTENT THAT ANIKA THERAPEUTICS, INC. SPECIFICALLY INCORPORATES THIS INFORMATION BY REFERENCE,
AND SHALL NOT OTHERWISE BE DEEMED FILED UNDER EITHER OF SUCH ACTS.</B></P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_030"></A>Executive
and Director Compensation</FONT></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_031"></A>Summary
Compensation Table</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the compensation information in respect of our NEOs for the year ended December&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Name
    and Principal Position</FONT></TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; white-space: nowrap; color: white; font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Salary
    ($) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(1)</SUP></FONT></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Bonus
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white">($)<SUP>(2)</SUP></FONT></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock
    Awards <BR>
($)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(3)</SUP></FONT></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option
    Awards <BR>
($) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(3)</SUP></FONT></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">All
    Other <BR>
Compensation <BR>
($) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(4)</SUP></FONT></FONT></TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Total
    ($)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="width: 23%; text-align: left">Cheryl R. Blanchard, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: center">2020</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">548,077</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;<SUP>(5)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">458,510</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;<SUP>(6)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">5,335,439</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;<SUP>(7)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">3,659,450</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;<SUP>(8)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">27,958</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;<SUP>(9)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">10,029,434</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">President and Chief</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2018</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Michael L. Levitz<SUP>(10)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">173,077</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">73,601</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">799,971</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">799,993</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,318</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,857,960</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">EVP, Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">and Treasurer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2018</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>David Colleran<SUP>(11)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">344,077</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">143,931</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">645,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">553,445</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,263</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,705,616</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">EVP, General Counsel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">and Secretary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2018</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Thomas Finnerty</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">353,505</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">143,169</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">626,367</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,746</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(12)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,143,787</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">EVP, Human Resources</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">341,550</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">184,437</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">585,540</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,352</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,135,879</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2018</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">330,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">118,800</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">285,831</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,002</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">758,633</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">James Loerop</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">381,563</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">171,703</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">464,449</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,156</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,039,871</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">EVP, Business Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">165,865</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">202,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">732,060</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">377,772</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,429</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,479,626</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">and Strategic Planning</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2018</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; background-color: white">Joseph G. Darling<SUP>(13)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: center; background-color: white">2020</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">80,752</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">208,001</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(14)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">$</TD><TD STYLE="text-align: right; background-color: white">288,753</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; background-color: white">President and Chief</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: center; background-color: white">2019</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">599,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">764,363</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,098,780</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">127,539</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">$</TD><TD STYLE="text-align: right; background-color: white">5,590,182</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; background-color: white">Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: center; background-color: white">2018</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">523,462</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">412,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">399,998</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">728,335</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">105,892</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">$</TD><TD STYLE="text-align: right; background-color: white">2,170,187</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>Sylvia Cheung<SUP>(15)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">294,252</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">924,637</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">89,644</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(16)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,308,534</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">Chief Financial Officer, Treasurer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">392,094</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">220,553</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">585,540</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,680</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,218,867</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">and Assistant Secretary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2018</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">371,653</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">167,244</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">728,335</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">19,970</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,287,202</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">The amounts in this column represent the annual base
        salary approved for the executive by the Board of Directors, prorated based on employment dates during the indicated year.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">The amounts in this column represent discretionary cash bonuses
        earned in the indicated year, but paid in February the following year, and have been prorated based on employment dates during the indicated
        year. See the section in the Compensation Discussion and Analysis titled &ldquo;Annual Cash Bonus&rdquo; for additional details regarding
        the cash bonuses earned for 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">The amounts in this column reflect the grant date fair value computed
        with respect to the stock and option awards issued during the indicated year calculated in accordance with Financial Accounting Standards
        Board Accounting Standards Codification Topic 718, or ASC 718. See the information appearing in Note 14 to our consolidated financial
        statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2020 for certain assumptions made in the
        valuation of stock and option awards. Unless otherwise noted, the Board granted equity awards on February 25, 2020, February 26, 2019,
        and January 24, 2018, respectively. Time-vesting awards granted in 2020 and 2019 vest ratably over 3 years beginning one year from the
        date of grant, while time-vesting awards granted in 2018 vest ratably over 4 years beginning one year from the date of grant. For 2020
        and 2019 performance-based restricted stock units, the fair value on the date of grant was determined at the probable outcome level of
        &quot;target,&quot; or 100% attainment level, pursuant to ASC 718. If the grant date fair value of the 2020 performance-based restricted
        stock units had been determined at the &quot;maximum,&quot; or 150%, attainment level, the fair value on the date of grant for the awards
        would have been $4,039,062 for Dr. Blanchard, $599,978 for Mr. Levitz, $484,425 for Mr. Colleran, $396,273 for Messrs. Finnerty and Loerop,
        and $639,150 for Ms. Cheung. These values represent incremental increases over the amounts set forth in this column for 2020 of $1,346,354
        for Dr. Blanchard, $199,993 for Mr. Levitz, $161,475 for Mr. Colleran, $132,091 for Messrs. Finnerty and Loerop, and $213,050 for Ms.
        Cheung. If the grant date fair value of the 2019 performance-based restricted stock units had been determined at the &quot;maximum,&quot;
        or 135%, attainment level, the grant date fair value of the awards would have been valued at $395,240 for Mr. Finnerty, $494,141 for Mr.
        Loerop, $2,766,677 for Mr. Darling, and $395,240 for Ms. Cheung. These values represent incremental increases over the amounts set forth
        in this column for 2019 of $102,470 for Mr. Finnerty, $128,111 for Mr. Loerop, $717,287 for Mr. Darling, and $102,470 for Ms. Cheung.
        See the section in the Compensation Discussion and Analysis titled &ldquo;Equity-Based Grants&rdquo; and &quot;The Death of Mr. Darling
        and the Appointment of Dr. Blanchard&quot; for additional details regarding the stock and option awards issued in 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">Unless otherwise noted, these amounts constitute matching contributions
        to our Employee Savings and Retirement Plan (401(k) Plan) and group term life insurance premiums. Matching contributions to the 401(k)
        Plan in the indicated year were as follows: $18,093 to Dr. Blanchard, $10,903 to Mr. Levitz, $17,349 to Mr. Colleran, $15,669 to Mr. Finnerty,
        $18,940 to Mr. Loerop, $4,842 to Mr. Darling, and $19,950 to Ms. Cheung.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">This amount represents $115,385 in salary and $10,345 in lieu of
        participation in the company&rsquo;s health plans paid to Dr. Blanchard during her service as the interim Chief Executive Officer from
        February 10, 2020 to April 25, 2020, and $432,692 in Dr. Blanchard's prorated 2020 base salary upon her appointment on April 26, 2020
        as President and Chief Executive Officer. See the section in Compensation Discussion and Analysis titled &quot;The Death of Mr. Darling
        and the Appointment of Dr. Blanchard&quot; for additional details.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-size: 8pt; color: black">(6)</FONT></TD>
    <TD STYLE="text-align: justify; width: 97%"><FONT STYLE="font-size: 8pt; color: black">This amount reflects the discretionary prorated cash
        bonus earned for the indicated year of $331,010 and a cash retention bonus of $127,500 provided under the terms of the interim Chief Executive
        Officer letter agreement entered into between the company and Dr. Blanchard. See the section in the Compensation Discussion and Analysis
        titled &ldquo;Annual Cash Bonus&rdquo; for additional details regarding the cash bonus earned for 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">In addition to the time-vesting and performance-based restricted
        stock units granted to her under her employment agreement (see the section in the Compensation Discussion and Analysis titled &ldquo;The
        Death of Mr. Darling and the Appointment of Dr. Blanchard&quot; for additional details regarding such awards), this amount includes the
        grant date fair value of the restricted stock unit award granted to Dr. Blanchard by the Board on February 10, 2020 in connection with
        her appointment as interim Chief Executive Officer. This award vests ratably on annual basis over 3 years beginning one year from the
        date of grant.&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">This amount includes the performance-based stock option award made
        by the Board to Dr. Blanchard on February 25, 2020. The 2020 performance-based stock option award fair value on the date of grant was
        determined at the &quot;target,&quot; or 100% attainment level, pursuant to ASC 718. If the fair value of the 2020 performance-based stock
        option award had been determined at the &quot;maximum,&quot; or 150%, attainment level, the award would have been valued at $5,242,364.
        The value represents an additional incremental increase over the amounts set forth in this column of $2,948,699. See the section in the
        Compensation Discussion and Analysis titled &ldquo;Equity-Based Grants&rdquo; and &quot;The Death of Mr. Darling and the Appointment of
        Dr. Blanchard&quot; for additional details regarding the option award.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">This amount includes $6,868 in fees earned
    as an independent director prior to her appointment as our interim Chief Executive Officer.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">As noted elsewhere in this proxy statement, Mr. Levitz was hired
        as our Executive Vice President, Chief Financial Officer and Treasurer on August 10, 2020, and his 2020 base salary represents his prorated
        salary for 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(11)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">As noted elsewhere in this proxy statement, Mr. Colleran was hired
        as our Executive Vice President, General Counsel and Secretary on March 4, 2020, and his 2020 base salary represents his prorated salary
        for 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(12)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">This amount includes a $142 company service award.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(13)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">As noted elsewhere in this proxy statement, Mr. Darling passed away unexpectedly
        on January 29, 2020, and his 2020 base salary represents the salary he earned as President and Chief Executive Officer prior to his death.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(14)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">This amount includes payments of $82,211 for accrued vacation time,
        $100,000 in housing allowance, and $20,400 in continued COBRA healthcare premiums for Mr. Darling's family following Mr. Darling's death
        in January 2020. See the section in the Compensation Discussion and Analysis titled &quot;The Death of Mr. Darling and the Appointment
        of Dr. Blanchard&quot; for additional details.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(15)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">As noted elsewhere in this proxy statement, Ms. Cheung resigned
        as Chief Financial Officer, Treasurer and Assistant Secretary of the company on August 10, 2020, and her 2020 base salary represents the
        salary she earned prior to the end of her employment.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(16)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">This amount includes a $991 company service award and $67,956 for
        accrued vacation time pursuant to Ms. Cheung's resignation on August 10, 2020.</FONT></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_032"></A>Grants
of Plan-Based Awards in 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The following
table sets forth each grant of equity awards under the Plan made to the NEOs during the year ended December 31, 2020. All such equity
awards vest over a three-year period commencing on the first anniversary of the grant date, except for performance-based equity awards
which vest on the performance measurement date. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(31,73,125)">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="11" STYLE="vertical-align: middle; white-space: nowrap; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;Estimated
future payouts under <BR> equity incentive plan awards</B></FONT></P>

</TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>All other <BR>
stock <BR>
awards:<BR>
Number
    of <BR>
shares of </B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>All other option <BR>
awards: <BR>
Number of
    <BR>
securities</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>Exercise or <BR>
base price <BR>
of option
</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>Grant date <BR>
fair value of <BR>
stock and
</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(31,73,125)">
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt; color: White"><B>Name</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>Grant Date</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>Threshold <BR>
(#)&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>Target <BR>
(#)&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;Maximum <BR>
(#)&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>stock or <BR>
units (#)</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>underlying<BR>
options (#)</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: white"><B>awards <BR>
($/Sh) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><SUP>(1)</SUP></FONT></B></FONT></TD><TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 8pt; color: white"><B>option<BR>
awards ($)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal"><SUP>(2)</SUP></FONT></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap; width: 18%; text-align: left">Cheryl R. Blanchard, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; text-align: center">February 25, 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">4,231</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">42.61</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">180,283</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">April 26, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,062</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,620</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,930</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33.40</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,692,708</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">April 26, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,319</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,638</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,957</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33.40</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,293,665</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">April 26, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,726</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33.40</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,462,448</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">April 26, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,638</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33.40</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,365,785</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">Michael L. Levitz</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">August 10, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,157</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,577</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,366</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">34.55</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">399,985</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">August 10, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,577</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">34.55</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">399,985</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">August 10, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,145</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">34.55</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">799,993</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap; text-align: left">David Colleran</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">March 4, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,250</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43.06</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">322,950</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">March 4, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43.06</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">322,950</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">March 4, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43.06</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">553,445</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap; text-align: left">Thomas Finnerty</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">February 25, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">620</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,200</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,300</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">42.61</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">264,182</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">February 25, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">42.61</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">362,185</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap; text-align: left">James Loerop</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">February 25, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">620</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,200</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,300</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">42.61</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">264,182</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">February 25, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,700</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">42.61</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">200,267</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left; background-color: white">Joseph G. Darling<SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: right; background-color: white">-</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: right; background-color: white">-</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: right; background-color: white">-</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: right; background-color: white">-</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: right; background-color: white">-</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD><TD STYLE="text-align: right; background-color: white">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">Sylvia Cheung<SUP>(6)</SUP></TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">February 25, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">42.61</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">426,100</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">February 25, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,700</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">42.61</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">498,537</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">The exercise price or base price of each award equals
        the grant date closing stock price, as reported on the NASDAQ stock exchange. With the exception of the February 25, 2020 grant to Dr.
        Blanchard, all other grants made to the NEOs with a grant date of February 25, 2020 were approved by the Compensation Committee on February
        3, 2020. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">This column represents the full grant date fair value of stock
        options and restricted stock unit awards under ASC 718 granted to each of the NEOs in the fiscal year ended December 31, 2020. Generally,
        the full grant date fair value is the amount that we will expense in our financial statements over the award's vesting period. For time-vesting
        restricted stock units and performance-based restricted stock units, fair value was calculated using the closing price of our common stock
        on the grant date. For stock options, except as otherwise noted, the fair value was calculated using the Black-Scholes value on the grant
        date. See the information appearing in Note 14 to our consolidated financial statements included as part of our Annual Report on Form
        10-K for the year ended December 31, 2020 for certain assumptions made in the valuation of these awards.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">These amounts represent performance-based restricted stock units
        granted by the Board on February 25, 2020, except for Dr. Blanchard, Mr. Levitz and Mr. Colleran, whose awards were granted on April 26,
        2020, August 10, 2020 and March 4, 2020, respectively, in connection with the commencement of their employment. The &quot;Threshold&quot;
        is equal to 10% of the Target, and the &quot;Maximum&quot; is equal to 150% of the Target. The performance measurement date for these
        awards is generally the date on which the Compensation Committee of the Board of Directors reviews the Company's financial and business
        achievements for the fiscal year ending December 31, 2022, including the Company's audited financial statements for such period, and determines
        and specifies, at the Compensation Committee's sole discretion, the percentage of the shares that have been earned by each individual
        NEO. See the section in the Compensation Discussion and Analysis titled &ldquo;Equity-Based Grants&rdquo; and &quot;The Death of Mr. Darling
        and the Appointment of Dr. Blanchard&quot; for additional details regarding the restricted stock units issued in 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">This amount represents the full grant date fair value of performance-based
        stock options under ASC 718 granted to Dr. Blanchard on April 26, 2020. For these performance-based stock options, fair value was calculated
        using the Monte Carlo value on the grant date. The &quot;Threshold&quot; is equal to 50% of the Target, and the &quot;Maximum&quot; is
        equal to 150% of the Target. The performance measurement date for this award is generally the date on which the Compensation Committee
        of the Board of Directors reviews the Company's Total Shareholder Return (as defined in the grant agreement) against the Comparison Group
        (as defined in the grant agreement), and determines and specifies, at the Compensation Committee's sole discretion, the percentage of
        the shares that have been earned by Dr. Blanchard. See the information appearing in Note 14 to our consolidated financial statements included
        as part of our Annual Report on Form 10-K for the year ended December 31, 2020 for certain assumptions made in the valuation of this award.
        See the section in the Compensation Discussion and Analysis titled &ldquo;Equity-Based Grants&rdquo; and &quot;The Death of Mr. Darling
        and the Appointment of Dr. Blanchard&quot; for additional details regarding the option award.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">As noted elsewhere in this proxy statement, Mr. Darling passed
        away unexpectedly on January 29, 2020, and, therefore, no awards were granted to him in 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">As noted elsewhere in this proxy statement, Ms. Cheung resigned
        from the company, effective August 10, 2020, on which date her awards were forfeited.</FONT></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_033"></A>Outstanding
Equity Awards at December&nbsp;31, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information on the
holdings of outstanding stock options and unvested stock awards held by the NEOs as of December&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="17" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option
    Awards</FONT></TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="15" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock
    Awards</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Name</FONT></TD><TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal; vertical-align: middle"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center"><FONT STYLE="font-size: 8pt">Number
    of <BR>
    securities <BR>
    underlying <BR>
    unexercised <BR>
    options (#) <BR>
    exercisable<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(1)</SUP></FONT></FONT></TD><TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal; vertical-align: middle"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center"><FONT STYLE="font-size: 8pt">Number
    of <BR>
    securities <BR>
    underlying <BR>
    unexercised <BR>
    options (#) <BR>
    unexercisable<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(1)</SUP></FONT></FONT></TD><TD STYLE="text-align: center; color: white; font-weight: bold; vertical-align: middle"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Equity
    <BR>
    incentive plan <BR>
    awards: <BR>
    number of <BR>
    securities <BR>
    underlying <BR>
    unexercised <BR>
    unearned <BR>
    options (#)</FONT></TD><TD STYLE="text-align: center; color: white; font-weight: bold; vertical-align: middle"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Option
    <BR>
    exercise <BR>
    price ($)</FONT></TD><TD STYLE="text-align: center; color: white; font-weight: bold; vertical-align: middle"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Option <BR>
    expiration <BR>
    date</FONT></TD><TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal; vertical-align: middle"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center"><FONT STYLE="font-size: 8pt">Number
    of <BR>
    shares or <BR>
    units of <BR>
    stock that <BR>
    have not <BR>
    vested (#)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(1)</SUP></FONT></FONT></TD><TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal; vertical-align: middle"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center"><FONT STYLE="font-size: 8pt">Market
    value <BR>
    of shares or <BR>
    units of <BR>
    stock that <BR>
    have not <BR>
    vested (#)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(2)</SUP></FONT></FONT></TD><TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal; vertical-align: middle"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center"><FONT STYLE="font-size: 8pt">Equity
    <BR>
    incentive plan <BR>
    awards: <BR>
    number of <BR>
    unearned <BR>
    shares, units <BR>
    or other rights <BR>
    that have not <BR>
    vested (#)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(3)</SUP></FONT></FONT></TD><TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal; vertical-align: middle"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center"><FONT STYLE="font-size: 8pt">Equity
    <BR>
    incentive plan <BR>
    awards: <BR>
    market or <BR>
    payout value <BR>
    of unearned <BR>
    shares, units <BR>
    or other rights <BR>
    that have not <BR>
    vested ($)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: 700; color: white"><SUP>(2)</SUP></FONT></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap; width: 10%; text-align: left">Cheryl R. Blanchard, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">8,062</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;<SUP>(4)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">33.40</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">4/26/2030</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,638</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33.40</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4/26/2030</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,726</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,336,839</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,062</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">364,886</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap; text-align: left">Michael L. Levitz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,145</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">34.55</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8/10/2030</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,577</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">523,975</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,157</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">52,366</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap; text-align: left">David Colleran</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43.06</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3/4/2030</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">339,450</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33,945</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(149,179,215); vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">Thomas Finnerty</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">656,270</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,620</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">435,401</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,787</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,786</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">61.47</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1/24/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">54.09</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10/30/2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap; text-align: left">James Loerop</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">40.67</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7/8/2029</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(149,179,215); vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,700</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">484,282</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,620</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">435,401</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap; font-weight: 400; font-style: normal; text-align: left">Joseph G. Darling<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 400"><SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,505</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">61.47</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1/24/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,739</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51.70</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7/27/2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="white-space: nowrap; font-weight: 400; font-style: normal">Sylvia Cheung<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 400"><SUP>(7)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(1)</FONT></TD>
    <TD STYLE="width: 96%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">Vesting of equity awards commences on the first anniversary
        of the grant date and continues on each subsequent grant date anniversary until the equity award is fully vested, except as otherwise
        noted below. Except as otherwise noted, equity awards are subject to a three-year vesting period, in each case subject to the holder's
        continued employment with us. The expiration date of each equity award is ten years after its grant date. Mr. Finnerty&rsquo;s stock option
        award expiring October 30, 2017 is subject to a four-year vesting period.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">Based on the closing price of our common stock on the NASDAQ stock
        exchange on December 31, 2020 ($45.26) per share.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">Except as otherwise noted, these amounts represent performance-based
        restricted stock units granted at Target in 2020. The performance measurement date for these awards and the date on which the shares underlying
        the award will vest (if any) is generally the date on which the Compensation Committee of the Board of Directors reviews the Company's
        financial and business achievements for the fiscal year ending December 31, 2022, including the Company's audited financial statements
        for such period, and determines and specifies, at the Compensation Committee's sole discretion, the percentage of the shares that have
        been earned by each individual NEO. See the section in the Compensation Discussion and Analysis titled &ldquo;Equity-Based Grants&rdquo;
        and &quot;The Death of Mr. Darling and the Appointment of Dr. Blanchard&quot; for additional details regarding the restricted stock units
        issued in 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">This amount includes performance-based stock options granted at
        Threshold in 2020. The performance measurement date for this award and the date on which the shares underlying the awards will vest (if
        any) is generally the date on which the Compensation Committee of the Board of Directors reviews the Company's Total Shareholder Return
        (as defined in the grant agreement) against the Comparison Group (as defined in the grant agreement), and determines and specifies, at
        the Compensation Committee's sole discretion, the percentage of the shares that have been earned by Dr. Blanchard. See the section in
        the Compensation Discussion and Analysis titled &ldquo;Equity-Based Grants&rdquo; and &quot;The Death of Mr. Darling and the Appointment
        of Dr. Blanchard&quot; for additional details regarding the option award. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">These amounts include performance-based restricted stock units
        granted at Target in 2019. The performance measurement date and the date on which the shares underlying the award will vest (if any) is
        generally the date on which the Compensation Committee of the Board of Directors reviews the Company's financial and business achievements
        for the fiscal year ending December 31, 2021, including the Company's audited financial statements for such period, and determines and
        specifies, at the Compensation Committee's sole discretion, the percentage of the shares that have been earned by each individual NEO.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">As noted elsewhere in this proxy statement, Mr. Darling passed
        away unexpectedly on January 29, 2020. Under the terms of his grant agreements, all vested and unexercised options remain exercisable
        for 12 months upon death of the option holder. All unvested equity awards were forfeited upon Mr. Darling's death.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">As noted elsewhere in this proxy statement, Ms. Cheung resigned
        from the company on August 10, 2020. All unvested equity awards were forfeited upon termination. All vested options remained exercisable
        for 3 months from the date of resignation, at which time any remaining unexercised options were cancelled.</FONT></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_034"></A>2020
Option Exercises and Stock Vested</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information regarding
options exercised and stock awards vested for the NEOs during the year ended December&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; text-align: right">&nbsp;</TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Awards</TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock Awards</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; color: white; font-weight: bold; text-align: center">Name</TD><TD STYLE="border-bottom: Black 1pt solid; color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; color: white; font-weight: bold; text-align: center">Number of <BR>
shares <BR>
acquired on <BR>
exercise (#)</TD><TD STYLE="border-bottom: Black 1pt solid; color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; color: white; font-weight: bold; text-align: center">Value realized <BR>
on exercise ($)</TD><TD STYLE="border-bottom: Black 1pt solid; color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; color: white; font-weight: bold; text-align: center">Number of <BR>
shares <BR>
acquired on <BR>
vesting (#)</TD><TD STYLE="border-bottom: Black 1pt solid; color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; color: white; font-weight: bold; text-align: center">Value <BR>
realized on <BR>
vesting ($)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="width: 48%; text-align: left">&nbsp;Cheryl R. Blanchard, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">8,073</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;<SUP>(1)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">303,640</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left">&nbsp;Michael L. Levitz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">&nbsp;David Colleran</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left">&nbsp;Thomas Finnerty</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,267</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">200,700</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">&nbsp;James Loerop</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">105,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left">&nbsp;Joseph G. Darling</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">&nbsp;Sylvia Cheung</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">118,800</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,013,288</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,975</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">206,915</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">Includes 3,842 restricted stock units granted to Dr.
        Blanchard as an independent director on February 26, 2019.</FONT></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_035"></A>Potential
Payments Upon Termination or Change in Control</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our President and Chief Executive Officer, Chief
Financial Officer, and our other NEOs have certain termination or change in control benefits described in the Compensation Discussion
and Analysis sections captioned &ldquo;Other Compensation Matters &ndash; <I>Employment and Executive Retention Agreements Effective at
December 31, 2020</I>&rdquo; and &ldquo;Other Compensation Matters &ndash; <I>The Death of Mr. Darling and the Appointment of Dr. Blanchard</I>.&rdquo;
The following table provides estimates of the potential payments and other post-termination benefits these individuals would receive assuming
a change in control occurred and/or their employment was terminated as of December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="vertical-align: middle; white-space: nowrap; color: white; font-weight: bold; text-align: center">Name</TD><TD STYLE="color: white; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; color: white">&nbsp;</TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Termination <BR>
without cause or <BR>
for good reason</TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Termination
    <BR>
    upon change in <BR>
    control without <BR>
    cause or for <BR>
    good reason <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1)(2)</SUP></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Change
    in control <BR>
    without termination <BR>
    or death or <BR>
    disability <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1)(2)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="width: 30%; text-align: left">Cheryl R. Blanchard, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: left">Salary Continuation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">937,500</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,250,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,062,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,040,981</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,467,713</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,232</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,232</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">2,008,712</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">11,810,445</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">Michael L. Levitz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">202,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,659,973</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,154</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,154</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">470,154</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">2,332,627</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">David Colleran</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">420,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">420,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">189,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">755,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,154</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,154</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">440,154</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,385,054</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">Thomas Finnerty</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">353,505</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">353,505</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">159,077</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,344,222</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,629</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,629</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">369,134</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,872,433</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left">James Loerop</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">381,563</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">381,563</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">171,703</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,213,544</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,154</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,154</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">401,717</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,786,965</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="font-weight: 400; font-style: normal; text-align: left">Joseph G. Darling<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 400"><SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="font-weight: 400; font-style: normal">Sylvia Cheung<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 400"><SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-size: 8pt; color: black">Termination for the purposes of this column is limited
        to termination without cause or termination for good reason within a period three months prior to or twelve months after a change in control.
        The indicated values for the accelerated vesting of stock options reflect the number of equity award shares that would vest on an accelerated
        basis, multiplied by the excess, if any, of the $45.26 closing price for our common stock as reported by NASDAQ on December 31, 2020,
        over the applicable exercise price for each option. This calculation assumes equity awards with an exercise price higher than the closing
        price of our common stock on December 31, 2020 will not be exercised.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-size: 8pt; color: black">(2)</FONT></TD>
    <TD STYLE="text-align: justify; width: 97%"><FONT STYLE="font-size: 8pt; color: black">The indicated values for the accelerated vesting of
        performance-based restricted stock units are included at Target.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">According to the terms of Dr. Blanchard's employment agreement
        as in place at December 31, 2020, if Dr. Blanchard&rsquo;s employment is terminated &ldquo;without cause&rdquo; or Dr. Blanchard terminates
        her employment with us for &ldquo;good reason&rdquo; not due to disability prior to December 31, 2021, she would be entitled to pro rata
        vesting of the time-vesting restricted stock unit grant and the time-vesting stock option grant awarded to her on April 26, 2020 in conjunction
        with the commencement of her employment as President and Chief Executive Officer.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">Includes the 2020 grant at Target of performance-based restricted
        stock units and the 2020 grant at Target of performance-based stock options. If the stock options were valued at Maximum, the equity awards
        vesting value would be $10,088,216. If the stock options were valued at Threshold, the equity awards vesting value would be $8,847,210.
        See the section in the Compensation Discussion and Analysis titled &ldquo;Equity-Based Grants&rdquo; and &quot;The Death of Mr. Darling
        and the Appointment of Dr. Blanchard&quot; for additional details regarding the equity grants to Dr. Blanchard in 2020 and her employment
        agreement with the company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">As noted elsewhere in this proxy statement, Mr. Darling passed
        away unexpectedly on January 29, 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; color: black">As noted elsewhere in this proxy statement, Ms. Cheung resigned
        from the company on August 10, 2020.</FONT></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_036"></A>CEO
Pay Ratio</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required by applicable SEC rules, we are providing
the following information about the relationship of the annual total compensation of our employees and the annual total compensation of
Dr. Blanchard, our year-end Chief Executive Officer or CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For 2020, our last completed fiscal year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">the median of the annual total compensation of all our employees (other than our CEO) was $105,864; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">the annual total compensation of our CEO, for the purposes of this disclosure, was $10,029,434.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on this information, for 2020 the ratio
of the annual total compensation of Dr. Blanchard, our year-end Chief Executive Officer, to the median of the annual total compensation
of all our employees was 95 to 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We took the following steps to identify the median
of the annual total compensation of all our employees, as well as to determine the annual total compensation of our median employee and
our CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">1.</TD>
    <TD>We determined that, as of December 31, 2020, our employee population consisted of 277 individuals. This population consisted of our full-time
        employees employed with us as of the determination date.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">2.</TD>
    <TD>To identify the &ldquo;median employee&rdquo; from our employee population, we aggregated for each applicable employee, other than our
        CEO, (a) annual base salary (or hourly rate multiplied by estimated work schedule, for hourly employees), (b) the bonus amount earned
        for 2020, which was paid out in early 2021, and (c) the grant date fair value of equity granted in 2020. Once aggregated, we ranked this
        compensation measure for our employees from lowest to highest and selected the median employee. Due to&nbsp;anomalous&nbsp;compensation
        characteristics of our median employee as a new hire, we substituted our median employee with another employee with compensation closest
        to our estimate used to identify the median employee.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">3.</TD>
    <TD>For the annual total compensation of our median employee, we identified and calculated the elements of that employee&rsquo;s compensation
        for 2020 in accordance with the requirements of Item 402(c)(2)(x), resulting in annual total compensation of $105,864.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pay ratio reported above is a reasonable estimate
calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The SEC rules for
identifying the median-compensated employee and calculating the pay ratio based on that employee&rsquo;s annual total compensation allow
companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect
their employee populations and compensation practices. Therefore, the pay ratio reported by other companies may not be comparable to the
pay ratio reported above, as other companies have different employee populations and compensation practices and may utilize different
methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.</P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_037"></A>Director
Compensation</FONT></P>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Cash Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For 2020, each of our non-employee directors was
entitled to annual retainers per the following schedule, with such amounts to be prorated based on the actual number of days served if
a director&rsquo;s service to us commenced after January 1, 2020 and/or ended prior to the end of 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #365F91">
    <TD STYLE="background-color: White; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="color: white"><B>Compensation Element</B></FONT></TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="color: white"><B>2020 Cash Compensation</B></FONT></TD>
    <TD STYLE="background-color: White; width: 20%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>Board of Directors</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Board Chair Retainer</TD>
    <TD STYLE="text-align: center">$80,000</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Other Directors Retainer</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">$50,000</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>Audit Committee</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Committee Chair Retainer</TD>
    <TD STYLE="text-align: center">$20,000</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Other Committee Members Retainer</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">$10,000</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>Compensation Committee</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Committee Chair Retainer</TD>
    <TD STYLE="text-align: center">$15,000</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Other Committee Members Retainer</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">$7,500</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>Governance and Nominating Committee</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Committee Chair Retainer</TD>
    <TD STYLE="text-align: center">$10,000</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C6D9F1">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Other Committee Members Retainer</TD>
    <TD STYLE="text-align: center">$5,000</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify">Equity Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors approved a grant of 4,107
restricted stock units to each non-employee director, valued at $174,999 under the Plan, based on the fair market value of our common
stock on February 25, 2020, the date of grant for our then-current directors. These restricted stock units granted to each then-current
non-employee director in 2020 vested in one installment one year from the date of grant. On September 3, 2020, Messrs. Henneman and Richard
joined the Board of Directors as non-employee directors, and they were each granted 9,310 restricted stock units, valued at $349,963 based
on the fair market value of our common stock as of that day. The restricted stock units granted to Messrs. Henneman and Richard vest in
three equal annual installments immediately prior to the company&rsquo;s Annual Meetings of Stockholders in 2021, 2022, and 2023. Each
non-employee director is eligible for an annual equity award grant with a value and vesting provisions as may be determined by the Board
based on their review of our compensation policies and general compensation trends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the compensation
we paid to non-employee directors for 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white">&nbsp;</TD><TD STYLE="color: white">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white">&nbsp;</TD><TD STYLE="color: white">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white">&nbsp;</TD><TD STYLE="color: white">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fees earned or <BR>
paid in cash ($)</TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Stock awards <BR> ($) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1) (2)</SUP></FONT></TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total ($)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(149,179,215)">
    <TD STYLE="width: 35%; text-align: left">&nbsp;Joseph L. Bower</TD><TD STYLE="width: 21%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">92,033</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">174,999</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">267,032</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;John B. Henneman, III<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,261</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">349,963</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,224</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(149,179,215)">
    <TD STYLE="text-align: left">&nbsp;Raymond J. Land</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,810</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,999</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,809</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Glenn R. Larsen, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,999</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">237,499</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(149,179,215)">
    <TD STYLE="text-align: left">&nbsp;Stephen O. Richard<SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,451</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">349,963</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369,414</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Jeffery S. Thompson</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,310</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,999</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">253,309</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(149,179,215)">
    <TD STYLE="text-align: left">&nbsp;Susan N. Vogt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,316</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,999</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">245,316</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-size: 8pt">(1)</FONT></TD>
    <TD STYLE="width: 96%; text-align: justify"><FONT STYLE="font-size: 8pt">Except as otherwise noted, an amount of 4,107 restricted stock units
        were awarded per director on February 25, 2020, based on the closing price of $42.61 per share, and which vested in their totality on
        February 25, 2021. The amounts in this column reflect the grant date fair value computed with respect to the restricted stock units made
        during 2020 in accordance with ASC Topic 718. See the information appearing in Note 14 to our consolidated financial statements included
        as part of our Annual Report on Form 10-K for the year ended December 31, 2020 for certain assumptions made in the valuation of these
        restricted stock unit awards.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 4%"><FONT STYLE="font-size: 8pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; width: 96%"><FONT STYLE="font-size: 8pt">The aggregate number of shares outstanding for each director as of
        December 31, 2020 were: 4,107 for each of Messrs. Bower, Land, Thompson, Dr. Larsen and Ms. Vogt, and, 9,310 for each of Messrs. Henneman
        and Richard.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Henneman joined our Board of Directors and became a Compensation Committee
        member and a Governance and Nominating Committee member on September 3, 2020.&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">An amount of 9,310 restricted stock units were awarded to each of Messrs. Henneman
        and Richard upon their appointments to the Board of Directors on September 3, 2020, based on the closing price of $37.59 per share. Such
        awards vest ratably over 3 years beginning on the date of the company's annual meeting in 2021, and vest on the date of each annual meeting
        thereafter.&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Richard joined our Board of Directors and became an Audit Committee member
        on September 3, 2020.&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 14pt"><A NAME="a_038"></A>Director
and Executive Officer Stock Retention Guidelines</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 6, 2015, the Board of Directors
adopted stock retention guidelines that generally require each of our directors and executive officers to beneficially own certain amounts
of our common stock. We believe that ownership of shares of common stock by directors and executive officers helps align the financial
interests of these individuals with the interests of stockholders, promotes sound corporate governance, and evidences a commitment to
our company. These stock retention guidelines supersede the director stock retention guidelines previously adopted by the Board on April
22, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, these guidelines require each director
to beneficially own, at a minimum, either (a) 3,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents)
of common stock having a market value equal to three times the amount of our annual Board retainer for the non-lead or non-chairman directors.&nbsp;The
minimum shareholding requirement became effective immediately, except that any director has three years from the date of their initial
election to achieve compliance. Compliance by each director will be reviewed annually by the Board&rsquo;s Governance and Nominating Committee,
which is authorized to approve exceptions upon a showing of serious hardship.&nbsp;A non-complying director must retain at least 75% of
the shares (net of shares sold or offset to pay the exercise price and taxes) the director subsequently acquires through exercise of equity
grants, until the director complies with the guidelines. As of December 31, 2020, each of the following directors had met his or her minimum
shareholding requirement: Joseph Bower, Raymond Land, Jeffery Thompson, and Susan Vogt. John Henneman and Stephen Richard are within the
three-year phase-in period for directors to meet their required ownership threshold, such phase-in period to be completed on September
3, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="p64.jpg" ALT="" STYLE="height: 231px; width: 350px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, the stock retention guidelines require
the Chief Executive Officer to beneficially own, at a minimum, either (a) 50,000 outstanding shares of common stock or (b) a number of
shares (or vested share equivalents) of common stock having a market value equal to three times the amount of his or her base salary.
The guidelines require any other executive officer to beneficially own, at a minimum, either (a) 10,000 outstanding shares of common stock
or (b) a number of shares (or vested share equivalents) of common stock having a market value equal to the amount of his or her base salary.&nbsp;The
minimum shareholding requirement became effective immediately upon adoption of the stock retention guidelines, except that any individual
has five years after initial election to achieve compliance. Compliance by each executive officer is reviewed annually by the Governance
and Nominating Committee, which is authorized to approve exceptions upon a showing of serious hardship.&nbsp;A non-complying executive
officer must retain at least 75% of the shares (net of shares sold or offset to pay the exercise price and taxes) he or she subsequently
acquires through exercise of equity grants, until he or she complies with the guidelines. Each of our executive officers is within the
five-year phase-in period to meet his or her required shareholding requirement, such period to be completed on April 26, 2025 for Cheryl
R. Blanchard, our President and Chief Executive Officer; August 10, 2025 for Michael L. Levitz, our Executive Vice President, Chief Financial
Officer and Treasurer; March 4, 2025 for David Colleran, our Executive Vice President, General Counsel, and Secretary; October 30, 2022
for Thomas Finnerty, our Executive Vice President, Human Resources; and July 8, 2024 for James Loerop, our Executive Vice President, Business
Development and Strategic Planning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock retention guidelines were most recently
reviewed and verified by the Governance and Nominating Committee on March 10, 2021.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_039"></A>Compensation
Committee Interlocks and Insider Participation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee as of December 31,
2020 consisted of Dr. Joseph L. Bower, John Henneman, Raymond Land, and Dr. Glenn Larsen. None of these individuals is or formerly was
an officer or employee of our company, nor have they engaged in any transactions involving our company that would require disclosure as
a transaction with a related person. There are no Compensation Committee interlocks between our company and any other entity involving
our or such entity&rsquo;s executive officers or board members. When Dr. Blanchard became our interim Chief Executive Officer on February&nbsp;10,
2020, she relinquished her role on the Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended December&nbsp;31,
2020, none of our executive officers served as: (1)&nbsp;a member of the Compensation Committee (or other committee of the Board of Directors
performing equivalent functions or, in the absence of any such committee, the entire Board) of another entity, one of whose executive
officers served on the Compensation Committee, with the exception of Dr. Blanchard who relinquished her role when she became our interim
Chief Executive Officer, as described above; (2)&nbsp;a director of another entity, one of whose executive officers served on the Compensation
Committee; or (3)&nbsp;a member of the compensation committee (or other committee of the Board performing equivalent functions or, in
the absence of any such committee, the entire Board) of another entity, one of whose executive officers served as a director on the Board.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><A NAME="a_040"></A>Equity
Compensation Plan Information</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information concerning
our equity compensation plan as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD COLSPAN="13" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity Compensation Plan Information</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Plan category</TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of securities to be issued upon <BR>
exercise of outstanding options, stock <BR>
appreciation rights, performance shares <BR>
and restricted stock units (1)</TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average exercise price <BR>
of outstanding options, stock <BR>
appreciation rights, and <BR>
performance shares</TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of securities remaining <BR>
available for future issuance under <BR>
equity compensation plans</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 55%; text-align: left">Equity compensation plans approved by security holders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: center">1,308,355</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: center">$41.50</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: center">1,618,173</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">N/A</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">N/A</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">N/A</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 40pt; text-align: left">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">1,308,355</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">$41.50</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">1,618,173</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_041"></A>Proposal
2: Amendment of 2017 Omnibus Incentive Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>History of the Anika Therapeutics,
Inc. 2017 Omnibus Incentive Plan (as amended June 16, 2020)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2017, the Board of Directors, upon
the recommendation of the Compensation Committee, adopted the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, or the Original Plan,
for officers, employees, non-employee directors and other key persons of Anika Therapeutics, Inc. and its subsidiaries, subject to the
approval of our stockholders. Our stockholders approved the Original Plan at the 2017 Annual Meeting of Stockholders. On March&nbsp;19,
2019, the Board, upon the recommendation of the Compensation Committee, approved the amendment of the Original Plan (or the First Amended
Plan) to increase the number of shares of common stock reserved by 1,500,000, from 1,200,000 to 2,700,000 shares, subject to the approval
of the amendment by our stockholders. Additionally, the Board approved certain clarifying amendments to the sections governing minimum
vesting and tax withholding to facilitate plan administration. Our stockholders approved the First Amended Plan on June 18, 2019. On April
23, 2020, the Board, upon the approval of the Compensation Committee, approved the amendment of the First Amended Plan (or the Second
Amended Plan) to increase the number of shares of common stock reserved by 800,000, from 2,700,000 to 3,500,000 shares, subject to the
approval of the amendment by our stockholders. The Board also approved an amendment to the First Amended Plan to allow for all 3,500,000
authorized under the plan to be issued as Incentive Stock Options under Section 422 of the Internal Revenue Code of 1986, or the Code.
No other provisions of the First Amended Plan were proposed to be amended. Our stockholders approved the Second Amended Plan on June 16,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2021, the Board, upon the recommendation
of the Compensation Committee, approved the amendment of the Second Amended Plan to increase the number of shares of common stock reserved
by 1,100,000 from 3,500,000 to 4,600,000 shares, subject to the approval of the amendment by our stockholders. The Board also approved
an amendment to the Second Amended Plan to allow for all 4,600,000 shares authorized under the plan to be issued as Incentive Stock Options
under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Plan Amendment to Provide Adequate
Shares to Attract and Retain Talent to Execute Strategic Plan and Drive Shareholder Value</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board recommends that stockholders approve
the amendment to the Second Amended Plan (the Third Amended Plan). The overall purposes of the Third Amended Plan continue to be to enhance
our ability to attract and retain highly qualified officers, non-employee directors, key employees and consultants, and to motivate those
service providers to serve us and to expend maximum effort to improve our business results and earnings, by providing to those service
providers an opportunity to acquire or increase a direct proprietary interest in our operations and future success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, since our appointment of Dr. Blanchard
as President and Chief Executive Officer following our early 2020 acquisitions of Parcus Medical and Arthrosurface, we have established
new strategic priorities that will guide the next phase of our transformation into a global, commercial joint preservation company. One
of our significant focuses and strategic priorities is investing in our people and strengthening our employee value proposition to help
us drive better outcomes for our customers and the patients that they treat, which will in turn help us create value for our stockholders.
Equity-based compensation is a critical component of our ability to both attract and retain talent in a very competitive Life Sciences
sector, especially near our corporate headquarters and major operating location outside of Boston, MA. Under Dr. Blanchard&rsquo;s leadership,
we have hired experienced senior talent as part of our transformation, and we will continue to recruit top talent throughout the organization.
It is critical that we have the ability to issue equity to these individuals to help attract them to the company, retain their services,
and align their interests to those of stockholders and the creation of long-term stockholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we realign our company with our new strategic
plan and priorities, our stock price has not appreciated in the short term, an effect that was exacerbated by market-wide impacts due
to the COVID-19 pandemic. The lack of appreciation thus far in our share price, combined with our growth through acquisitions and new
hires, has impacted the pool of shares we have available under the Second Amended Plan. In order to continue to attract and retain employees
and align their interests with those of our stockholders, we are seeking stockholder approval to make an additional 1,100,000 shares available
for issuance under the Third Amended Plan, which would increase the number of available shares under the Plan from 758,748 shares as of
April 20, 2021 to 1,858,748 shares in total, pending stockholder approval. The 1,100,000 shares requested reflects our estimate of the
number of shares we would grant under the Third Amended Plan over the course of the next year based on our current share price, recent
burn rate history, and new-hire and annual grant practices. If the proposed Third Amended Plan is not approved by our stockholders, we
currently anticipate that we will exhaust the 758,748 shares that remain available for issuance under the Second Amended Plan by early
2022, and we would not be able to maintain our competitive annual equity grant practices to key employees during the 2022 annual compensation
cycle due to lack of shares available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the opinion of the Board, our future success
depends in large part on our ability to maintain a competitive position in attracting, retaining, and motivating key employees with experience
and ability. The Board believes that approval of the Third Amended Plan, including the authorization of the additional shares for issuance
thereunder, is appropriate and in the best interests of our stockholders given our current expectations on hiring, the highly competitive
environment in which we recruit and retain employees, and our historical burn rate. Our Compensation Committee will carefully consider
all proposed grants under the Third Amended Plan. Nevertheless, we are in a transition period and are seeking shareholder approval only
for an amount of additional shares necessary to align to one annual grant cycle to ensure that we are able to appropriately incentivize
our key employees. We expect to roll out shortly a comprehensive strategic plan to deliver superior value to our stockholders and other
stakeholders and look forward to engaging with our stockholders regarding it once we do so. Our compensation programs will be a part of,
and tie directly into, this comprehensive strategic plan, and we anticipate seeking shareholder approval at next year&rsquo;s annual meeting
for the additional shares needed to fund an equity incentive program designed to align closely with the goals of our comprehensive strategic
plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>Shares
Subject to the Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes information regarding
awards outstanding and shares of our common stock remaining available for grant under the Second Amended Plan as of April 20, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; width: 88%">Stock Options Outstanding</TD>
    <TD STYLE="text-align: center; width: 12%">1,247,393</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; background-color: #C6D9F1">Weighted Average Exercise Price of Stock Options Outstanding</TD>
    <TD STYLE="text-align: center; background-color: #C5D9F1">$39.36</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">Weighted Average Remaining Term of Stock Options Outstanding</TD>
    <TD STYLE="text-align: center">8.9</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; background-color: #C6D9F1">Full Value Awards Outstanding (RSAs, RSUs and PSUs)</TD>
    <TD STYLE="text-align: center; background-color: #C5D9F1">621,026</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; background-color: white">Shares Available for Grant under the Second Amended Plan*</TD>
    <TD STYLE="text-align: center">758,748</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">* The Third Amended
Plan will continue to employ a &ldquo;fungible&rdquo; plan design that assigns a higher cost to &ldquo;full-value&rdquo; awards (all awards
other than stock options and stock appreciation rights) by reducing the share pool on a greater than one-for-one basis when full-value
shares are granted. Consistent with the First and Second Amended Plans, we have maintained a fungible rate of 2.0 common shares per full-value
award in the Third Amended Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares remaining available for grant
under the Second Amended Plan as noted in the previous table differs from those reported as of December&nbsp;31, 2020 because that information
does not take into account&nbsp;year-to-date&nbsp;grants for our annual grant cycle and grants to new-hires who started after January
1, 2021. Information regarding the number of shares remaining available for grant as required by SEC disclosure rules are discussed in
detail under &ldquo;Equity Compensation Plan Information&rdquo; on page 61. In addition, the company has historically made equity grants
to directors in the first quarter of each year to align to the annual grant cycle that we utilize for employees. In 2021, we have augmented
this approach to align the annual grant cycle for directors to our annual meeting cycle. As a result, we expect to make our annual equity
grant to directors immediately following the annual meeting, and shares granted to our directors in 2021 will further reduce the shares
available for grant under the Second Amended Plan.</P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>Historic
Equity Usage</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of our ongoing review of our compensation
plans, we calculate our annual &ldquo;burn rate&rdquo; to help us determine, among other things, the expected remaining life of our equity
incentive plans based on the current number of outstanding shares. Burn rate is calculated by dividing the aggregate number of stock options
and full-value awards (as adjusted by the fungible rate) granted during the year by our basic weighted average common shares outstanding
during the year. The following table provides detailed information regarding the activity related to our equity incentive plans and weighted
average ordinary shares outstanding for the three fiscal years ending on December&nbsp;31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: middle; background-color: white">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: left; width: 71%">Award Type</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 9%">FY 2018</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 9%">FY 2019</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 11%">FY 2020</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; background-color: #C6D9F1">Stock Options Granted</TD>
    <TD STYLE="text-align: center; background-color: #C6D9F1">199,970</TD>
    <TD STYLE="text-align: center; background-color: #C6D9F1">254,517</TD>
    <TD STYLE="text-align: center; background-color: #C5D9F1">598,815</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: white">
    <TD STYLE="text-align: left">Stock Settled Restricted Stock/RSUs Granted</TD>
    <TD STYLE="text-align: center">160,070</TD>
    <TD STYLE="text-align: center">712,464</TD>
    <TD STYLE="text-align: center">924,499</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: #C6D9F1">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Basic Weighted. Avg. Common Shares Outstanding</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">14,442,000</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">14,121,000</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">14,222,000</TD></TR>
  <TR STYLE="vertical-align: middle; background-color: white">
    <TD STYLE="font-weight: bold; text-align: left">Annual Burn Rate</TD>
    <TD STYLE="text-align: center">2.49%</TD>
    <TD STYLE="text-align: center">6.85%</TD>
    <TD STYLE="text-align: center">10.71%</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="font-weight: bold; text-align: left">Three Year Avg. Burn Rate (FY 2018-2020)</TD>
    <TD STYLE="text-align: center; background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: center; background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: center; background-color: white">6.68%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the current range of our stock price,
our current compensation practices, our anticipated future awards, as well as our three-year burn rate experience, we are requesting an
additional 1,100,000 shares to be added to the 3,500,000 shares already authorized under the Second Amended Plan. We believe this request
for additional shares, together with the shares currently available, will be sufficient for us to grant equity awards for approximately
one and a half years. We expect that 1,100,000 shares approximates our share usage in a single annual compensation cycle based on our
stock price and compensation philosophy and policies. Our actual share usage will vary depending on a number of factors, including the
number of employees receiving equity awards, the prevailing price per share of our common stock, the methodology used to value and determine
the size of equity awards, and the mix of award types provided to participants. We believe that our requested number of common shares
will give us the necessary flexibility we need to respond to these changes and other unanticipated circumstances that may arise during
the life of the Third Amended Plan. As stated above, we anticipate that we will be seeking stockholder approval at next year&rsquo;s annual
meeting for an additional number of shares to fund an equity program in line with our comprehensive strategic plan. As of April 20, 2021,
the closing price of a share of common stock on the NASDAQ Global Select Market was $40.60.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Third Amended Plan marked to show
the amendment approved by the Board on March 17, 2021 is attached as <I>Appendix&nbsp;A</I> to this proxy statement and is incorporated
herein by reference. The following discussion summarizes certain features and effects of the Second Amended Plan as proposed to be amended
herein, which we refer to below as the Third Amended Plan, and it is qualified in its entirety by reference to the terms of Third Amended
Plan set forth in <I>Appendix A</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>Key
Features of the Third Amended Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of key features of
the Third Amended Plan, which are intended to protect the interests of our stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Limitation on terms of stock options and stock appreciation rights</I>. The maximum term of each stock
        option and Stock Appreciation Right, or SAR, is 10 years.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Minimum vesting requirement</I>. The Third Amended Plan includes minimum vesting requirements that were
        updated in the First Amended Plan to reflect current administrative practices. Equity-based awards generally cannot vest earlier than
        one year after grant. Certain limited exceptions are permitted.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>No repricing or grant of discounted stock options.</I> The Third Amended Plan does not permit the repricing
        of options or SARs either by amending an existing award or by substituting a new award at a lower price without stockholder approval.
        The Third Amended Plan prohibits the granting of stock options or SARs with an exercise price less than the fair market value of the common
        stock on the date of grant.</TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>No transferability</I>. Awards generally may not be transferred, except by will or the laws of descent
        and distribution, unless approved by the plan administrator.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>No single-trigger vesting on a change in control</I>. In the event of a change in control of our company,
        the plan administrator may provide for accelerated vesting of outstanding awards, but there is no automatic acceleration of awards upon
        a change in control.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>No dividends on options, SARs or unvested share awards</I>. The Third Amended Plan prohibits the payment
        of dividends or dividend equivalents on stock options and SARs, or on any other awards that have not vested.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Multiple award types</I>. The Third Amended Plan permits the issuance of incentive stock options, non-qualified
        stock options, SARs, restricted stock units, restricted stock awards, and other types of share and cash-based awards, subject to the share
        limits of the Third Amended Plan. This gives us the flexibility to grant different type of awards as compensation tools to motivate our
        workforce.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Independent oversight</I>. The Third Amended Plan is administered by the Compensation Committee, which
        is comprised of independent members of the Board of Directors.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Director limits</I>. The Third Amended Plan contains annual limits on the value of awards that may be granted
        to non-employee directors.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>Summary
of the Third Amended Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of certain features
of the Third Amended Plan is intended to be a summary only, and it is qualified in its entirety by reference to the terms of the Third
Amended Plan set forth in <I>Appendix A</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Plan Administration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As with the Second Amended Plan, the Third Amended
Plan may be administered by the Board of Directors or the Compensation Committee. The Board or Compensation Committee so acting is referred
to below as the Administrator. The Administrator, in its discretion, selects the individuals to whom awards may be granted, the time or
times at which such awards are granted and the terms and conditions of such awards. In addition, the Administrator may not reprice outstanding
options or cancel stock options or SARs for cash without prior stockholder approval, other than to appropriately reflect changes in our
capital structure. The Administrator may delegate to the Chief Executive Officer the authority to grant stock options to employees who
are not subject to the reporting and other provisions of Section 16 of the Exchange Act, subject to certain limitations and guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Eligibility</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As with the Second Amended Plan, all full-time
and part-time officers, employees, non-employee directors, and other key persons of our company and subsidiaries are eligible to participate
in the Third Amended Plan, subject to the discretion of the Administrator. The number of individuals potentially eligible to participate
in the Third Amended Plan is currently approximately 281 persons, including 5 executive officers and 7 non-employee directors. The Administrator
will use its discretion to select individuals to participate in the Third Amended Plan who are responsible for, or contribute to, our
management, growth, or profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Plan Limits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock authorized
for issuance under the Third Amended Plan is 4,600,000 shares comprised of the 3,500,000 shares approved under the Second Amended Plan
and 1,100,000 additional shares if the amendment to the Second Amended Plan is approved by the stockholders. These additional shares represent
7.7% of the fully diluted common stock outstanding as of April 20, 2021. In addition, any shares subject to outstanding awards under the
Second Amended Plan that subsequently expire, terminate, or are surrendered or forfeited for any reason without issuance of shares will
automatically become available for issuance under the Third Amended Plan. In addition, under the Third Amended Plan, up to 4,600,000 shares
may be granted as incentive stock options under Code Section 422. The shares of common stock issuable under the Third Amended Plan will
consist of authorized and unissued shares, treasury shares, or shares purchased on the open market or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Third Amended Plan makes no changes to the
share counting and share recycling provisions under the Second Amended Plan. For purposes of determining the number of shares available
for issuance under the Third Amended Plan, the grant of any &ldquo;full value award&rdquo; (<I>i.e.</I>, a restricted stock award, deferred
stock award, unrestricted stock award, or performance share) shall be deemed an award of two shares for each share subject to such full
value award. For purposes of determining the number of shares available for issuance under the Third Amended Plan, the grant of any option
or SAR shall be deemed an award of one share for each share subject to such option or SAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any award expires, terminates, is settled in
cash, or is surrendered or forfeited, the shares subject to such awards will not count against the aggregate number of shares of common
stock available for grant under the Third Amended Plan. Additionally, awards granted in assumption of or in substitution for awards previously
granted by an acquired company will not count against the shares available for grant. Shares issuable upon exercise, vesting, or settlement
or an award, or shares surrendered or tendered to pay the exercise price or taxes required to be withheld with respect to an award, shall
not be available again for the grant of awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Third Amended Plan makes no changes to the
individual award limits included in the Second Amended Plan, although these award limits are no longer needed as the result of changes
in the federal tax laws effective in 2018. The maximum award of stock options or SARs granted to any one individual will not exceed 400,000
shares of common stock (subject to adjustment for stock splits and similar events) for any calendar-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Awards to Non-Employee Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As under the Second Amended Plan, the maximum
value of plan awards granted during any calendar year to any non-employee director, taken together with any cash fees paid to such non-employee
director during the calendar year and the value of awards granted to the non-employee director under any other equity compensation plan
of our company or an affiliate during the calendar year, may not exceed the following in total value (calculating the value of any equity
compensation plan awards based on the grant date fair market value for financial reporting purposes): (a)&nbsp;$500,000 for the Chair
of the Board; and (b)&nbsp;$425,000 for each non-employee director other than the Chair of the Board. However, awards granted to non-employee
directors upon their initial election to the Board of Directors or the board of directors of an affiliate will not be counted towards
this limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Tax Withholding</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Participants under the Third Amended Plan are
responsible for the payment of any federal, state, or local taxes that we are required by law to withhold upon any option or SAR exercise
or vesting or payment of other awards. Subject to approval by the Administrator, participants may elect to have the tax withholding obligations
satisfied either by authorizing us to withhold shares of common stock to be issued pursuant to an option exercise or other award, or by
transferring to us shares of common stock having a value equal to the amount of such taxes. Such share withholding may be made at up to
maximum statutory tax rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Change of Control Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As under the Second Amended Plan, the Third Amended
Plan provides that upon the effectiveness of a &ldquo;change in control&rdquo; as defined in the Third Amended Plan, the Administrator
may take any one or more of the following actions, with or without the consent of a participant: (a) accelerate the vesting or settlement
of awards on the terms and conditions determined by the Administrator (including upon a participant&rsquo;s separation from service following
the change in control); (b) permit the assumption or substitution of outstanding awards by the acquiror in the change in control, and
cancel any awards that are not assumed or substituted for; or (c) cancel outstanding vested awards in exchange for cash, the stock of
the acquiror, or other property having a fair market value equal to the consideration paid for shares in the change in control (reduced
by the exercise price of an award, if necessary).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"></P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Adjustments for Stock Dividends,
Mergers, etc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As under the Second Amended Plan, subject to any
required action by our stockholders, in the event of any change in our common stock effected without receipt of consideration by us, whether
through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse
stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in our capital structure, or
in the event of payment of a dividend or distribution to our stockholders in a form other than our common stock (excepting normal cash
dividends) that has a material effect on the fair market value of our common stock, appropriate and proportionate adjustments will be
made in the number and class of shares subject to the Third Amended Plan and to any outstanding awards, and in the option exercise price,
SAR exercise price, or purchase price per share of any outstanding awards in order to prevent dilution or enlargement of participant rights
under the Third Amended Plan. If a majority of our common shares are exchanged for, converted into, or otherwise become shares of another
corporation, the Administrator may unilaterally amend outstanding awards under the Third Amended Plan to provide that such awards are
for new shares. In the event of any such amendment, the number of shares subject to, and the option exercise price, SAR exercise price,
or purchase price per share of, the outstanding awards will be adjusted in a fair and equitable manner as determined by the Administrator.
The Administrator may also make such adjustments in the terms of any award to reflect, or related to, such changes in our capital structure
or distributions as it deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>No Repricing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without stockholder approval, the Administrator
is not authorized to (a) lower the exercise or grant price of a stock option or SAR after it is granted, except in connection with certain
adjustments to our corporate or capital structure permitted by the Third Amended Plan, such as stock splits, (b) take any other action
that is treated as a repricing under generally accepted accounting principles or (c) cancel a stock option or SAR at a time when its exercise
or grant price exceeds the fair market value of the underlying stock, in exchange for cash, another stock option or SAR, restricted stock,
restricted stock units or other equity award, unless the cancellation and exchange occur in connection with a change in capitalization
or other similar change. These provisions are unchanged from the Second Amended Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Minimum Vesting Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity-based awards granted under the Third Amended
Plan will have a one-year minimum vesting requirement. This requirement does not apply to (1) substitute awards resulting from acquisitions,
(2) shares delivered in lieu of fully vested cash awards, or (3) awards to non-employee directors that vest on the earlier of the one-year
anniversary of the date of grant or the next annual meeting of stockholders (but not sooner than 50 weeks after the grant date). Also,
the Compensation Committee may grant equity-based awards without regard to the minimum vesting requirement with respect to a maximum of
five percent of the available share reserve authorized for issuance under the Third Amended Plan. In addition, the minimum vesting requirement
does not apply to the Administrator&rsquo;s discretion to provide for accelerated exercisability or vesting of any award, including in
cases of retirement, death, disability or a change in control, in the terms of the award or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Amendments and Termination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless earlier terminated by the Board of Directors,
the Third Amended Plan will terminate, and no further awards may be granted, 10 years after the date on which the Original Plan was approved
by stockholders. The Board may amend, suspend, or terminate the Third Amended Plan at any time, except that, if required by applicable
law, regulation, or stock exchange rule, stockholder approval will be required for any amendment. The amendment, suspension, or termination
of the Third Amended Plan or the amendment of an outstanding award generally may not, without a participant&rsquo;s consent, materially
impair the participant&rsquo;s rights under an outstanding award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Transferability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awards are not transferable other than by will
or the laws of descent and distribution, except that in certain instances transfers may be made to or for the benefit of designated family
members of the participant for no value.</P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>Types
of Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Third Amended Plan makes no changes to the
types of awards as authorized under the Second Amended Plan, which are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options granted under the Third Amended Plan may
be either incentive stock options, which must comply with Code Section&nbsp;422, or non-qualified stock options. Incentive stock options
may be granted only to employees of our company or any subsidiary. Options granted under the Third Amended Plan will be non-qualified
stock options if they (a) fail to qualify as incentive stock options, (b) are granted to a person not eligible to receive incentive stock
options under the Code, or (c)&nbsp;otherwise so provide. Non-qualified stock options may be granted to persons eligible to receive incentive
stock options and to non-employee directors and other key persons. The Administrator has authority to determine the terms and conditions
of options at the time of grant, including quantity of shares covered, exercise price, method of exercise, vesting conditions, the term
(which cannot exceed 10 years), and other conditions on exercise. Stock options must be granted with an exercise price not less than 100%
of the fair market value of our common stock on the date of grant (excluding stock options granted in connection with assuming or substituting
stock options in acquisition transactions). The Third Amended Plan prohibits the payment of dividends or dividend equivalent rights on
unvested stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Stock Appreciation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Administrator may award SARs, with a term
not to exceed 10 years. Upon exercise of an SAR, the holder will be entitled to receive an amount equal to the excess of the fair market
value on the date of exercise of one share of common stock over the exercise price per share specified in such right times the number
of shares of common stock with respect to which the SAR is exercised. This amount may be paid in cash, common stock, or a combination
thereof, as determined by the Administrator. The exercise price is the fair market value of the common stock on the date of grant. The
Third Amended Plan prohibits the payment of dividends or dividend equivalent rights on SARs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Restricted Stock and Restricted
Stock Unit Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Administrator may grant shares of restricted
stock, which are shares of common stock subject to specified restrictions, and restricted stock units or RSUs, which represent the right
to receive shares of our common stock in the future. These awards may be made subject to repurchase, forfeiture, or vesting restrictions
at the Administrator&rsquo;s discretion. The restrictions may be based on continuous service with us or the attainment of specified performance
goals, as determined by the Administrator. RSUs may be paid in stock or cash or a combination of stock and cash, as determined by the
Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Other Share- and Cash-Based
Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Administrator may also grant awards based
on shares of stock, either alone or in addition to or in conjunction with other awards. Such awards may be granted in lieu of other cash
or other compensation to which a participant is entitled from us or may be used in the settlement of amounts payable under any of our
other compensation plans or arrangements. The Administrator shall have the authority to determine the persons to whom and the time or
times at which such Awards will be made, the number of shares to be granted pursuant to such Awards, and all other terms of such Awards.
The Administrator may grant cash bonuses under the Third Amended Plan. The cash bonuses may be subject to achievement of certain performance
goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Performance Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of grant, the Administrator may condition
the grant, exercise, vesting, or settlement of any award on such performance conditions as it may specify. We refer to these awards as
&ldquo;performance awards.&rdquo; The Administrator may select such business criteria or other performance measures as it may deem appropriate
in establishing any performance conditions.</P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>New
Plan Benefits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A new plan benefits table for the Third Amended
Plan and the benefits or amounts that would have been received by or allocated to participants for the last completed fiscal year under
the Third Amended Plan if the Third Amended Plan was then in effect, as described in the SEC proxy rules, are not provided because all
awards made under the Third Amended Plan will be made at the Administrator&rsquo;s discretion, subject to the terms and conditions of
the Third Amended Plan. Therefore, the benefits and amounts that will be received or allocated under the Third Amended Plan are not determinable
at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>Federal
Income Tax Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following is a brief summary of the U.S.
federal income tax consequences of the Third Amended Plan generally applicable to us and to participants in the Third Amended Plan who
are subject to U.S. federal taxes. The summary is based on the Code, applicable Treasury Regulations, and administrative and judicial
interpretations thereof, each as in effect on the date of this Proxy Statement, and is, therefore, subject to future changes in the law,
possibly with retroactive effect. The summary is general in nature and does not purport to be legal or tax advice. Furthermore, the summary
does not address issues relating to any U.S. gift or estate tax consequences or the consequences of any state, local or foreign tax laws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Non-qualified Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A participant generally will not recognize taxable
income upon the grant or vesting of a non-qualified stock option with an exercise price at least equal to the fair market value of the
common stock on the date of grant and no additional deferral feature. Upon the exercise of a non-qualified stock option, a participant
generally will recognize compensation taxable as ordinary income in an amount equal to the difference between the aggregate fair market
value of the exercised shares underlying the stock option on the date of exercise and the aggregate exercise price of the exercised shares.
When a participant sells the shares, the participant will have short-term or long-term capital gain or loss, as the case may be, equal
to the difference between the amount the participant received from the sale and the tax basis of the shares sold. The tax basis of the
shares generally will be the fair market value of the shares on the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Incentive Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A participant generally will not recognize taxable
income upon the grant of an incentive stock option. If a participant exercises an incentive stock option during employment or within three
months after employment ends (one year in the case of permanent and total disability), the participant will not recognize taxable income
at the time of exercise for regular U.S. federal income tax purposes (although the participant generally will have taxable income for
alternative minimum tax purposes at that time as if the stock option were a non-qualified stock option). If a participant sells or otherwise
disposes of the shares acquired upon exercise of an incentive stock option after the later of (a) one year from the date the participant
exercised the option and (b) two years from the grant date of the stock option, the participant generally will recognize long-term capital
gain or loss equal to the difference between the amount the participant received in the disposition and the exercise price of the stock
option. If a participant sells or otherwise disposes of shares acquired upon exercise of an incentive stock option before these holding
period requirements are satisfied, the disposition will constitute a &ldquo;disqualifying disposition,&rdquo; and the participant generally
will recognize taxable ordinary income in the year of disposition equal to the excess of the fair market value of the shares on the date
of exercise over the exercise price of the stock option (or, if less, the excess of the amount realized on the disposition of the shares
over the exercise price of the stock option). The balance of the participant&rsquo;s gain on a disqualifying disposition, if any, will
be taxed as short-term or long-term capital gain, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to both non-qualified stock options
and incentive stock options, special rules apply if a participant uses shares of common stock already held by the participant to pay the
exercise price or if the shares received upon exercise of the stock option are subject to a substantial risk of forfeiture by the participant.</P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Stock Appreciation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A participant generally will not recognize taxable
income upon the grant or vesting of a SAR with a grant price at least equal to the fair market value of common stock on the date of grant
and no additional deferral feature. Upon the exercise of a SAR, a participant generally will recognize compensation taxable as ordinary
income in an amount equal to the difference between the aggregate fair market value of the exercised shares underlying the SAR on the
date of exercise and the aggregate grant price of the exercised shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Restricted Stock Awards, Restricted
Stock Units, and Performance Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A participant generally will not have taxable
income upon the grant of restricted stock, restricted stock units or performance awards. Instead, the participant will recognize ordinary
income at the time of vesting or payout equal to the fair market value (on the vesting or payout date) of the shares or cash received
minus any amount paid. For restricted stock only, a participant may instead elect to be taxed at the time of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Other Stock or Cash-Based Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. federal income tax consequences of other
stock or cash- based awards will depend upon the specific terms of each award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Tax Consequences to Us</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the foregoing cases, we generally will be entitled
to a deduction at the same time, and in the same amount, as a participant recognizes ordinary income, subject to limitations imposed under
the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Section 409A</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend that awards granted under the Third
Amended Plan comply with, or otherwise be exempt from, Code Section 409A, but make no representation or warranty to that effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Tax Withholding</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are authorized to deduct or withhold from any
award granted or payment due under the Third Amended Plan, or require a participant to remit to us, the amount of any withholding taxes
due in respect of the award or payment and to take such other action as may be necessary to satisfy all obligations for the payment of
applicable withholding taxes. We are not required to issue any shares of common stock or otherwise settle an award under the Third Amended
Plan until all tax withholding obligations are satisfied.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Annual Meeting, the approval of the amendment
to the Second Amended Plan requires the affirmative vote of the holders of a majority of the shares of common stock that are voting on
the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Board
Recommendation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
A VOTE &ldquo;FOR&rdquo; THE AMENDMENT OF THE SECOND AMENDED PLAN.</B></P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_042"></A>Proposal
3: Approval of 2021 Employee Stock Purchase Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2021, the Board of Directors, upon
the recommendation of its Compensation Committee, adopted the Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan, or the ESPP,
subject to stockholder approval. The Board unanimously recommends that stockholders vote to approve the ESPP. The ESPP will encourage
stock ownership by all eligible employees of our company and participating subsidiaries so that they may share in our growth by acquiring
or increasing their proprietary interest in our company. Stockholder approval of the ESPP is necessary in order to satisfy the stockholder
approval requirements of The Nasdaq Stock Market and requirements under Section&nbsp;423 of the Internal Revenue Code of 1986, as amended,
or the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the ESPP is approved by the stockholders at
the Annual Meeting, it will become effective immediately. If the ESPP is not approved by the stockholders, it will not become effective
and employees of our company and subsidiaries will not be able to participate in the ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>Summary
of the ESPP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the material terms
of the ESPP. These sections are qualified in their entirety by the full text of the ESPP, which is included as <I>Appendix B</I> to this
Proxy Statement. If the terms of the ESPP are amended in a manner that would require stockholder approval under the requirements of The
Nasdaq Stock Market or under Code Section 423, stockholders will be asked to approve such amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Purpose</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ESPP is intended to encourage stock ownership
by all eligible employees of our company and participating subsidiaries so that they may share in our growth by acquiring or increasing
their proprietary interest in our company. The ESPP is designed to encourage eligible employees to remain in the employ of our company
and participating subsidiaries. The ESPP is intended to constitute an &ldquo;employee stock purchase plan&rdquo; within the meaning of
Code Section&nbsp;423(b), except as described below under &ldquo;International Participation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>General</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As further described below, the ESPP permits eligible
employees to use payroll deductions to purchase shares of common stock at a discount. The payroll deductions accumulate over &ldquo;offering
periods.&rdquo; On the first day of each offering period, each participant in the ESPP is automatically granted an option to purchase
as many whole shares of common stock as the participant will be able to purchase with the payroll deductions credited to his or her account
during the offering period, subject to various limits described below. At the end of the offering period, the total payroll deductions
of all participants are used to purchase common stock directly from us at the discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Stock Subject to the ESPP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock subject to options under the ESPP will
be shares of our authorized but unissued common stock, or shares of common stock we reacquire, including shares purchased in the open
market. The aggregate number of shares of common stock that may be issued pursuant to the ESPP is 200,000, subject to adjustment as described
below. If any option granted under the ESPP expires or terminates for any reason without having been exercised in full or ceases for any
reason to be exercisable in whole or in part, the unpurchased shares subject thereto will again be available under the ESPP. As of April
20, 2021, the closing price of a share of common stock on the NASDAQ Global Select Market was $40.60.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Administration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ESPP will be administered by the Compensation
Committee, or such other committee as determined by the Board of Directors, or the Administrator. The interpretation and construction
by the Administrator of any provisions of the ESPP or of any option granted under it will be final, unless otherwise determined by the
Board. The Administrator may from time to time adopt such rules and regulations for carrying out the ESPP as it may deem best, <I>provided</I>
that any such rules and regulations will be applied on a uniform basis to all employees under the ESPP. No member of the Board or the
Administrator will be liable for any action or determination made in good faith with respect to the ESPP or any option granted under it.</P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Eligibility</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise determined by the Administrator
with respect to an offering period prior to the start date thereof, all employees of our company or any of the participating subsidiaries
who are (a) so employed on the start date of any offering period and (b) have continuously been employed with our company or the participating
subsidiary for at least one month prior to such start date will be eligible to participate and receive an option with respect to such
offering period. All eligible employees will have the same rights and privileges under the ESPP with respect to such offering period.
In no event, however, may an employee be granted an option if such employee, immediately after the option is granted, would be treated
as owning stock possessing five percent or more of the total combined voting power or value of all classes of stock of our company or
of any parent corporation or subsidiary corporation, as the terms &ldquo;parent corporation&rdquo; and &ldquo;subsidiary corporation&rdquo;
are defined in Code Sections 424(e) and&nbsp;(f). For purposes of determining stock ownership under this paragraph, the rules of Code
Section 424(d) will apply, and stock that the employee may purchase under outstanding options (including options not granted under the
ESPP) will be treated as stock owned by the employee. Notwithstanding the foregoing, except as otherwise determined by the Administrator
with respect to an offering period prior to the start date thereof, employees who are otherwise eligible employees and who are citizens
or residents of a non-U.S. jurisdiction (without regard to whether such employee is also a citizen of the United States or a resident
alien) will not be considered an eligible employee if their participation is prohibited under the laws of the applicable non-U.S. jurisdiction
or if complying with the laws of the applicable non-U.S. jurisdiction would cause the ESPP or an offering period to violate Code Section
423. As of April&nbsp;20, 2021, 265 employees would have been eligible to participate in the ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Offering Periods; Exercise
Dates; Certain Limits.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise determined by the Administrator,
the first offering period will start on November&nbsp;15, 2021 and will end on May 14, 2022, <I>provided</I> that if such end date is
not a business day, such offering period will end on the first business day preceding such end date. Thereafter, except as otherwise determined
by the Administrator: an offering period will start on each May 15 (<I>provided </I>that if such start date is not a business day, such
start date will be the first business day following the immediately preceding exercise date (as described below) and end on the following
November 14 (<I>provided</I> that if such end date is not a business day, such end date will be the first business day preceding such
end date); and offering period will start on each November 15 (<I>provided</I> that if such start date is not a business day, such start
date will be the first business day following the immediately preceding exercise date) and end on the following May 14 (<I>provided</I>
that if such end date is not a business day, such end date will be the first business day preceding such end date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The end date within each offering period will
be the day on which shares of common stock are purchased by participants in an offering period, which date we refer to as exercise date.
On the start date of each offering period, we will grant to each eligible employee who has then elected to be a participant in the ESPP
an option to purchase shares on the relevant exercise date, at the option price hereinafter provided for, covering a maximum of 800 shares
of common stock (which maximum number may be amended by the Administrator from time to time with respect to an offering period prior to
the start date thereof), on condition that such employee remains an eligible employee through the exercise date. A participant will be
entitled to exercise the option so granted only to the extent of the participant&rsquo;s accumulated payroll deductions on the exercise
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, the Administrator
may in its discretion determine to implement offering periods of up to twenty-seven months. Those offering periods may consist of one
or more exercise dates. Each eligible employee who elects to be a participant in such an offering period will be granted an option, at
the option price, to purchase shares of common stock on such exercise date or dates. Each such option will cover a maximum number of shares
of common stock for such offering period as determined by the Administrator prior the start date of such offering period. In no event
will an offering period under the ESPP exceed twenty-seven months.</P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Option Price </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The option price per share for each exercise date
within an offering period will be 85% of the lesser of (a)&nbsp;the fair market value of the common stock on the start date of the offering
period and (b)&nbsp;the fair market value of the common stock on the exercise date, in either event rounded up to the nearest cent. Prior
to the start date of an offering period, the Administrator may increase, but not decrease, the option price with respect to such offering
period. The foregoing limitation on the number of shares subject to an option and the option price will be subject to adjustment as described
below. For purposes of the ESPP, the term &ldquo;fair market value&rdquo; on any date means the value of the common stock as determined
below. If the common stock is listed on any established stock exchange or a national market system, including the New York Stock Exchange
or the NASDAQ Stock Market, the fair market value will be the closing price of a share of common stock (or if no sales were reported on
such date, the closing price on the last trading date) as quoted on such exchange or system. In the absence of an established market for
the common stock, the fair market value will be determined in good faith by the Administrator and such determination will be conclusive
and binding on all persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>$25,000 Limitation </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No employee will be granted an option that permits
the employee&rsquo;s right to purchase stock under the ESPP, and under all other Code Section 423(b) employee stock purchase plans of
our company and any parent corporations or subsidiary corporations, as &ldquo;parent corporation&rdquo; and &ldquo;subsidiary corporation&rdquo;
are defined in Code Section 424(e) and&nbsp;(f), to accrue at a rate that exceeds $25,000 of fair market value of such stock (determined
on the date or dates that options on such stock were granted) for each calendar year in which such option is outstanding at any time.
The purpose of the limitation in the preceding sentence is to comply, and such limitation will be administered in accordance, with Code
Section 423(b)(8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Payroll Deductions; Maximum
Amount of Payroll Deductions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise determined by the Administrator
with respect to an offering period prior to the start date thereof, an employee may authorize payroll deductions in an amount (expressed
as a whole percentage) not less than 1% but not more than 15% of the employee&rsquo;s Compensation. For this purpose, &ldquo;Compensation&rdquo;
means, unless otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, an employee&rsquo;s
base pay or salary from our company or participating subsidiary, including such amounts of base pay or salary as are deferred by the employee
(a) under a qualified cash or deferred arrangement described in Code Section 401(k) or (b) to a plan qualified under Code Section 125.
Except as otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, deductions may
not be increased or decreased during an offering period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Plan Withdrawal </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise determined by the Administrator
with respect to an offering period prior to the start date thereof, a participant may withdraw from the ESPP and such offering period
(in whole but not in part) by giving notice at least three business days prior to the end date of such offering period, in which case
the entire balance of his or her unused payroll deduction account under the ESPP will be promptly refunded, without interest. Except as
otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, to re-enter the ESPP, an
employee who has previously withdrawn must file a new authorization at least ten business days before the first day of the next offering
period in which he or she wishes to participate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Adjustments; Change in Control</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any required action by the stockholders,
the Administrator, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under
the ESPP, will, in such manner as it may deem equitable, adjust the number of shares of common stock available for issuance under the
ESPP, the option price, the maximum number of shares that may be purchased during an offering period, as well as any other terms that
the Administrator determines require adjustment, for: (a) any increase or decrease in the number of issued shares of common stock resulting
from a stock split, reverse stock split, stock dividend, combination or reclassification of the common stock; (b) any other increase or
decrease in the number of issued shares of common stock effected without receipt of consideration; or (c) as the Administrator may determine
in its discretion, any other transaction with respect to common stock, including a corporate merger, consolidation, acquisition of property
or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation (whether partial or
complete), or any similar transaction; <I>provided</I> that conversion of any convertible securities will not be deemed to have been &ldquo;effected
without receipt of consideration.&rdquo; Such adjustment, if any, will be made by the Administrator and its determination will be final,
binding and conclusive. Except as the Administrator determines otherwise, no issuance of shares of stock of any class, or securities convertible
into shares of stock of any class, will require adjustment hereunder. Except as otherwise determined by the Administrator, in the event
of a Change in Control (as defined in our 2017 Omnibus Incentive Plan, as amended from time to time), all outstanding options under the
ESPP will automatically be exercised immediately before the closing of such Change in Control for whole shares as if the date of such
closing is the next exercise date, subject to the maximum 800 share limitation and the $25,000 limitation described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Transfers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An option granted under the ESPP may not be transferred
or assigned, except by will or the laws of descent and distribution, and will be exercised, during a participant&rsquo;s lifetime, only
by the participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Employee Terminations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whenever a participant ceases to be an eligible
employee because of retirement, voluntary or involuntary termination, resignation, layoff, discharge, death, or for any other reason,
his or her rights under the ESPP will immediately terminate, and the entire balance of his or her payroll deduction account under the
ESPP will be promptly refunded, without interest. Notwithstanding the foregoing, eligible employment will be treated as continuing intact
while the participant is on military leave, sick leave, or other bona fide leave of absence (such as temporary employment by the government)
if the period of such leave does not exceed three months, or if longer, so long as the participant&rsquo;s right to reemployment with
our company or participating subsidiary is provided either by statute or by contract. If the period of leave exceeds three months and
the participant&rsquo;s right to reemployment with our company or participating subsidiary is not provided either by statute or by contract,
the employment relationship will be deemed to terminate on the first day immediately following such three-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Termination of Plan; Amendment
of ESPP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless terminated sooner as provided below, the
ESPP will terminate on the tenth anniversary of its approval by the stockholders. The ESPP may be terminated at any time by the Board
of Directors but such termination will not affect options then outstanding under the ESPP. The ESPP will terminate in any case when all
or substantially all of the unissued shares of stock reserved for the purposes of the ESPP have been purchased. If at any time shares
of stock reserved for the purpose of the ESPP remain available for purchase but not in sufficient number to satisfy all then unfilled
purchase requirements, the available shares will be apportioned among participants in proportion to the amount of payroll deductions accumulated
on behalf of each participant that would otherwise be used to purchase stock, and the ESPP will terminate. Upon such termination or any
other termination of the ESPP, all payroll deductions not used to purchase stock will be refunded, without interest. The Administrator
or the Board may from time to time adopt amendments to the ESPP, <I>provided</I> that, without the approval of the stockholders, no amendment
may (a)&nbsp;increase the number of shares that may be issued under the ESPP, (b)&nbsp;change the class of employees eligible to receive
options under the ESPP, if such action would be treated as the adoption of a new plan for purposes of Code Section 423(b), or (c) be made
if it would be treated as the adoption of a new plan for purposes of Code Section 423(b) or would require stockholder approval under applicable
exchange listing rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Participation Subsidiaries
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term &ldquo;participating subsidiary&rdquo;
means any of our present or future subsidiaries, as that term is defined in Code Section&nbsp;424(f), that is designated from time to
time by the Board of Directors to participate in the ESPP. The Board will have the power to make such designation before or after the
ESPP is approved by the stockholders. The following subsidiaries are currently designated as participating subsidiaries: Arthrosurface,
Inc. and Parcus Medical, LLC.</P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>International Participation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding anything to the contrary in the
ESPP, to provide us with greater flexibility in structuring our equity compensation programs for our non-U.S. employees, the ESPP also
permits us to grant employees of our non-U.S. subsidiary entities rights to purchase shares pursuant to other offering period rules or
sub-plans adopted by the Administrator in order to achieve tax, securities law or other compliance objectives. While the ESPP is intended
to be a qualified &ldquo;employee stock purchase plan&rdquo; within the meaning of Code Section 423, any such international sub-plans
or offerings are not required to satisfy those U.S. tax code requirements and therefore may have terms that differ from the ESPP terms
applicable in the U.S. However, the international sub-plans or offering periods are subject to the ESPP terms limiting the overall shares
available for issuance, the maximum payroll deduction rate, maximum purchase price discount and the maximum offering period length.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Stockholder Status </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither the granting of an option to an employee
nor the deductions from his or her pay will constitute such employee a stockholder of the shares covered by an option until such shares
have been actually purchased by the employee. A participant will have no interest or voting right in shares covered by the participant&rsquo;s
option until such shares are actually purchased on the participant&rsquo;s behalf in accordance with the applicable provisions of the
ESPP. Except as set described above, no adjustment will be made for dividends, distributions or other rights for which the record date
is prior to the date of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Governing Law</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity and construction of the ESPP will
be governed by the laws of Delaware, without giving effect to the principles of conflicts of law thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Plan Benefits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Benefits under the ESPP will depend on participants&rsquo;
elections to participate and the fair market value of common stock at various future dates. As a result, it is not possible as of the
date of this proxy statement to determine future benefits that will be received by executive officers and other employees. Each participant
is limited to the $25,000 annual purchase restriction described above as well as the 800 share per-offering period limit described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Employees as General Creditors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will accumulate and hold for each participant&rsquo;s
account the amounts deducted from the participant&rsquo;s pay. No interest will be paid on these amounts. We may use payroll deductions
that we receive or hold under the ESPP for any corporate purpose, and we will not be obligated to segregate such payroll deductions or
hold them exclusively for the benefit of participants. All payroll deductions that we receive or hold may be subject to the claims of
our general creditors. Participants will have the status of general unsecured creditors of our company. Any amounts payable to participants
pursuant to the ESPP will be unfunded and unsecured obligations for all purposes, including Title I of the Employee Retirement Income
Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Form S-8</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate filing a registration statement
on Form S-8 with the SEC to register shares of common stock under the ESPP as soon as practicable, subject to and effective upon stockholder
approval of the ESPP.</P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><I>Certain U.S. Federal Income
Tax Consequences</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following brief summary of the effect of U.S.
federal income taxation upon a participant and our company with respect to shares of common stock purchased under the ESPP does not purport
to be complete and does not discuss the tax consequences of a participant&rsquo;s death or the income tax laws of any state or non-U.S.
jurisdiction in which the participant may reside. The ESPP, and the right of U.S. participants to make purchases thereunder, is intended
to qualify under the provisions of Code Sections 421 and 423. Under these provisions, no income will be taxable to a participant until
shares purchased under the ESPP are sold or otherwise disposed of. Upon sale or other disposition of shares, the participant generally
will be subject to tax in an amount that depends upon whether the sale occurs before or after expiration of the holding periods described
in the following sentence. If the shares are sold or otherwise disposed of more than two years from the first day of the applicable offering
period and one year from the applicable exercise date, the participant will recognize ordinary income measured as the lesser of (a) the
excess of the fair market value of the shares at the time of such sale or disposition over the option price and (b) the excess of the
fair market value of a share on the first day of the applicable offering period over the option price. Any additional gain will be treated
as long term capital gain. If the shares are sold or otherwise disposed of before the expiration of either of these holding periods, the
participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares
are purchased over the option price. Any additional gain or loss on such sale or disposition will be long- or short-term capital gain
or loss, depending on how long the shares been held from the date of purchase. We generally are not entitled to a deduction for amounts
taxed as ordinary income or capital gain to a participant, except to the extent of ordinary income recognized by participants upon a sale
or disposition of shares prior to the expiration of the holding periods described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>Vote
Required</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Annual Meeting, the approval of the 2021
Employee Stock Purchase Plan requires the affirmative vote of the holders of a majority of the shares of common stock that are voting
on the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 12pt"><B>Board
Recommendation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT OUR STOCKHOLDERS APPROVE THE 2021 EMPLOYEE STOCK PURCHASE PLAN.</B></P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_043"></A>Audit
Committee Report</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.15pt; text-align: justify">The Audit Committee of the Board of
Directors consists entirely of members who meet the independence requirements of the listing standards of NASDAQ and the rules and regulations
of the SEC, as determined by the Board. The Audit Committee is responsible for providing independent, objective oversight of the financial
reporting processes and internal controls of Anika Therapeutics, Inc., or Anika. The Audit Committee operates under a written charter
approved by the Board. A copy of the current charter is available on the investor relations portion of Anika&rsquo;s website at <I>https://ir.anikatherapeutics.com/corporate-governance</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 2pt; text-align: justify">Management is responsible for Anika&rsquo;s
system of internal control and financial reporting processes, for the preparation of consolidated financial statements in accordance with
U.S. generally accepted accounting principles and for the annual report on Anika&rsquo;s internal control over financial reporting. The
independent auditor is responsible for performing an independent audit of Anika&rsquo;s consolidated financial statements in accordance
with the standards of the Public Company Accounting Oversight Board, or PCAOB, and for issuing a report on the financial statements and
the effectiveness of Anika&rsquo;s internal control over financial reporting. The Audit Committee&rsquo;s responsibility is to monitor
and oversee these processes. In performing its functions, the Audit Committee acts only in an oversight capacity and necessarily relies
on the work and assurances of management, the internal audit group, and the independent auditor. Audit Committee members do not serve
as professional accountants or auditors for Anika, and their functions are not intended to duplicate or certify the activities of Anika&rsquo;s
management or independent auditor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 2pt; text-align: justify">Consistent with its monitoring and
oversight responsibilities, the Audit Committee met with management and Deloitte &amp; Touche LLP, or Deloitte, Anika&rsquo;s independent
auditor, to review and discuss the December 31, 2020 audited consolidated financial statements. Management represented that Anika had
prepared the consolidated financial statements in accordance with U.S. generally accepted accounting principles. The Audit Committee discussed
with Deloitte the matters required by the PCAOB in accordance with Auditing Standard No. 1301, &ldquo;Communications with Audit Committees.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 2pt; text-align: justify">The Audit Committee received from
Deloitte the written communication that is required by PCAOB Rule 3526, &ldquo;Communication with Audit Committees Concerning Independence,&rdquo;
and the Audit Committee discussed with Deloitte that firm&rsquo;s independence. The Audit Committee also considered whether Deloitte&rsquo;s
provision of non-audit services and the audit and non-audit fees paid to Deloitte were compatible with maintaining that firm&rsquo;s independence.
On the basis of these reviews, the Audit Committee determined that Deloitte has the requisite independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 2pt; text-align: justify">Management completed the documentation,
testing, and evaluation of Anika&rsquo;s system of internal control over financial reporting as of December 31, 2020 as required by Section
404 of the Sarbanes-Oxley Act of 2002. The Audit Committee received periodic updates from management and Deloitte at Audit Committee meetings
throughout the year and provided oversight of the process. Prior to filing Anika&rsquo;s Annual Report on Form 10-K for the fiscal year
ended December 31, 2020, or the Form 10-K, with the Securities and Exchange Commission, the Audit Committee also reviewed management&rsquo;s
report on the effectiveness of Anika&rsquo;s internal control over financial reporting contained in the Form 10-K, as well as the Report
of Independent Registered Public Accounting Firm provided by Deloitte and also included in the Form 10-K. Deloitte&rsquo;s report included
in the Form 10-K related to its audit of Anika&rsquo;s consolidated financial statements and the effectiveness of Anika&rsquo;s internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 2.15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 2.15pt; text-align: justify">Based upon the Audit Committee&rsquo;s
discussions with management and Deloitte and the Audit Committee&rsquo;s review of the information provided by, and the representations
of, management and Deloitte, the Audit Committee recommended to the Board that the audited consolidated financial statements as of and
for the year ended December 31, 2020 be included in the Annual Report. The Audit Committee selected Deloitte as Anika&rsquo;s independent
auditor for the fiscal year ending December&nbsp;31, 2021 and recommended that the selection be submitted for ratification by the stockholders
of Anika.</P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 2.15pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 2.15pt; text-align: justify">This report is submitted by the
following independent directors who comprise the Audit Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; text-align: center; padding-left: 2pt">Raymond J. Land, Chair</TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center">Stephen O. Richard</TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">Susan N. Vogt</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE FOREGOING REPORT SHOULD NOT BE DEEMED INCORPORATED
BY REFERENCE INTO ANY FILING UNDER THE SECURITIES ACT OF&nbsp;1933 OR THE SECURITIES EXCHANGE ACT OF&nbsp;1934 BY ANY GENERAL STATEMENT
INCORPORATING BY REFERENCE THIS PROXY STATEMENT, EXCEPT TO THE EXTENT THAT ANIKA SPECIFICALLY INCORPORATES THIS INFORMATION BY REFERENCE,
AND SHALL NOT OTHERWISE BE DEEMED FILED UNDER SUCH ACTS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_044"></A>Proposal
4: Ratification of Appointment of Independent Auditor for 2021</FONT></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Appointment
of Independent Auditor by Audit Committee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee annually evaluates the performance
of our independent auditor, including the senior audit engagement team, and determines whether to reengage the current independent auditor
or consider other audit firms. The Audit Committee&rsquo;s initial appointment of Deloitte &amp; Touche LLP, or Deloitte, as independent
auditor of our consolidated financial statements for 2017, was ratified by a vote of stockholders at our 2017 Annual Meeting of Stockholders.
The Audit Committee again appointed Deloitte as our independent auditor for the years ended December 31, 2018, 2019, and 2020, which were
ratified by votes of our stockholders at our 2019 and 2020 Annual Meetings of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This year the Audit Committee has again approved
the retention of Deloitte as our independent auditor to report on our consolidated financial statements and the effectiveness of our internal
control over financial reporting for the year ending December 31, 2021. Factors considered by the Audit Committee in deciding whether
to retain Deloitte included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Deloitte&rsquo;s global capabilities&#894;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Deloitte&rsquo;s technical expertise and knowledge of our global operations and industry&#894;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">the quality and candor of Deloitte&rsquo;s communications with the Audit Committee and management&#894;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">the quality and efficiency of the services provided by Deloitte, including input from management on Deloitte&rsquo;s
        performance;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Deloitte&rsquo;s objectivity and professional skepticism&#894;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">external data on audit quality and performance, including recent PCAOB reports on Deloitte and its peer firms&#894;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Deloitte&rsquo;s use of technology to aid in audit efficiency;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Deloitte&rsquo;s independence, how effectively Deloitte demonstrated its independent judgment, and the controls
        and processes in place that help ensure Deloitte&rsquo;s independence; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">the appropriateness of Deloitte&rsquo;s fees.</TD></TR>
  </TABLE>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Proposed
Ratification of Independent Auditor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee is responsible for the appointment,
retention, termination, compensation, and oversight of the work of our independent registered public accounting firm for the purpose of
preparing or issuing an audit report or related work. Although ratification of the appointment of our independent auditor is not required
by our bylaws or otherwise, the Board of Directors is submitting the appointment of Deloitte to our stockholders for ratification because
we value the views of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee considers Deloitte to be well
qualified. In the absence of contrary specification, the Proxy Committee will vote proxies received in response to this solicitation in
favor of ratification of the appointment. In the event that stockholders fail to ratify the appointment of Deloitte, the Audit Committee
will reconsider the appointment of Deloitte. Even if the appointment is ratified, the ratification is not binding and the Audit Committee
may in its discretion select a different independent auditor at any time during the year if it determines that such a change would be
in the best interests of our company and stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representatives of Deloitte are expected to be
present at the Annual Meeting. They will have an opportunity to make a statement, if they desire, and will be available to respond to
appropriate questions.</P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Annual Meeting, the ratification of our
independent auditor for 2021 requires the affirmative vote of the holders of a majority of the shares of common stock that are voting
on the matter. Abstentions will not be treated as votes cast and will have no effect on the vote. Because this proposal is considered
a routine matter, discretionary votes by brokers will be counted.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Board
Recommendation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
A VOTE &ldquo;FOR&rdquo; THE RATIFICATION OF THE APPOINTMENT OF DELOITTE &amp; TOUCHE LLP AS OUR INDEPENDENT AUDITOR FOR THE YEAR ENDING
DECEMBER&nbsp;31, 2021.</B></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Fees
Paid to Our Independent Auditor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the fees that we
paid or accrued for audit and other services provided by Deloitte, our independent auditor, for the years ended December 31, 2020 and
2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold; border-bottom: Black 1pt solid">Fee Category</TD>
    <TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD>
    <TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="background-color: White; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: left">Audit fees</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">1,314,815</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">697,022</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White; width: 20%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Audit-related fees</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Tax fees</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">196,269</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">127,783</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #95B3D7">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">All other fees</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,685</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,790</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.25pt">Total fees</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,516,769</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: right">828,595</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the preceding table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Audit fees consist of fees for the audit of our consolidated financial statements, the review of the interim
        financial statements included in our Quarterly Reports on Form&nbsp;10-Q, and other professional services provided in connection with
        statutory and regulatory filings or engagements for those years, inclusive of fees related to work performed with respect to our acquisitions
        of Arthrosurface and Parcus Medical in early 2020. In addition, Audit fees include: fees for comfort letters, consents, assistance with
        and review of documents filed with the SEC, Section 404 attest services, other attest services that generally only the principal independent
        auditor can provide, work done by tax professionals in connection with the audit or quarterly review, and accounting consultations billed
        as audit services, as well as other accounting and financial reporting consultation research work necessary to comply with the standards
        of the PCAOB.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Audit-related fees consist of the aggregate fees billed by the principal accountant in each of the last two
        fiscal years for assurance and related services reasonably related to the performance of the audit or review.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Tax fees consist of fees for tax compliance, tax advice, and tax planning services for those years.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">All other fees consist of the aggregate fees billed by the principal accountant in each of the last two fiscal
        years for products and services other than the services reported herein.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In considering the nature of the services provided
by a principal independent auditor, the Audit Committee determined that such services are compatible with the provision of independent
audit services. The Audit Committee discussed these services with the independent auditor and management to determine that they are permitted
under the rules and regulations concerning auditor independence promulgated by the SEC to implement the Sarbanes-Oxley Act of 2002, as
well as the American Institute of Certified Public Accountants. In accordance with its charter, the Audit Committee has procedures for
pre-approving audit and non-audit services to be provided by the independent auditor. These procedures are designed to ensure the continued
independence of the independent auditor. More specifically, the use of the independent auditor to perform either audit or non-audit services
is prohibited unless specifically approved in advance by the Audit Committee. As a result of this approval process, the Audit Committee
has pre-approved specific categories of services and associated fee budgets. All services outside of the specified categories and all
amounts exceeding the approved fee budgets are approved by the Chair of the Audit Committee, who has been delegated the authority to review
and approve audit and non-audit related services during the year. A listing of the audit and non-audit services and associated fees approved
by the Chair outside the scope of the services and fees initially approved by the full Audit Committee is reported to the full Audit Committee
no later than its next meeting. The Audit Committee also regularly receives updates from Deloitte and management about the services actually
performed and the associated fees and expenses actually incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Audit Committee evaluates other
known potential engagements of the independent auditor, including the scope of audit-related services, tax services, and other services
proposed to be performed and the proposed fees, and approves or rejects each service, taking into account whether the services are permissible
under applicable law and the possible impact of each non-audit service on the independent auditor&rsquo;s independence from management.
All such services were approved by the Audit Committee pursuant to Rule&nbsp;2-01 of Regulation&nbsp;S-X under the Exchange Act to the
extent that rule was applicable. Since May 2003 each new engagement of a principal independent auditor has been approved in advance by
the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_045"></A>Proposal
5: Advisory Vote on Executive Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Section&nbsp;14A of the Exchange
Act, we are providing our stockholders with the opportunity to vote on a non-binding, advisory resolution to approve the compensation
of our NEOs for the year ended December 31, 2020, which is described in the section titled &ldquo;Compensation Discussion and Analysis&rdquo;
in this Proxy Statement. At our 2017 Annual Meeting of Stockholders, we asked our stockholders to indicate if we should hold a &ldquo;say-on-pay&rdquo;
vote every one, two or three years. Consistent with the recommendation of the Board of Directors, our stockholders indicated by advisory
vote their preference to hold a &ldquo;say-on-pay&rdquo; vote annually. After consideration of the 2017 voting results, and based upon
its prior recommendation, the Board elected to hold a stockholder &ldquo;say-on-pay&rdquo; vote annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described in the section titled &ldquo;Compensation
Discussion and Analysis&rdquo; of this Proxy Statement, our executive compensation program is designed to attract and retain highly qualified
executive officers and motivate them to provide a high level of performance for the benefit of our company and stockholders. Stockholders
are urged to read the section titled &ldquo;Compensation Discussion and Analysis,&rdquo; which more thoroughly discusses how our compensation
policies and procedures implement our compensation philosophy and objectives. The Compensation Committee and the Board believe that these
policies and procedures are effective in implementing our compensation philosophy and in achieving our objectives. This vote is not intended
to address any specific item of compensation, but rather the overall compensation of our NEOs and the policies and practices described
in this Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, the following resolution is submitted
for a stockholder vote at the Annual Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 1in">&ldquo;RESOLVED:</TD>
    <TD STYLE="text-align: justify; padding-right: 0.25in">That the stockholders of Anika Therapeutics, Inc. approve, on an advisory basis, the
        compensation paid to the named executive officers of Anika Therapeutics, Inc. as disclosed pursuant to Item&nbsp;402 of Regulation S-K
        under the Securities Exchange Act of 1934, including the Compensation Discussion and Analysis, compensation tables, and narrative discussion
        set forth in the Proxy Statement for the 2021 Annual Meeting of Stockholders.&rdquo;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This vote is advisory and will not be binding
upon us, the Compensation Committee or the Board. However, the Board and its Compensation Committee value the opinions of our stockholders
and to the extent there is any significant vote against the NEO compensation as disclosed in this Proxy Statement, we will consider our
stockholders&rsquo; concerns, and the Compensation Committee will evaluate whether any actions are necessary to address those concerns.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Annual Meeting, approval of our 2020 executive
compensation requires the affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions
and broker non-votes will not be treated as votes cast and will have no impact on the proposal. While this vote is required by law, it
will not be binding on us, the Compensation Committee, or the Board of Directors, nor will it create or imply any change in the fiduciary
duties of, or impose any additional fiduciary duty on, our company, the Compensation Committee or the Board. However, the Compensation
Committee and the Board will take into account the outcome of the vote when considering future executive compensation decisions.</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt">Board
Recommendation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT STOCKHOLDERS VOTE TO APPROVE THE OVERALL COMPENSATION OF THE NAMED EXECUTIVE OFFICERS BY VOTING &ldquo;FOR&rdquo; THIS RESOLUTION.</B></P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_046"></A>Other
Matters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors does not know of any other
matters that will come before the Annual Meeting. However, if any other matters are properly presented at the Annual Meeting, it is the
intention of the persons named in the accompanying proxy card to vote, or otherwise act, in accordance with their judgment on such matters.</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_047"></A>Solicitation
Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All costs of solicitation of proxies will be borne
by us. In addition to solicitation by mail, our directors, officers, and employees, without additional remuneration, may solicit proxies
in person or by telephone, e-mail, and facsimile. We will reimburse banks, brokerage firms, and other custodians, nominees, trustees,
and fiduciaries for reasonable out-of-pocket expenses incurred by them in sending proxy materials to and soliciting proxies from beneficial
holders of our shares. We have retained Innisfree M&amp;A Incorporated to assist in the solicitation of proxies for a fee of $25,000,
plus reimbursement of expenses.</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_048"></A>Stockholder
Proposals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for stockholder proposals for the 2022
Annual Meeting of Stockholders to be eligible for inclusion in the proxy statement and form of proxy card for that meeting, we must receive
the proposals before December 31, 2021. These proposals must also comply with the rules of the SEC governing the form and content of proposals
in order to be included in our proxy statement and form of proxy, and proposals should be directed to: Secretary, Anika Therapeutics,
Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730. All proposals will need to comply with Rule&nbsp;14a-8 of the Exchange Act, which
sets forth the requirements for the inclusion of stockholder proposals in our sponsored proxy materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bylaws and Policy and Procedures for Stockholder
Nominations to the Board set forth the procedures you must follow in order to nominate a director for election or make a proposal at an
annual meeting of our stockholders, other than proposals intended to be included in our sponsored proxy materials. In addition to any
other applicable requirements, in order for business to be properly brought before the 2022 Annual Meeting by a stockholder, the stockholder
must have given us timely notice thereof in proper written form, including all required information, at our corporate headquarters, 32&nbsp;Wiggins
Avenue, Bedford, Massachusetts 01730, directed to the attention of the Secretary, between February 16, 2022 and March&nbsp;18, 2022. The
proposal must also comply with the other requirements contained in the bylaws, including supporting documentation and other information.
Proxies solicited by the Board of Directors will confer discretionary voting authority with respect to these proposals, subject to SEC
rules governing the exercise of this authority. We have posted copies of our bylaws and our Policy and Procedures for Stockholders to
the Board in the investor relations section of our website at&nbsp;<I>https://ir.anikatherapeutics.com/investor-relations</I> under &ldquo;Corporate
Governance.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The chair of the meeting has the power and duty
to (a) determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may
be, in accordance with the procedures set forth in our bylaws and (b) declare that a proposed nomination shall be disregarded or that
proposed business shall not be transacted if such proposed nomination or business was not made or proposed in compliance our bylaws. Additionally,
unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) does not appear at the Annual
Meeting to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted,
notwithstanding that proxies in respect of such vote may have been received by us.</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><A NAME="a_049"></A>Householding</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SEC rules permit us to deliver a single copy of
our 2020 Annual Report to Stockholders and this Proxy Statement, or one Notice of Internet Availability of Proxy Materials, to two or
more stockholders who share an address, unless we have received contrary instructions from one or more of the security holders. This delivery
method, which is known as &ldquo;householding,&rdquo; can reduce our expenses for printing and mailing. Any stockholder of record at a
shared address to which a single copy of the documents was delivered may request a separate copy of the 2020 Annual Report to Stockholders
and this Proxy Statement, or a separate Notice of Internet Availability of Proxy Materials, as applicable, by sending us a written request
made to Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730, Attention: Secretary or by calling (781) 457-9000.
Stockholders of record who wish to receive separate copies of these documents in the future may also contact us as stated above. Stockholders
of record who share an address and are receiving multiple copies of our annual reports to stockholders and Proxy Statements, or of our
Notices of Internet Availability of Proxy Materials, may contact us as stated above to request delivery of a single copy of such documents.
Stockholders who hold their shares in &ldquo;street name&rdquo; and who wish to obtain copies of these proxy materials should follow the
instructions on their voting instruction forms or contact the holders of record. STOCKHOLDERS MAY OBTAIN, WITHOUT CHARGE, A COPY OF OUR
ANNUAL REPORT ON FORM&nbsp;10-K, INCLUDING THE FINANCIAL STATEMENTS CONTAINED THEREIN, FILED WITH THE SEC FOR THE YEAR ENDED DECEMBER
31, 2020, BY WRITING TO OUR SECRETARY AT ANIKA THERAPEUTICS,&nbsp;INC., 32 WIGGINS AVENUE, BEDFORD, MASSACHUSETTS 01730.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in; color: #2F5496"><FONT STYLE="font-size: 14pt"><I><A NAME="a_050"></A>Appendix
A</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">ANIKA
THERAPEUTICS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">2017 OMNIBUS INCENTIVE PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-weight: normal; text-underline-style: double"><U>(Marked
to Show 2021 Amendment)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Anika Therapeutics, Inc. sets
forth herein the terms of its 2017 Omnibus Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">1.</TD>
    <TD STYLE="text-align: justify">PURPOSE</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan is intended to enhance
the ability of the Company and its Affiliates to attract and retain highly qualified officers, Non-employee Directors, employees, consultants
and advisors, and to motivate such individuals to serve the Company and its Affiliates and to expend maximum effort to improve the business
results and earnings of the Company, by providing to such persons an opportunity to acquire or increase a direct proprietary interest
in the operations and future success of the Company. To this end, the Plan provides for the grant of stock options, stock appreciation
rights (&ldquo;<B>SARs</B>&rdquo;), restricted stock, restricted stock units (&ldquo;<B>RSUs</B>&rdquo;), unrestricted stock, other share-based
awards and cash awards. Any of these awards may, but need not, be made as performance incentives to reward attainment of performance goals
in accordance with the terms hereof. Upon the Plan becoming effective, no further awards shall be made under the Prior Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">2.</TD>
    <TD STYLE="text-align: justify">DEFINITIONS</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of interpreting
the Plan and related documents (including Award Agreements), the following definitions shall apply:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Acquiror<FONT STYLE="font-weight: normal">&rdquo;
shall have the meaning set forth in </FONT>Section&nbsp;15.2.1<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Affiliate<FONT STYLE="font-weight: normal">&rdquo;
means any company or other trade or business that &ldquo;controls,&rdquo; is &ldquo;controlled by&rdquo; or is &ldquo;under common control
with&rdquo; the Company within the meaning of Rule 405 of Regulation C under the Securities Act, including any Subsidiary. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Annual
Incentive Award<FONT STYLE="font-weight: normal">&rdquo; means a cash-based Performance Award with a performance period that is the Company&rsquo;s
fiscal year or other 12-month (or shorter) performance period as specified under the terms of the Award as approved by the Board.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Award<FONT STYLE="font-weight: normal">&rdquo;
means a grant under the Plan of an Option, SAR, Restricted Stock, RSU, Other Share-based Award or cash award. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Award
Agreement<FONT STYLE="font-weight: normal">&rdquo; means a written agreement between the Company and a Participant, or notice from the
Company or an Affiliate to a Participant that evidences and sets out the terms of an Award. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Board</B>&rdquo; means the Board of Directors
of the Company<B>.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Business
Combination<FONT STYLE="font-weight: normal">&rdquo; shall have the meaning set forth in </FONT>Section&nbsp;15.2.2<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Cause<FONT STYLE="font-weight: normal">&rdquo;
shall be defined as that term is defined in the Participant&rsquo;s offer letter or other applicable employment agreement; or, if there
is no such definition, &ldquo;Cause&rdquo; means, as determined by the Company in its sole discretion and unless otherwise provided in
the applicable Award Agreement: (i) any material breach by the Participant of any agreement between the Participant and the Company; (ii)
the conviction of or plea of nolo contendere by the Participant to a felony or a crime involving moral turpitude; or (iii) any material
misconduct or willful and deliberate non-performance (other than by reason of disability) by the Participant of the Participant&rsquo;s
duties to the Company. A Separation from Service for Cause shall be deemed to include a determination by the Company in its sole discretion
following a Participant&rsquo;s Separation from Service that circumstances existing prior to such Separation from Service would have entitled
the Company or an Affiliate to have terminated the Participant&rsquo;s service for Cause. All rights a Participant has or may have under
the Plan shall be suspended automatically during the pendency of any investigation by the Company, or during any negotiations between
the Company and the Participant, regarding any actual or alleged act or omission by the Participant of the type described in the applicable
definition of Cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 90; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Change in Control</B>&rdquo; shall have
the meaning set forth in <B>Section&nbsp;15.2.2</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Code</B>&rdquo; means the Internal Revenue
Code of 1986.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Committee</B>&rdquo; means the Compensation
Committee of the Board, or such other committee as determined by the Board. The Compensation Committee of the Board may designate a subcommittee
of its members to serve as the Committee (to the extent the Board has not designated another person, committee or entity as the Committee).
The Board will cause the Committee to satisfy the applicable requirements of any securities exchange on which the Common Stock may then
be listed. For purposes of Awards to Covered Employees intended to qualify as Performance-Based Compensation, to the extent required by
Section&nbsp;162(m), Committee means all of the members of the Compensation Committee who are &ldquo;outside directors&rdquo; within the
meaning of Section&nbsp;162(m). For purposes of Awards to Participants who are subject to Section&nbsp;16 of the Exchange Act, Committee
means all of the members of the Compensation Committee who are &ldquo;non-employee directors&rdquo; within the meaning of Rule 16b-3 adopted
under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company</B>&rdquo; means Anika Therapeutics,
Inc., a Massachusetts corporation, or any successor corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Common Stock</B>&rdquo; means the common
stock of the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Consultant<FONT STYLE="font-weight: normal">&rdquo;
means a consultant or advisor that provides bona fide services to the Company or any Affiliate and who qualifies as a consultant or advisor
under Form S-8.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Covered
Employee<FONT STYLE="font-weight: normal">&rdquo; means a Participant who is a &ldquo;covered employee&rdquo; within the meaning of Section&nbsp;162(m)
as qualified by </FONT>Section&nbsp;12.4<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Disability<FONT STYLE="font-weight: normal">&rdquo;
shall be defined as that term is defined in the Participant&rsquo;s offer letter or other applicable employment agreement; or, if there
is no such definition, &ldquo;Disability&rdquo; means, as determined by the Company in its sole discretion and unless otherwise provided
in the applicable Award Agreement, the Participant is unable to perform each of the essential duties of such Participant&rsquo;s position
by reason of a medically determinable physical or mental impairment which is potentially permanent in character or which can be expected
to last for a continuous period of not less than 12 months; <I>provided</I>, <I>however</I>, that, with respect to rules regarding expiration
of an Incentive Stock Option following termination of the Participant&rsquo;s employment, &ldquo;Disability&rdquo; means &ldquo;permanent
and total disability&rdquo; as set forth in Code Section&nbsp;22(e)(3).</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Effective
Date<FONT STYLE="font-weight: normal">&rdquo; means June 13, 2017, the date the Plan was approved by the Stockholders. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Exchange
Act<FONT STYLE="font-weight: normal">&rdquo; means the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Fair
Market Value<FONT STYLE="font-weight: normal">&rdquo; means, as of any date, the value of the Common Stock as determined below. If the
Common Stock is listed on any established stock exchange or a national market system, including without limitation, the New York Stock
Exchange or the NASDAQ Stock Market, the Fair Market Value shall be the closing price of a share of Common Stock (or if no sales were
reported the closing price on the date immediately preceding such date) as quoted on such exchange or system on the day of determination.
In the absence of an established market for the Common Stock, the Fair Market Value shall be determined in good faith by the Board and
such determination shall be conclusive and binding on all persons. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Family
Member<FONT STYLE="font-weight: normal">&rdquo; means a person who is a spouse, former spouse, child, stepchild, grandchild, parent, stepparent,
grandparent, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother, sister, brother-in-law or sister-in-law,
including adoptive relationships, of the applicable individual, any person sharing the applicable individual&rsquo;s household (other
than a tenant or employee), a trust in which any one or more of these persons have more than 50% of the beneficial interest, a foundation
in which any one or more of these persons (or the applicable individual) control the management of assets, and any other entity in which
one or more of these persons (or the applicable individual) own more than 50% of the voting interests.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Grant
Date<FONT STYLE="font-weight: normal">&rdquo; means the latest to occur of (i)&nbsp;the date as of which the Board approves an Award,
(ii)&nbsp;the date on which the recipient of an Award first becomes eligible to receive an Award under </FONT>Section&nbsp;6 <FONT STYLE="font-weight: normal">or
(iii)&nbsp;such other date as may be specified by the Board in the Award Agreement. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Incentive
Stock Option<FONT STYLE="font-weight: normal">&rdquo; means an &ldquo;incentive stock option&rdquo; within the meaning of Code Section&nbsp;422.
</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Incumbent
Directors<FONT STYLE="font-weight: normal">&rdquo;shall have the meaning set forth in </FONT>Section&nbsp;15.2.2<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>New
Shares<FONT STYLE="font-weight: normal">&rdquo; shall have the meaning set forth in </FONT>Section&nbsp;15.1<FONT STYLE="font-weight: normal">.
</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Non-employee
Director<FONT STYLE="font-weight: normal">&rdquo; means a member of the Board or the board of directors of an Affiliate, in each case
who is not an officer or employee of the Company or any Affiliate. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Nonqualified
Stock Option<FONT STYLE="font-weight: normal">&rdquo; means an Option that is not an Incentive Stock Option. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Option<FONT STYLE="font-weight: normal">&rdquo;
means an option to purchase one or more Shares pursuant to the Plan. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Option
Price<FONT STYLE="font-weight: normal">&rdquo; means the exercise price for each Share subject to an Option. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Other
Share-based Awards<FONT STYLE="font-weight: normal">&rdquo; means Awards consisting of Share units, or other Awards, valued in whole or
in part by reference to, or otherwise based on, Shares.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Participant<FONT STYLE="font-weight: normal">&rdquo;
shall mean a person who, as a Service Provider, has been granted an Award under the Plan; <I>provided</I>, <I>however</I>, that in the
case of the death or Disability of a Participant, the term &ldquo;Participant&rdquo; refers to the Participant&rsquo;s estate or other
legal representative acting in a fiduciary capacity on behalf of the Participant under applicable state law and court supervision. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Performance
Award<FONT STYLE="font-weight: normal">&rdquo; means an Award made subject to the attainment of performance goals (as described in </FONT>Section&nbsp;12<FONT STYLE="font-weight: normal">)
over a performance period established by the Committee, and includes an Annual Incentive Award.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Performance-Based
Compensation<FONT STYLE="font-weight: normal">&rdquo; means &ldquo;performance-based compensation&rdquo; under Section&nbsp;162(m).</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Plan<FONT STYLE="font-weight: normal">&rdquo;
means this Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Policy<FONT STYLE="font-weight: normal">&rdquo;
shall have the meaning set forth in </FONT>Section&nbsp;3.2.2<FONT STYLE="font-weight: normal">. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Prior
Plan<FONT STYLE="font-weight: normal">&rdquo; means the Anika Therapeutics, Inc. Second Amended and Restated 2003 Stock Option and Incentive
Plan, as amended. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Purchase
Price<FONT STYLE="font-weight: normal">&rdquo; means the purchase price for each Share pursuant to a grant of Restricted Stock. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Restricted
Stock<FONT STYLE="font-weight: normal">&rdquo; means restricted Shares, awarded to a Participant pursuant to </FONT>Section&nbsp;10<FONT STYLE="font-weight: normal">.
</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Restricted
Stock Unit<FONT STYLE="font-weight: normal">&rdquo; or &ldquo;</FONT>RSU<FONT STYLE="font-weight: normal">&rdquo; means a bookkeeping
entry representing the equivalent of Shares, awarded to a Participant pursuant to </FONT>Section&nbsp;10<FONT STYLE="font-weight: normal">.
</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>SAR
Exercise Price<FONT STYLE="font-weight: normal">&rdquo; means the per Share exercise price of a SAR granted to a Participant under </FONT>Section&nbsp;9<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>SEC<FONT STYLE="font-weight: normal">&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Section&nbsp;162(m)<FONT STYLE="font-weight: normal">&rdquo;
means Code Section&nbsp;162(m).</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Section&nbsp;409A<FONT STYLE="font-weight: normal">&rdquo;
means Code Section&nbsp;409A. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Securities
Act<FONT STYLE="font-weight: normal">&rdquo; means the Securities Act of 1933.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Separation
from Service<FONT STYLE="font-weight: normal">&rdquo; means the termination of the applicable Participant&rsquo;s employment with, and
performance of services for, the Company and each Affiliate. A Participant employed by, or performing services for, an Affiliate or a
division of the Company or an Affiliate shall not be deemed to incur a Separation from Service if such Affiliate or division ceases to
be an Affiliate or division of the Company, as the case may be, and the Participant immediately thereafter becomes an employee of (or
service provider to), or member of the board of directors of, the Company or an Affiliate or a successor company or an affiliate or subsidiary
thereof. Approved temporary absences from employment because of illness, vacation or leave of absence and transfers among the Company
and its Affiliates shall not be considered Separations from Service. Notwithstanding the foregoing, with respect to any Award that constitutes
nonqualified deferred compensation under Section&nbsp;409A, &ldquo;Separation from Service&rdquo; shall mean a &ldquo;separation from
service&rdquo; as defined under Section&nbsp;409A.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Service
Period<FONT STYLE="font-weight: normal">&rdquo; shall have the meaning set forth in </FONT>Section&nbsp;10.1<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Service
Provider<FONT STYLE="font-weight: normal">&rdquo; means an employee, officer, Non-employee Director or Consultant of the Company or an
Affiliate. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Share<FONT STYLE="font-weight: normal">&rdquo;
means a share of Common Stock.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Stock
Appreciation Right<FONT STYLE="font-weight: normal">&rdquo; or &ldquo;</FONT>SAR<FONT STYLE="font-weight: normal">&rdquo; means a right
granted to a Participant pursuant to </FONT>Section&nbsp;9<FONT STYLE="font-weight: normal">. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Stockholders<FONT STYLE="font-weight: normal">&rdquo;
means the stockholders of the Company.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Subsidiary<FONT STYLE="font-weight: normal">&rdquo;
means any &ldquo;subsidiary corporation&rdquo; of the Company within the meaning of Code Section&nbsp;424(f). </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Substitute
Award<FONT STYLE="font-weight: normal">&rdquo; means any Award granted in assumption of or in substitution for an award of a company or
business acquired by the Company or an Affiliate or with which the Company or an Affiliate combines. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Ten
Percent Stockholder<FONT STYLE="font-weight: normal">&rdquo; means an individual who owns more than 10% of the total combined voting power
of all classes of outstanding stock of the Company, its parent or any of its Subsidiaries. In determining stock ownership, the attribution
rules of Code Section&nbsp;424(d) shall be applied. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Termination
Date<FONT STYLE="font-weight: normal">&rdquo; means the date that is 10 years after the Effective Date, unless the Plan is earlier terminated
by the Board under </FONT>Section&nbsp;5.2<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Voting
Securities<FONT STYLE="font-weight: normal">&rdquo; shall have the meaning set forth in </FONT>Section&nbsp;15.2.2<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">3.</TD>
    <TD STYLE="text-align: justify">ADMINISTRATION OF THE PLAN</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
General</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board shall have such
powers and authorities related to the administration of the Plan as are consistent with the Company&rsquo;s certificate of incorporation
and bylaws and applicable law. The Board shall have the power and authority to delegate its responsibilities hereunder to the Committee,
which shall have full authority to act in accordance with its charter, and with respect to the power and authority of the Board to act
hereunder, all references to the Board shall be deemed to include a reference to the Committee, unless such power or authority is specifically
reserved by the Board. Except as specifically provided in <B>Section&nbsp;14</B> or as otherwise may be required by applicable law, regulatory
requirement or the certificate of incorporation or the bylaws of the Company, the Board shall have full power and authority to take all
actions and to make all determinations required or provided for under the Plan, any Award or any Award Agreement, and shall have full
power and authority to take all such other actions and make all such other determinations not inconsistent with the specific terms and
provisions of the Plan that the Board deems to be necessary or appropriate to the administration of the Plan. The Committee shall administer
the Plan; <I>provided</I>, <I>however</I>, the Board shall retain the right to exercise the authority of the Committee to the extent consistent
with applicable law and the applicable requirements of any securities exchange on which the Common Stock may then be listed. All actions,
determinations and decisions by the Board or the Committee under the Plan or any Award Agreement, or with respect to any Award, shall
be in the sole discretion of the Board and shall be final, binding and conclusive on all persons. Without limitation, the Board shall
have full and final power and authority, subject to the other terms of the Plan, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(i)</TD>
    <TD STYLE="text-align: justify">designate Participants;</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(ii)</TD>
    <TD STYLE="text-align: justify">determine the type or types of Awards to be made to Participants;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(iii)</TD>
    <TD STYLE="text-align: justify">determine the number of Shares to be subject to an Award;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(iv)</TD>
    <TD STYLE="text-align: justify">establish the terms of each Award (including the Option Price of any Option, the nature and duration of any
        restriction or condition (or provision for lapse thereof) relating to the vesting, exercise, transfer or forfeiture of an Award or the
        Shares subject thereto and any terms or conditions that may be necessary to qualify Options as Incentive Stock Options);</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(v)</TD>
    <TD STYLE="text-align: justify">subject to applicable law, delegate its authority and duties to the Chief Executive Officer with respect to
        the granting of Options to individuals who are not Covered Employees or &ldquo;insiders&rdquo; within the meaning of Section 16 of the
        Exchange Act. Any such delegation by the Board shall include a limitation as to the amount of Options that may be granted during the period
        of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Board may revoke
        or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Board&rsquo; delegate or
        delegates that were consistent with the terms of the Plan.;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(vi)</TD>
    <TD STYLE="text-align: justify">prescribe the form of each Award Agreement; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(vii)</TD>
    <TD STYLE="text-align: justify">amend, modify or supplement the terms of any outstanding Award including the authority, in order to effectuate
        the purposes of the Plan, to modify Awards to foreign nationals or individuals who are employed outside the United&nbsp;States to recognize
        differences in local law, tax policy or custom.</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Separation from Service for Cause; Clawbacks</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>3.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Separation from Service for Cause</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company may annul an Award
if the Participant incurs a Separation from Service for Cause.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>3.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Clawbacks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All awards, amounts or benefits
received or outstanding under the Plan shall be subject to clawback, cancellation, recoupment, rescission, payback, reduction or other
similar action in accordance with the terms of any Company clawback or similar policy (the &ldquo;<B>Policy</B>&rdquo;) or any applicable
law related to such actions, as may be in effect from time to time. A Participant&rsquo;s acceptance of an Award shall be deemed to constitute
the Participant&rsquo;s acknowledgement of and consent to the Company&rsquo;s application, implementation and enforcement of any applicable
Policy that may apply to the Participant, whether adopted prior to or following the Effective Date, and any provision of applicable law
relating to clawback, cancellation, recoupment, rescission, payback or reduction of compensation, and the Participant&rsquo;s agreement
that the Company may take such actions as may be necessary to effectuate any such policy or applicable law, without further consideration
or action.</P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Deferral Arrangement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board may permit or require
the deferral of any Award payment into a deferred compensation arrangement, subject to such rules and procedures as it may establish and
in accordance with Section&nbsp;409A, which may include provisions for the payment or crediting of interest or dividend equivalents as
provided in <B>Section 17.10</B>, including converting such credits into deferred Share units.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No Liability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No member of the Board or
of the Committee shall be liable for any action or determination made in good faith with respect to the Plan, any Award or Award Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Book Entry</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any other
provision of the Plan to the contrary, the Company may elect to satisfy any requirement under the Plan for the delivery of stock certificates
through the use of book entry.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No Repricing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any provision
herein to the contrary, the repricing of Options or SARs is prohibited without prior approval of the Stockholders. For this purpose, a
&ldquo;repricing&rdquo; means any of the following (or any other action that has the same effect as any of the following): (i) changing
the terms or conditions of an Option or SAR to lower its Option Price or SAR Exercise Price; (ii) any other action that is treated as
a &ldquo;repricing&rdquo; under generally accepted accounting principles; and (iii) repurchasing for cash or canceling an Option or SAR
at a time when its Option Price or SAR Exercise Price is greater than the Fair Market Value of the underlying Shares in exchange for another
Award, unless the cancellation and exchange occurs in connection with a change in capitalization or similar change under <B>Section&nbsp;15</B>.
A cancellation and exchange under clause (iii) would be considered a &ldquo;repricing&rdquo; regardless of whether it is treated as a
&ldquo;repricing&rdquo; under generally accepted accounting principles and regardless of whether it is voluntary on the part of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">4.</TD>
    <TD STYLE="text-align: justify">STOCK SUBJECT TO THE PLAN</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Authorized Number of Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to adjustment under
<B>Section&nbsp;15</B>, the total number of Shares authorized to be awarded under the Plan shall not exceed <FONT STYLE="text-underline-style: double"><U>4,600,000</U></FONT>
<STRIKE>3,500,000</STRIKE> shares. The grant of any full value Award (i.e., an Award other than an Option or a SAR) shall be deemed, for
purposes of determining the number of Shares available for issuance under this <B>Section 4.1</B>, as an Award of two (2) Shares for each
Share actually subject to the Award. The grant of an Option or SAR shall be deemed, for purposes of determining the number of Shares available
for issuance under this <B>Section 4.1</B>, as an Award for one (1) Share for each such Share actually subject to the Award. Any Shares
returned to the Plan pursuant to <B>Section 4.2</B> shall be returned to the reserved pool of Shares under the Plan in the same manner.
In addition, Shares underlying any outstanding award granted under a Prior Plan that, following the Effective Date, expires, or is terminated,
surrendered or forfeited for any reason without issuance of Shares shall be available for the grant of new Awards. As provided in <B>Section&nbsp;1</B>,
no new awards shall be granted under the Prior Plan following the Effective Date. Shares issued under the Plan may consist in whole or
in part of authorized but unissued Shares, treasury Shares or Shares purchased on the open market or otherwise.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Share Counting</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">Any Award settled in cash shall not be counted as issued Shares for any purpose under the Plan.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued
Shares covered by such Award shall again be available for the grant of Awards.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">If Shares issued pursuant to the Plan are repurchased by, or are surrendered or forfeited to the Company
at no more than cost, such Shares shall again be available for the grant of Awards.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">If Shares issuable upon exercise, vesting or settlement of an Award, or Shares owned by a Participant
(which are not subject to any pledge or other security interest), are surrendered or tendered to the Company in payment of the Option
Price or Purchase Price of an Award or any taxes required to be withheld in respect of an Award, in each case, in accordance with the
terms of the Plan and any applicable Award Agreement, such surrendered or tendered Shares shall not be available again for the grant of
Awards.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">Substitute Awards shall not be counted against the number of Shares available for the grant of Awards.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Award Limits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Incentive Stock Options</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to adjustment under
<B>Section&nbsp;15</B>, <FONT STYLE="text-underline-style: double"><U>4,600,000</U></FONT> <STRIKE>3,500,000</STRIKE> Shares available
for issuance under the Plan shall be available for issuance as Incentive Stock Options.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Individual Award Limits for Section 162(m) -- Share-Based Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to adjustment under
<B>Section 15</B>, the maximum number of each type of Award (other than cash-based Performance Awards) granted to any Participant in any
calendar year shall not exceed the following number of Shares: (i) Options and SARs: 400,000 Shares; and (ii) all share-based Performance
Awards (including Restricted Stock, RSUs and Other Share-based Awards that are Performance Awards): 400,000 Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Individual Award Limits for Section 162(m) -- Cash-Based Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The maximum amount of cash-based
Performance Awards intended to qualify as Performance-Based Compensation granted to any Participant in any calendar year shall not exceed
the following: (i) Annual Incentive Awards: $1,000,000; and (ii) all other cash-based Performance Awards: $1.000,000.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Director Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The maximum value of Awards
granted during any calendar year to any Non-employee Director, taken together with any cash fees paid to such Non-employee Director during
the calendar year and the value of awards granted to the Non-employee Director under any other equity compensation plan of the Company
or an Affiliate during the calendar year, shall not exceed the following in total value (calculating the value of any Awards or other
equity compensation plan awards based on the fair market value as of grant date for financial reporting purposes): (i) $500,000 for the
non-employee Chair or Lead Director of the Board and (ii) $425,000 for each Non-employee Director other than the Chair or Lead Director
of the Board; <I>provided, however</I>, that awards granted to Non-employee Directors upon their initial election to the Board or the
board of directors of an Affiliate shall not be counted towards the limit under this <B>Section 4.3.4</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">5.</TD>
    <TD STYLE="text-align: justify">EFFECTIVE DATE, DURATION AND AMENDMENTS</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Term</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan shall be effective
as of the Effective Date, <I>provided</I> that it has been approved by the Stockholders. The Plan shall terminate automatically on the
10-year anniversary of the Effective Date and may be terminated on any earlier date as provided in <B>Section&nbsp;5.2</B>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Amendment and Termination of the Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board may, at any time
and from time to time, amend, suspend or terminate the Plan as to any Awards which have not been made. An amendment shall be contingent
on approval of the Stockholders to the extent stated by the Board, required by applicable law or required by applicable securities exchange
listing requirements. No Awards shall be made after the Termination Date. The applicable terms of the Plan, and any terms applicable to
Awards granted prior to the Termination Date, shall survive the termination of the Plan and continue to apply to such Awards. No amendment,
suspension or termination of the Plan shall, without the consent of the Participant, materially impair rights or obligations under any
Award theretofore awarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">6.</TD>
    <TD STYLE="text-align: justify">AWARD ELIGIBILITY AND LIMITATIONS</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Service Providers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to this <B>Section&nbsp;6</B>,
Awards may be made to any Service Provider as the Board may determine and designate from time to time.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Successive Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An eligible person may receive
more than one Award, subject to such restrictions as are provided herein.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stand-Alone, Additional, Tandem, and Substitute Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Awards may be granted either
alone or in addition to, in tandem with, or in substitution or exchange for, any other Award or any award granted under another plan of
the Company, any Affiliate or any business entity to be acquired by the Company or an Affiliate, or any other right of a Participant to
receive payment from the Company or any Affiliate. Such additional, tandem or substitute or exchange Awards may be granted at any time.
If an Award is granted in substitution or exchange for another award, the Board shall have the right to require the surrender of such
other award in consideration for the grant of the new Award. Subject to the requirements of applicable law, the Board may make Awards
in substitution or exchange for any other award under another plan of the Company, any Affiliate or any business entity to be acquired
by the Company or an Affiliate. In addition, Awards may be granted in lieu of cash compensation, including in lieu of cash amounts payable
under other plans of the Company or any Affiliate, in which the value of Shares subject to the Award is equivalent in value to the cash
compensation (for example, RSUs or Restricted Stock).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Minimum Vesting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any other
provision of the Plan to the contrary, Share-based Awards granted under the Plan shall vest no earlier than the first anniversary of the
date the Award is granted, excluding, for this purpose, any (i) Substitute Awards, (ii) Shares delivered in lieu of fully vested cash
Awards, and (iii) Awards to Non-employee Directors that vest on the earlier of the one year anniversary of the date of grant or the next
annual meeting of stockholders (provided that such vesting period under this clause (iii) may not be less than 50 weeks after grant; provided,
that, the Board may grant Share-based Awards without regard to the foregoing minimum vesting requirement with respect to a maximum of
five percent (5%) of the available share reserve authorized for issuance under the Plan pursuant to Section 4.1 (subject to adjustment
under Section 15); and, provided further, for the avoidance of doubt, that the foregoing restriction does not apply to the Committee&rsquo;s
discretion to provide for accelerated exercisability or vesting of any Award, including in cases of retirement, death, disability or a
Change in Control, in the terms of the Award or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">7.</TD>
    <TD STYLE="text-align: justify">AWARD AGREEMENT</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The grant of any Award may
be contingent upon the Participant executing an appropriate Award Agreement, in such form or forms as the Board shall from time to time
determine. Without limiting the foregoing, an Award Agreement may be provided in the form of a notice which provides that acceptance of
the Award constitutes acceptance of all terms of the Plan and the notice. Award Agreements granted from time to time or at the same time
need not contain similar provisions but shall be consistent with the terms of the Plan. Each Award Agreement evidencing an Award of Options
shall specify whether such Options are intended to be Nonqualified Stock Options or Incentive Stock Options, and in the absence of such
specification such options shall be deemed Nonqualified Stock Options.</P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">8.</TD>
    <TD STYLE="text-align: justify">TERMS AND CONDITIONS OF OPTIONS</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Option Price</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Option Price of each Option
shall be fixed by the Board and stated in the related Award Agreement. The Option Price of each Option (except those that constitute Substitute
Awards) shall be at least the Fair Market Value on the Grant Date; <I>provided</I>, <I>however</I>, that in the event that a Participant
is a Ten Percent Stockholder as of the Grant Date, the Option Price of an Option granted to such Participant that is intended to be an
Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the Grant Date. In no case shall the Option Price
of any Option be less than the par value of a Share.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Vesting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <B>Section&nbsp;8.3</B>,
each Option shall become exercisable at such times and under such conditions (including performance requirements) as stated in the Award
Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Term</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Option shall terminate,
and all rights to purchase Shares thereunder shall cease, upon the expiration of the Option term stated in the Award Agreement not to
exceed 10 years from the Grant Date, or under such circumstances and on such date prior thereto as is set forth in the Plan or as may
be fixed by the Board and stated in the related Award Agreement; <I>provided</I>, <I>however</I>, that in the event that the Participant
is a Ten Percent Stockholder, an Option granted to such Participant that is intended to be an Incentive Stock Option at the Grant Date
shall not be exercisable after the expiration of five years from its Grant Date.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Limitations on Exercise of Option</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any other
provision of the Plan, in no event may any Option be exercised, in whole or in part, (i)&nbsp;prior to the date the Plan is approved by
the Stockholders as provided herein or (ii)&nbsp;after the occurrence of an event which results in termination of the Option.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Method of Exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Option that is exercisable
may be exercised by the Participant&rsquo;s delivery of a notice of exercise to the Company, setting forth the number of Shares with respect
to which the Option is to be exercised, accompanied by full payment for the Shares. To be effective, notice of exercise must be made in
accordance with procedures established by the Company from time to time.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Rights of Holders of Options</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise provided
in the applicable Award Agreement, an individual holding or exercising an Option shall have none of the rights of a Stockholder (for example,
the right to direct the voting of the subject Shares) until the Shares covered thereby are fully paid and issued to him or her. An individual
holding an Option shall not have the right to receive cash or dividend payments or distributions attributable to the subject Shares until
the Option has been exercised and the Shares covered thereby are fully paid and issued to him or her. Except as provided in <B>Section&nbsp;15</B>
or the related Award Agreement, no adjustment shall be made for dividends, distributions or other rights for which the record date is
prior to the date of such issuance.</P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Delivery of Stock Certificates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <B>Section&nbsp;3.5</B>,
promptly after the exercise of an Option by a Participant and the payment in full of the Option Price, such Participant shall be entitled
to the issuance of a stock certificate which evidences, or electronic notice of a book entry which records, his or her ownership of the
Shares subject to the Option.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Limitations on Incentive Stock Options</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Option shall constitute
an Incentive Stock Option only (i)&nbsp;if the Participant of such Option is an employee of the Company or any Subsidiary of the Company;
(ii)&nbsp;to the extent specifically provided in the related Award Agreement; and (iii)&nbsp;to the extent that the aggregate Fair Market
Value (determined at the time the Option is granted) of the Shares with respect to which all Incentive Stock Options held by such Participant
become exercisable for the first time during any calendar year (under the Plan and all other plans of the Participant&rsquo;s employer
and its Affiliates) does not exceed $100,000. This limitation shall be applied by taking Options into account in the order in which they
were granted. No Option shall be treated as an Incentive Stock Option unless the Plan has been approved by the Stockholders in a manner
intended to comply with the stockholder approval requirements of Code Section 422(b)(1); <I>provided</I>, <I>however, </I>that any Option
intended to be an Incentive Stock Option shall not fail to be effective solely on account of a failure to obtain such approval, but rather
such Option shall be treated as a Nonqualified Stock Option unless and until such stockholder approval is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">9.</TD>
    <TD STYLE="text-align: justify">TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS (SAR<FONT STYLE="text-transform: none">s)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Right to Payment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A SAR shall confer on the
Participant a right to receive, upon exercise thereof, the excess of (i)&nbsp;the Fair Market Value on the date of exercise over (ii)&nbsp;the
SAR Exercise Price, as determined by the Board. The Award Agreement for a SAR (except those that constitute Substitute Awards) shall specify
the SAR Exercise Price, which shall be fixed on the Grant Date as not less than the Fair Market Value on that date. SARs may be granted
alone or in conjunction with all or part of an Option or at any subsequent time during the term of such Option or in conjunction with
all or part of any other Award. A SAR granted in tandem with an outstanding Option following the Grant Date of such Option shall have
a grant price that is equal to the Option Price; <I>provided</I>, <I>however</I>, that the SAR&rsquo;s grant price may not be less than
the Fair Market Value on the Grant Date of the SAR to the extent required by Section&nbsp;409A.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Other Terms</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board shall determine
at the Grant Date or thereafter, the time or times at which and the circumstances under which a SAR may be exercised in whole or in part
(including based on achievement of performance goals or future service requirements), the time or times at which SARs shall cease to be
or become exercisable following Separation from Service or upon other conditions, the method of exercise, whether or not a SAR shall be
in tandem or in combination with any other Award and any other terms of any SAR.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Term of SARs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of a SAR granted
under the Plan shall be determined by the Board; <I>provided</I>, <I>however</I>, that such term shall not exceed 10 years.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Payment of SAR Amount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon exercise of a SAR, a
Participant shall be entitled to receive payment from the Company (in cash or Shares, as set forth in the Award Agreement) in an amount
determined by multiplying:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(i)</TD>
    <TD STYLE="text-align: justify">the difference between the Fair Market Value on the date of exercise over the SAR Exercise Price; by</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(ii)</TD>
    <TD STYLE="text-align: justify">the number of Shares with respect to which the SAR is exercised.</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">10.</TD>
    <TD STYLE="text-align: justify">TERMS AND CONDITIONS OF RESTRICTED STOCK AND RESTRICTED STOCK UNITS (RSU<FONT STYLE="text-transform: none">s)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Restrictions (applicable to Restricted Stock and RSUs)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the time of grant, the
Board may establish a period of time (a &ldquo;<B>Service Period</B>&rdquo;) and any additional restrictions including the satisfaction
of corporate or individual performance objectives applicable to an Award of Restricted Stock or RSUs. Each Award of Restricted Stock or
RSUs may be subject to a different Service Period and additional restrictions. Neither Restricted Stock nor RSUs may be sold, transferred,
assigned, pledged or otherwise encumbered or disposed of during the Service Period or prior to the satisfaction of any other applicable
restrictions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Delivery of Shares (applicable to Restricted Stock and RSUs)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <B>Section&nbsp;3.5</B>,
upon the expiration or termination of any Service Period and the satisfaction of any other conditions prescribed by the Board, the restrictions
applicable to Shares of Restricted Stock or RSUs settled in Shares shall lapse, and, unless otherwise provided in the applicable Award
Agreement, a stock certificate for such Shares shall be delivered, free of all such restrictions, to the Participant or the Participant&rsquo;s
beneficiary or estate, as the case may be.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Rights of Holders of Restricted Stock (applicable to Restricted Stock, not RSUs)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise provided
in the applicable Award Agreement, holders of Restricted Stock shall have rights as Stockholders, including voting and dividend rights;
<I>provided</I>, <I>however</I>, any dividends with respect to the Restricted Stock shall be withheld by the Company for the Participant&rsquo;s
account, and interest may be credited on the amount of the dividends withheld at a rate and subject to such terms as determined by the
Committee. The dividends so withheld by the Committee and attributable to any particular share of Restricted Stock (and earnings thereon,
if applicable) shall be distributed to the Participant in cash or, at the discretion of the Committee, in Shares having a Fair Market
Value equal to the amount of such dividends, if applicable, upon the release of restrictions on such Share and, if such Share is forfeited,
the Participant shall have no right to such dividends.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Purchase of Restricted Stock (applicable to Restricted Stock, not RSUs)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Participant shall be required,
to the extent required by applicable law, to purchase the Restricted Stock from the Company at a Purchase Price equal to the greater of
(i)&nbsp;the aggregate par value of the Shares represented by such Restricted Stock or (ii)&nbsp;the Purchase Price, if any, specified
in the related Award Agreement. If specified in the Award Agreement, the Purchase Price may be deemed paid by services already rendered.
The Purchase Price shall be payable in a form described in <B>Section&nbsp;11</B> or, if so determined by the Board, in consideration
for past services rendered.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Restricted Stock Certificates (applicable to Restricted Stock, not RSUs)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <B>Section&nbsp;3.5</B>,
the Company shall issue, in the name of each Participant to whom Restricted Stock has been granted, stock certificates or other evidence
of ownership representing the total number of Shares of Restricted Stock granted to the Participant, as soon as reasonably practicable
after the Grant Date. The Board may provide in an Award Agreement that either (i)&nbsp;the Secretary of the Company shall hold any stock
certificates for the Participant&rsquo;s benefit until such time as the Restricted Stock is forfeited to the Company or the restrictions
lapse or (ii)&nbsp;such certificates shall be delivered to the Participant; <I>provided</I>, <I>however</I>, that such certificates shall
bear a legend or legends that comply with the applicable securities laws and regulations and make appropriate reference to the restrictions
imposed under the Plan and the Award Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Rights of Holders of RSUs (applicable to RSUs, not Restricted Stock)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.6.1.&nbsp;&nbsp;&nbsp;
Settlement of RSUs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">RSUs may be settled in cash
or Shares, as set forth in the Award Agreement. The Award Agreement shall also set forth whether the RSUs shall be settled (i)&nbsp;within
the time period specified in Section 409A for short term deferrals or (ii)&nbsp;otherwise within the requirements of Section&nbsp;409A,
in which case the Award Agreement shall specify upon which events such RSUs shall be settled.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.6.2.&nbsp;&nbsp;&nbsp;
Voting and Dividend Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Unless otherwise provided in
the applicable Award Agreement, holders of RSUs shall not have rights as Stockholders, including voting or dividend or dividend equivalents
rights. Dividend equivalent rights may be granted with respect to RSUs pursuant to <B>Section 17.10</B>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.6.3.&nbsp;&nbsp;&nbsp;
Creditor&rsquo;s Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A holder of RSUs shall have
no rights other than those of a general creditor of the Company. RSUs represent an unfunded and unsecured obligation of the Company, subject
to the terms of the applicable Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">11.</TD>
    <TD STYLE="text-align: justify">FORM OF PAYMENT FOR OPTIONS AND RESTRICTED STOCK</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
General Rule</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of the Option Price
for the Shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock shall be made in cash or in
cash equivalents acceptable to the Company, except as provided in this <B>Section&nbsp;11</B>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Surrender of Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent the Award Agreement
so provides, payment of the Option Price for Shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted
Stock may be made all or in part through the tender to the Company of Shares, which Shares shall be valued, for purposes of determining
the extent to which the Option Price or Purchase Price for Restricted Stock has been paid thereby, at their Fair Market Value on the date
of exercise or surrender. Notwithstanding the foregoing, in the case of an Incentive Stock Option, the right to make payment in the form
of already-owned Shares may be authorized only at the time of grant.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cashless Exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to an Option
only (and not with respect to Restricted Stock), to the extent permitted by law and to the extent the Award Agreement so provides, payment
of the Option Price may be made all or in part by delivery (on a form acceptable to the Company) of an irrevocable direction to a licensed
securities broker acceptable to the Company to sell Shares and to deliver all or part of the sales proceeds to the Company in payment
of the Option Price and any withholding taxes described in <B>Section&nbsp;17.3</B>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Other Forms of Payment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent the Award Agreement
so provides, payment of the Option Price or the Purchase Price for Restricted Stock may be made in any other form that is consistent with
applicable laws, regulations and rules, including the Company&rsquo;s withholding of Shares otherwise due to the exercising Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">12.</TD>
    <TD STYLE="text-align: justify">TERMS AND CONDITIONS OF PERFORMANCE AWARDS</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Performance Conditions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The right of a Participant
to exercise or receive a grant or settlement of any Award, and the timing thereof, may be subject to such performance conditions as may
be specified by the Board. The Board may use such business criteria and other measures of performance as it may deem appropriate in establishing
any performance conditions, and may reduce the amounts payable under any Award subject to performance conditions, except as limited under
<B>Section 12.2 </B>in the case of Performance-Based Compensation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Performance Awards Granted to Designated Covered Employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If and to the extent that
the Board determines that a Performance Award to be granted to a Participant who is designated by the Board as likely to be a Covered
Employee should qualify as Performance-Based Compensation, the grant, exercise or settlement of such Performance Award shall be contingent
upon achievement of pre-established performance goals and other terms set forth in this <B>Section&nbsp;12.2</B>. Notwithstanding anything
herein to the contrary, the Board may provide for Performance Awards to Covered Employees that are not intended to qualify as Performance-Based
Compensation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.2.1.&nbsp;&nbsp;&nbsp;
Performance Goals Generally</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The performance goals for Performance
Awards shall consist of one or more business criteria and a targeted level or levels of performance with respect to each of such criteria,
as specified by the Board consistent with this <B>Section&nbsp;12.2</B>. Performance goals shall be objective and shall otherwise meet
the requirements of Section&nbsp;162(m), including the requirement that the level or levels of performance targeted by the Board result
in the achievement of performance goals being &ldquo;substantially uncertain.&rdquo; The Board may determine that Performance Awards shall
be granted, exercised or settled upon achievement of any one performance goal or that two or more of the performance goals must be achieved
as a condition to grant, exercise or settlement of the Performance Awards. Performance goals may be established on a Company-wide basis,
or with respect to one or more business units, divisions, Affiliates or business segments, as applicable. To the extent consistent with
the requirements of Section&nbsp;162(m), the Committee may determine at the time that goals under this <B>Section&nbsp;12 </B>are established
the extent to which measurement of performance goals may exclude the impact of charges for restructuring, discontinued operations, extraordinary
items, debt redemption or retirement, asset write downs, litigation or claim judgments or settlements, acquisitions or divestitures, foreign
exchange gains and losses and other extraordinary, unusual or non-recurring items, and the cumulative effects of tax or accounting changes
(each as defined by generally accepted accounting principles and as identified in the Company&rsquo;s financial statements or other SEC
filings). Performance goals may differ for Performance Awards granted to any one Participant or to different Participants.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.2.2.&nbsp;&nbsp;&nbsp;
Business Criteria</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">One or more of the following
business criteria for the Company, on a consolidated basis, or specified Affiliates or business units of the Company (except with respect
to the total stockholder return and earnings per share criteria), shall be used exclusively by the Board in establishing performance goals
for Performance Awards: (i) cash flow; (ii) earnings per share, as adjusted for any stock split, stock dividend or other recapitalization;
(iii) earnings measures; (iv) return on equity; (v) total stockholder return; (vi) share price performance, as adjusted for any stock
split, stock dividend or other recapitalization; (vii) return on capital; (viii) revenue; (ix) income; (x) profit margin; (xi) return
on operating revenue; (xii) brand recognition or acceptance; (xiii) customer satisfaction; (xiv) productivity; (xv) expense targets; (xvi)
market share; (xvii) cost control measures; (xviii) balance sheet metrics; (xix) strategic initiatives; (xx) implementation, completion
or attainment of measurable objectives with respect to recruitment or retention of personnel or employee satisfaction; (xxi) regulatory
body approval for commercialization of a product; (xxii) implementation or completion of critical projects; or (xxiii) any other business
criteria established by the Board; <I>provided</I>, <I>however</I>, that such business criteria shall include any derivations of business
criteria listed above (<I>e.g.</I>, income shall include pre-tax income, net income and operating income).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.2.3.&nbsp;&nbsp;&nbsp;
Timing for Establishing Performance Goals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Performance goals shall be established
not later than 90 days after the beginning of any performance period applicable to Performance Awards, or at such other date as may be
required or permitted for Performance-Based Compensation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.2.4.&nbsp;&nbsp;&nbsp;
Settlement of Performance Awards; Other Terms</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Settlement of Performance Awards
may be in cash, Shares, other Awards or other property. The Board may reduce the amount of a settlement otherwise to be made in connection
with such Performance Awards.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Written Determinations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All determinations by the
Board as to the establishment of performance goals, the amount of any Performance Award pool or potential individual Performance Awards
and the achievement of performance goals relating to Performance Awards, shall be made in writing in the case of any Award intended to
qualify as Performance-Based Compensation to the extent required by Section&nbsp;162(m). To the extent permitted by Section&nbsp;162(m),
the Board may delegate any responsibility relating to Performance Awards.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Status of Section&nbsp;12.2 Awards under Section&nbsp;162(m)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is the intent of the Company
that Performance Awards under <B>Section&nbsp;12.2</B> granted to persons who are designated by the Board as likely to be Covered Employees
within the meaning of Section&nbsp;162(m) shall, if so designated by the Board, qualify as Performance-Based Compensation. Accordingly,
the terms of <B>Section&nbsp;12.2</B>, including the definitions of Covered Employee and other terms used therein, shall be interpreted
in a manner consistent with Section&nbsp;162(m). The foregoing notwithstanding, because the Board cannot determine with certainty whether
a given Participant will be a Covered Employee with respect to a fiscal year that has not yet been completed, the term Covered Employee
as used herein shall mean only a person designated by the Board, at the time of grant of Performance Awards, as likely to be a Covered
Employee with respect to that fiscal year. If any provision of the Plan or any agreement relating to such Performance Awards does not
comply or is inconsistent with the requirements of Section&nbsp;162(m), such provision shall be construed or deemed amended to the extent
necessary to conform to such requirements.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">13.</TD>
    <TD STYLE="text-align: justify">other SHARE-based awards</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Grant of Other Share-based Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other Share-based Awards may
be granted either alone or in addition to or in conjunction with other Awards. Other Share-based Awards may be granted in lieu of other
cash or other compensation to which a Service Provider is entitled from the Company or may be used in the settlement of amounts payable
in Shares under any other compensation plan or arrangement of the Company, including any other Company incentive compensation plan. The
Board shall have the authority to determine the persons to whom and the time or times at which such Awards will be made, the number of
Shares to be granted pursuant to such Awards, and all other terms of such Awards. Unless the Board determines otherwise, any such Award
shall be confirmed by an Award Agreement, which shall contain such provisions as the Board determines to be necessary or appropriate to
carry out the intent of the Plan with respect to such Award.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Terms of Other Share-based Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Common Stock subject to
Awards made under this <B>Section&nbsp;13</B> may not be sold, assigned, transferred, pledged or otherwise encumbered prior to the date
on which the Shares are issued, or, if later, the date on which any applicable restriction, performance or deferral period lapses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">14.</TD>
    <TD STYLE="text-align: justify">REQUIREMENTS OF LAW</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
General</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall not be required
to sell or issue any Shares under any Award if the sale or issuance of such Shares would constitute a violation by the Participant, any
other individual exercising an Option or the Company of any provision of any law or regulation of any governmental authority, including
any federal or state securities laws or regulations. If at any time the Board determines that the listing, registration or qualification
of any Shares subject to an Award upon any securities exchange or under any governmental regulatory body is necessary or desirable as
a condition of, or in connection with, the issuance or purchase of Shares hereunder, no Shares may be issued or sold to the Participant
or any other individual exercising an Option pursuant to such Award unless such listing, registration, qualification, consent or approval
shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay caused thereby shall in no way
affect the date of termination of the Award. Specifically, in connection with the Securities Act, upon the exercise of any Option or the
delivery of any Shares underlying an Award, unless a registration statement under such Act is in effect with respect to the Shares covered
by such Award, the Company shall not be required to sell or issue such Shares unless the Board has received evidence satisfactory to it
that the Participant or any other individual exercising an Option may acquire such Shares pursuant to an exemption from registration under
the Securities Act. The Company may, but shall in no event be obligated to, register any securities covered hereby pursuant to the Securities
Act. The Company shall not be obligated to take any affirmative action in order to cause the exercise of an Option or the issuance of
Shares pursuant to the Plan to comply with any law or regulation of any governmental authority. As to any jurisdiction that expressly
imposes the requirement that an Option shall not be exercisable until the Shares covered by such Option are registered or are exempt from
registration, the exercise of such Option (under circumstances in which the laws of such jurisdiction apply) shall be deemed conditioned
upon the effectiveness of such registration or the availability of such an exemption. The Committee may require the Participant to sign
such additional documentation, make such representations and furnish such information as it may consider appropriate in connection with
the grant of Awards or issuance or delivery of Shares in compliance with applicable laws, rules and regulations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Rule 16b-3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During any time when the Company
has a class of equity security registered under Section&nbsp;12 of the Exchange Act, it is the intent of the Company that Awards and the
exercise of Options will qualify for the exemption provided by Rule 16b-3 under the Exchange Act. To the extent that any provision of
the Plan or action by the Board or Committee does not comply with the requirements of Rule 16b-3, it shall be deemed inoperative to the
extent permitted by law and deemed advisable by the Board, and shall not affect the validity of the Plan. In the event that Rule 16b-3
is revised or replaced, the Board may modify the Plan in any respect necessary to satisfy the requirements of, or to take advantage of
any features of, the revised exemption or its replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">15.</TD>
    <TD STYLE="text-align: justify">EFFECT OF CHANGES IN CAPITALIZATION</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Adjustments for Changes in Capital Structure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to any required action
by the Stockholders, in the event of any change in the Common Stock effected without receipt of consideration by the Company, whether
through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse
stock split, split-up, split-off, spin-off, combination of shares, exchange of shares or similar change in the capital structure of the
Company, or in the event of payment of a dividend or distribution to the Stockholders in a form other than Shares (excepting normal cash
dividends) that has a material effect on the Fair Market Value, appropriate and proportionate adjustments shall be made in the number
and class of shares subject to the Plan and to any outstanding Awards, and in the Option Price, SAR Exercise Price or Purchase Price per
Share of any outstanding Awards in order to prevent dilution or enlargement of Participants&rsquo; rights under the Plan. For purposes
of the foregoing, conversion of any convertible securities of the Company shall not be treated as &ldquo;effected without receipt of consideration
by the Company.&rdquo; If a majority of the Shares which are of the same class as the Shares that are subject to outstanding Awards are
exchanged for, converted into, or otherwise become (whether or not pursuant to a Change in Control) shares of another corporation (the
&ldquo;<B>New Shares</B>&rdquo;), the Board may unilaterally amend the outstanding Awards to provide that such Awards are for New Shares.
In the event of any such amendment, the number of Shares subject to, and the Option Price, SAR Exercise Price or Purchase Price per Share
of, the outstanding Awards shall be adjusted in a fair and equitable manner. Any fractional share resulting from an adjustment pursuant
to this <B>Section 15.1 </B>shall be rounded down to the nearest whole number and the Option Price, SAR Exercise Price or Purchase Price
per share shall be rounded up to the nearest whole cent. In no event may the exercise price of any Award be decreased to an amount less
than the par value, if any, of the stock subject to the Award. The Board may also make such adjustments in the terms of any Award to reflect,
or related to, such changes in the capital structure of the Company or distributions as it deems appropriate. Adjustments determined by
the Board pursuant to this <B>Section 15.1</B> shall be made in accordance with Section 409A to the extent applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Change in Control</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">15.2.1.&nbsp;&nbsp;&nbsp;
Consequences of a Change in Control</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the requirements
and limitations of Section 409A if applicable, the Board may provide for any one or more of the following in connection with a Change
in Control, which such actions need not be the same for all Participants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>Accelerated Vesting</B>. The Board may provide in any Award Agreement, or in the event of a Change in Control may take such actions
as it deems appropriate to provide, for the acceleration of the exercisability, vesting or settlement in connection with such Change in
Control of each or any outstanding Award or portion thereof and Shares acquired pursuant thereto upon such terms, including a Participant&rsquo;s
Separation from Service prior to, upon, or following such Change in Control, to such extent as determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>Assumption, Continuation or Substitution</B>. In the event of a Change in Control, the surviving, continuing, successor or purchasing
corporation or other business entity or parent thereof, as the case may be (the &ldquo;<B>Acquiror</B>&rdquo;), may, without the consent
of any Participant, either assume or continue the Company&rsquo;s rights and obligations under each or any Award or portion thereof outstanding
immediately prior to the Change in Control or substitute for each or any such outstanding Award or portion thereof a substantially equivalent
award with respect to the Acquiror&rsquo;s stock, as applicable. For purposes of this <B>Section 15.2.1</B>, an Award denominated in Shares
shall be deemed assumed if, following the Change in Control, the Award confers the right to receive, subject to the terms of the Plan
and the applicable Award Agreement, for each Share subject to the Award immediately prior to the Change in Control, the consideration
(whether stock, cash, other securities or property or a combination thereof) to which a Stockholder on the effective date of the Change
in Control was entitled; <I>provided, however</I>, that if such consideration is not solely common stock of the Acquiror, the Board may,
with the consent of the Acquiror, provide for the consideration to be received upon the exercise or settlement of the Award, for each
Share subject to the Award, to consist solely of common stock of the Acquiror equal in Fair Market Value to the per Share consideration
received by Stockholders pursuant to the Change in Control. If any portion of such consideration may be received by Stockholders pursuant
to the Change in Control on a contingent or delayed basis, the Board may determine such Fair Market Value as of the time of the Change
in Control on the basis of the Board&rsquo;s estimate of the present value of the probable future payment of such consideration. Any Award
or portion thereof which is neither assumed or continued by the Acquiror in connection with the Change in Control nor exercised or settled
as of the time of consummation of the Change in Control shall terminate and cease to be outstanding effective as of the time of consummation
of the Change in Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>Cash-Out of Awards.</B> The Board may, without the consent of any Participant, determine that, upon the occurrence of a Change in Control,
each or any Award or a portion thereof outstanding immediately prior to the Change in Control and not previously exercised or settled
shall be canceled in exchange for a payment with respect to each vested Share (and each unvested Share, if so determined by the Board)
subject to such canceled Award in (i) cash, (ii) stock of the Company or of a corporation or other business entity a party to the Change
in Control or (iii) other property which, in any such case, shall be in an amount having a Fair Market Value equal to the Fair Market
Value of the consideration to be paid per Share in the Change in Control, reduced by the exercise or purchase price per Share, if any,
under such Award. If any portion of such consideration may be received by Stockholders pursuant to the Change in Control on a contingent
or delayed basis, the Board may determine such Fair Market Value as of the time of the Change in Control on the basis of the Board&rsquo;s
estimate of the present value of the probable future payment of such consideration. In the event such determination is made by the Board,
the amount of such payment (reduced by applicable withholding taxes, if any) shall be paid to Participants in respect of the vested portions
of their canceled Awards as soon as practicable following the date of the Change in Control and in respect of the unvested portions of
their canceled Awards in accordance with the vesting schedules applicable to such Awards. For avoidance of doubt, if the amount determined
pursuant to this <B>Section 15.2.1(c) </B>for an Option or SAR is zero or less, the affected Option or SAR may be cancelled without any
payment therefore.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">15.2.2.&nbsp;&nbsp;&nbsp;
Change in Control Defined</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Unless otherwise provided in
the applicable Award Agreement, a &ldquo;<B>Change in Control</B>&rdquo; means the consummation of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the acquisition, other than from the Company, by any individual, entity or group (within the meaning of Section&nbsp;13(d)(3) or Section&nbsp;14(d)(2)
of the Exchange Act), other than the Company or any subsidiary, affiliate (within the meaning of Rule 144 promulgated under the Securities
Act) or employee benefit plan of the Company, of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange
Act) of more than 50% of the combined voting power of the then outstanding voting securities of the Company entitled to vote generally
in the election of directors (the &ldquo;<B>Voting Securities</B>&rdquo;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
a reorganization, merger, consolidation or recapitalization of the Company (a &ldquo;<B>Business Combination</B>&rdquo;), other than a
Business Combination in which more than 50% of the combined voting power of the outstanding voting securities of the surviving or resulting
entity immediately following the Business Combination is held by the persons who, immediately prior to the Business Combination, were
the holders of the Voting Securities; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
a complete liquidation or dissolution of the Company, or a sale of all or substantially all of the assets of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
during any period of 12 consecutive months, the Incumbent Directors cease to constitute a majority of the Board; &ldquo;<B>Incumbent Directors</B>&rdquo;
means individuals who were members of the Board at the beginning of such period or individuals whose election or nomination for election
to the Board by the Stockholders was approved by a vote of at least a majority of the then Incumbent Directors (but excluding any individual
whose initial election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
if it is determined that an Award is subject to the requirements of Section&nbsp;409A and payable upon a Change in Control, the Company
will not be deemed to have undergone a Change in Control for purposes of the Plan unless the Company is deemed to have undergone a &ldquo;change
in control event&rdquo; pursuant to the definition of such term in Section&nbsp;409A.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Adjustments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adjustments under this <B>Section&nbsp;15</B>
related to Shares or other securities of the Company shall be made by the Board. No fractional Shares or other securities shall be issued
pursuant to any such adjustment, and any fractions resulting from any such adjustment shall be eliminated in each case by rounding downward
to the nearest whole Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">16.</TD>
    <TD STYLE="text-align: justify">No Limitations on Company</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The making of Awards shall
not affect or limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of
its capital or business structure or to merge, consolidate, dissolve or liquidate, or to sell or transfer all or any part of its business
or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">17.</TD>
    <TD STYLE="text-align: justify">TERMS APPLICABLE GENERALLY TO AWARDS</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Disclaimer of Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No provision in the Plan or
in any Award Agreement shall be construed to confer upon any individual the right to remain in the employ or service of the Company or
any Affiliate, or to interfere in any way with any contractual or other right or authority of the Company or any Affiliate either to increase
or decrease the compensation or other payments to any individual at any time, or to terminate any employment or other relationship between
any individual and the Company or any Affiliate. In addition, notwithstanding anything contained in the Plan to the contrary, unless otherwise
provided in the applicable Award Agreement, no Award shall be affected by any change of duties or position of the Participant, so long
as such Participant continues to be a Service Provider. The obligation of the Company to pay any benefits pursuant to the Plan shall be
interpreted as a contractual obligation to pay only those amounts described herein, in the manner and under the conditions prescribed
herein. The Plan shall in no way be interpreted to require the Company to transfer any amounts to a third party trustee or otherwise hold
any amounts in trust or escrow for payment to any Participant or beneficiary under the terms of the Plan.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Nonexclusivity of the Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the adoption of the
Plan nor the submission of the Plan to the Stockholders for approval shall be construed as creating any limitations upon the right or
authority of the Board or its delegate to adopt such other compensation arrangements as the Board or its delegate determines desirable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Withholding Taxes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company or an Affiliate,
as the case may be, shall have the right to deduct from payments of any kind otherwise due to a Participant any federal, state or local
taxes of any kind required by law to be withheld (i)&nbsp;with respect to the vesting of or other lapse of restrictions applicable to
an Award, (ii)&nbsp;upon the issuance of any Shares upon the exercise of an Option or SAR or (iii)&nbsp;otherwise due in connection with
an Award. At the time of such vesting, lapse or exercise, the Participant shall pay to the Company or the Affiliate, as the case may be,
any amount that the Company or the Affiliate may reasonably determine to be necessary to satisfy such withholding obligation. In addition,
the Board may provide one or more Participants with the right to direct the Company to withhold, from the Shares otherwise issuable upon
the exercise of an Option or Stock Appreciation Right or upon the issuance of fully-vested Shares (whether pursuant to Restricted Stock,
RSUs, Other Share-based Awards, or otherwise), a portion of those Shares with an aggregate Fair Market Value equal to the percentage of
the applicable withholding taxes (not to exceed one hundred percent (100%)) designated by the Participant;&nbsp;<B><I>provided, however</I></B>,
that the amount of any Shares so withheld shall not exceed the amount necessary to satisfy the Company&rsquo;s required tax withholding
obligations using not more than the applicable maximum statutory withholding rates (or such other rates as required to avoid adverse accounting
treatment as determined by the Board). The Fair Market Value of the Shares used to satisfy such withholding obligation shall be determined
by the Company or the Affiliate as of the date that the amount of tax to be withheld is to be determined. A Participant who has made an
election pursuant to this <B>Section&nbsp;17.3</B> may satisfy his or her withholding obligation only with Shares that are not subject
to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Other Provisions; Legends</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Award Agreement may contain
such other terms not inconsistent with the Plan as may be determined by the Board. Any stock certificates for any Shares issued under
the Plan shall be subject to such stop-transfer orders and other restrictions as the Company in its sole discretion may deem advisable
under the rules, regulations and other requirements of the SEC, any securities exchange on which the Common Stock may then be listed and
any applicable federal or state securities law, and the Company in its sole discretion may cause a legend or legends to be placed on such
certificates to make appropriate reference to such restrictions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Severability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any provision of the Plan
or any Award Agreement shall be determined to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions
hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any
other jurisdiction.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Governing Law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan shall be governed
by and construed in accordance with the internal laws of the Commonwealth of Massachusetts without regard to the principles of conflicts
of law thereof or principles of conflicts of laws of any other jurisdiction that could cause the application of the laws of any jurisdiction
other than the Commonwealth of Massachusetts. For purposes of resolving any dispute that arises directly or indirectly in connection with
the Plan, each Participant, by virtue of receiving an Award, shall be deemed to have submitted to and consented to the exclusive jurisdiction
of the Commonwealth of Massachusetts and to have agreed that any related litigation shall be conducted solely in the courts of Middlesex
County, Massachusetts or the United States District Court for the District of Massachusetts, where the Plan is made and to be performed,
and no other courts.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Section&nbsp;409A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan is intended to comply
with Section&nbsp;409A, and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance
therewith. Any payments described in the Plan that are due within the &ldquo;short-term deferral period&rdquo; as defined in Section&nbsp;409A
shall not be treated as deferred compensation unless applicable laws require otherwise. Notwithstanding anything to the contrary in the
Plan, to the extent required to avoid accelerated taxation and tax penalties under Section&nbsp;409A, amounts that would otherwise be
payable and benefits that would otherwise be provided pursuant to the Plan during the six-month period immediately following the Participant&rsquo;s
Separation from Service shall instead be paid on the first payroll date after the six-month anniversary of the Participant&rsquo;s Separation
from Service (or the Participant&rsquo;s death, if earlier). Notwithstanding the foregoing, neither the Company nor the Committee shall
have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Participant under Section&nbsp;409A
and neither the Company nor the Board shall have any liability to any Participant for such tax or penalty.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Separation from Service</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board shall determine
the effect of a Separation from Service upon Awards, and such effect shall be set forth in the applicable Award Agreement. Without limiting
the foregoing, the Board may provide in the Award Agreements at the time of grant, or any time thereafter with the consent of the Participant,
the actions that will be taken upon the occurrence of a Separation from Service, including accelerated vesting or termination, depending
upon the circumstances surrounding the Separation from Service.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Transferability of Awards</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">17.9.1.&nbsp;&nbsp;&nbsp;
Transfers in General</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Except as provided in <B>Section&nbsp;17.9.2</B>,
no Award shall be assignable or transferable by the Participant to whom it is granted, other than by will or the laws of descent and distribution,
and, during the lifetime of the Participant, only the Participant personally (or the Participant&rsquo;s personal representative) may
exercise rights under the Plan.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.7in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">17.9.2.&nbsp;&nbsp;&nbsp;
Family Transfers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If authorized in the applicable
Award Agreement, a Participant may transfer, not for value, all or part of an Award (other than Incentive Stock Options) to any Family
Member. For the purpose of this <B>Section&nbsp;17.9.2</B>, a &ldquo;not for value&rdquo; transfer is a transfer which is (i)&nbsp;a gift,
(ii)&nbsp;a transfer under a domestic relations order in settlement of marital property rights or (iii)&nbsp;a transfer to an entity in
which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity.
Following a transfer under this <B>Section&nbsp;17.9.2</B>, any such Award shall continue to be subject to the same terms as were applicable
immediately prior to transfer. Subsequent transfers of transferred Awards are prohibited except to Family Members of the original Participant
in accordance with this <B>Section&nbsp;17.9.2</B> or by will or the laws of descent and distribution.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.10.&nbsp;&nbsp;&nbsp;&nbsp;
Dividends and Dividend Equivalent Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If specified in the Award
Agreement, the recipient of an Award may be entitled to receive, currently or on a deferred basis, dividends or dividend equivalents with
respect to the Common Stock or other securities covered by an Award; <I>provided</I>, <I>however</I>, that no dividends or dividend equivalents
may be paid or granted with respect to an Option or SAR or the Shares subject thereto until such Award has been exercised. The terms of
a dividend equivalent right may be set forth in the Award Agreement. Dividend equivalents credited to a Participant may be paid currently
or may be deemed to be reinvested in additional Shares or other securities of the Company at a price per unit equal to the Fair Market
Value on the date that such dividend was paid to Stockholders. Notwithstanding the foregoing, in no event will dividends or dividend equivalents
on any Award that is subject to vesting conditions (including the achievement of performance criteria) be payable before the Award has
become vested.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.11.&nbsp;&nbsp;&nbsp;&nbsp;
Data Protection</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Participant&rsquo;s acceptance
of an Award shall be deemed to constitute the Participant&rsquo;s acknowledgement of and consent to the collection and processing of personal
data relating to the Participant so that the Company and the Affiliates can fulfill their obligations and exercise their rights under
the Plan and generally administer and manage the Plan. This data shall include data about participation in the Plan and Shares offered
or received, purchased or sold under the Plan and other appropriate financial and other data (such as the date on which the Awards were
granted) about the Participant and the Participant&rsquo;s participation in the Plan.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.12.&nbsp;&nbsp;&nbsp;&nbsp;
Plan Construction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the Plan, unless otherwise
stated, the following uses apply: (i)&nbsp;references to a statute or law refer to the statute or law and any amendments and any successor
statutes or laws, and to all valid and binding governmental regulations, court decisions and other regulatory and judicial authority issued
or rendered thereunder, as amended, or their successors, as in effect at the relevant time; (ii)&nbsp;in computing periods from a specified
date to a later specified date, the words &ldquo;from&rdquo; and &ldquo;commencing on&rdquo; (and the like) mean &ldquo;from and including,&rdquo;
and the words &ldquo;to,&rdquo; &ldquo;until&rdquo; and &ldquo;ending on&rdquo; (and the like) mean &ldquo;to and including&rdquo;; (iii)&nbsp;indications
of time of day shall be based upon the time applicable to the location of the principal headquarters of the Company; (iv)&nbsp;the words
&ldquo;include,&rdquo; &ldquo;includes&rdquo; and &ldquo;including&rdquo; (and the like) mean &ldquo;include, without limitation,&rdquo;
&ldquo;includes, without limitation&rdquo; and &ldquo;including, without limitation&rdquo; (and the like), respectively; (v)&nbsp;all
references to articles and sections are to articles and sections in the Plan; (vi)&nbsp;all words used shall be construed to be of such
gender or number as the circumstances and context require; (vii)&nbsp;the captions and headings of articles and sections have been inserted
solely for convenience of reference and shall not be considered a part of the Plan, nor shall any of them affect the meaning or interpretation
of the Plan or any of its provisions; (viii)&nbsp;any reference to an agreement, plan, policy, form, document or set of documents, and
the rights and obligations of the parties under any such agreement, plan, policy, form, document or set of documents, shall mean such
agreement, plan, policy, form, document or set of documents as amended from time to time, and any and all modifications, extensions, renewals,
substitutions or replacements thereof; and (ix)&nbsp;all accounting terms not specifically defined shall be construed in accordance with
GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="3" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 46%; font-weight: bold; text-align: left">Adopted by the Board:</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 44%; font-weight: bold">March 31, 2017</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">Approved by the Stockholders:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">June 13, 2017</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">Amended by the Stockholders:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">June 18, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.25pt"><FONT STYLE="text-underline-style: double"><U>Amended by the Stockholders:</U></font></TD><TD STYLE="font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.25pt"><FONT STYLE="text-underline-style: double"><U>June 16, 2020</U></font></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">Scheduled Termination Date:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">June 13, 2027</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #2F5496"><FONT STYLE="font-size: 14pt"><A NAME="a_051"></A><I>Appendix
B</I></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase">ANIKA
THERAPEUTICS, INC.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase">2021
EMPLOYEE STOCK PURCHASE PLAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article
1 - Purpose.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This 2021 Employee Stock Purchase
Plan (the &ldquo;<B>Plan</B>&rdquo;) is intended to encourage stock ownership by all eligible employees of Anika Therapeutics, Inc., a
Delaware corporation (including any successor corporation, the &ldquo;<B>Company</B>&rdquo;), and its participating subsidiaries (as defined
in <B>Article&nbsp;17</B>) so that they may share in the growth of the Company by acquiring or increasing their proprietary interest in
the Company. The Plan is designed to encourage eligible employees to remain in the employ of the Company and its participating subsidiaries.
Except as described below in <B>Article 2</B>, the Plan is intended to constitute an &ldquo;employee stock purchase plan&rdquo; within
the meaning of Section&nbsp;423(b) of the Internal Revenue Code of&nbsp;1986, as amended (the &ldquo;<B>Code</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article
2 - Administration of the Plan.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan will be administered
by the Compensation Committee of the Company&rsquo;s Board of Directors (the &ldquo;<B>Board</B>&rdquo;), or such other committee as determined
by the Board (the &ldquo;<B>Committee</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything to
the contrary in the Plan, the Committee may establish sub-plans (which need not qualify under section 423 of the Code) and initiate separate
Offering Periods (as defined in <B>Article&nbsp;5</B>) through such sub-plans for the purpose of (i) facilitating participation in the
Plan by non-U.S. employees in compliance with foreign laws and regulations without affecting the qualification of the remainder of the
Plan under section 423 of the Code or (ii) qualifying the Plan for preferred tax treatment under foreign tax laws (which sub-plans, at
the Committee&rsquo;s discretion, may provide for allocations of the authorized shares reserved for issue under the Plan as set forth
in <B>Article 4</B>). The rules, guidelines and forms of such sub-plans (or the Offering Periods thereunder) may take precedence over
other provisions of the Plan, with the exception of the maximum Offering Period term set forth in <B>Article 5</B>, the maximum payroll
deduction set forth in <B>Article 8</B>, the limitation on the decrease to the Option Price defined and described in <B>Article 5</B>
and the aggregate stock limit described in <B>Article 4</B>, but unless otherwise superseded by the terms of such sub-plan, the provisions
of the Plan shall govern the operation of such sub-plan. Alternatively, notwithstanding anything to the contrary in the Plan, in order
to comply with the laws of a foreign jurisdiction, the Committee shall have the power, in its discretion, to grant options in an Offering
Period to citizens or residents of a non-U.S. jurisdiction (without regard to whether they are also citizens of the United States or resident
aliens) that provide terms which are less favorable than the terms of options granted under the same Offering Period to employees resident
in the United States, subject to compliance with section 423 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The interpretation and construction
by the Committee of any provisions of the Plan or of any option granted under it will be final, unless otherwise determined by the Board.
The Committee may from time to time adopt such rules and regulations for carrying out the Plan as it may deem best, provided that any
such rules and regulations will be applied on a uniform basis to all employees under the Plan. No member of the Board or the Committee
will be liable for any action or determination made in good faith with respect to the Plan or any option granted under it.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 110; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article
3 - Eligible Employees.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee with respect to an Offering Period prior to the start date thereof, all employees of the Company or any of its participating
subsidiaries who are (i) so employed on the start date of any Offering Period and (2) have continuously been employed with the Company
or such participating subsidiary for at least one month prior to such start date will be eligible to participate and receive an option
with respect to such Offering Period. All such eligible employees will have the same rights and privileges hereunder with respect to such
Offering Period. In no event, however, may an employee be granted an option if such employee, immediately after the option is granted,
would be treated as owning stock possessing five&nbsp;percent or more of the total combined voting power or value of all classes of stock
of the Company or of any parent corporation or subsidiary corporation, as the terms &ldquo;parent corporation&rdquo; and &ldquo;subsidiary
corporation&rdquo; are defined in Section&nbsp;424(e) and Section&nbsp;424(f) of the Code. For purposes of determining stock ownership
under this paragraph, the rules of Section&nbsp;424(d) of the Code will apply, and stock which the employee may purchase under outstanding
options (including options not granted under the Plan) will be treated as stock owned by the employee. Notwithstanding the foregoing,
except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, employees who are
otherwise eligible employees and who are citizens or residents of a non-U.S. jurisdiction (without regard to whether such employee is
also a citizen of the United States or a resident alien (within the meaning of Section 7701(b)(1)(A) of the Code)) will not be considered
an eligible employee if his or her participation is prohibited under the laws of the applicable non-U.S. jurisdiction or if complying
with the laws of the applicable non-U.S. jurisdiction would cause the Plan or an Offering Period to violate Section 423 of the Code.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;4
- Stock Subject to the Plan.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock subject to the options
under the Plan will be shares of the Company&rsquo;s authorized but unissued common stock (the &ldquo;<B>Common Stock</B>&rdquo;), or
shares of Common Stock reacquired by the Company, including shares purchased in the open market. The aggregate number of shares of Common
Stock which may be issued pursuant to the Plan is 200,000, subject to adjustment as provided in <B>Article&nbsp;12</B>. If any option
granted under the Plan expires or terminates for any reason without having been exercised in full or ceases for any reason to be exercisable
in whole or in part, the unpurchased shares subject thereto will again be available under the Plan.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;5
- Offering Period and Stock Options.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee, the first Offering Period will start on November 15, 2021 and will end on May 14, 2022, provided that if such end date
is not a business day (as defined below in this <B>Article 5</B>), such Offering Period will end on the first business day preceding such
end date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Thereafter, except as otherwise
determined by the Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>An offering period (&ldquo;<B>Offering Period</B>&rdquo;) will start on each May 15 (provided that if such start date is not a
business day, such start date will be the first business day following the immediately preceding Exercise Date (as defined below in this
<B>Article 5</B>)) and end on the following November 14 (provided that if such end date is not a business day, such end date will be the
first business day preceding such end date); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>An Offering Period will start on each November 15 (provided that if such start date is not a business day, such start date will
be the first business day following the immediately preceding Exercise Date) and end on the following May 14 (provided that if such end
date is not a business day, such end date will be the first business day preceding such end date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The end date within each Offering
Period will be the day on which shares of Common Stock are purchased by participants in an Offering Period (&ldquo;<B>Exercise Date</B>&rdquo;).
On the start date of each Offering Period, the Company will grant to each eligible employee who has then elected to be a participant in
the Plan an option to purchase shares on the relevant Exercise Date, at the Option Price hereinafter provided for, covering a maximum
of 800 shares of Common Stock (which maximum number may be amended by the Committee from time to time with respect to an Offering Period
prior to the start date thereof), on condition that such employee remains an eligible employee through the Exercise Date. If a participant&rsquo;s
accumulated payroll deductions on the end date of an Offering Period would enable the participant to purchase more than such maximum number
of shares of Common Stock, the excess of the amount of the accumulated payroll deductions over the aggregate purchase price of such maximum
number of shares will be promptly refunded to the participant by the Company, without interest. A participant will be entitled to exercise
the option so granted only to the extent of the participant&rsquo;s accumulated payroll deductions on the Exercise Date. The Option Price
per share for each Exercise Date within an Offering Period will be the lesser of (i)&nbsp;85% of the Fair Market Value of the Common Stock
on the start date of the Offering Period and (ii)&nbsp;85% of the Fair Market Value of the Common Stock on the Exercise Date, in either
event rounded up to the nearest cent. Prior to the start date of an Offering Period, the Committee may increase, but not decrease, the
Option Price with respect to such Offering Period. The foregoing limitation on the number of shares subject to an option hereunder and
the Option Price will be subject to adjustment as provided in <B>Article&nbsp;12</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the Committee may in its discretion determine to implement Offering Periods of up to twenty-seven months. Such Offering Periods may consist
of one or more Exercise Dates. Each eligible employee who elects to be a participant in such Offering Period will be granted an option,
at the Option Price, to purchase shares of Common Stock on such Exercise Date(s). Each such option will cover a maximum number of shares
of Common Stock for such Offering Period as determined by the Committee prior the start date of such Offering Period. In no event will
an Offering Period under the Plan exceed twenty-seven months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee with respect to an Offering Period prior to the start date thereof, unless a participant files a new authorization (as
described in <B>Article&nbsp;7</B>) or withdraws from the Plan (as described in <B>Article&nbsp;10</B>), the deductions and purchases
under the authorization a participant has on file under the Plan will continue from one Offering Period to succeeding Offering Periods
as long as the Plan remains in effect and the participant continues to be an eligible employee at the start date of the relevant Offering
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the Plan,
the term &ldquo;<B>Fair Market Value</B>&rdquo; on any date means the value of the Common Stock as determined below. If the Common Stock
is listed on any established stock exchange or a national market system, including without limitation, the New York Stock Exchange or
the NASDAQ Stock Market, the Fair Market Value will be the closing price of a share of Common Stock (or if no sales were reported on such
date, the closing price on the last trading date) as quoted on such exchange or system. In the absence of an established market for the
Common Stock, the Fair Market Value will be determined in good faith by the Committee and such determination will be conclusive and binding
on all persons. For purposes of the Plan, the term &ldquo;business day&rdquo; means a day on which there is trading on such exchange or
system and that is not a Saturday, Sunday or legal holiday in the State of Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No employee will be granted
an option which permits the employee&rsquo;s right to purchase stock under the Plan, and under all other Code Section&nbsp;423(b) employee
stock purchase plans of the Company and any parent corporations or subsidiary corporations, as &ldquo;parent corporation&rdquo; and &ldquo;subsidiary
corporation&rdquo; are defined in Section&nbsp;424(e) and Section&nbsp;424(f) of the Code, to accrue at a rate which exceeds $25,000 of
Fair Market Value of such stock (determined on the date or dates that options on such stock were granted) for each calendar year in which
such option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply, and such limitation will
be administered in accordance, with Section&nbsp;423(b)(8) of the Code. If a participant&rsquo;s accumulated payroll deductions on any
Exercise Date would otherwise enable a participant to purchase Common Stock in excess of the Section&nbsp;423(b)(8) limitation described
in this paragraph, the excess of the amount of the accumulated payroll deductions over the aggregate purchase price of the shares actually
purchased will be promptly refunded to the participant by the Company, without interest.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;6
- Exercise of Option.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each eligible employee who
continues to be a participant in the Plan on an Exercise Date will be deemed to have exercised his or her option on such date and will
be deemed to have purchased from the Company such number of full shares of Common Stock reserved for the purpose of the Plan as the participant&rsquo;s
accumulated payroll deductions on such date will pay for at the Option Price, subject to the 800 maximum share limit of the option and
the Section&nbsp;423(b)(8) limitation described in <B>Article&nbsp;5</B>. If the individual is not a participant on an Exercise Date,
then he or she will not be entitled to exercise his or her option. Only full shares of Common Stock may be purchased under the Plan. Except
as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, unused payroll deductions
remaining in a participant&rsquo;s account at the end of an Offering Period, by reason of the inability to purchase a fractional share,
will be carried forward to the next Offering Period.</P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;7
- Authorization for Entering the Plan.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An employee may elect to enter
the Plan by filling out, signing and delivering to the Company an authorization form provided by the Company (including electronically),
which will include the percentage to be deducted regularly from the employee&rsquo;s pay, and any other terms or conditions as determined
by the Committee in its sole discretion, and authorizing the purchase of stock for the employee in each Offering Period in accordance
with the terms of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee with respect to an Offering Period prior to the start date thereof, such authorization must be received by the Company
(or made electronically) at least ten (10) business days before the start date of the Offering Period to which it relates and will take
effect only if the employee is an eligible employee on the first business day of such Offering Period and otherwise meets the terms and
conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee with respect to an Offering Period prior to the start date thereof, unless a participant files a new authorization or
withdraws from the Plan, the deductions and purchases under the authorization the participant has on file under the Plan will continue
from one Offering Period to succeeding Offering Periods as long as the Plan remains in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will accumulate
and hold for each participant&rsquo;s account the amounts deducted from his or her pay. No interest will be paid on these amounts. All
payroll deductions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company
will not be obligated to segregate such payroll deductions or hold them exclusively for the benefit of participants. All payroll deductions
received or held by the Company may be subject to the claims of the Company&rsquo;s general creditors. Participants will have the status
of general unsecured creditors of the Company. Any amounts payable to participants pursuant to the Plan will be unfunded and unsecured
obligations for all purposes, including, without limitation, Title I of the Employee Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;8
- Maximum Amount of Payroll Deductions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee with respect to an Offering Period prior to the start date thereof, an employee may authorize payroll deductions in an
amount (expressed as a whole percentage) not less than one&nbsp;percent (1%) but not more than ten percent (10%) of the employee&rsquo;s
Compensation. For this purpose, &ldquo;<B>Compensation</B>&rdquo; means, unless otherwise determined by the Committee with respect to
an Offering Period prior to the start date thereof, an employee&rsquo;s base pay or salary from the Company or participating subsidiary,
including such amounts of base pay or salary as are deferred by the employee: (i) under a qualified cash or deferred arrangement described
in Section 401(k) of the Code; or (ii) to a plan qualified under Section 125 of the Code. Unless otherwise determined by the Committee
with respect to an Offering Period prior to the start date thereof, &ldquo;<B>Compensation</B>&rdquo; does not include overtime, bonuses,
annual awards, other incentive payments, reimbursements or other expense allowances, fringe benefits (cash or non-cash), moving expenses,
deferred compensation, contributions (other than contributions described in the preceding sentence) made on the employee&rsquo;s behalf
by the Company or a participating subsidiary under any employee benefit or welfare plan now or hereafter established, benefit plan payments,
short-term disability pay, long-term disability pay, maternity pay, military pay, tuition reimbursement and adoption assistance, and any
other payments not specifically referenced in the prior sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;9
- Change in Payroll Deductions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee with respect to an Offering Period prior to the start date thereof, deductions may not be increased or decreased during
an Offering Period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;10
- Withdrawal from the Plan.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee with respect to an Offering Period prior to the start date thereof, a participant may withdraw from the Plan and such
Offering Period (in whole but not in part) by giving notice (in the form provided by the Company from time to time, including electronically)
at least three business days prior to the end date of such Offering Period, in which case the Company will promptly refund, without interest,
the entire balance of his or her unused payroll deduction account under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee with respect to an Offering Period prior to the start date thereof, to re-enter the Plan, an employee who has previously
withdrawn must file a new authorization at least ten business days before the first day of the next Offering Period in which he or she
wishes to participate. The employee&rsquo;s re-entry into the Plan becomes effective at the beginning of such Offering Period, provided
that he or she is an eligible employee on the first business day of the Offering Period and otherwise meets the terms and conditions of
the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
any application of the maximum share limitation set forth in <B>Article 5</B> hereof, Code Section 423(b)(8) and fractional-share limitations
on the amount of stock a participant would be entitled to purchase will not constitute a withdrawal from the Plan.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;11
- Issuance of Stock.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock purchased by participants
under the Plan will be evidenced in such a manner as the Company, in its discretion, deems appropriate, including, without limitation,
book-entry or direct registration or the issuance of one or more stock certificates. Stock purchased under the Plan will be issued only
in the name of the relevant participant.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;12
- Adjustments.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to any required action
by the stockholders of the Company, the Committee, in order to prevent dilution or enlargement of the benefits or potential benefits intended
to be made available under the Plan, will, in such manner as it may deem equitable, adjust the number of shares of Common Stock available
for issuance under the Plan, the Option Price, the maximum number of shares that may be purchased during an Offering Period, as well as
any other terms that the Committee determines require adjustment, for: (i) any increase or decrease in the number of issued shares of
Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock; (ii)
any other increase or decrease in the number of issued shares of Common Stock effected without receipt of consideration by the Company;
or (iii) as the Committee may determine in its discretion, any other transaction with respect to Common Stock, including a corporate merger,
consolidation, acquisition of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization,
liquidation (whether partial or complete) or any similar transaction; provided, however, that conversion of any convertible securities
of the Company will not be deemed to have been &ldquo;effected without receipt of consideration.&rdquo; Such adjustment, if any, will
be made by the Committee and its determination will be final, binding and conclusive. Except as the Committee determines otherwise, no
issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, will require adjustment
hereunder. Notwithstanding the foregoing, any adjustments made pursuant to this paragraph&nbsp;will be made only after the Committee,
based on advice of counsel for the Company, determines whether such adjustments would constitute a &ldquo;modification&rdquo; (as that
term is defined in Section&nbsp;424 of the Code). If the Committee determines that such adjustments would constitute a modification, it
may refrain from making such adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee, in the event of a Change in Control (as defined in the Company&rsquo;s 2017 Omnibus Incentive Plan, as amended from
time to time), all outstanding options under the Plan will automatically be exercised immediately before the closing of such Change in
Control as if the date of such closing is the next Exercise Date, subject to the maximum share limitation set forth in <B>Article 5</B>
hereof, Code Section&nbsp;423(b)(8) and fractional-share limitations on the amount of stock a participant would be entitled to purchase,
and the Plan will terminate immediately thereafter.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;13
- No Transfer or Assignment of Employee&rsquo;s Rights.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An option granted under the
Plan may not be transferred or assigned, except by will or the laws of descent and distribution, and will be exercised, during a participant&rsquo;s
lifetime, only by the participant.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;14
- Termination of Employee&rsquo;s Rights.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whenever a participant ceases
to be an eligible employee because of retirement, voluntary or involuntary termination, resignation, layoff, discharge, death or for any
other reason, his or her rights under the Plan will immediately terminate, and the Company will promptly refund, without interest, the
entire balance of his or her payroll deduction account under the Plan. Notwithstanding the foregoing, eligible employment will be treated
as continuing intact while the participant is on military leave, sick leave, or other bona fide leave of absence (such as temporary employment
by the government) if the period of such leave does not exceed 3 months, or if longer, so long as the participant&rsquo;s right to reemployment
with the Company or the participating subsidiary is provided either by statute or by contract. If the period of leave exceeds 3 months
and the participant&rsquo;s right to reemployment with the Company or the participating subsidiary is not provided either by statute or
by contract, the employment relationship will be deemed to terminate on the first day immediately following such three-month period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;15
- Termination and Amendments to Plan.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless terminated sooner as
provided below, the Plan will terminate on the tenth anniversary of its approval by the Company&rsquo;s stockholders. The Plan may be
terminated at any time by the Board but such termination will not affect options then outstanding under the Plan. The Plan will terminate
in any case when all or substantially all of the unissued shares of stock reserved for the purposes of the Plan have been purchased. If
at any time shares of stock reserved for the purpose of the Plan remain available for purchase but not in sufficient number to satisfy
all then unfilled purchase requirements, the available shares will be apportioned among participants in proportion to the amount of payroll
deductions accumulated on behalf of each participant that would otherwise be used to purchase stock, and the Plan will terminate. Upon
such termination or any other termination of the Plan, all payroll deductions not used to purchase stock will be refunded, without interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee or the Board
may from time to time adopt amendments to the Plan provided that, without the approval of the stockholders of the Company, no amendment
may (i)&nbsp;increase the number of shares that may be issued under the Plan; (ii)&nbsp;change the class of employees eligible to receive
options under the Plan, if such action would be treated as the adoption of a new plan for purposes of Section&nbsp;423(b) of the Code;
or (iii)&nbsp;be made if it would be treated as the adoption of a new plan for purposes of Section&nbsp;423(b) of the Code or would require
stockholder approval under the exchange listing rules applicable to the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;16
- Limits on Sale of Stock Purchased under the Plan.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee will designate
a financial services firm or other agent to maintain accounts on behalf of participants who have purchased shares of Common Stock under
the Plan (&ldquo;<B>Designated Broker</B>&rdquo;). Promptly following each Exercise Date, the number of shares of Common Stock purchased
by each participant will be deposited into his or her account established in his or her name with the Designated Broker (&ldquo;<B>ESPP
Share Account</B>&rdquo;). A participant will be free to undertake a sale of the shares of Common Stock in his or her ESPP Share Account
at any time, subject to compliance with applicable laws and the Company&rsquo;s insider trading policy, but in the absence of such a sale,
except as otherwise determined by the Committee, the shares of Common Stock must remain in the participant&rsquo;s ESPP Share Account
at the Designated Broker until the holding period set forth in Section 423 of the Code (i.e., the later of one year from the Exercise
Date and two years from the start of the Offering Period corresponding to such Exercise Date) has been satisfied. With respect to shares
of Common Stock for which the holding period set forth in Section 423 of the Code have been satisfied, the participant may move those
shares of Common Stock to another brokerage account of the participant&rsquo;s choosing.</P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;17
- Participating Subsidiaries.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;<B>participating
subsidiary</B>&rdquo; will mean any present or future subsidiary of the Company, as that term is defined in Section&nbsp;424(f) of the
Code, which is designated from time to time by the Board to participate in the Plan. The Board will have the power to make such designation
before or after the Plan is approved by the stockholders. Any such currently designated participating subsidiary is listed on <B>Annex
A</B> hereto, which may be updated by the Board from time to time.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;18
- Optionees Not Stockholders.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the granting of an
option to an employee nor the deductions from his or her pay will constitute such employee a stockholder of the shares covered by an option
until such shares have been actually purchased by the employee. A participant will have no interest or voting right in shares covered
by the participant&rsquo;s option until such shares are actually purchased on the participant&rsquo;s behalf in accordance with the applicable
provisions of the Plan. Except as set forth in <B>Article 12</B>, no adjustment will be made for dividends, distributions or other rights
for which the record date is prior to the date of such purchase.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;19
- Application of Funds.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proceeds received by the
Company from the sale of Common Stock pursuant to options granted under the Plan will be used for general corporate purposes.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article
20 - Designation of Beneficiary</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each participant may file
a designation (using such form or method (including electronic forms) as the Committee may designate from time to time) of a beneficiary
who is to receive any shares and cash, if any, from the participant&rsquo;s account under the Plan in the event of such participant&rsquo;s
death. If a participant is married and the designated beneficiary is not the spouse, spousal consent will be required for such designation
to be effective. Such designation of beneficiary may be changed by the participant (and the participant&rsquo;s spouse, if any) at any
time by written notice (using such form or method (including electronic forms) as the Committee may designate from time to time). In the
event of the death of a participant and in the absence of a beneficiary validly designated under the Plan who is living (or in existence)
at the time of such participant&rsquo;s death, the Company will deliver such shares and/or cash to the executor or administrator of the
estate of the participant, or if no such executor or administrator has been appointed (to the knowledge of the Committee), the Committee
will deliver such shares and/or cash to the spouse (or domestic partner, as determined by the Committee) of the participant, or if no
spouse (or domestic partner) is known to the Committee, then to the issue of the participant, such distribution to be made per stirpes
(by right of representation), or if no issue are known to the Committee, then to the heirs at law of the participant determined in accordance
with applicable law.</P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;21
- Withholding of Additional Income Taxes.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By electing to participate
in the Plan, each participant acknowledges that the Company and its participating subsidiaries are required to withhold taxes with respect
to the amounts deducted from the participant&rsquo;s compensation and accumulated for the benefit of the participant under the Plan, and
each participant agrees that the Company and its participating subsidiaries may deduct additional amounts from the participant&rsquo;s
compensation, when amounts are added to the participant&rsquo;s account, used to purchase Common Stock or refunded, in order to satisfy
such withholding obligations. Each participant further acknowledges that when Common Stock is purchased under the Plan the Company and
its participating subsidiaries may be required to withhold taxes with respect to all or a portion of the difference between the Fair Market
Value of the Common Stock purchased and its purchase price, and each participant agrees that such taxes may be withheld from compensation
otherwise payable to such participant. It is intended that tax withholding will be accomplished in such a manner that the full amount
of payroll deductions elected by the participant under <B>Article&nbsp;7</B> will be used to purchase Common Stock. However, if amounts
sufficient to satisfy applicable tax withholding obligations have not been withheld from compensation otherwise payable to any participant,
then, notwithstanding any other provision of the Plan, the Company may withhold such taxes from the participant&rsquo;s accumulated payroll
deductions and apply the net amount to the purchase of Common Stock, unless the participant pays to the Company, prior to the relevant
Exercise Date, an amount sufficient to satisfy such withholding obligations. Each participant further acknowledges that the Company and
its participating subsidiaries may be required to withhold taxes in connection with the disposition of stock acquired under the Plan and
agrees that the Company or any participating subsidiary may take whatever action it considers appropriate to satisfy such withholding
requirements, including deducting from compensation otherwise payable to such participant an amount sufficient to satisfy such withholding
requirements or conditioning any disposition of Common Stock by the participant upon the payment to the Company or such subsidiary of
an amount sufficient to satisfy such withholding requirements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;22
- Governmental Regulations.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s obligation
to sell and deliver shares of Common Stock under the Plan is subject to the approval of any governmental authority required in connection
with the authorization, issuance or sale of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government regulations may
impose reporting or other obligations on the Company with respect to the Plan. For example, the Company may be required to identify shares
of Common Stock issued under the Plan on its stock ownership records and send tax information statements to employees and former employees
who transfer title to such shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;23
- Governing Law.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity and construction
of the Plan will be governed by the laws of Delaware, without giving effect to the principles of conflicts of law thereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><U>Article&nbsp;24
- Approval of Board and Stockholders of the Company.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan was adopted by the
Board on March 17, 2021 and was approved by the stockholders of the Company on [&#9679;], 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase">ANNEX
A</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase"><U>DESIGNATED
SUBSIDIARIES</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Arthrosurface, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Parcus Medical, LLC</P>

<P STYLE="color: #365F91; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; color: #365F91; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #365F91; text-align: center"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #2F5496"><FONT STYLE="font-size: 14pt"><B><I><A NAME="a_052"></A>Appendix
C</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Anika
Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>2021
Annual Meeting of Stockholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Rules
of Conduct and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Welcome to the 2021 Annual
Meeting of Stockholders (the &ldquo;<B>Annual Meeting</B>&rdquo;) of Anika Therapeutics, Inc. (the &ldquo;<B>Company</B>&rdquo;). In the
interest of providing a fair and informative Annual Meeting, participants are required to honor the following Rules of Conduct and Procedures:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">1.</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s bylaws describe requirements for meetings of our stockholders, and the Annual Meeting
        will be conducted consistent with those requirements.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">2.</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s Chief Executive Officer will serve as the chair of the Annual Meeting (the &ldquo;<I>Chair</I>&rdquo;)
        and will have the authority and discretion necessary to preside over the Annual Meeting, including following adjournment of the formal
        business of the Annual Meeting. In the event of disorder, technical malfunction or any other issue that disrupts the Annual Meeting, the
        Chair may adjourn, recess or expedite the Annual Meeting or may take any other action that she determines is appropriate in light of the
        circumstances. In the event of any question of conduct or procedures that is not addressed expressly and clearly by these Rules of Conduct
        and Procedure, the Chair is authorized to address the question in the manner she determines, in her reasonable judgment, to be in the
        best interest of conducting a fair and informative Annual Meeting consistent with the purposes of the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">3.</TD>
    <TD STYLE="text-align: justify">The Annual Meeting is a virtual-only meeting. The live audio webcast of the Annual Meeting will be available
        for listening by the general public, but participation in the Annual Meeting, including voting shares and submitting questions, will be
        limited to stockholders.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">4.</TD>
    <TD STYLE="text-align: justify">Participants may access a live webcast of the Annual Meeting, and stockholders may submit questions and vote
        their shares, at <I>www.virtualshareholdermeeting.com/ANIK2021</I>.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">5.</TD>
    <TD STYLE="text-align: justify">Each stockholder of record as of 5&nbsp;p.m., Eastern time, on April 20, 2021 may log into the webcast by
        entering the 16-digit control number included on the Notice of Internet Availability of Proxy Materials or proxy card received from the
        Company. If you have voted your shares prior to the start of the Annual Meeting, your vote has been received by the Company&rsquo;s inspector
        of elections and there is no need to vote those shares during the Annual Meeting, unless you wish to revoke or change your vote.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">6.</TD>
    <TD STYLE="text-align: justify">The Meeting will begin at 9:00 a.m., Eastern time, on June 16, 2021. The only business to be conducted at
        the Annual Meeting will consist of the consideration of, and voting on, the five proposals set forth in the Proxy Statement. These proposals
        will be considered sequentially at the Annual Meeting, in the order they are enumerated and set forth in the Proxy Statement.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">7.</TD>
    <TD STYLE="text-align: justify">If a stockholder has a question about one of the agenda matters that is to be voted on at the Annual Meeting
        as set forth in the Proxy Statement, the question may be submitted in the field provided in the web portal at or before the time the matters
        are presented for consideration at the Annual Meeting. We will answer questions on any matters set forth in the Proxy Statement to be
        voted on by the stockholders at the Annual Meeting before voting is closed. During this period, the Company will not permit discussions
        or questions that are not relevant or pertinent to the agenda matter then being discussed, as determined by the Chair in her reasonable
        judgment.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 119; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">8.</TD>
    <TD STYLE="text-align: justify">Following adjournment of the formal business of the Annual Meeting, the Company will address appropriate general
        business-related questions as time allows from stockholders regarding the Company. The following rules will apply to this process:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">a.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To ensure that as many stockholders as possible are able to ask questions, each
        stockholder will be permitted to submit no more than two questions. Questions must be succinct and cover a single topic.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">i.</TD>
    <TD STYLE="text-align: justify">Questions from multiple stockholders related to the same topic, or that are otherwise related, may be grouped
        and answered together.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">ii.</TD>
    <TD STYLE="text-align: justify">Any second question from a stockholder will be deferred until such time as all appropriate first questions
        from stockholders have been addressed.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">iii.</TD>
    <TD STYLE="text-align: justify">If more questions are presented than time permits to be answered, the Chair shall determine, in her discretion,
        which questions the Company will answer.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in">b.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The views, questions and constructive comments of all stockholders are valued
        and welcomed. The purpose of the Annual Meeting must be observed, however, and the Company will not permit questions that:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">i.</TD>
    <TD STYLE="text-align: left">are not relevant or pertinent to the business of the Company;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">ii.</TD>
    <TD STYLE="text-align: left">are related to material non-public information of the Company;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">iii.</TD>
    <TD STYLE="text-align: left">are related to pending or threatened litigation or investigations;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">iv.</TD>
    <TD STYLE="text-align: left">are in furtherance of a stockholder&rsquo;s personal or business interests;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">v.</TD>
    <TD STYLE="text-align: left">are repetitious of statements made by another stockholder;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">vi.</TD>
    <TD STYLE="text-align: left">are related to personal grievances;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">vii.</TD>
    <TD STYLE="text-align: left">include derogatory references to individuals or are otherwise in bad taste; or</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in">viii.</TD>
    <TD STYLE="text-align: justify">are out of order or not otherwise suitable for the conduct of the Annual Meeting as determined by the Chair
        in her reasonable judgment.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">9.</TD>
    <TD STYLE="text-align: justify">If there are any matters of individual concern to a stockholder and not of general concern to all stockholders,
        or if a question posed was not otherwise answered, such matters may be raised separately after the Annual Meeting by contacting Investor
        Relations at <I>investorrelations@anika.com</I>.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">10.</TD>
    <TD STYLE="text-align: justify">Recording of the Annual Meeting is prohibited without the prior written permission of the Company. A webcast
        playback of the Annual Meeting will be available at <I>https://ir.anikatherapeutics.com/financial-information/annual-reports</I> within
        approximately 24 hours after the completion of the Annual Meeting and will remain publicly available until our annual meeting of stockholders
        in 2022. The webcast playback will include each stockholder question addressed during the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.25in">11.</TD>
    <TD STYLE="text-align: justify"><B>A violation of any of the above conduct requirements will be cause for dismissal from the Annual Meeting.</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THANK YOU FOR YOUR COOPERATION AND FOR JOINING
THE ANNUAL MEETING.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="proxy_01.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">KEEP THIS PORTION FOR YOUR RECORDS  DETAC H AN D RETUR N THI S PORTIO N ONLY TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Signatur e (Join t Owners) Signature [PLEASE SIGN WITHIN BOX] Date Date 0000512371_1 R1.0.0.177 For Against Abstain 0 0 0 0 0 0 For Against Abstain 0 0 0 0 0 0 0 0 0 0 0 0 ANIKA THERAPEUTICS, INC.  ATTN: DAVID COLLERAN 32 WIGGINS AVE.  BEDFORD, MA 01730 VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit  your voting  instructions and for electronic delivery of  information. Vote by 11:59 P.M. ET on 06/15/2021 for  shares held directly and by 11:59 P.M. ET on 06/13/2021 for  shares  held in  a  Plan. Have  your  proxy  card  in hand when  you  access the web  site  and follow the instructions to obtain  your records  and to  create  an  electronic voting instruction form. VOTE BY PHONE - 1 - 800 - 690 - 6903 Use any touch - tone telephone to transmit  your voting  instructions. Vote by 11:59 P.M. ET  on 06/15/2021 for  shares  held directly and by 11:59 P.M. ET on 06/13/2021 for  shares  held in  a  Plan. Have  your  proxy  card  in hand when  you call  and then follow the  instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage - paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 . The Board of Directors recommends you vote  FOR  the following: 1. Election of Directors Nominees 1a. Stephen O. Richard 1b. Jeffery S. Thompson The Board of Directors recommends you vote  FOR  proposals 2, 3, 4 and 5. 2. Approval of the amendment to the Anika   Therapeutics, Inc. 2017 Omnibus Incentive  Plan. 3. Approval of the Anika Therapeutics, Inc.  2021  Employee Stock Purchase Plan. 4. Ratification of Deloitte &amp; Touche LLP as  the  Company's independent registered  public  accounting firm. 5. Advisory vote on the compensation of  the  Company's named executive  officers. NOTE:  Such other business as may properly  come  before the meeting or any adjournment  thereof. Please sign exactly as your name(s) appear(s) hereon. When signing as  attorney, executor, administrator, or other fiduciary, please give full  title as such. Joint owners should each sign personally. All holders  must  sign. If a corporation or partnership, please sign in full  corporate or  partnership name by authorized officer.</P>

<!-- Field: Page; Sequence: 121 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="proxy_02.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">0000512371_2 R1.0.0.177 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice and Proxy Statement and Annual Report are available at www.proxyvote.com ANIKA THERAPEUTICS, INC. Annual  Meeting  of Stockholders  June 16, 2021 9:00 AM This proxy is solicited on behalf of  the Board of Directors The undersigned, having received notice of the Annual Meeting of Stockholders and the Proxy Statement furnished herewith, revoking all prior proxies, hereby appoints Dr . Cheryl Blanchard, Mr . David Colleran and Mr . Michael L . Levitz, and each of them, with full power of substitution, as proxies to represent and vote all shares of common stock which the undersigned would be entitled to vote, if personally present, at the 2021 Annual Meeting of Stockholders of Anika Therapeutics, Inc . (the "Company") to be held live via webcast at www . virtualshareholdermeeting . com/ANIK 2021 on Wednesday, June 16 , 2021 , at 9 : 00 a . m . , local time, and at any adjournment or postponement thereof, with respect to the matters set forth on the reverse side . Any proxy may be revoked by a stockholder by delivery of a written revocation or a subsequently dated proxy to the Secretary of the Company before the taking of the vote at the 2021 Annual Meeting, by properly casting a new vote via the Internet or Telephone at any time before the closure of the Internet or Telephone facilities . Attendance of the stockholder at the meeting or any adjournment or postponement thereof will not in and of itself constitute revocation of this proxy . This proxy, when properly executed, will be voted in the manner directed herein . If no such direction is made, this proxy will be voted "FOR" the election of each of the directors and "FOR" items 2 , 3 , 4 , and 5 , in each case, in accordance with the Board of Directors' recommendations, and voted in accordance with the discretion of the persons named as proxies on any other matters that may properly come before the Annual Meeting . Continued and to be signed on reverse side</P>




<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>blanchard.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 blanchard.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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MTS6OH^AR7EA%=QIO@D0.K#I@U))8M&<.I!KXVI4UL=/(<G-8L<C'?-95[:[
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MP?(D5QOCD7_@:G+8]Z^2/A=\:O$'AO3;>UN%;Q!9VY6-+S2@TLD8(!$;*>7
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-9HHHKXNE\)])/<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>blanchard_sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 blanchard_sig.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MO$_[/?B+PE\*?$&I-KG@G7HQ8Z!JDD86XTO4 A=K.4J 'BDQ(8VP"""ISP:
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>colleran.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 colleran.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>envelope.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 envelope.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ $P# 2(  A$! Q$!_\0
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M8.0"6Y.*^F_B,O[/W[.&G0^*_%.B^!_!OV5_-M+K^R;:.Z:1>1Y"I'YC./\
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MOJ[6O#6D>)4MDUC2K'54MIEN(%OK9)A%(OW77<#M8=B.:TJ /G3X3_L.^!O
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M0?\ 15/!7_A0VG_QRL/_ (8S^ __ $1_P7_X)8/_ (FC_AC/X#_]$?\ !?\
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6RVTB!)89%.5=&"Y# \@CH17JU '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>henneman.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 henneman.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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M^Z\60^$M%M45//OKA?W,*C. .K'VK@+:ZNM2U?<95N-3N#O:9N3"N>BCH/\
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M^(Z>";"*,2>3=W"YC14+NW')"CL*Y;P;XV35KJ 7&NK=WMVOF16D\#6[;?\
M9#=:Z+I+0Y;-N[+WCI0L,KK@<Y/H>*^6UU(KJURY?.YV.?QKZ?\ B]/%IG@"
M\NV(6<GRE7/<BOCB.[;[4YS7F9@U-1AV1S4_=G)G/^/M8FEU-HXR<$9-<M>V
M\MS<1,>N!6[KCI-J3L?2LF\U)8;B-0. *K#M<B1A4^)L]$^'\;Q0X;I157P9
MJPEC( YHKAK64V=--^Z:=NHZU!<M\U1K=>6O6H&:28Y X]:R4=2&Q\DRHN*I
MS7#,,(,U8%L.KG)J&:>*W[@5M%(AW+EKO-\)'ED2&.W50HZ,Q.2?PZ5V?A73
MH-4O?*N LL4@VE&'6N%MM7BGT]X3*$97&U3_ !9-=!X=U-[&\+\A8V'YUZT?
M?IV1Z5+EE44NY]"6?AS^R;*,VQQ$%Z''R?0XKB[X+8^(X+F+,9,RJ9@,%LGF
MM>Z\7M%X>AC,H6[G7]TI[>YKDO"<G]H>*;&"_8K.&8,';Y9#V(_&H43U4E&:
M/I'5/#MKXFT>TO+C]_/:IE2R;LC'0T_3[>#5K..$V-O!%&05VQ ,".^<<5M6
M]JG]CQ0VUUY$S188K_>QQ6'X9UJ5OM=G=HL=W"V&QT;_ &A[&M7%)Z[,YM)*
M373;R/.?VDI3IWA&QB<G)E8C/?C_ /57RG92>8TC#TKZ2_:MURUDT_3-/5]U
MW$K2R?[*L  #]<5\R:*X8N,\8KRZ]N:3/+F_?L<UKTQ2^<@]JY^\D\R9"?2N
MAUVW,UW(!TKDM49[>15/4"M</S-Z['+5L]MSTCP"PW$9HKDOA_K4OV[9VS16
M5>D^<Z:<;1/2G$4(!8\U5GU9(QA!FLB:1YB"S$TPDK6=C"Y9GU*61NNT56V/
M<-T)J>&$28+=*F:ZAM5PO)]JN)+U*#1&*6,D8PPKNM#F5U1FY7S4+8],XKEO
M!L$WC;XC6OAJT1'F^PW%](K>B)\B_4L1^5;NCQO87"PRJ58@AT(_ CZBO4IP
ME""<OM;%8>JN=J/0]'^*MAKBZ3I\OAZVM;F>+YW28E3*F/NJ1T/UK1^%-[9Z
M\L+:C!%:WB)^]M[TF)X3CG!;AOJ#6/I?BHWFFK:328GMSL#'N.U>C?#DB9-L
MX1^>,X.!2;MHSWH151\Z9Z;J6L7.FZ=:Z?H-NFJW\H C56/E1\?>D<# 'L,F
MG^$[RYOK W6LVL=EJ$)D28H<H ,YP3U'>NJT5XVM8P H*C"\8KR3]I+XC6'@
M?1(=)-Y%9W>J;@&9L'8/O8^N<4ZC=KQ5SCE*-.]]/4\ ^-WB3_A)-6U*^1LQ
MO)MB_P!Q>%_0?K7EOAV9FF;/3%:OB#6(]2CVQ3)(I/56!K#_ +2BTE<*?F->
M1RSY&FM6<+DG.Y4U^Y%K=2$]&XK!U73Q<J).G&14NN7AU"7(I&8ND<3OQC K
MMHQ<8HY9R]X3P+I[1ZD3VS179>%-%B@C\PD;NU%8UJEY'3#FY=2>&V 7+53N
MFVR87I5SS?E-9MPQW&L[& YYFV@9X]JQ_$'B*V\/Z?)=7+?='R1_Q.>P%1>)
M/%-MX=LM[D/<O_JXL]?<^@KQ;5M:N?$5W/-=2&3:V%'8?2O<P.7RQ'OSTC^9
MP8C%*E[L=ST+]FWXJ-X=_:(TC7-3EVV]Z[64SGI&DG"_@#MK[L^*WP1ED6;Q
M'X>3S5),MS9+R5;J73U![C\J_+/R'MKI7C)!!R,=J_4_]C?XWK\3O \6FWLP
M;Q!I,:PW*,>9HQPLH]?0^_UKZ/%8:-2'+;;\#RL/7G1J<Z>^YY?#H[:I:Q7E
MN?)G4[&/8G^ZWI[&O2_ 8N+'(:)T=AM^;D5[=K/P+TWQ))<W^E[-/N[E<3PX
MQ%-[X'W6]Q6%:_#V^T6U%OJ5J]M=P<))_#*H[ANAKYNI1G3=JBT[GU^'QD91
MO2E9]CIO#-Q(]FJE054=@:^1_P!OKP\[7O@O6=S%+I;JU;<?ERI5ACT.":^N
M%U*#3-*(E?"JNXM]*\Q_;9^',^I?LRZ5J[QDWVCWRW\B@<K'+\K#\ 5_*N[+
MTOK":Z'#F$Y2HWENV?G#:ZE)I5T(;C<8V. PZK796T:7,2-_KD/\6:R[O1XM
M1@C)XD ^5O2MGP]:?8[5H2P+9Y KZQTH5-)I,^94Y1V8Z31HY"'C)7C&*CTC
MP'J_BS5GM+ QM<0KO,;/@E?[P]16X %( Z=>:SO$&IW7AV[TG5K"5X+B&X$6
M^,X.U^"/IFO/K990E%N"L_(WABJB>KN:<FC:IX6D^SWA57'& V:*YBX\1:AJ
MFJR_;9FEF5B"317Y_6II3:2/HJ<FXZG3K(6!.< =S7#^+OB!;::LD=JZS3#C
M?_"/\:Y[QS\2%?S+&P<^0.'D4X+G_"O.%DEU&;<[$CTKZ? Y6K*I77R_S_R/
M%Q&,UY*7WFC>:M<:Q<O+.[2LQY)J?3+4/]K0]=R_RIUC9^6!\OTS5FPF33+F
MY:Z1Q%,V1*HRHX[^E?3J*221Y:[E!K#RYAGYAC(KT+X(_$:^^$_Q TSQ!9N?
M+C?9-$#Q)$>'0_A^N*Y1C;W42M&RR*03E3TJ6"']R<C)'>GRIC/VU\ ^++/Q
M)H6G:MI\JSV-["LT4B]U(Z?45Z)B"_M3%-&LL3#E'&0:_/+_ ()^_&4R17/@
M#4Y_G7=<Z:7/_?<8_P#0A^-?>>FWA\L#->?*/*W%G1%]4>;_ !&T'2?#>N:8
M\-O<WOSBY&GB98X6VGH[$$D9P<>U=/XJFTCXS?#7Q)H$) FN+&2":T?&^)F0
M[3[C.,'VKPGXS>.M8T/XP W97^QYXTBM=R_*%7[V??)S]/I7HOA&SDC9M?TA
M,:E;%'D@!^6ZMR,.G]1[U4</3HT^>FMPGB*M:IRU'>VQ^7MK&]O&T$H(FMW:
M)QZ,I(/ZBM*U9&(.T;L\XZUJ_%!=-A^+WC>#2+@7&G+JDLD1P5*ASN*D>JDD
M'Z5EPPK(T;$993P17IQU29SRW+BGYBN<UB>.U#>%KG.<QLDBX/.0PK4DD.XD
M=O6LGQE(/^$9O3C<-F<?B*TEL3U(EA_TZ*:1-KRQ@GZT4^%FDCLB3GY!S]11
M7YSFL%3Q<DNNOWGTV#?-11\\^8L[Y:5>3SEA6SIQMXP/W\(Y[N/\:**^[N?,
MJ)L1W%ML'^EP=?\ GJO^--U+5((XA%#<0/+*0J_O!@>YYZ444^9E#K-=/M81
M$MW -O.[S%R6[GKWJQ_:5KN"_:H /^NB_P"-%%%RCH/!_C8^$_$5CJVGZE%;
M7EG*LT4BS*""#GUK]8OA[^T5X&\2>%=*U&[\8^'K*ZO($=H9M5MXV!(YRI?*
MD'.0:**PJZI,N/8\M^/GC_P-XL\4:%IJ>*O#]Q;POYLLT6K0%>> -P? J#X)
M_'C0M(\0:GIFJ^*M%C6WNI##,^IP*CVY. F2^.!THHK>E_"L<E7^(G_6Q\9?
M%/5M'M?CKXZ6UU73[BRDU!Y8KB&ZC>-PV#E6!P?PJE;^(-,4_P#(3LO_  )3
M_&BBG3D^5'1+<>WB+2S(?^)I9?\ @2G^-9GB;6--O/#E]!'J5FS/'A56X3/7
MZT45IS.Q%B.WUS38;2)1J-IE O'VA.F,>M%%%?'YM2C.NI/L>Y@YN-.R[G__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>land.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 land.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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M>9;QLN<D%1BO"E4;J.*/KL/0IPHIM'YZZ7\*O$&F^'7T^WTF$W-W<?-/Y?\
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?N)3*V>I["BBH6LB6:VIWRQABI ^;&****4MRHG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>laptop.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 laptop.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ #P# 2(  A$! Q$!_\0
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MK\2?_!;??_$5^I?_  KWPM_T+6C_ /@!%_\ $T?\*]\+?]"UH_\ X 1?_$T
M?EE)\4OAC)&R/^WG\2&1A@JVFWQ!'I]ROI__ ()-_:8_V59H&N+F[TF#Q)J,
M>DW%Q&8_-M-R%74'L7,I^I8=J^KO^%>^%O\ H6M'_P# "+_XFMJSLX-/M8[:
3U@CMK>,;4AA0(BCT ' % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>larsen.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 larsen.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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MLGX:7N=-M^?X17R7H\*QNAQWKZ8^&]TR:;!UZ"O)R^MJT;8ZEJF>X6NJK;Q
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MXM)6BD7Z,I!KZ9-GQ,J,;Z'[5?&1!)I-XY')4@J:_)KXM6L=EX^U:*+[GF9
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>4SDCHVBO(P69_K2;MM%%<994N&R<^AHHHK-@?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !N E(# 2(  A$! Q$!_\0
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M)<JS0I?W20F0*0"5W$9 R.GK51BY.T5=DRDHJ[V.FHKSW_AH;X8?]% \.?\
M@SB_^*KLM#U[3?%&DV^IZ1?6^IZ;<#=#=6L@DBD&2"58'!Y!'X54J<X*\HM$
MQJ0GI&5S0HHHK,T"BCWK@[WX]?#?3;V>TNO'?A^"Y@=HI8GU*(,CJ2&4C=P0
M0015QA.?P*Y$IQA\3L=Y17GO_#0WPP_Z'_PY_P"#.+_XJMCPK\4/"'CF\EM/
M#OB;2]<N8D\R2*PNDF9%R!N.TG R1S[BJE1J15Y1?W$JK3D[1DCJJ***R-0H
MHHH **** "BN3\4?%?P9X)U)=/\ $'BK2-&OFC$HMKZ\CBD*$D!MK$'&0?RK
M(_X:&^&'7_A8'AP?]Q.'_P"*K6-&I)746UZ&3K4XNSDKGH=%5]/O[;5+&WO;
M*XCNK.XC66&>%PZ2(PRK*PX(((.:L5D:^84444 %%%% 'Y.?MN?$Z7XC_'K6
M;=)6;3/#Y_LJVC(*X9#^^)!.,^9N&1C*JOI7@57]?UR[\3:[J.L:A)YU_J%S
M)=7$F,;I'8LQ_,FJ%?N&%H+#T(4DMD?DF(JNO5E5?4****ZSG"OH']F_]F^U
M\<:?=>/_ !]<G0?AAHX,MQ<RDHVH,IYCC(YV9^4L.23M7YLD7?V5_P!E=OBR
M[^,/%[_V1\.M-W2S7$S^5]NV<LJL<;8A@[I/J!SDK6_:L_:4B^+%_;^%/"48
MTSX>:*1#9V\">4ET4&U9"F!A /NKC@<]3BO Q&)J8JJ\'A'_ (I=O)>?Y'LT
M,/##TUB<0O\ "N__  "A^T#^U-JGQ6C;PQX=@_X1CX<VNV&ST:U41^=&GW6F
MQ] 0@X''4C-6/V%_!TGBS]H[0)!'#+:Z/%-J4Z3@X*JNQ=O'W@\B$9]">U>
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MHS] PN,I8N'-39:HHHK@.T_'7]K!1_PTK\1>!_R%#V_Z9I76_L$J!^TYX?P
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MD/BQ\2]*^$/@'5_%>LLPL["/(2-2S2R$A8XP!W9B!Z#.3@5U]?F)^WE\?/\
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MY\_\%*O 6NW7C3PYXLMM.GNM"CTS[%+<P1LZP2+,S?O,#Y01(N">ISZ5XO\
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MQ_NL_7]$?"9__O$?0^__ /@EY_R+?Q"_Z_[3_P!%/7W#7P]_P2\_Y%OXA?\
M7_:?^BGK[AKX[./]_J^OZ(^GRO\ W.GZ!1117C'J!7Y\_P#!4#_D;/A]_P!>
M5Y_Z,BK]!J_/G_@J!_R-GP^_Z\KS_P!&15[V1_\ (PI_/\F>-F_^YS^7YGQ+
M7JFJ?M)>,;CX2:'\.-/O#H_AO3[1K>X2T.);XM(SDN_4+\V-JX!YSGMY77K&
MJ?LT^+[?X0Z'\2-,MCK/AR_LS<W1MQ^]L2)60ADSEEX!WKTYR !D_IV*^K<T
M/K%M]+]SX&A[>TO8]M;=CRA5:1U506=B !W))P!]<U]M?L\_\$];K5_LFO\
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M_P""H'_(U_#[_KRO/_1D5>]D?_(PI_/\F>-F_P#N<_E^9\2U^N?[%HW?LO>
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>p31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p31.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!\P,@ P$1  (1 0,1 ?_$ +T  0 " @,!
M       %!@0' 0(#" $!  ,! 0$!              (#! $%!@<0  $# P,!
M!@,%!@,$!P8$!P$  @,1! 4A$@8Q05%A(A,'<3(4@9%"4B.AL<%B%0AR,R31
M@D,6X9*BLE,T=',E-387-_%C@SC"LT14=288$0 " @$$ 00! P$%!P4  P$
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MC+9E$HM/#,I3.! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! <'L^* Y0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M-Z_M)'#V<MGC8+:4@R1MHXCI5>C]=UY4T1KEO%%%\U.;:,Q;2H( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M)X _#6@6'O-JPB:)YQNGR0A822#3;XK7U5B.2^*PB%9CLA91;W-?'&_1KJ$
MT5T\,LK1-<,M<A<7<LK0^1D0JXZD!'C!!?N,O.6MW=W?Z4;GN8=V@Z47$2:-
MB8:6ZO>/PV=PPAVW:*KPKNO\=G)>2BVG**__ ,J WILHF![RZKG#6BW0E*3U
M%'6<5EDU:6TF)O1;-EI(RAJT]"M#33/4KPT;>X/[H6[YAB<M.'2,HUET?V!Z
MV5V^&8K:?,39S7->T.:0YI%01J"%I,IR@" ( @" ( @" (#@]GQ0'* ( @"
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MZ/C=^(#M'<M=/8DO:]C'?U*Y?YD4N7GTE^&1_.\ID;>]>]Q<VY<PRS7%J_\
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M@]GQ0'* ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M?<]&4Q/IGVL]PFY"5W'K]U+NW:#:2N/^9&!\I/Y@G1['.*3W*+(>4;+6\I"
M( @" (#@]GQ0'* ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M48+8X>A:%I*P@" X/9\4!R@" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MJ)+\'C=KMXT\D=+))+(9)'%[W:EQ7J)):(\IMMY9THN@Y0"B 40X$ 0"B (
MAT(<.6ES7!S26N&H(Z@HSI(7UIC.58W^E9<!MR-;2\&CFO[""O+[O24HGH4=
MC.CW)GACK^#%_P!+R.M[CCZ+G]DD8^1X^(6/KY4>,MT:DR?5YT(#@]GQ0'*
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M,X'96SX\C=W#H7-<#';TU K0U7R=O=5CX1U_)7*3;PBT9#&?4V\5E;_KNN9
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M"0S5>!ZK"33[DKB\D+&G'0EL!QPQ6;99B2YX#CN\>@5R1%;$TVSCMI6W&XM
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MLAQ>#UJY\EDR5 F<'L^* Y0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MGFTV;M9<9D)6R9&R +9 162/I7XCM7T77MYQR?)]WKJN6FQL"BO,(0"B'11
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M0N/Y0IQKR5N31MFVM8+6!L$#!'$P4:T+2E@J/5= 0! $ 0! $ 0! $ 0! $
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MU/7_ 'E5*?H::NOKF1?XHHXHVQQM#&-%&M&@ 51M2P=D 0! $ 0! $ 0! $
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M9PNN887:M=*PC;7X=5JZ]:3,G;NE):GU6 .SH-%M/-.=J YH%P'"Z#A#AQ1
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MHNC$K^W:X!;^X\0JM],'G]*.9W4^N2-CRKV\M=GI'_Z!TYMMX_(&5"RQO?\
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M_:C).V4MV85E937EW!9P-W37$C8HVCM+C162EQ3;\$(K+PCZMP.)@Q&'M,=
M*1VT;65[R!J?M*^2ML<Y.3\GTE<.,4C/59,C\_R#$<?Q4^5RUPVUL;9NZ25W
M[@.TGN4H0<GA')2266:5F_N[XDVX>(<-?36;"0;D;0/ T[%O7UTO5&?^2O0N
M/(O?/CV&XA@^4?1W%S8YUXCMV,VM>PG\U51#J2E)QSL6.Y))ELSO+;3#\1FY
M+-"^2VAMQ<F%M-Y:X TUTKJJ85N4N)-RPLD-Q[W8X]EN!/YK.U^/Q<8<7MFH
M7C;I33J3V*R?7DI\-V15BQDH^-_NGX]?Y6VM(\#D!;7<HAM[H-W!SB:5  U^
M]7R^ODEG**UV%Z$KS[^XC!<,Y'-A+S$7ES+#''(Z>+:&4D;N U[E"GI.<<IG
M9WJ+P8O#?[E^/<IY'8X.UP][#+?R>FRX>6F-II76BE;T90BVVM!&]-XP6/W(
M][.(<$ECM+YS[S)R .%A;T+PT]"X]&U[%51U96:K8E.U1*MQ_P#NFX7D,G#8
M92QNL,9S1D]R/TZDT%: $#Q5T^A-+*>2"["\FT^2<DL<%QN\S\P,]I9P&X(C
M(J]M*C:>FJQP@Y242Z4L+)5?:OWEP/N(;YF/M9K.>Q#'213EI):_HX;?%7=C
MJRJQGR0KM4B.NO[@.-0>XHX0+*>2[^I;:.O&N;Z0D=^W1373EPYY..Y<L&?[
MI^\V']O+BP@R%A/>.R#7NC,!:-NP@:[OBH=?JNW.'L=LM42(X/\ W#X;EO);
M7!6^$OK26Z#BV><#TV[177166]-PCG*.0NR\8(_-?W/\?Q>>O\-_0K^ZGQ\K
MHIGP;7#R&A=0 FBE'H2<4\K4B^PD\8+K[;>Z_&>?VD\N*]2&YM2!<VDPH]@/
M0Z=0L]_7E6]2RNQ2V*SSG^XOC'&<[-@[:PN<Q?6P_P!5]**MC(Z@FAZ*ZKI2
MG'.<$)WI/!<_;SGMCS? -S-E:3VD1>6>G<-VFH_*>T*BZEURPRR$^2R6=4DS
MSN(Q)!)&?Q-(_8NQ>&<DLHHSFEKBTZ$&A7IGE! *H#D.7!DYWI@[D;TP,@R-
M:"YQH!U)7<''+"U(ZYY#90@B,F9_<WI7Q*OAU9/?0P7?9UPV]S_!JWFQR&2R
MOU5[+1D#-UM&!1C8R?,#XKSOM*DGA>A[7_C_ &'9!R>^=2IY?V\P67VW<@,<
MIT<Z,TK\0O&C?*)]'/K1D\LU5RSBLF%OBQC_ %+5Q_3=V_ K73=R,%_7X?H8
MG'N19/C>3AR>-F,%U&=N]O7:[J%LILXO)CMKY+!O#"^^'([![&7T,=[;O&]Q
M/E?5^M:A>W+KQ?X/)3?@VCQ'W/XWR1Q@C>;.]%*6\Y +Z_D/:L]O6E#7='8V
M)EN6<F<+IP( N'0@+?B9-^/@-:D"A^Q8+5B3/1J>8HS566$/RO#W&7P[[.!S
M6R.<T@NZ:+%W^M*ZIQ6YO^N[4:+5.6QUOL+<3\8_I37-$_HMCW'Y:MHN6]:4
MJ/C\XP=J[48]CY'MG)%X7"<QQ_TUN;N$V,) =&!KL[159.MUNS7B/)<$;.WV
M^I;REQES9VFX5_4L[=W^7(D@> VVC82" .E5*7UORW2G9JO!R/VOQ4QA5I+R
M<,X3_3LW9W^'(BACJ+F-Y)+FGK3[%Q?6?';&=6B6X?VORTRA;JWL9>+XY<PY
MG*WUVYCV7X+&M&OE)[?L5U'3E&V<Y?UE/8[T955PAG,#%Q_"GVO',AC2]KI[
MQSBV0=*#Y 533]9PHE7YE_Z1==]JI]B%F-(_^F>TW&+N?A[,/,]ANHV@,?\
MA!::C]BLET92ZWQ-^Y%<>_&/:^5+VLPW\(N'<29B?49]4R3U1)^&I/3[E2_K
M)/K?'GW9R7K[:*[7RX?'&":Q. BM^.LQ-R \%A;-MZ$NZD+;U^HHT_'+TU//
M[/<<KW;'UT("#B_+L6)+7%7[/HGD[ _YF@]R\^/1[-68UR]IZ<_L.K=B5L'S
M)7CW%/Z7:W+I9?7R%VUPEF/34= M?4Z'Q1>7F<O)B[OV/S2CA8A'9$7#P&8X
M*6SGD8+P3&:VF;^$]Q62'U+^%Q;]V<IFV?W*^932]F,-&9E^.YG)\=MK&>6/
MZR%[7/DUVN#?XJ_L=.VVA0;7)&?K=VJF]SBGP:.<SQ*XG?97V.E;!E+4-:Y_
MX7AH[4[/U\I<9P>+(CJ_91BI0L6:Y?X%EM_7]!GK@":@]3;TKVT7J0SC7<\B
M>,OCL>BD1" ( @" (#7?O%<W LL=9@EMI<S@7#AI4#L*]3ZR*RWY2/ ^^F^,
M8_TMZDODN/\ #(,"S&W$=O;MEA/H/=M#R0VNX.ZDJBNZUSY++-=O5Z\:N#26
M5H4G&W-Q+[59>&1YDBMIO3@<=?+4%>A9%+LQ?JCQ:IM]&:>R>A:<B1_]):UT
M^B9^\+'7_P!3_:>I=_T'_P!3TQ689A_;&WOG&CH[:D0Z$O<2&T7+*N?8:_)V
MB]5=)2_Y37O'[R+!9/#YSZZ.XEOGO;D8&NJ]@D=3S#]J]*Z+LC*&,8V/!ZTU
M3.%O++E^Y>F2\>[[FNPN,<TU:Z]C(/>"TK!];^^7_P 3VOO7FN'_ ,D3G/?_
M ))R/_L1^\+-T_\ 67ZFW[/_ *:7Z$7@+&RN?;6&2X@CE?%93&-SVAQ;HXZ$
M]%?=-KL/#_J,O5KC+IIM)XBSK[165F>)V]T8&?4^I*WUMHWTK2F[JGV4G\K6
M=#GT5<?XZEC774JG,^.W>/Y2W&8Z<P6/(G-]2$&@!W^:H^*V=6Y2KY26L#S/
ML.K*N_A!XC:;:Q.,M<7CH+"U;MA@8&M\>\GXE>+98YR<GY/J:*8UP48[(RU
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MH799RP("GY6V]&_E:!H3N'VZK?5+,4>=;'$F8FTJS)7@XVH<%"N@X<0T$DT
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M'@T]=;D\LQJ" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M+J=R;6<T! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MF?:[W1QV%S;@RTY-9QDG4,#Y!NCU.E6G1RV]EJVMM?TE%682P_)<O[PJ'BN
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MN5G*;9O57&"1]((<)+!_YTGP"JNV+:=R;6<O" ( @" ( @" ( @" ( @" (
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MV]*4C1A(*'&T?3GM;=.N>!8A[_G$18X?X7$+YCO1Q=(][J2S6BU+(: @" (
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MQ\,/FQ]K("QQ<T4CVM.NQ@/4]5G[%L(5_'%Y+*X.4N3/HQ>6:@@" ( @" (
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M!BH76^)LH'_-'!&UWQ# O8/G66S%,VV4?\QJLMFYIK6AFJ!,( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" AN86WU''+UFW
M>1&7!O7Y=5HZDL6(R]V/*J7Z&E1+CGPQET,ELX:/D80:G[%]+B6=\GR'M:VP
M9?\ 3C]&;RTN3.UO^8W\3!_A[U7\FN&L%GQ>W,7DA'F.6<.=&74ZNI0E:-D9
MF\LRX;B43O-NR)SG-V?,*@'P4)+34G'\'2[L;:VBC)<\S$5DW_(#W-*1FV_P
M)P27Y(:[($T4H(&UPT'CHNW1S!K\%G4EQDOU)3/6[X,)ZT7F.VKE\OU9*5O%
MGUW>BXT\D5/#PL-J=U-SB7'MZKZOCC0^5C)\<^IS=8VV=0T)[G#0A24F<=:E
M^&=[#%2O9^JTO [@NREDA'$%KC)GBRC;7:*>!ZJ)WYS#Q=NZWY-:/>"&2/U/
M>LW>CFB1?TY8[,<>2P\U(N,G96[?*U]03V!>7]+A1DV>M]W-J<<'C88BVCE;
M5[7GN)H%[;9\^[7(GWB 0/9$R..1@T.[0JI-Y$HK'Y(661P=YPTGKY157(S8
M/87KRS:VT;*>PD:J+7Y+%^AVB=E*T9:B,'^7_H1\?4ZE+T,QK+KT_4E]1KV&
MNX=--5#*)\7N;UPUU]5B;2XK4RQ,<3XTU7RUL>,VOR?:T3Y03_!F*LM" ("I
M>[?_ -M.1_\ HI?W*[K?ZB_4KM_:S27]N7M+P7DG$&YW-6'U=_'<OC&]Q]/:
MRA%6K?W>Q.,L)E%-::RRV_W+\E&'X99\4Q31'=YF1MO#!%H1"TTH .PG14]&
M'*?)^"?8EA81KF^]I_?%WMZSCDUK8?T"S!O&1,+?7W ;B=W4N6I=BGGRUR5.
MN?'!M3^WGF3L][:R8^Y>3D,('VDS7?-L#3L/W:+'W:N-F?#+J)9B5C^U'_SO
M,?\ UO\ $J[[#:)#K>2/Y9_^['#_ .&#_N%2K_Z9G)?ZA4O<2ZXE:_W'9*?E
ML3IL PM^KC:TN))M@&:#7YJ*ZE2="X[D)XYZFR>-93VDON#\X' ;1]M(S&N_
MJ!>QS-P,;_3IN^U99QM4X\_4M3CQ>" ]B>#8SFWLEEL'?  OO'OM9Z:Q3-C&
MQX_BK.W:Z[4UZ$:H<HM?DUUQ*#DF.]X>,\>SY>;C"7K;: /KI'NJ-I/5IZA:
MK'%U2E'RBF.5-)FZO[NO_D&P_P#6M_[I6#Z[][_0T=G8V3Q[+6^(]L\;D[AK
MGPVF,AE>R,%SB&Q T "RSCRL:_)=%XCD^9?=+W"]J.9\=?<V.%EL.9/E CV1
M[:@.ZO+=#7[UZO7ILA+5YB9+)QDMM3Z.]EH<Y#[:X6/-[_K1%TDKO$=?(#7P
M7F=IKY'@U59XK)=UG+ @" TK_<][@MP7%8N/VDG_ +SS;MI8WYA T^8Z?F.B
MA/8A-Z&F_;KVJ]QN1/;<16)L<>ZG^LNJL!'>UIU*S2Z_(KBFS=F)]C^&8T"7
M/W3LK<@>:( "/[NM%*'5BBU+!7>1^[/#^%2/LN.<6MA+'JR5[6@5[ZT+EJXX
M)*62C9'^Z[W">\BWM;2V:.@#2ZGWH=(67^Z+W9!);=6H!U ]$?[5P'>U_NP]
MTH"/6^DG[PZ+;^XKH+-B?[R,G3T\[QZ&XC/4V[]3]C]$3.-9+QA/=OV2YW/'
M97,)QF3GHU@D9Z?F/8'M\I6JKO6U[,\_L?546[Q6?P>O+O9C)W;8W8*^;<8E
MOFGM0:2O\-PT7J4_:J>%/0\2WZ!TIRJ]T_&?!0LC:3XPFQ-L;65GE$3AMHO9
MC.+7MV/FG3-3?R9R8$%LUO4[Y#J7E=P3E,\;UUK!$_0;C\Q*$ZE*3*VZ?(Y6
M\%AC(][SU+>C1WK/.QMXB>K&J%4>=AC9\6.%M9K"*47%Y3=>W0Z-(_X;?XJF
MV2A%^ODT=-3NDK&N,/Z5_O-D_P!K_(&W7#[_ !,5/KL3=ONA'^*2&YIN^XA>
M!6\H^DLCAF[VY&T>T%CO4<X?Y0U=X@A3P5GSM#[=.Q'O'DKB6)OT#*WUL /*
M'3G1G^Z:KS>[+CHO)Z_U\>6K\'/)XY;OGN+M1T-S$=W>0X%5]5:FCNR]I](D
M>:G=HO5/ +3;,#+>)H[ /W+')ZFR*T/9<.A $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0'E<PMFMI87"K9&N:1\112B\/)&
M<<IHT1>8FYM+^6W,L<3ZNV1//45T7T\+5**9\=.AQDT=#>LLK9T32T7#]'/_
M  D=REQY//@CRXK"W/.W?,]OJ",DD^79M#2NLC%9U,M]GC&PB2YB,4W5I:==
MWC104I9T+'7'&J.U^^.6WC9%LF!'G:[L*Y!8>IV;36A6<SCY6P$[/3=U:*K4
MGDQ0GB6&2^!,IQ8L\F*QR-IKJ:$+Y'MM*QRANF?<]).5*C9JFB N<%)CKLQ1
M2;K=^L?P[E]%TNXKXY_J6Y\_]AUU0\?T^#(CQU?,1]BVX/$EVO!GV\<\<9V.
M+6="*+N#-*[)ZQ-CIJP$]]$:*>3R8%S UMQ',7!QB>' ]/N6?LK-<E^#U^C)
M*V+_ ">UZU\SQ,[4[2!5>!UY<=#ZCMPY+/X/"*"R-NUSP\R$5-.B^D3;/DF_
M4]8[.-]"V*3;V'JCE@8R2$.(8(@]^YH'YC15NTNC2CU#,8T>68-<.HU*CF7H
M2XQ]23M+A_TI^E89'CH\N&GV%522SJ7QSC0\OH,C/62YNI&1GJ*-HN\XK9'/
MCD]6S:/%;IC.,V;]Q>QHV;CUH'$+P>VO\QGTO2?^5$GP014:@]%F-80! >-[
M96M[:RVEW$V:VF:62Q/%6N:>H(74VGE'&LF/AL%A\+:?1XJTCL[;<7>E$-K:
MGJ:+LIN3RPHI;'CD>+\?R5];W]_817-Y:D&WFD;N<P@U&U=C9)+"9QQ3)0@$
M$$5!T(4"1%8KBO'<1-<38S'PVDEW_P"9=$W;O[?,IRLE+=D5%+8[X?C6!PKI
MW8JQBLW7+M\YB;MWN[RDIRENSJBEL=)N*\=GS+,U+CX7Y6.@CO"W]04Z4**R
M6,9T.<5G)B9/@'#,I>R7V0P]M<WDU/5GD8"YU!05/P4HW32PF<<$_!ZXWA7%
M,9!=06&+@MH;YGIW;(V4$C-11W?U7)6R>[.J"1EX7C^%P=JZUQ-G'96[G;W1
M1#:TNZ5493<GEG5%+8\KKBG&[O+19>XQT$N3AIZ5VY@]0;>GF\%U622QG0XX
MK.3US7'\+F[9MMEK.*]@8[>V.5NX!W>N1FX['7%/<RX;6W@MF6L4;66\;1&R
M(#RAH% VG=1<;.X( >V_!!D_ZF,':"]W;O5],?-WTZ*SYYXQDA\<<YP60
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MP?6V%C]2]W=C!5:+7H8*EJ6 ]GQ68T'* ( @" ( @" ( @" ( @" ( @" (
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MP,-(7RD?,: ^ 4[7J9ZEH2A[/BJBTY0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MXE52>63BL(]CV?%1)'* ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M-M9GD=7T(JLJJ?JC2[5Z,PY,DR<[39W'Q *FH8\HASSX9DV^'M[BA?#/'NT
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MS6CU*;W@=B)ZE;U*\RW,5DX'34?M76]2.-#!GA,=FV'M%2U26Y"1%P6,DEP
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M ( @" ( @" ( @" ( @" (#K+%'+&Z.0!S'BCFGM!74\:G&LK!J7F<;,!?\
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MBCR"K3*<PQ.EE9&W5SS0(W@ZEDN<$38H61MZ- "QMY-:6#NN'3@]GQ0'* (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MM'SBNH[^]6E#W)*6+? (Z:Q'0>!5%2PV6V:HA<O'0,TUU6DI,!D+IJ1@>9U
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M\DHI:EGY;&8LUQR(N+BQX:7'J:%HJO2[RQ94C3>L2B=?<.PLHVV4D<#&R2W
M]5X: 75[US[2N*XM+=CM16GZEFGP6.N,1)8"%D<,[-0P 4=31R]&76A*MQQH
MS0ZTXX*1Q'$7%[GC#?R^M#AJMAC.HK71>-T:'.W$WE5F.B#<L/\ I-E+Z(]
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M-6M;%!])<?P5A@<+9XBP8([2RB;%&.T[1JX^).I4 E@D$.A $!P>SXH#E $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 5NWXO=1\AO<F9F&*YC<QD8
M!W N%-5Y\>G)72GG1HSJEJ;EZGIQCC,F+L+NTO'LG;<O+B&@TVD4H:KO3Z;K
MBXRUR=IIXII^3$X[PN7#9J:[9,U]J\.;%'0[P"=*]BJZOU[JL<D_:0JZ_"6?
M!FOX]<NY:S->JST&Q>GZ5#NK2GP5SZK^?Y,Z8)_$_DY&-R?C&4R62M;ZPNF6
MTELVC7.!)K6M115]SISLFI1>&B-U,I--/!DXO"98V=W:YV\;?Q7 #6@"FT=O
M8%93U[.+C;+DF2A7+#4GDA8N%<FL1);XS+^E9/)+6.!K0_#^"QQ^ONAE0GB)
M2NO..D9:$K;\0CM..W>,MY=US>-/JW+QU>>W3L6J/14:7!/67DM5&(.*\F'<
M<'FDPN/@BG9'D\?_ )=R =I%:T[U5+ZYNN*3Q./D@^N^*7]2,S*\=R.1NL1=
M2S1-EL3NN*!U'FH/E^Y6W=6=DH2;68[DYU.33]#VY5Q^XS$=JV&5D1@E$CMX
M)J!W44^YU7:EAXPR5U3GC!.,;M8UO< /N6Q+0N(' <=N<;E,A>2RL>R\=5C6
M@U;K76JQ=;JNN<I-_N**JG&3?J3ZW%X0! $!C7<&X;V_,.OP7&CJ,4!0&#D4
M7<C!V 7,@YHN@["B#!R*(#F@3(%$R,'-$R,"B9&!1,C HF1@JWN9RS_E?B%Y
MD8__ #;QZ-H/_P Q^E?L55T^,39T.M\MJ3VW9\8WV1FGN'RS/+Y97ESWGJ2=
M22L2B?6-X/"*:I)\4:.09DM>:'L':3H HJ+>QVRR,%EO"(^ZS+Y)/I<8#+,=
M'3 :#OI_M6R%"@N4SY_L_8SO?QTK3U,S%XN*U(GD/KWAU,KM0T_RU[?%9KKY
M2TV1NZ/UD*URE[I&7'#+-=EK22]XK4]I"I;PCU8P;D7KVU]I,OS"X=/46N-@
M>&S7#QU':&#M*LK@YO"(]CN5]59EK)[(^E>*^W?%.,Q!N.LF&< ;KJ4;Y">^
MIZ?8MM?7A'\L^5[?V5U_[GIZ(LM5>>><H#E *KH.04!R@"Z!5 </8U[',<*M
M<"' ]H* ^>>;X1V%Y'<V@&VW>?5@/\KM?V+-)89<GE&L^>6(D@BNF!V]C@PE
MAU->BE BR@32".\])UK(][*;XY7'<5/!S)8),#C;@1S;Y((G $Q- ) [0*KF
M<'2\\=XQQJ>Q,.&NXS<2 >K#=$1S$_$Z$?!5S39HJM4="0_^FV1+6,FE:&"O
MEC!+:>"I;QX-,;/4EH>+8K%M;<SO; V&+TW/E( I6M:=ZAQE+0X[$GDK?(N5
M.>&,Q1VV<)T+A\[OS$+577Q1CMMYLLOMOSFR%K<-R<D<,]?+V5"JOR2IQY+_
M &_)\6ZS?<13,=Z>NT$:CM"S0FXZE\H)Z%?YMB[:ZQC+R+6U>T2QO':UPZ'X
M%;\>3$GX*YQMWTV&NHK8-9)=O]%KFC7Q^Q-SK9L::[;Q_CUO;4H_TB7R=C=*
MEU5&;.P12N-^ME<7=WI&Z-\SB*?Q66V!LHGJ0>3C:R<LKT65FLIW*,3#$UEW
M#& !5LE!W]JU469T9FOK\HP^.65)_J*AH:/T]-*]JUQ,4RUPO+6-<37=Y3XJ
M1 C;VW$D$\<SMPET:3V5Z47&LA/#*[GL;LL[2!\S6F%NH[5SX]"?R%T_MOXF
MR\]P7Y8GUH,-;NE(_P#S9/*RGB-5.$,,C.63Z#X5PEF,R^8Y/D6A^?SDQ=*\
MZ^A;-TBMV'N %3XJYLJ+@N ( @" X/9\4!R@" ( @" ( @" ( @" ( @" (
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M[=!4K?TX\:SY#[>;EV'^-"V56K)Y@JF1@YJNY&#E,G#D$+H%0AP[570<50!
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MXKPIDDPK?Y1WU,[B-0TBD;?^JIHXS9:Z<" ( @" X/9\4!R@" ( @" ( @"
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MY@N8&3V\C989!5DC#5I'>"N-$91:>'N>B' @" ( @" ( @" ( @" ( @" (
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MN'6/JRD769G'^INR.G\C.X+B1TO*Z @" ( @" ( @.#V?% <H @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M6*)S)>_;WEYP&%@BCEC'K2%Q:_Y7T["#V*+W!M"VS<&<A'J7D=M=- D;%;]
MTC2B'<EARD8_HT-I:WC63/9N?4 EP[!7X(,E;@98N@%I=2R_4,>',D<UP%7%
M,C!XRV<\-W,Z6]B#2X!LLQVU%.@'S'QHI8T(DQ@>!SYF$&W'J-FK^J1^D#7J
M#3HF&%C<V;Q#VTP^!(NI@+S(D4,[QHT=S&]BDHG&RX*1P( @" ( @" ( @"
M( @" X/9\4!R@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MG'/;S*L89<O<L;+(W:^.$5< >HWE18(_DWLWQNZC/TEW-93$?*T[P3XA<^3
M46S7=[[$\@BAD?;S03N:261U+7.'_2I*Y'7!D/9^U/-[F=EM;X:YDN:T<P1D
M-'\V_I16*63G'3.38W%_[5^2WA;-GKR+&Q'K#%^K+3_NJ6"&3<G%O8KV_P
MR,_1?U&XC.YLMX?4 =WM;\H75%(.;9?XH888Q'"QL<;=&L8 T > "D1.Z (
M@" ( @" ( @" ( @" ( @" ( @.#V?% <H @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @,>\QUA>Q^G>6T5Q'^65C7C]H*#!1\W['<"R<OKQ6TF/G+MSGV
MKRP$^+3444N3(\$0UW[&-A;7&WP<X?*V=NGVD)R8XHK6:]H.0M@E8VR%R]X\
MLL4@ :? =5W)S!7'\"YU;6[;>3'32, HYVQSB?N"ZFD<U9%7G$N50/I#QR[N
M7#H1;NH"N.:'$EK3VS]Q,K;QNBPS[.3H9IWLCH/\).Y1Y$N)8<+[$"Q$E[R'
M.PVCG#_4&W=YMH_F=2BYS.J!=^+V7MKAH-V#A;D98_FO74D+G#MWG3[@J7=$
MM531SG.;W4H=#$X1M.FUG\2L=W;\(T5T>64;*\BM[=Q=/(#(?PUUU\%A;<F:
M5%(PVY6R];U9KH/)^6-N@"E'"#39A\E=:9;$36\3G_4,&ZWDC/G:\=*45M=V
M&5RJT*I@..<P%W%?7C9[^2+_ "K5S'2 G^9M**Z5J>D45JK&LF;AX[<<SG@]
M.7C4L):WR$4B:?L=2BLBI^A!J'J6FRXYR*]A!O&-L2>L8>''[VJU52>Y6Y16
MQGVW [5IK<7#GD]0T4_:IJA'':2]IQO#6IW1V[7/_,_S']JFJHKP0<VR2:UK
M11H  Z :*PB<H @" ( @" ( @" ( @" ( @" ( @" ( @" X/9\4!R@" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" X?\CNG0]>GVH#75Q]-
M_69:_P!!W^F__P#N/5_WJ>6G>LFF?Z30_P!ODKN._IGU$W_P;=4U^B_J'I_;
M^'[EEMQR_I_Q+Z\\?/\ @>EW_3=IK_2J4[?K_P""I?'_ )?_ .Q8L_\ -_@5
MN'^C_4R[?^6:ZU^H_J>_[=ROAC']/^)7+/\ S?X$S8?0;QL_Y1ZCYOK*_P#;
M5BQ_R?XD'G_F+E@?3^H&W_ESJ/\ RF_?_P!I75__ %*Y_P#V+M;]G^5_^FM"
M*&>ZD<" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" X/9\4!R@" (
6@" ( @" ( @" ( @" ( @" ( @/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>p3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p3a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!] 'T P$1  (1 0,1 ?_$ +<  0 !!0$!
M       % P0&!P@! @$!  ,! 0$               (#! 4!!A   @(! @0#
M! 4&"@4*!@,   $" P01!2$Q$@9!$P=187$B@9$R0A2AP5(C%0BQT>%B<C-3
MLQ8W@I)#='7PLL)SDS2T)347HF,DQ%8X)C:&$0$  @(! P," P8%!0$
M 0(1 P0A,1)!46$B$W$R,_"10G(C!8'!T5(4L6*"0S2A_]H # ,!  (1 Q$
M/P#JD
M
M
M
M
M
M
M                                                          >=
M</TE]8P*/XW#_MZ_]>/\9[XS[//*'MV7CTXT\JZZ%>-7%V3NG)1A&"XN3D^"
M6GB>8GL91E?>/:5DXUU[Y@3LFU&$(Y5+;D^"22EQ;+)U7]I_<C]RONE%EXNN
MGG5Z^SJ7\9#$I9A5/'H
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MQ=,XS:\.*3U7TF6U+5[QA?6\3V7^J(I/0
M                       'S.<81<I-1BN;?! 1V5O^)5K&K6Z:]G".OQ+*
MZIE"=D0B<G>\Z_6*DJHOPAS_ -;F71JB%<WF5C*4I/63;;\7Q?$F@\/0
M "^[P_RTWC_A>1_<LIU_JQ_,LO\ IS^#DL[KD     !Z^JK;:;%;3.55L6G&
M<&XR3B]5Q7L9Y,&6==M^M7?.RQA3;D1W3%C_ ++-3G9IJF]+DU9R7#JZC+LX
M>NWQ^"^G)M7Y;4[6]>^U=T=6-NL9[1FST4I6?/C.7NM7%:_SHKXF+;PKUZQU
MAKIRJSWZ-D8F7BY=$<C%NKR*+%K7=5)3A)>Z46TS',3'=IB<JQX]
M                                     #R4HQBY2:44M6WP20$1E]P4
MUZQQEYLOTWPBOSLMKJF>ZN=D(7)S,G)EK=-R7A'E%?!(OK6([*IM,]U$D\
M       %]WA_EIO'_"\C^Y93K_5C^99?].?P<EG=<@         3';7>'<?;
M63YVS9L\9-ZV4/YZ9_TZW\K^//WE6S56_>%E-EJ]FZ>S_P!X'9LWR\7N.G]F
M9+X?C*]9XTG[9+3KK_*O><[;P+1UKU;=?+B>ENC;&-E8V5CUY.-;"['NBIU7
M5M2A*,N*E&2X-,PS$Q.):XG*J>/0
M         %AN&[8^(G'[=WA6O#XOP)UI,HVO$,?R]PR<J6MDM(>%<>$5]!IK
M2(46M,K8D\           !?=X?Y:;Q_PO(_N64Z_U8_F67_3G\')9W7(
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MEOWM[XV3CY-$+\>V%U-BZJ[:Y*49+VIK@SES&&^)RJ@
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MLM?NC%<Y/V(]K69GH\F<,7S<^_,L4[>$5]F"Y(U4I%6>ULK<F\
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M;:.Y-HJW3:[O-Q[>$HOA.N:^U79'[LH_\N!P]FN:3B75I>+1F$J03
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MT[9I/PZIV_/P]PPZ<W"NAD8F1%64W5O6,HOQ3.',3$XEU8F)ZPN#QZ
M                   !J!CN^;CYUCQJG^J@_G?MDOS(T:J8ZJ;V]$27*P
M     "1V[9KLK2RW6NCFGXR^'\95?9$=DZTRR'&Q*,:'13!07CIS?Q9GFTSW
M71$0K'CT                  $5O_;&Q]P87X/>,.O+I6KAUKYX-_>KFOF@
M_@R=-EJ3FLH7I%HQ+GWU$]&=W[:5FX;6[-RV5:RG+1._'C%:MVJ*2E'G\T5\
M4=;1S*WZ3TES]O&FO6.L-<<UJN1L90       #:7HEZB_L7<(]O;E9IM6?9_
M]+/3^IR;&EQEX5V<G['Q]I@YG'\H\H[PU\;=XSXSV=&+D<ET@
M             ,",WO<'CT>56_UUJT_HQ\7^9%FNF95WMB&-&I2        3
MVU;(H]-^4OFYQI?)>SJ_B,]]GI"VE/64REHM/84K7H
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M4_VGC5:YN,DW^(JK7VH):OS(1_UE[S=P^3X_3/9DY.C/U1W<^)IK5'7<X#P
M    #<_[OO>SIR;>T\R7ZJ_KR-MG*7*SG94EI]Y:S7'VG-YVG^./\6[B;?X6
M]T<QO                     4\BZ-%,[9?9A%R9[$9EY,X8;;;.VR5DWK.
M;;E\6;(C#-,Y?)Z      2FR;=Y]OXBQ?JJW\J_2ES^I%.V^.BS77U9(C.N
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MW\J0S4SK@                 @NY+G^II3]LY?P+\Y?ICO*K;*$+U0
M$_VYC:569#YS?3'X1Y_E,^ZW7"[7'JF2E8
M         U%^\-VW^+V##WVFOJNVZWRLB45J_P /=XMZ\HV)>'B;^!LQ::^[
M'RZ9C/LY^.LYP     &ZOW;MWDLO>=FE)N$X5YE,='HG%^79QUX:]4.&AS?[
MA3M9NX=N\-Z',;P                 Q3>;?,W&W1ZJ&D%]"X_E-6N,59[S
MU618B    !HVTES?!?%@9EB4^1C5U::=$4G\?$Q6G,M,1B%8\>@
M                         (_N':*-XV//VN]:UYE$Z7PUT<HM1>G#D^)*
ME_&T3'HC:N8F'&=E5M5DZ;8]-M4G"R+YJ<7I)/X-'T4.*^3UX    #,/2+=O
MV9ZA[19)Z5Y4Y8<]4W_WA=,=-/'KZ3-RZ^6N5_'MB\.K8ZZ<3ANL]
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M0'*7J[L_[+]0=VK46JLJ<<NG7IXQOCU2T4>24^I+X'<XM_+7#D\BN+RP\TJ
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M>2BOI:)Z_P R%^S%36H      G^VX:8]TVOM324O:DC/N[KM?9,E*P
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MN.2     !T-^[A__ %'<O^(2_N*CD_W#\\?@Z7#_ "S^+;!@:P
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MU[LIY=VT85F4Y*;R)X]4K')<I=3CKJM"<;+8QF4)UUGT2BBDDEP2X)$$WH
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MUUGZ58=V)Z=[%3;T];QE:NEZKIND[8\_'IFM3A<F<[)=?1&*0RLH6@
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M_.C)HCR-U_.8STRGIU5\8G'5KW;.YKO2_<>[^W'U33CY^R3DN'F22C6VI?\
MRYIR?'[!KMK^_%;?O9JW^U-J_N;$]$^U8[+V=3FVQ?[0WC3+R)234E!K]5#1
MZ<H_-\68^9L\KX](:>-3QK\RV$96@       ?(#FKU^W7\9WY^$6G3MN-72W
MHT^NS]=+5OGPG$[/!KC7GW<SEVS?\&MC8R@    :3E\L$Y3EPA%<6Y/@DOB>
M#L[M_ AM^Q;=@04HPQ<:FF*G]I*%:C\WOX'SM[9M,NW2,1$) BD
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M)VO]J]W[-M[BYPORZO-BI=+\N$NNS1^Z$6RK=;QI,_"S57-HAV(CY]V0
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M5ENE_8N_YRY%6VO3*>N>K)5R,R\
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MJ]B,NRNWMHIV;9,#:J>->%1"E-:\7"*3?%R?%\>9\[>_E:9]W:I7$1"1(I
M                8&,[]B^5F>:OLW+7_27!FG5;IA1LCJC2U      "2V/.
M\C(\F;TJMX?"?@RK;7,93I;$X9-J9EX
M  >2Y <X^N7?/[:WQ;'A6]6V;5)J[3E9EK6,GKIRK7RKPUU.OPM/C7RGO+F\
MK;Y3B.T-8&YD      V+Z%]M+=^](YUT%+%V>'XB2DFT[I:QI6JX:IZR^@Q\
MW9XTQ[M7%IFV?9TR<9TP                   +'>,7\1A345K97\\/;JN:
M^HGKMB4;QF&*FMG       9-LVX?BJ?+G_75+1^]<E(R[*8E?2V4D5I@
M                         # ?5WU!AVML3Q<2?_G>XPE##2U_5P^S.YM:
M:=.OR_SOI-/%T?<MF?RPS\C;X1\RY@E*4I.4FY2DVY2;U;;XMM^T[;EO#UX
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M<MNPM,K/?@X0?RU_Z<]%\-3-RMOA3YE?HU^5G5D5HM.6G@<-UGH
M            %ENN#^*Q91BM;8?-7\?9]).EL2C:N88HTTVGP:X&MG
M 7.!G68F1YB75!\+(>U?R$+UB8>UMAE6/D57U1MJ?5"7C[/<S+,8:(G*J>/0
M                        ,"/WS?-KV3:[]SW.]8^'CK6<WS;\(Q7WI2?!
M)$J4F\XA&UHK&9<M^H??^X=Y;O')MAY&WXO5';\3AK",M-93:YSGHM?#P1V^
M/HC7&/5RMVZ;S\,5-"D      DWR3;\$EJW\ ]=3>D794.V.UZG?6X[MN*CD
M;@Y<XMK]75[NB+XKVZG#Y6[SM\0ZO'U>%?EG!F7@
M !@8YON ZKOQ%<=*[/M:>$_Y31JMGHIV5QU11<K       76W[A;A6]4?FKE
M_65^U>U>\A>GDE6V&48F73E4JVIZI\T^:?L9EM68GJOB<JQX]
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MG'P:]C1&U8E[$X9)M^ZX^7%1^Q=IQK?_ $?:9KTFJ^MXE?:D$@
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M)ZJ.5#A_:0_.G^8IMI]EL;/=+8V;BY"_4V*>G->*U]J?$IFLPLBT2KZH\>@
M         U0%'(S<7'6MUBAKR7-OZ%Q/8K,]GDS$+/%WFC*RO(A%Q33<92\6
MO#3X$K:YB,HQ>)<_>O6U;OA]X+*RLB[)V[.K5F K)-PJ<$HVU07V8Z/27P?B
M=7@VK-.D=6#E5F+=>S6AM9         WHM?8!T/Z.^E#V.-7<.\Q_P#.+8-X
MN-KJL:NR.C<M.=DHOCX17#F<CE\KR^FO9TN/H\>L]VUS"U@
M               #0"%WC9^OJR,9?/SLK7C[U[R[7L])57IZP@30J
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M=V/'IN7&4%P4OY2VFS'25=Z>S'Y1E%N,DU)<T^#7Q-"EX>@
M/'FB]@>FB]@>&B]@'H>@     3?;V9QEBS?MG7_TE^<HW5]5NN?1SEZM]H?X
M:[OR(T0<=MW#7*PGX)2?ZRM?T)_D:.KQ=OG2/>'.Y&OQM\,+-*@    'W33=
M?="FBN=UUCZ:ZJXN<Y2?)1C'5M_ \R]PW]Z5>C6-MM%6]]R8\;MTETV8F%/Y
MH8VG&,IKE*W\D?B<KE<N;?37LZ&CCXZV[MN)>TP-CT
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MJ9[%ICL\F(ECN?LV3C-S@O,I7'J7-+WHTUV1*FU)A'EB
M        G.W\I3KGB6<>GYH)\4XOFC/NKZK==O1S'ZD=L/MOO'/VZ%?EX<I?
MB,%:ZKR+>,4GHOLO6/T'8X^WSI$^KF[]?C;#&2]2 9[V)Z/]Q]S2JR\B,MMV
M:6DOQ=B^>V.JU5-;X\5KI)\/B9=_+K3I'66C5Q[6Z]H=#]K=I;%VSML,#:<=
M5027FWR2=ULEK\ULTEU/C\%X''V;;7G,NE37%8Q":()@
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M7I#?JXU:]9ZRV:N1C:0
M  !Y*$)Q<9)2B^::U0$7E[!BV<:/U,_9SB_BBVNV8[JYUPALK;,W&XSAU1_3
MA\R^GV%U=D2KFDPM2:(                  +K%VW,R7^KKTASZY<(_RD+7
MB$HI,LAQ=NA';Y865TY-4XRA97.*<'":T<&GKJN/B9K6S.8717IA7Q,+#P\>
M&-B40Q\>I=-=-45"$4O!1CHD>3,SUE[$1'962T/'H
M                            !@6F3M>%D-NRI=;^_'Y7^0E%YA&:Q*-O
M[;DGK1:FOT9K\Z+8W>\(3K1UVU[A5JY4R:]L/F7+W%D;(E":2M6FGH^#]CX,
MFB          !<7HN+]BX@75.UY]VG33))_>E\J]OB0G96/5**2D,?MNQI/(
MM4?YL.+^ME<[O9*-?NDL;:L+':E"M.:Y3E\S_*56O,K(K$+PBD
M                                             T ^+**;$U97&:?/
MJ2?\(B7F%K9LNVV:_JE%MZZQ;1.-EGGA"VGVWAO7ILLCKR6J:7UHE]Z4?MPH
M3[:?2^C(UEX:QX?D9+[WP\^TI_X;R/[:'U,]^]#S[<G^&\C^WA]3'WH/MR?X
M;R/[>'U,?>@^W*I'MIZ+KR-)>*4=5^5GGWOA[]M6K[;Q%IYEDYM<]-(I_G_*
M1G=+W[<+FK9-MK>OE=;UUUFVR,[+/8I"ZKQZ*_ZNN,$N72DB,REA4T/'H
M
M
M
M
M
M
M
M
M
M
..               __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>p3b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p3b.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!] 'T P$1  (1 0,1 ?_$ +$  0 " @,!
M       &!P0% @,( 0$!  ,! 0$               (#! $%!A   0,# @,#
M!@D)!@0#"0    $" Q$$!1(&(3$'05$387$B,A0(@9&AT5*3%5460F)R@I+2
M(Q<8L:(S0U-4P;+"E'.#),/31"5%=396-Q$!  (" 0,# P,#! ,! 0    $"
M$0,$(3$205$3(C(488$%<5(5\$)B,Y&A(['1_]H # ,!  (1 Q$ /P#U2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                            <7R1QMU/<C&IS<Y4
M1/E ^M<US4<U45J\45.* ?0
M                                8>:REOB<3>9.Y6D%G"^>6GT6-5RD
MJ5\IB/=R9Q&7BW>?43<^Z\I+>WUY*R!7+[-:1/<R*-E>"(B*E>':I]#JT5I&
M(AYE]DVEMNF/57/;4SELV:[DN,)-(UEY:RN<]&L<M%>RM51S2'(XU=D=NJ6K
M;-9_1['8]KV->WU7(BIYE/GWI/H
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M-VV-=9F7==)M.'N&&-(XF1IR8U&I\"4/FWJN0
M                         /(WO$WU]<=3;R"X5W@6<,,=HB\D8Z-KW4_7
M<I[O K$:XP\[D3]2LS8H>I/=BO[ZXV-=07"JZWM+QT=I7L8YJ/<B?K*IXO\
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M<E6N3BBHO:AYC6Y
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M>S.B>5?DNFN&F>]7OAC6W<Y>*_P7*SC\1\_S*XV2]/3.:PG)F6@
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MLO?H]M+,;3V7#ALMX:W44\\E8G*YNF5ZN3BJ)WGF<K;%[YAKTTFM<2FYG6@
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MC:?")G'678>]L1%-%BK**?\ QHX(F2U^DC$1?E/F+=Y>M'9ED70
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MY'.3>FVUF5)(X?HZN:.<WL1/1;V$]W)Z>-.E4-/'Z^5^MEF4,;8
M                     .NXMK>Y@?!/&V:&1-,D3T1S7(O8J+P41..SDQE4
MFX=D9W8U[-N;9+U6Q:U%O\2ZLG\-%JY41:JYB?M-[.!OU[J[(\;]_=AOIMKG
MRIV]D_V7O3$[JQ27MD[1,RC;NT<J*^)ZIR7O:OY+NTR[M,ZYQ+5JVQ>,PWTD
M44B4D8UZ=SD1?[2I:Z_8K/\ T(_V&_,=S+F#V*S_ -"/]AOS#,F#V*S_ -"/
M]AOS#,F#V*S_ -"/]AOS#,F'9'%%&E(V(Q.YJ(B?(<=<@
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MWQ%9A;>2JMC:U534SR1^JGYVI3;R+12OQU_=CT5F]O.W[+90PMP
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MIC+231BK)RJK-<:U:C:\%9&J5=])_F+M]XU4\*]_55IK.RWG/9=R)0\UN
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M, JO;L;LQUKSN1>G\+#0I;151.#U1&=_=KXF[9].F(]V+7]6Z9]EJ)R,+:
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M>M9A>IVZMOM5&6]Q2[MHZKWH^C45/HS47S&[?]6JMF+1].RU5IF%M
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MJK2B>$Y]?[ANQGC_ +L6?_O^RU3"V@                     &NW)?R8_
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MXASU5%G]I8QS=*N19'*K_-21$-W)ZZZ2Q<?ILM"TD6J&%M
M                        "K\4_P!OZ[Y2:)&K'C[!(97:D7TJ,XI3ROHI
MMOTT1^LL=>N^?TA:!B;                      #0[ZCN9-J7[+>)T\JM9
M2*-*N<GB-U43]&I;IGZHRA?LQ(=[V44,<:8W(48U&I_Z9_8E"7PS[PYYN2[Z
MLU2BXS(*B\T]F<<^&?>'?D?&[XL6I1N+R#4[DMG(=^&?>'/.'+\=V?W;D?\
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M<2.7#9."]5GKLC<BN;YV\Q?5:GW1@K>)[2W16D
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M/VWM&)O([IB>NQJT>SR/8M'-^%#'?7:L]8:Z;*VCI+:50@F
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MG-CL7&7./L[N6ZBN9O'<Z;2BH[2C>&E$[C+R-\[9S*[7K\(PEY0L
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M^VUN\M--5:]H;DK6
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MS?Y+'C'NU\7.9>D#R&T
M     '5=75O:6TES<RMAMX6J^65ZHUK6IQ5553L1DF5+;J]YW V3Y+?;]D_)
M2L542XE7PX5IW?E+\1Z&K^.M/6TX9;<F/1O,1MOIYU6V_:;COL:Q,A*FB\?
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MD;+$]*LD8J.:J=Z*G!3',87N8
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M5Y:N1AY^F)KY>L-''V3$X>HSQ6\
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M
M      :N;:NVYY7S38RVDED74][HF*JJO:JJA.-EO='PCV</P?M7[IM/J6?,
M=^6WO)X1['X/VK]TVGU+/F'RV]Y/"/8_!^U?NFT^I9\P^6WO)X1[.46U=M0R
MLEAQ=K'+&J.8]L3$5%3DJ+0Y\EO<\(]FU()
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
?                                      ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>p3c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p3c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!] 'T P$1  (1 0,1 ?_$ *,  0 # 0$! 0$
M       %!P@&! ,! @$! 0$! 0$!              4$ P(& 1   0," @4&
M"P8% @0' 0    $" P0%$08A$G0V!S&QLA.S-T$BTE.3%!55=1<(4>$RHI08
M8=%4-59Q4H%"8H*1<N(C@R06)1$!  $# P0" @,! 0$       $",@-Q@001
M43,4,15A$B%B!4$B$__:  P# 0 "$0,1 #\ U2
M
M
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MZ"<V@
M     S1Q_P"\-VQ0<[RSP?'NF<N]7!L90       "?X?;]Y?V^'I''/XZM'3
M#?&K7Y 60
M         9HX_P#>&[8H.=Y9X/CW3.7>K@V,H       !/\ #[?O+^WP](XY
M_'5HZ8;XU:_("R
M              #-''_O#=L4'.\L\'Q[IG+O5P;&4        G^'V_>7]OAZ
M1QS^.K1TPWQJU^0%D
M                 &:./_>&[8H.=Y9X/CW3.7>K@V,H       !/\/M^\O[
M?#TCCG\=6CIAOC5K\@+(
M                    ,T<?^\-VQ0<[RSP?'NF<N]7!L90       "?X?;]
MY?V^'I''/XZM'3#?&K7Y 60
M                       9HX_]X;MB@YWEG@^/=,Y=ZN#8R@       $_P
M^W[R_M\/2..?QU:.F&^-6OR L@
M                          S1Q_[PW;%!SO+/!\>Z9R[U<&QE
M)_A]OWE_;X>D<<_CJT=,-\:M?D!9
M                            !FCC_P!X;MB@YWEG@^/=,Y=ZN#8R@
M    $_P^W[R_M\/2..?QU:.F&^-6OR L@
M                                 S1Q_P"\-VQ0<[RSP?'NF<N]7!L9
M0       "?X?;]Y?V^'I''/XZM'3#?&K7Y 60
M                                     9HX_P#>&[8H.=Y9X/CW3.7>
MK@V,H       !/\ #[?O+^WP](XY_'5HZ8;XU:_("R
M                                          #-''_O#=L4'.\L\'Q[
MIG+O5P;&4        G^'V_>7]OAZ1QS^.K1TPWQJU^0%D
M                                             &:./_>&[8H.=Y9X
M/CW3.7>K@V,H       !/\/M^\O[?#TCCG\=6CIAOC5K\@+(
M                                                ,T<?^\-VQ0<[
MRSP?'NF<N]7!L90       "?X?;]Y?V^'I''/XZM'3#?&K7Y 60
M                                                   9HX_]X;MB
M@YWEG@^/=,Y=ZN#8R@       $_P^W[R_M\/2..?QU:.F&^-6OR L@
M                                                      S1Q_[P
MW;%!SO+/!\>Z9R[U<&QE        )_A]OWE_;X>D<<_CJT=,-\:M?D!9
M                                                        !FCC
M_P!X;MB@YWEG@^/=,Y=ZN#8R@       $_P^W[R_M\/2..?QU:.F&^-6OR L
M@
M S1Q_P"\-VQ0<[RSP?'NF<N]7!L90       "?X?;]Y?V^'I''/XZM'3#?&K
M7Y 60
M     9HX_P#>&[8H.=Y9X/CW3.7>K@V,H       !/\ #[?O+^WP](XY_'5H
MZ8;XU:_("R
M          #-''_O#=L4'.\L\'Q[IG+O5P;&4        G^'V_>7]OAZ1QS^
M.K1TPWQJU^0%D
M             &:./_>&[8H.=Y9X/CW3.7>K@V,H       !/\/M^\O[?#TC
MCG\=6CIAOC5K\@+(
M                ,T<?^\-VQ0<[RSP?'NF<N]7!L90       "?X?;]Y?V^
M'I''/XZM'3#?&K7Y 60
M                   9HX_]X;MB@YWEG@^/=,Y=ZN#8R@       $_P^W[R
M_M\/2..?QU:.F&^-6OR L@
M                      S1Q_[PW;%!SO+/!\>Z9R[U<&QE        )_A]
MOWE_;X>D<<_CJT=,-\:M?D!9
M                        !FCC_P!X;MB@YWEG@^/=,Y=ZN#8R@
M$_P^W[R_M\/2..?QU:.F&^-6OR L@
M                             S1Q_P"\-VQ0<[RSP?'NF<N]7!L90
M    "?X?;]Y?V^'I''/XZM'3#?&K7Y 60      %<<0^,#<G7R*UK:G5JR0-
MJ.M29(\-9SFZN"M=_M-F#B?_ $IZ]>C-FY'Z3TZ.8_<M'_C[_P!2WR#M]?\
MV<O=_!^Y:/\ Q]_ZEOD#Z_\ L>[^#]RT?^/O_4M\@?7_ -CW?P?N6C_Q]_ZE
MOD#Z_P#L>[^#]RT?^/O_ %+?('U_]CW?P?N6C_Q]_P"I;Y ^O_L>[^#]RT?^
M/O\ U+?('U_]CW?P?N6C_P ??^I;Y ^O_L>[^'KL_P!0[+C=Z&W>PGQ>NU$5
M/UOK#5U>M>C=;#4TX8GFO@=(F>OP_:>9UF(Z+C)[:
M                     !FCC_WANV*#G>6>#X]TSEWJX-C*        3_#[
M?O+^WP](XY_'5HZ8;XU:_("R       SC]0^_%-L$?:/+' LW3>9?LJ\VL@
M      !+9/WNL?Q"F[5ISRV3H]X[HU;(/GEH
M                #-''_O#=L4'.\L\'Q[IG+O5P;&4        G^'V_>7]O
MAZ1QS^.K1TPWQJU^0%D      !G'ZA]^*;8(^T>6.!9NF\R_95YM9
M "6R?O=8_B%-VK3GELG1[QW1JV0?/+0
M           &:./_ 'ANV*#G>6>#X]TSEWJX-C*        3_#[?O+^WP](X
MY_'5HZ8;XU:_("R       SC]0^_%-L$?:/+' LW3>9?LJ\VL@       !+9
M/WNL?Q"F[5ISRV3H]X[HU;(/GEH
M       #-''_ +PW;%!SO+/!\>Z9R[U<&QE        )_A]OWE_;X>D<<_CJ
MT=,-\:M?D!9       9Q^H??BFV"/M'EC@6;IO,OV5>;60        ELG[W6
M/XA3=JTYY;)T>\=T:MD'SRT
M   !FCC_ -X;MB@YWEG@^/=,Y=ZN#8R@       $_P /M^\O[?#TCCG\=6CI
MAOC5K\@+(      #./U#[\4VP1]H\L<"S=-YE^RKS:R        $MD_>ZQ_$
M*;M6G/+9.CWCNC5L@^>6@
M ,T<?^\-VQ0<[RSP?'NF<N]7!L90       "?X?;]Y?V^'I''/XZM'3#?&K7
MY 60      &<?J'WXIM@C[1Y8X%FZ;S+]E7FUD        );)^]UC^(4W:M.
M>6R='O'=&K9!\\M                                         9HX_
M]X;MB@YWEG@^/=,Y=ZN#8R@       $_P^W[R_M\/2..?QU:.F&^-6OR L@
M     ,X_4/OQ3;!'VCRQP+-TWF7[*O-K(        2V3][K'\0INU:<\MDZ/
M>.Z-6R#YY:                                         S1Q_[PW;%
M!SO+/!\>Z9R[U<&QE        )_A]OWE_;X>D<<_CJT=,-\:M?D!9
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M^T>6.!9NF\R_95YM9        "6R?O=8_B%-VK3GELG1[QW1JV0?/+0
M                                   &:./_ 'ANV*#G>6>#X]TSEWJX
M-C*        3_#[?O+^WP](XY_'5HZ8;XU:_("R       SC]0^_%-L$?:/+
M' LW3>9?LJ\VL@       !+9/WNL?Q"F[5ISRV3H]X[HU;(/GEH
M                               #-''_ +PW;%!SO+/!\>Z9R[U<&QE
M       )_A]OWE_;X>D<<_CJT=,-\:M?D!9       9Q^H??BFV"/M'EC@6;
MIO,OV5>;60        ELG[W6/XA3=JTYY;)T>\=T:MD'SRT       8@
M     #$                      !FCC_WANV*#G>6>#X]TSEWJX-C*
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MK3GELG1[QW1JV0?/+0      #/?U(;TVK87=LXJ_Y]LZIW,NC14I08P
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MY6NM0M7F%Z0SU3U76<UL*+BYZ^'%RZB+X<%,'%IZY*JHM:^1/2B*9^5+%)A
M $MD_>ZQ_$*;M6G/+9.CWCNC5L@^>6@      &>_J0WIM6PN[9Q5_P ^V=4[
MF71HJ4H,8       ![K#_?K7ME-VS3Q7;.CU1\PV@?.K8
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MT>6.!9NF\R_95YM9        "6R?O=8_B%-VK3GELG1[QW1JV0?/+0
M#/?U(;TVK87=LXJ_Y]LZIW,NC14I08P !]*>GJ*F>.GIHGSU$KD9%#&U7O<Y
M>1&M32JGY,Q'\R_8CJD+_EB^Y>J(::\TCJ.>>/KHHW.8Y59CACXBNPTGBC)3
M7_-,O5=$T_*+.CP  /=8?[]:]LINV:>*[9T>J/F&T#YU;
M      9HX_\ >&[8H.=Y9X/CW3.7>K@V,H       !/\/M^\O[?#TCCG\=6C
MIAOC5K\@+(      #./U#[\4VP1]H\L<"S=-YE^RKS:R        $MD_>ZQ_
M$*;M6G/+9.CWCNC5L@^>6@      &>_J0WIM6PN[9Q5_S[9U3N9=&BI2@Q@
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M8;0/G5L                    !FCC_ -X;MB@YWEG@^/=,Y=ZN#8R@
M   $_P /M^\O[?#TCCG\=6CIAOC5K\@+(      #./U#[\4VP1]H\L<"S=-Y
ME^RKS:R        $MD_>ZQ_$*;M6G/+9.CWCNC5L@^>6@      &>_J0WIM6
MPN[9Q5_S[9U3N9=&BI2@Q@       'NL/]^M>V4W;-/%=LZ/5'S#:!\ZM@
M                  ,T<?\ O#=L4'.\L\'Q[IG+O5P;&4        G^'V_>
M7]OAZ1QS^.K1TPWQJU^0%D      !G'ZA]^*;8(^T>6.!9NF\R_95YM9
M    "6R?O=8_B%-VK3GELG1[QW1JV0?/+0      #/?U(;TVK87=LXJ_Y]LZ
MIW,NC14I08P       #W6'^_6O;*;MFGBNV='JCYAM ^=6P
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M9O=/YOO ]-ON5\GJVQU5O]7@5%UI=;'!431_X@3
M
M
M                           .%N.>\R5-[N%MRI8FW6.SN2.XU4\Z4[%F
M5$<L,.*.UG-1=.('0Y1S/29EL<%UIHW0ZZOCGII,->*6)RLDC=AX6J@#.5^D
MR_E>Y7J.%L[Z&%9FPN56H[!4T*J8@0^7[YQ'KJRC=<;#14MJJ$UY:F*L621K
M',5S52/43'%<$Y0.Q             !S^;LV)8F4=/3T<ERN]RE6&W6^)6M6
M1S6ZSW.>[0QC$TN<!_.6+GG2JJIX<Q66"W1L8U]/44U2E0QZJJHK%35:Y%3E
MQ Z(#@Y>*"39KMEHM]MEEMM;524<EVF1T4;I8F.<YM.U4QDU=32[D Z#.6:Z
M?+-G]>? ^KJ)I64U#11?CFJ)5P9&BKR8_:!"V?.^8HK_ $5ES5966J:Z-D6V
MU,%0E1$]\3=9T3]#5:_#2!VP            %5$1570B<J@<+;^)OM3-]NM%
M%;96VBO;4K#=:A'1=<ZF9K.6"-4UG,QT:RX8^ "9SIFYN7**F6&D?<+I<9TI
M;901JC5EF<BKI<NAK6HF*J!'9?SI>WYACR[F>TLM5RJ87U-!)!,E1!,R-41[
M4=@U4>W'%4 ZFKN5#1R4T53,V)]9+U%*UW+)*K5=J-_CJM50/2
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MDN9);>KLPP4M/<.L<B1T;WR1=7HU5UGHU<?M E
M      <??>&5INESJ;E!7U]IJ:YJ,N*6^=8F5"-353K&JCDQU=&* =%9+);;
M):Z>UVV%(**E;J11IBOAQ555=*JJKBJ@?+,67Z._6U:"JEG@;KLECGII'0RL
MDC76:YKV_8H$+9N&]LH+I#=*VX5][KJ7'U.2Y3]<V%7:%=&Q$:U'?]6&('6@
M             @<U9,M69&4SJM\]-64+UDHJ^DD6&>)SDP75<G@7PHH'RROD
M6U6"KJ+@V>JN%UJVI'47&NE6:98VKBUB+H:UJ?8B =&!PUVX4P7.Z>T9\PW=
MLT<[ZBD8R=FK3NDQ14AQ8NHF"X?Z 353DNVUV5V9=ND]1<:=B)_]N>15J5>U
MVNR3K6ZJZ[5Y% \>7N'5KM%V2[SUM;=[G'&L%-57&;KG0Q+^)L>AJ)CX5Y0.
MK             !P-7PD@JKBVXR9DO7K<3I5II4J&:T+9E\=D:ZF+6JFC_0"
M>NN2K7=LO4UEN4U14I2=6Z"O616U;9HDP;,DK</' ^&6L@6NQW&:ZOJJNZW:
M:-(?:%PEZZ5D*:>K9H:C4QY= $W7VB@KYJ*:JCUY+?.E32KK*FK*C',UM"IC
MXKUT*![                                     'DN]S@M=KJ[E4(YU
M/10OGE1B8N5L;5<NJFC3@AZII_:8B/\ K\JJZ1U5S^XG(W]/7^A9Y9K]"O\
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M&HW%7: .K1^#$614:N'C:=&/^J@?UB@'XU['?A<BX<N"X@%>Q,<7(F'+I^T
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MU,,^LCE<Q[G>,S#%%0#X560LK5O&&II*FD<^":W>TI&)+*W&I=4X*_%'(O\
MV\G\ +8DBCDB=%(U'Q/:K'L72BM5,%1?^ %3\/LJOASU7V^IG2>VY,5T=D@5
M%\3VCC-K.QT*L;/%0"/S"M9F'/%^BKK!7YBH+4^*DI*.EJTIH(%6-'ND<W68
MYTC];EY, ).UOJ+9PWO--G2GN%):8:GJ[= Z9'USZ=[F+# V6)V+G:_B)IY
M(:S02V7/>6UMF7Z_+%-<9I:>J94U*3QU4?5.>UJQJ^16O;@B_P  )R3*-KS/
MQ1S53W9\[Z&GAM[_ %..5\4<DCH51KWZBHY=33JZ?"!^9ZRQ.F8?:%YM=7F#
M*45)%##3TE0]LM&Z/%))5@:YBS:R<JHN(%@Y5GM4^7+=+:)G5%L= SU2:17.
M>Z-$P365WC*[1IQ K[*F4K/GVCKLQ9D?/5UTU94T]/&V>2)E)%!(K(XXVQJU
M$=@FLJJFD"/FI$NW"?,D%WDDN+LL5-PBM5=(]^NY*5J]4][D7"16ZZMTXIH
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M:<5P ]?#FV7ZV9LF936&ML>6JJE<LU)65+:F-M4QZ:CXL'.<W78JHJ 6F
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M2+J$EKY^L1D>LCM5C$1K4\9.7#$#I
M
M
..              !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>p64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p64.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!^@+_ P$1  (1 0,1 ?_$ ,$  0 " @,!
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M3JO1&8ZR;?N34FT$D0V]VOQ/.BBGHIOK,1'=!M+D_3*+)_KY_P#KW_ZZ[_\
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MMY[NCL\L2G-O)_R;<TDB%KJNJ@).IX]$0E3T)XUSW\1WQADGL\>V?FKS'_\
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M7HM<MMN9M^D^L)W['?\ -7<?BKF>"BVR%=.U;M0;0VIS@-("+JB@&B&""J^
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M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#BXX
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M#!TD^)('R/ O_A<'0OX/"NEN]51RESKM4U<X5+(C91Q->6GF'3N6+RBT,%Z
MJE\9%'XK;W3423H7\5^)IOTY5*,Q58G.E<MBOMLOEL9N-M>1Z*\G1? A)/C
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MZF3H<)GOS)#49G5![CQBV.J^";B5$H,6]7ZVV>P3;]+-2ML",Y-?<:3>JLM
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M@FEDOUEOMO"XV:<Q<8#BD(2HK@NMJ0KH2(0*J:HOC09U H% H% H% H% H%
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MZE H%!3GO%_V:Q?RI7XK=:/X_P#ET9^_Y0MZ)_96?Z,?XJSYYK\<G;7CTH%
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MGC06EC3F1.6.(>1LQF+V0K[:U"(SCB6Y=.V1^;3;IXT&SH% H% H% H% H%
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M5WM5W@-7&U3&9\!_56)<9P76CVDHEM,%45T(51=/309= H% H% H% H% H%
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MTO13'S>E*"_;7:K9:H+4"UQ&8$%C=V8D9L66@W$I%M $$4U(E7HGC095 H%
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M;#E*WZSU\H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M%*!0*!0*!0*!0*!0*!0*!0*!0*!00GF;_3NY?RX_^("K.S^Y"ON_MRVO'?\
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M6W<V\I6&7#B9M*M%KLTHR*<4B2Y+?D/B/S9&+B'VVP'5$W(**O@J]4#<<O\
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MH.F;']IB/1]VWO-FWNTUTWBHZZ?PU[$X3B\F,851[O2 U#OK&]")N0TGPJB
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M5=I=VQS$^.;C(<LN)7^[37+I<5) &X=I&52W@X*H3>Y=!+54U4Q_A#VI;;9
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M[+M643^B'V>YKM+_ /+\:";<N<=WG,>*WL1MC\9FXN)$07I)&+/_ "[@&>I
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MSCFNU-K0F7X/JH-X!"8B8KJ)(BHOP+0?:!0*!0*""7?DURW\OV/CU+<C@7B
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MU54H+NRFT.7K&+O9FW$9.Y0I,,'535 )]HFT)4Z:Z;J#SSBMXY8L/$LOC)K
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MMH0-"<- 0MHIKU)>E!O^3\A>AOK:[Q@4W+\6F,#\[;F6YS@2=Q(3;D4U$A1
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M1-J:"JIKMW:Z4&NX[PUK"\,MF,-2BFMVT# 91 C:GO<)S5112T^/IXT$CH%
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M% H% H% H% H% H% H% H% H% H% H%!J,NO-RLN.S+E;+4]>[@P(^S6J.2
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MA*#>8?P[AN+X;<</8;=N%BNC[LB6Q/('%57@ "%%;!K011H=O35%ZZT$5_\
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M*NG[1H0"@*&WY]/$T7X*#YBG&][M',>7YK)?C':[^Q':ALMDXL@29!L2[HJ
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M3H*4&PH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H--C>'8UC7MW
MT'!&%])R"F3MA&7<?/XQKO(M-?@Z4&YH-=D&.6+(;8[:[Y!9N-O>_G(T@$,=
M4\"37XI)KT).J>B@CF-<,\7XU<$N5EQV)%GBFC<E4-XP^%M7B<V+\(Z+031*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0%
MH(NWE&1ER$[CA8\\-@"$DH,DWKVB?U1/9T#9INZK^'Z/"@RH.<XQ.RVXXC%F
M*YD%J:"1/A]IU.VVX@$)=Q11LM4='H)+0:&7R<;',4+CKZ.0@EVQ;DMS[VBB
MJ*XG;[.SK_->._T^%!//101C$LGR.[WK(H-UQYVSP[3*1BUSG#4QGM*3B=X$
M4 VIH KXE\:@D] H--EV88_B-C>OF02EAVQ@@!U]&W'="<) #R-"9]27U4&'
MFN9-X[@EQRV.Q[>U"B>V,L*2M=T51%%-RB2CJA?)H,G!\D7)\/L^0E'2(MUB
M-2UC(?<[?=%"V[] W:>O1*#>4"@4%4WWG<X.=7;#K5B5TOUQLPM.2C@]HAV/
M-@XA:$J+I\Z@_=H)A@V773)8DI^X8[/QPX[B-@Q<4$3=11W;PVJO1/"@DU H
M% H% H% H% 6@@G'O)IY=E&96,K<D),3G#!&0CW=]HW&\.]1V!V_YCPU7QH)
MW0*!0*!0*#"ODV9!LL^;"B%/FQ8SST:""[2?=;;4@:1="T4R1!\*#!PR]7>]
M8S!NEXM3ECN4H2*1:G24S943(41246]=1%"^+Z:#=T"@4"@4"@4$7Q')\CO%
MWR"'=L>=LT2U2_9[9,=-3&>SN-.^"* ;4T 5TU7XWC02B@4&IRZ^KC^*WB_(
MS[2MIA2)J1]VSN>SM$YLW:%MW;=-=%H,#C;,2S/"+5DY1$@E<VR<6(CG=0-K
MA-Z;]H;OB:_%H)+0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!00?FN-D;O&=[?QN=)M]Z@,^VQ7HA$#A>SKO<
M;\J$J[VT)$3UZ4$!Y3Y#R6Z<08K(PY]QO)\L[!1O9'O9W11B.4F8H*YM51!6
MU!=53Q3Q](=V<<DWBY<+XG(QV<<7*,T<M\"&]'71P'G%3VLD4TWH(*! 1HG3
M5%^&@RK9?\C;]Y1_%G+K)?LS&.@ZD5P]6R?16Q5Y1\-ZZJJK05SBW'5]D^\'
MF5B;S2\1ID*WQG7;VT;:2Y FW&5&W55-NT=Z(FGR4H-[R!$R>3[T5I@X[+:A
M7*1CG9*Y/BKBQV2.0CKS8=$-T1^(B]-WCTH-WB-XSG#><VN.[QD#^36.\VX[
MC D34'VJ.8;_ (SB#J7]G--NNG5%Z+KJ&QX:R?(;MG7*L.Y7!^7%M-V[%L9=
M-2&.WW)*;&T7XJ: /WJ"O^&;?S/R3@DNXR,]EVQB.\\U:S:T-]V4@HJK*=5-
M_9'<B" KZU]'4+5]W;/K[FW'07&_$+MUA2WX$F4*""/JT@F+B@ B(KM=05T3
MT:^F@BWO?627(XV=NX722Q&A.,MO6IM4]FD*Z^"";J>.YO\ !H.>28E<[![O
M^4N3<BGWT9]G9<9">0DD9!;34&=J)H*[O^"4$3@6?E>+P5;LW@Y<=G.QVME^
MUV2* E$.%'#7=)WH7<?=34NJ**=!T]*!-LNYQN=GX/L.7LL,A?\ (PCQHO=7
M_EV9+P$IOGJFFP.V1(B_P]*"!Y1G\_"847*++RRUF%Q:?:2\X\\Y&=9D-NDG
M=]E::ZM;2\-O@/I]"AZ?A2VYD*/+;11;D-@Z EXH)BA)KIKUZT%)S<)Y@L?,
MF49KBUMMEP@WUF/':"=)-HD%IED27:":Z[VEH)1Q?R^[DTN]6')K:F/97CB(
M=U@JZ+C2M*FJOMFB_%'\+JJ)J*[EUH-_!Y.XYO<H+5:LHM\FX3$)N,S&E-&\
MI**KY!15551$UH(AP=FEU+&LEM.7SCD7C"I\J-<9LDM2**&YQMXS4033:)HB
MJJ]!U\%2@BT#EO)\<X0NG(]T)V=<,AN;Q8[!DJO:CM/.*VP&U.HM@+1GMUZ]
M.O76@C>29Q=\9QYO+K5R\QD.31U9>N6-N.Q78<A'"$7F8[#7Q=JET4?P454V
MT%P9C<KY?<2L%YM>5,838[A'&;>)SXM%)[#\='098)WYL#1%)5-%U'1%3732
M@@G'6?3K?S+$PJ%F99WC=XM[DH)KQLO.Q);2&2CWFD7<B@Q\3I\9%^Z&,_(Y
M.RKG[+\0M64R;-CL)N(]*)HMSK+799/9#1=1 W'"\Q>K7[BA?6.6R;:[#"MT
MZ>Y=)<5I&GKB\FCCRC^&?4O,OIZT%'W:[\H7OWALBPFPY"5KL7T=&?F$0HX<
M9GM,[SA"70'S-[;N\.JEXHE!M<)O>7XAS0]QQD%\?R*U7>W_ $G99TU$*4V8
M:H;9D/X*HRY]Y---5H(;QUC^87_E#E6V6:]%CUJ*]*[=+E%1%G$8.R>PRPI>
M4 )5(G"\=$04\5H)YP#EV83;GF&&Y3/2\3<1F-QV;NJ()O-.*X*(:(B*JHK&
M[<2JOFT55TH(CG$_([):KG=;MS(TSF<!EV5"L$!8K4129(C;C>SEYG5(A4-3
M35>B*BZ=0W&:<O9L'N\63-;."1KO<UCLW*:#7?&*"]P'I0AM44W.-HB;D5$W
MZ>.BT$FXJM#J2_INW\E2<SLOLQ,RXL@FGQ%]5$@<$@7<THH)HHJFJZ^/2@K:
MV\F)R*[=+O<N3 P*W-2'(U@LT9^.R\K0"G_,RE<47#[BJF@]$31=*"9\-\WQ
M;AB-P>SB]P6Y%FN1VOZ=(VX\:=J)&TX"ZB.X@ E\HIJB(OKH)CD.>6"[<>Y9
M<L3O<><_;+7,<25!>%U6'AC.&T6H*NTM1U2@I?*N0,WC>Z[B61Q;S*"_S+@#
M4BXHXJ/.CW)2;3/Q5/FQ^]09_)#_ #)QK9;5G]PS%RZRREM,W['U;;"WJ+WF
M[484'RH(M[%/3<OQM?%%#T>V6]L3TTW(BZ?=ZT% 7J\<GWGWA[[A-@R K79#
MMD=^81BCI1F>VUW'(8KT!\B=VH7AUU\42@V>&WK,,.YI7CJ_7V1D=IO=O6Y6
M:;-1"E-N-H2&V1CTVJC+GH]":::KJ$<?Y.#.LIR!J?R . 8_9)2P;5$8?88E
MRW&U(79+QN^?9Z!%.G\(ZJ&^X?Y-OU\LF<6*Y7=J^3L4 T@Y)%0!&5'-MWLN
M:@NBF*L_&3[ZKU4-+P);>5LVQRUY5>LVF,P(<K2%!:7>LMMF3ND)-,M%)#T5
MH$1>@_\ $)#Q5G=W*_\ +TF^SY$VV8U<WRB,&2FC$9@I)$VT*^";6D33X*#5
MX;:N5^5L>=S5_-)6+1[D3J8]:;6(JRPRTX3>LE= )TE,%].OPHBH*!F8ES=?
M&^&<IOE_0).58:\_;YCJ B,R)2&C<<U%M&T05-P1/;IX:^F@C]YQCE^3PQ.S
M.1FCTV==;.],N]BDMM>P+;Y,=3-M@1'YIT650A(=.NJ>F@LSW<?]$\5_N[O^
M(=H+(H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H.N3'9DQW8[X(XP\!-NMKX$!IM)%^ZBT'F[A?C_,8')0V2
M_6V0&,8,-T&PS7V%2/)^D7A0=A&B 1=HC)2#5?P5732@<7X!F4/EINQ7&UOQ
M\*PF9=9]BEO,J+#WMY",<0<06P,@$E/4==.J:)03"+8;X/O3S+TMODI9CQ]&
M!N2LN>S*[O;^;1[39OZ?%UUH--=4RW!N?\ART,5N60V?)+>S'A.6EOO*V^TV
MP&U_71&TW,]25>B+JFNBH@;>?8K\Y[TEHOGT;)^B QXF7K@C1E&!Y2>7M*\B
M=O=YDZ:ZT'*_V"^N^])C-[;M\D[-'L3K#]R%DUC-NJLK1LWD38)+O'HJZ]:#
MCPK8+[;L\Y8E7"W28<:Y7?NV]]]DVPD-]R4N]DB1$<'SCU'UT';[JMAOECXN
M6%>;?)MLSZ1DN>S3&C8<V$+>A;'$$M%TZ+0<?=6L-\LG'4Z)>;?)MDH[O*="
M/+:-AQ6R;91#07$%=JJ*Z+0;SWAL2OF5\57:T61CVFXD3#[49%T)Q&7A,A'7
MINVITH(U=+]D68\%Y);4Q*[VF=$M3,1J+-CD+TF1L^<&,RB*X8#M'0MJ:Z^'
M2@SEL=Z_]KOT+[!(^F/LW[/]&]H_:>]V-.WV=-^_7IMTUH(U?.+LBR/W;L5M
ML>"X.2V (T^/:)0=M776MP&P\#NS35MQ>BZ=>E!D0\CL,CM0'>"IH7HR1ET"
MM$,(".(6AK[:0[>WHBJA[>OA\-!?0-@VV+;8H  B"("FB(B>"(B4%97?EO*\
M?OMQMMVP"]SXK3Q+:KE8V4GM/QM5VDYY@[1^L=5__B&MXDPW*)^9Y-R5F%O&
MTS,D9;A0K"2H9-0FQ =9*+KYS%H$TZ?A:HFNB!8L# \'M\MJ9 QZV1);"[F)
M#$..TX"Z*FH& (0]%TZ4%"<]6?)K-R((8T (SRA#:L-P5-4,)#3P"3R(T._3
MV<M%7S=-VO@B4%B\O\3C?^'2Q"P 0/6AIARS1]1^<*&.T6C4MJ><%)->GFT6
M@AT#([6$-J!<."IAY&(HRZ#%HA_1YR$335)A)M%HEZ[M%0?6NFM!F<\XE=W[
MU@UY;QQW(,/L1DW<\9@-]UT>Z(B!!'!$0A;043IT333HBZT&FQ6RWJX>\!CF
M5PL$D8GB_L$N,R)Q CEN!EW5V6VPFQ@W#>V AKJ2#02K!;!?(WO&\@W>3;I+
M-JFQ(8PY[C)C'>(6F$)&W51 -445UT6@N;T4'F:YW_);#[U.3W*R65R_,M6F
M,EW@1M%E>QJU&W.1@)10W <0/)^$FJ?#02G#+7E.:\V?O(NEAF8[8;1;5MUE
MC7$4CS7G#4T,W6/.J"G==]*?@Z:]:#,X0L-\MO(G*LNXV^3#BW&\ [;WWV3;
M;D-H[)7>R1(B&.ACU'UT&)Q=C64Q>0^8)!0Y%M^EI+?T-<)#3C3+A?\ ,[7&
MC(=#$5,551UH*TQ[%;Q;>/;Q@C_%LN=GDA9C!Y*_%:*$HN*6DEN<YUW-@?D%
MOXRHG76@MK 9.58EP5C"?9>5=I48%;N]DV]F8$8C>(S!AY$WF/E^;7J2+01?
MCK&;G.YI'*L9Q*X8/AR076+W#N#?L*S)!B>WMQ!4AT$G 5-/+Y5\%Z*&KQ/&
MOW8O77',BXRDY?:O;7GK'?X-OC7%]Q@MFT'T+J&B>M4ZZHB>F@N#";/B^18X
MX[,P"/C\%V4KD>TW"%%%QQ ;06Y+L<046W%0R#0M21/3HM!E9?B5H@<>99!Q
MRS1XC\^U302-;HP-&^ZL9P&QV,BBF2J6@^F@HO*,-R]_W6,.LC-DGN7F+<6W
M)-M",\4EL.[*7<;*#O%-#'JJ>F@L3WJK#?+YQ;[#9;?)N4SZ0C'[-$:-]W8(
MFA%L;0BT37JM!;["*C#:*FBH(ZHOW*#S3>;]DMA]ZO(+E8[,Y?0:L\?Z6@1U
M3VKV)0C[W(PDHH;@'L5 _"35/A0)1B%LRG-^;6^1KE8)F.V"R6TK?9V+D*1Y
MCSKF]#)QCSJ@IWG/2GX.FO6@CD'%7..<PR9F\\=OYMC5XG+.M%VAP8]PEM$\
M*F;+C9^9 1>FOE35->N[H%E8D<*YXID<FUX*[AXR([K$9AZ(S$ERT1DM%-AE
M-P[7"(00E77Q3QH,7W9K/=[/P_:H%V@R+=.;>EJY$E-&RZ*%(,A4@<0235%U
M3I0:'B;"[J[D',<*]09=OM^0W-]J-)<:-I'H[Y2A)U@C'::;745"35.J4&IX
M_P NY#XTQ4\#G8#=[O/M)O-V2Y6YCN09(O/&XV3[R*2-)N/55354'Q1-.H;'
M&^#\A<X:RVS7HVVLJS-UVYR([9[6(\I2%YAG?HYT1P$[FFOCHB]-:#2.YIRC
M,X>>P.-Q_=@R*-:W+7/F2(ZMP/966E8,X[F[<^\;0H@ "=275-4\0M/@.V7*
MU\0XU N45Z#.88<1^+(;)IT%5]PD0P-$(>BZ]4H)_0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*"'7/CEBZ\DVK,[A,[[=DBNL6JU*RFQI]Y?/)5Q252
M/3HB;>G1?%*"8I0*!0*!0*"$VSC)B!RO>.0DGDX]=H#=O*W*VB"VC?9\Z.;M
M5U]G\-OIH)M0*!0*!0*!0*!0*!0%H(3;^,6(?+%TY#2X&;USMX6XK<K:((('
M:^<1S=JO\QX;?303:@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
/4"@4"@4"@4"@4"@4'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>p8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p8.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!- .$ P$1  (1 0,1 ?_$ +<  0 " P$! 0
M       %!@,$!P$"" $!  ,! 0$               (#! 4!!A   00! P(#
M!00%!PH% @<  0 " P0%$1(&(0<Q01-182(R%'&!(Q61H4)2"+'18G*",Q;!
MDJ)#LR2T-74WLE-S-!?P5/'"TH.3)3@1 0 " @$$  4# @0$!04    ! A$#
M!"$Q01)1<2(R$V%",X$4P7*"(]'A4@7PD:&Q0_%B)#1$_]H # ,!  (1 Q$
M/P#]4H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M/PZYO;RANG\EXK'A-AN_^(:O!)^)'1Q@;6W :LTB/7IY_&[]*K__ )_G*?\
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M/B:0?-6:]DTG,(7UQ:,2DZU>*M6BKQ B*%C8XP3J=K!H.OV!0F<I1&&1>/1
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M4+6F9S*58B(Q#97CTT0- @:! T"!H$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M$D@!<UNGRC7V()9 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M'BL5DL)Q-XLRY;'Y*>">L)WDF/Z#8YTC=7]2?,(.O(" @(" @(" @(" @("
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M\ER3$8W*XO%6Y2R[F'2LQ\88YP>Z%F]^K@"&Z-_>02: @(" @(" @(" @("
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 04/EF8=;N&K$?]VKN(.AZ.D'B?N\
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MDR1HXN1[#I-)^'%[=7>?W#JKM&OVMA5NOZU<Z76<L0$! 0$! 0;]3_D')?\
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ML;#;C$CNO]W(?3D\.OR/*JW5]J3'Z+-5L6B7[#7S[LB @(" @(" @(" @("
M@(" @(" @(" @(" @KW-Y=N)8S=H9)6C;[0 3_,M7$CZ_P"C-RI^G^JCKI.>
M(" @(" @OO%,2VG0;.\?[Q9 >\^QOBUO^4KE\G;[6QXAT>/K]:Y\RG%G:! 0
M4OF>*;#*R_$W1DQVS@> ?Y.^];^)MS'K+#R=>)]H5I;600$! 0$'A\$'4,7*
M)<=5D&OQQ,/7Q^4+C;(Q:8=;7.:PVE!,0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M1CY99IG!S2"/VB" 1X*$[]T^4HTZX7]CVO8US3JUP!!]Q61I>H" @(" @("
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MBM9W(XOC>$AOMIT*V4;:LV379Z%B+U=KF['NWGP:!T\=2$&UANZAR]WA3*U
M1UN65[<\CI'DO@=49J6MT&CP7:C7IT01N6[SV<=0S4[\="'8_/G UY99GLK@
M;=WU%F0,>8VCST!0;69[LS8C$886XL;'FLR9S"]U]HQ;(JY/XYN;#JUXV[6A
MNNIT01+N_D8X]-:%2H[(U\G%BIIF6R_&-]9AD99-IL9/I$-(^375!TOC.2OY
M+!UKM^*O%9F#B]M.<6JY >6M?%, W<U[0'>""40$! 0$! 0$#5 U0-4#5 0$
M%$YACC7R7U+1I%:&[7^F.COT^*Z7%OFN/@YW)IBV?B@5J9Q 0$! 0$! 0$!
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M"&.&)D48VQQ@-8WV #0+D3.9RZL1A]KQZ(" @(" @(" @(" @(" @(" @("
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M XUA!CJF^4?[W-H9?Z(\F?=YKE<C;[S^D.EHU>L?JF%0O$! 0$! 0$! 0$!
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M3ZS-(@(" @(" @(" @(" @(" @(,-R[3HUI+5V>.M5B&LL\SVQQM!.FKG.(
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MMVZW6R>L41_U?O/]+^1<WD<CVZ1V;]&C'6>ZR@:+*U" @(" @(" @(" @("
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M-ND=F_3HBO6>Z?69I$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M "[J -!T061 01V4P..R(W3,VS>4S.COO]OWJW7NM3LJOJK;NJ>1XCDZI<Z
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MS8WP8-??XH)O#=J;U/+\?R60Y)8R;N.!\./KO@BBB%=T)AV:,Z[^K=9"3KM
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%$!!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>phone.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 phone.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ % # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4MM+110
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M+RV\?[6WP*5V8737 VJG0KYZY)SQC./?FOKJOCG]I[_D\SX"?]=/_;E*^QZ
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LKZ1-(FF#69+>.WLF:/:TJ06T,,9D*NR^8ZLP#$ C)KVJ@ HHIN[Y@* /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>proxy_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy_01.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X0Z917AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,C$Z,#0Z
M,C<@,3@Z-#$Z,#,      Z !  ,    !__\  * "  0    !   #!: #  0
M   !   #Z          & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   UC
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M         0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:  P# 0 "$0,1 #\ ]2IIJHJ932QM5530RNM@#6M:T;6,8QOM
M:QK5-)))2DDDDE*22224I))))2DE@EH]1Y-E@'OF,FTD#WGVL%VWZ'\IGI?X
M/^;35MV-<?4L:2-EA=D7/$'WN])SKSZ3_P W]&QG_&)*=])<^8X.18PD0=U]
MP C;O/\ /;MW[O\ ZE1:<NVEA N!<\EY:YY>1'MC=8Z[;[?W/9_GI*=M)9!Z
MAD N'K5S.FH$?G3]'Z/YB)5U-^XL.VQY(VM#@#']5K7.WN_,24Z:28&0#Q/B
MG24__]#U51>2&.(Y )'?52224\]7G]:L;4T"T&6NNM=C.:-C_38UK:GCU-];
M_4]7_P!(JUAOZSD2U]@J&V'E]9:]I)=Z;V>S[/;]#](QMC]G^8M=))2PF!)D
M]RG2224I))))3A.=>U[P!3M<7 10\R7;MGN^U!K_ ,S=]!*<EK""RDW!TA_I
M/VAC1!:YOVK>Y_T_SO["1N(>Z,:H@%[@UV19KM)=+Z_LSF[7NV*U7E]/=6'W
MU5LM=.]K1O!+C^;9L9ZGJ_U?>DI'C9>92]K+/3-# 9KKJ<UVI.S:Y^0_^3O]
MBN'J+08]"TZ R V-?Y6]"^T]),AK&.$:@,' $_\ 13?:>D'AE9F3 8TGB7>T
M>[Z*2DCNIL:/=3:#W$-D#MP_;V^C]-2.>-VUM3W$Z-XU/AK]'^T@#+Z,0?8P
M#698!P?=.X?OHM74,!GZ.N&$N@UANT[B=NK/I;DE-U))))3_ /_1]522224I
M))))2DDDDE*22224B9C4,<'-8 6S!^,S_P!4B)TDE+0/!*!,QJG224M 2VM\
M G224I))))3_ /_2]522224I))))2DDDDE*22224I))))2DDDDE*22224I))
M))3_ /_3]520[K?2#3L<_<8AL2-"[\XM_=0/M^C(Q[B7S( :2V)C?[_\)_@T
ME-M)5/VAX8]Y_LCP<[]_^2G^W>X-]"W7@[1'&[]])3:253]H>TG[/=(;NC:V
M3Q[&^_W/U3NS@)BBUT3&T S'[OO_ #_I,24VDD-ES'-:Z=I< =KB)$B=KE+U
M*S^<W[QW24R24?4K/#AKQJ._"7J5GAPU\QWX24R24?4K_?;V[COPHNOI:PO+
MQM:-Q,SH!N_ZD)*2)*H.J8! (N$.!<W0Z@%S=-/Y#DF]4P'[=MP.XL#=#_A)
M]+M_A-OM24VTE3/6.FANXWMVQ,Z]ODK'K5>C]HW#T=N_?VVQNW?YJ2G_U/4+
M6ASF-VM<=2"X3$#M]Z&VJN 6BF-"(:.(AG?]WZ**[^<9\'?P5!W3L!FW]4L)
M#(#@==I+K'5%WJ;OI6/W)*;0IKTVBG2(AH[#:._YJ7HL'YM(B(]OA[6]T+[-
MB,C=AFUS?\(YC'N/FY[CO<B-P.GV.]9V)4+"22YU;-TS.IC][W)*1W8-3RQQ
M?Z/I\>DXU@@?Z1H]K]G_ $%&OIE8>;F6O<'ZM:;'.K$C3T:YVLV[OT/^B_,5
MG[%A@@BBJ1NCV-_.^GV_/_/16,96QM=;0QC &M:T0 !HUK6A)32JZ6VIH:VV
MQT/%@-CRXR!M%<_]Q_\ @4PZ2P CU;=6N:#O,MW?G5N'N8^O_ /_ ,"Q:"22
MG/?TEKV5M]:UGI\.986.=X>JYOT]GYB1Z2TW-M%MK2UP<*VO(KTX9Z7^C_D+
M0224Y_[);K%UHW6>II81$ M%5>W^;Q_=_,M4V]-K&.,=T6,$>ZR76&#+9M!8
M_P!GYBNI)*:!Z1C$ ;&@"8@O'(V?Z3\UGM9_H_\ !I#I6*S4,8 '%_+X!(#/
M])]'8WZ'T%?224XF-_S?OL91BY6+;8\0QE5Q<XQ^E]C67;_8UG_;7L_FEJ0S
M[)LV-V;=FS\V/H1_5396.^V[$L:1&/<;'SS!JOH]NGTM]S$__:;Y_P#?DE/_
MU?4G?SK/@?X+/R,?$OL;9:_#>^QC07/K#G/$S['>L/T?[BOO_G&?!W\%GLRN
MIN^EC5@;)))8)/N<WZ-]GL=[/_!$E-FR\5EK1E8]8VR&N';75OZ9GM]JM @B
M1J#P50MNSPX 556-!/@"!)]_NL_=V/\ ^N*?J=1<_P!IQPS]T[BX:\':=GT4
ME-U)50_,<0&OHUW?O.TU](C5O]M'J]3TV>J6FW:-Y;(;NCW;-TNV[DE.>_%Q
M7]/ <,4BJUSJW%H]%I+W,^C_ *3:]S/^-1?L.$W/J+:J&N97[1L'JC9#*G,=
M_HZV>Q)^36W$:_[(7UNL+7U@TPTASOTC]]S*?YUOYK_5W_X-2&2XY3&.Q'A[
MF ^H74RUI@V-/Z;U=M;]K;/38DIN))))*4DDDDI22222E('_ &F^?_?D= _[
M3?/_ +\DI__6]1?_ #C/@[^"H9-!-FN$'D4M:75V%HT=_, -#?:U7WZV,!\'
M?P56_IK;+ ^MS:FAC:PT,!]K3]'D>W]Q)3!]))+?LAL ),O>3,EH[[]S+?I6
MU_\ GQ#;CD?S>%L+G'=%KF>XD>YSF?3K_<_T6Q&_9;70'/ 9!:YC&AH/9IUW
M^[:VO_,1#TW',:N&D&(UY]SO;_*VI*8MP6@M/HM:X$#VVO$-V[7.;#6_I&[O
M_4B/C5/9O=8(<X\"Q]@@?\;&QWN_,0F]-QFD<EK>&F(YW\;?SMJLUUUU@BMH
M8"22&@ 2>3HDIJ&MWV%[/1JW>H3Z4^S^<^D3^]^?_71G-/VQCMC(]-P]3\_E
MOM_J)?8\;T#C^F/2<[<6:\EWJ_\ 5HAIJ-PO+?TK6E@=_))W1^"2F:2222E)
M)))*4DDDDI2!_P!IOG_WY'0/^TWS_P"_)*?_U_4'.!O:R.&D_?HLUH%XK>ZC
M(QY#:S6V" T$>GNW-=_+^A_;_,6@0!F!W+C7$:< H3>ITO$AC^) ]NH&KG-A
M_P"8DIK- L<7-;D@V C:0T#0>GZGZ1G_  FW_7U$VRAVW<S*.YH'@0WW#\R/
MH-KV_P"D_2*V.I4EKW!KBVL$EWM@@&-S??\ G)'J50B&/,NVZ >$A_N</8Y)
M378ZD5R^F]X=[F[FZZ%K_;Z8;L]W^D6BQQ<QKG-+"0"6F)!_=.W<U5W9[&V>
MF:K-Q^CHV"0)+6^_Z7YB0ZA47.:UCR6AT?1&XM_,;N>/<[^6DIG]BQOLYQMI
M])SB\MD\EWJ_2G=]-3-%9O%Y'Z1K2P&3]$D./M^C^:J[>IT.B&N/ /T="?S'
M>_Z:L4VMM9N +=2"'"#(24D22224I))))2DDDDE*0/\ M-\_^_(Z!_VF^?\
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M 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M!    !XX0DE-!!D       0    >.$))30/S       )           ! #A"
M24T$"@       0  .$))32<0       *  $          CA"24T#]
M$@ U     0 M    !@       3A"24T#]P      '   ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #30    8              ^@   ,%
M    # !P '( ;P!X 'D 7P!0 &$ 9P!E %\ ,0    $
M         0             #!0   ^@                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   ^@     4F=H=&QO;F<   ,%    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   /H     %)G:'1L;VYG   #!0    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M224I))))2DDDDE*22224B9C4,<'-8 6S!^,S_P!4B)TDE+0/!*!,QJG224M
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, ,@    $ .$))300&
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M# P,# P,# P,_\  "P@#Z ,% 0$1 /_=  0 8?_$ -(    ' 0$! 0$
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MOI%_Y,U'5O+GUJ2Y6>35K*[LX/\ 2Y$0K';TNQLBNYH35=AG+O,/YM>>+?\
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M\DNY(85,,4@2)*_$ZU+?&$4D/YZ^;=5T:&^T7S5Y>T>2%;/2=,36+-))M?\
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MJID6-U9U+(&+*)!I_P":4MY^0VI?G+?^28-,U?3M(U;5+GR@\WK&.XTZ>8-
M]PEOS+-);@L5B)Y= Q K%[7SEYUU'5/*\7_*N?)KP>=M6G\O7EU>?IC3[E$M
M;"ZU"7G;ZEHEO)*ABB=5VXEFI7[62[S5^;'Y;>2-<UJ#4_+=_P"KHD::??>8
M++25F@:[2U&JQ:3'*O[QYOJY$ZJ%]/L']3X<VM?FH]MH'E_4_(OE2&YUKS1>
MZO:R:3K<ITKZN^@)=MJ,=R]O#=GU4DM7B4*K*6/+GQ^USCRU_P Y Z7YMO=(
M?3ORVC2PO+JVC_+*6[1K>[G:74ETW49(!+:K H@5GE8P3O\ " K\>0.2"T_-
M&^TS3/*WFI?RLTSRW;7^N7GECS<[72?6=)BM==DTI TUE:2P>FG![B5Y98X%
M(]-)'=U)BNI_F5?3W/D'48?RHT=K?S/JL&H>1X!J\L$T5W?O]0T[6-8M;>T,
M26TD<ZJK,99!*5X1DKS2?:1^;GF_5M0T4Q?EW9:C)?VVK6KZ?INK+)JB7FD-
M<174@6XMX(4L9+NU^KQRRS(S.R$QC< 'Y@_-W2M+_+_\H/.>L>08IM+_ ##2
MSN_,%N@2ZAT6UM](N=9DDH(@]PT MV2$)&"6/(<>AFGE/\SO*7F+7]8T2P\J
M:OI.OQV<U]YSM[O3HHI;5K9A"D-X89)#-+(A#1"+U0R?M#ID$TW_ )R2\A^8
M+KRFMGY<U&XT#6DN(WOG@@DETJ>*]TW3XDO+:)Y# LCZE&""PE0[-$*/P=;?
M\Y+?E&JZU=1Z;J-O_A6/4;S7)TLK=Q9PV45O.TS/#,XK.VI(B*I,GJ2,LBH>
M=!?DS\Y/R>\X^<=&T_1O+<FG^:/-5M>2IJ=_IMK9R/)!)/!<V_UAW#7+UMFY
M&W,J<2A9Z.M2+4?^<F?RTM] N1YX\KZA;26>J36=GH#6,=XMY'9W>I0QW=F)
M"BNB#29GW"L"H"!^49<^\M_GWH'F'S3HWE[1_*]W)<:IYFOM O-;2)DL[6-8
M=2O;=Y)7C1_6N8K 2F+C1>8YOSHK&>G?F3^6UQYFL/(7^&"+A-7O+2UN8-,0
MZ9:7AN]5M$#2$+PEN#I=SNJ$?S, ZDG*?FIY'U[S'Y^\C1Z<]YKWE#2)[O5;
M"[AA,%W:0NT4B*5>4A1)\)69$)#!E5D/+.%>7/S[TCS)!I#><?RPT:?RY=:,
MNN6NL6 DN+2&0VBRM8J-5L+&,SQKZ8=E?TU1E+.@%,ZAY9_-/\H?S%U+1M(T
M[RI)?Q^<A'?+J-YI$)LFOI+:\E6&XE/(&X]&PN-P&6B4YT>/F,\Y?G+HOD;S
M!YB\L2>6KBXNM+MO+0LWMK2[DMITUR^EL5CGN+>TE@ME@X$@2N P/[(WPOT7
M\^/RBU/6M2MK33IK77K>^M]'):QMS-=7 DMDLK>*6%Y SM]:#)$S!T59"Z)Z
M;4,/+/YX?E5YWLO.GF_1[*ZNXO(=M%)JNKR:<#++IK22R17-M(.1>&MN\G$D
M.H7FT:\DY%\WYY?E*E[>W9T*]EL;6:72F\W)I2-92W5NDMTEE'<5YN9+</<1
MGCZ91OM\W"F30>>_RZU:_P#/EDOEM[F+RW93ZMYTU.33X3;R'3+V]L KLQ+3
M2B339C'\)HJ@U6JC(\O_ #D+Y#NY8$'ECS)-K$B1$Z3)IB+>1O++8C3HW$DH
M4-=/J5N8?BHO(F0Q\'X[2_SA_**^M[S3(O+]QIUKI]O;ZAKNGW6D+!#96]SJ
M*6@N+D$>FJK?"5'(J0]O._V8^9DMU^97DJX/D62+RUJ>N/YBMGU/0?JVF+,]
MAIJ306QU&0.0T4),\1'IUD*MR"<5;C!8O^<A?RDU&W)C\NZC?G0]1N UG#IU
MM=-:7-G#:2Q3KZ,TB!I?K]O%%P;U [\'5"&XF;_FOY.T[R78^?M=\GR:'!>>
M:M=TUM,6R$NIK>:;+J$#RB.)*_69AI]31N] [?"2CJ/YC^1O)7Y=>2GL_)&I
M7WDS4]2U31]1\OS0?6;^P;1K?4KN_>YAG>7UWBGTZ7U6:4EFJX>1BO-U[^?7
MY6QZAK_EF+0-1UG4M->"V_0MCI]O</?KJ'K0UBC$M%4BV97$_IGCQ:AC(;!^
MA_FSY,\YZ_8^6]!\HW>K>78]%U+7;#69=/"6LTNE/IQ,%A#(M7D5K\!JA.+K
M1>6Y6%P?\Y$_E5Y<73M)_+K2]3\W7OF/S*_Z2TW3XYIKMGU"%+^XON=R3ZB^
MI<+ "SA%D5X0RB%@IU%_SDQ^4.HWT^A:98ZKK<MM;V<>G06>F>HET^I/8P+9
MP!F7@]=1@5Q*(U^W1F].3C*KS\S/RK&E>7M9U#3 ;7\QK2WU/3UGTY&ENW@N
M+2V2.9""6FMVND/$UXHKNIXH3C-/_P"<A/(M];W<\UIK>DO:::VLFTO['TI9
M--(M&@NT4.P*3K>(4!(<4975&4KG<\V;-FS9LV;-G__2^_F;-FS9LV;-FS9L
MV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV0GSOYA\D^4[73/,GG
M:[M]/MM'NWFTS49XY)3;S-;31RRJ(E<J%MWEYN1Q5.18@;YS3S7YR_YQ[UIM
M;A\V:II&M&PN/J.HPSQSW8:61X7>*W5$<3!'TU&E]#D(S"3)Q*MC9?S%_P"<
M>+C3]?\ */\ B31[S3]:N)='U?0+<SS+=O?-=O,(88E8R([I<EY804!63DP*
M&C;7S/\ D=Y-\K^:?-FCS/J6C?EEJ,]YK%W;_7]4EM;X))ILS6SSM(9" 9(6
M])BH/,'<'([=>=?^<9-?NM>\^>8ETFVUBQN9=$UR?4H)!<\X)KJS5S H;F2M
MA,/552ZQ1NCLBHZKT+S/#^2.L6&G>5/,\VA3Z?JE_#JFDV$LXC2XN]>:^GCF
M@D1UY_7>-V3Q:DB^H#520>:6_P"9'_.+.CZW;^<M#N=%N=3N]2BCDUS38GD^
MK/<6=_(MU&@ _=2+#<1N]NC RDA_B#%9CYM_Y4%<7EG8:]::)J^I0:7?^:]/
MLEK)')8WDDVH3W4DJGT!%<30R3(9GX-(AD3XDJ(=H5]_SB[YZ\PRVEI!9Q>9
M_,CRZ#)H]U]=LI+@Z$\UA!&(2R1!HQI[M:D4>D9DBW5B#VVOO^<;?R_\Q:EK
M-I<Z?Y;\P^5HK32+XPM?(WIJL]I;1) M4N:&.5 41Z2<ZGU"</H/-'Y*>9-0
MT[\K["'3?,EGH.@WVH6]A;PBZT^TT^WM+>REB!')7]2UU4)Q0/\  S!J$J#S
M_P B?FO_ ,X^:3Y2LM<\J:4-)N-:TFVNI/+;P\M4EM-0N$D1+EI9&224B\6=
MXVE:01.'(XTPW\HZM_SC/.+'3]*@T33-2UVWM+QM,O5(N&:X2QOTMY9I"Z/)
M (;7E&)&](+$M%7@"%EN?^<8_*'EOZ]I&B:5J>@^;?J7EZ7]#VSZ@MQ#KMG'
M>6D+E>=(I;:"%D->*(L0'%0M%?+OF_\ YQDE3R!YLL[[2;._N62V\K3W[S/<
MPW,J1L&N#(T@$@&I(JSRD_WX"2$3#D?>8O\ H7Z'6(_*_FBWT;3-7&I+9Z="
M[M%-ZX9;DE9H&#0J9=;*MS90QN.#5$H#1NP\[_\ .,9\YZ%KNF6]D=?FM9-7
MT'S/;Z==B!S>7IL5:&18^+RSRZFRQ$*2R2MP/!MYM=>9?R%T/4-/U":^T2VU
M/5[N+5+":-'DFEFDN=1*W=(U9@JS37A:0@(A=N1'(9#O*/GW_G&^:\F\UZ5'
MI^@:G^88>*XN+V"2WNKE-2G4W'KP-5K>*2X92[NJ1M(X;D6DJQY?^;_^<<O.
M.F:'Y>O-3T77+"*<:%Y=TM(YGDB98XG'U98T]1$14C(G6B(5'QAEP'<>8_\
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M>2ZM(Y?WXJTC,5:E,A$GYY^6/+3_ /.1,J_E=Y)T?3H-46"PO-/M+G0Y]?\
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M2K&&C$C3RE@I%2[D_::JFE>2?)FA2V4^B>4M%T>?3%N$TV:QL+>W>W6[$*W
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MEKB6?F&\/E.'S%JZ/86K6[:E<V,=^6:^BEM+=N$[&LL95*].F!/)^L^;]?\
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M7D&^CO\ 5KW0[.SM]7N+?2;[5X;8R/(;FUN9(+O2+I;7C]7X-=5;D@0>TO\
MG';6M/\ ,_EJU/FR^\L>:M0L]6U71_RN\XVFE6FEG7=$L(8%NKO3[9*K]72X
MFGA#V](Y(E23I)5H_P#\Y6>=?./Y>Z9Y=7\J_+/E;4-;LK+7_.OF"/S!9B2V
M33/*^EB%98C&I87,=Q>6GH@4+JAB#(&Y*5_\X\?GGYO_ #3_ #0U?RYYJL4N
M="T;R=INH^3?,<NBSZ?^DM0LY&T[7=3LKF5?3EAN+F7B@A-$C"UKZIH[S!^8
M?F:^_P"<@K[\J_+UOY9.@Z.GZ+U?R+?Z8K_6-*3R]-JZZUJ%T%=K>RBU"XM;
M.!53@[_6=V<?!'_*?F_\R-6\J_\ .-TEAKNE^2?,WF/1M4\Y^=M+T?RU;-86
MWE%+J&\GDAA837$#2Q36]O%'&2\CR&5^1B(//M9_YR>_-"/RIK=SH/YB:!K2
MZSYAUF/\O?/-CHHEM]3&G:%9W]GHNEVZSRI/<7]_?1VZ1LSS1)%<K)66.L?T
MUL6O'LK-M0CCBOV@C-]%"2T:S%1ZBH3N5#5H3VP5FS9LV;-FS9LV;-FS9LV;
M-FS9LV;-FS9SC\QOS'M?R\M=*D?0[[S'J&LRW2V6E6$EK#(8K&TEOKJ5I+R:
MWB CAA8TY\F- !2I$)TK\_M%US3_ #CJ6F^6=62T\MZ#JGF#1KN[-O'%J]MI
M,LL$Y@$<LLL7[V, >M&I(:H&QSET_P#SD1YZTCS$OE?5]$T6\DT&33;_ ,Y^
M:-/CG&F1Z3JATT1^FLERTZ21'4/B95GKQ1O259&,1GJWYH><_,-G8R7'Y<Z)
M?FX\O6?G3\O(+J]4R27\FK0VMBTT5Q):PH88;N&4 W%7EJ%,9"5&'\[/.^I:
M???H"+R\-1\N00VFNG5;:[AEN?,3W-_;G0[&QMKJXY3%K-%YK<2*HD]5?504
MPLL_ST_,C4=(EOEL?*FD7FI:3!K^B:?<B]NI85GNKRRBT5XX) ;N]FGMD17B
M]-03)2)_3 ?JNG_F3YO,OYKQZYY0M--N/(6AV.LZ-I-M?_69[OZU97$[Q7$K
M1Q11L)K=HQQY"E&+;T6 ^7O^<F&N-(\NIKWD75&\R:VEG8016#V"VUWK4DVG
MVU[9P"2^=XDMY=2C_>3$*RJQ4M\ >0?F+^?]MY+UWS!Y2M?+-]=>8-)L[.ZT
MJ2Y,,-KJLD\L'J6MDSS(994BE+$;<2*M1/BPGUC_ )RJ\IZ)/9V=WY5UQ]0N
MK>]$FF0R:?)/#J-B;P/82A;LJCL;&4([,(VV(8J20 UO_G)CR='J>JK=?EOY
MHU6[\AZG/#8ZG%8));+?6TCZ5J30W)?BOU8S21NW[2<V7X*G)AYA_/O3/+FO
MZ8;G2)]0\AZEY9TSS#+YOL'MYTM$U.>>*!I5$]98Y!&O$VZR=2WV:'(/:_\
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M.8TY =>(\,%%%8U*@FE*D=O#,J*M JA0HHH I0> S<%J6XCDPHS4W('8Y@B
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MY#TRTMO*Z^1++R#J\XN;:V4:/JFI7<6O6J0,0U%L)D=0%XL5"@U%,@'Y??\
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M-FS9LV;-FS9LV;-FS9LV;-FS9LV!+BPL;N>PNKJTAN+C2YFN--GD0,T$KQ/
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M+R^FJ33:P);JZO+'5+JR@2Q,,]IIDUD[RR/+$3!63BK4C;H7YC_\Y%7/Y?\
MYQZ%^6LGE[3;O2-0M_+#WNK7&HW%O?&7S3K%UH\"VELMC+;.+=K;U93-=0U0
MTC#. "IK7_.1T6C_ )!6GYSR>7;;])ZK=-I^B>4;C4DMH[F\_2$MFL/UZ6(*
ME4A>6I38 CWQ'6O^<@];_P ->?/S&\F>3;#S1^6GD+2+G4+S6I=6^IWERT/E
MY-?CEA@-M)&;<K/# S>KZ@9F81E4^+J/Y3?F2GYL^7[GSMI%E##Y)U&Z>+R3
MJJW!DGU&VMB8;BZE@X+]74W*2)&A8N44.X1FX+P6/_G*?6]"M/)U_P#F#Y%T
MW1]/\U_F3YB\@W.H:/J\]_#IMOH#7UJVJW1GL+0B-[RSX,H%(XG$K-\+)DB_
M)O\ YR6/YR^:[_RCI'EFUT_4?*S?6//BRZB7;3[*YM(9=/,*?5U,\MS+*P*B
MBQQH7=^3QH\C\[_\Y Z?Y/\ S7L?RL@T+]/ZG>^6KS5XHK2]A6^EU-(+N[T_
M2X+-P#(UW!IMV0_(!&6-2#Z@(.?R8_-J[_-'0-?U._T[2=/OM NDMKFSTK4)
MKMHV>VCN&AN[>\M+&\LYXF<H\4\"DT#J2K;<-_+'_G*?SK^:GE_RSJ/EGRAY
M*U#6?.SP1:'HUIYEU&1;"1M,N=5GCUB670X?19(X%B7T!,#(^Y"KR/0?*7_.
M2EMYQ_*#\U_S<T[RK);V?Y<:0VJVFCW%T!)>!?+%CYB,4DBQD1$->&"H#CX>
M?[7$'7YF_G9JWD:.*XT?RC!K]MI'E&Z\]^=I+B_:S-KH]E) LL=F!;S">Y=9
M)71',:'TJ%QS!'.KS_G+BTG\O>7I_*_E)O,/FV]YGSEY=CEN#_AR!'$9O;U(
M+6:ZD@7ES;T8'<("2HH:>@?RX_,)?/7EKRKK4EE;";S):7UR+O0[K]+Z.OU&
MY%LW#4HXXD_>DAHTD1)*!U9%>-U'2LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;
M-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS__U/OYFS9RO7/R<\F:Z/,$
MDT=_8:AYA\R67FV?6+"\FM[NWUC3[.VT^WN;613^[I;VJ1LH'%U+AE(=JR"Q
M_+[RKIWD-_RVM=.8>4I=+N-(N+!Y9'DEM[M'2X,DS,9&>7U&9W+<F9BQ-3D"
MM_\ G'C\M+/_  A'9V6I6UCY.TK2-&M]*34;DVM_::#<F]TQ=3B9R+MK>Y9I
M@\E69V;F6#$89ZQ^27DG5XKM0=3TJZNO. \]C4]/O9(+F+6Q:"Q]>-_B"J8!
MP*4X[DTKDSTWRS<:;J>E7H\R:K?6NF:/)I3Z?>3>JMU(\L4BWD[;<IE$90-0
M;,WMD8\R_DYY(\V2><YM5M;P3^?8]*B\Q7%M=S02.NBM(UD8FC8&(H96J5H3
MWPA;_G'+\F_TK'J<'DFRL85TZ32Y]!LU^K:9/;S65WITHGLHN,4C/:WLD3,P
MJ5X@_96@KR?^0WY?^1KSR]J>@1:JFJ^6[G4KBUU:ZU*ZN;FX75H88;R&\EE=
MFN(G^KPR<9*TDC23[8K@3S-_SCS^77F_S+K?F;7DU>ZD\Q30WFL:(FI7$6FS
MWEM8?HV"[>UC95:6*W "$[*P#TY@-@>X_P"<=_)=[HNBZ%?ZWYIO;?R]#-9:
M->/K$\=W!IUU:+976GK/#Z;&WGA10Z-4\E5P0ZA@HW_..?Y9<[V.*TU2VTBZ
MNQ?VWEB#4[N/2K.Z-[;:A)/:V2R"*)I+BTC=J"@^,(%$DG)*X_YQO_+::6Y$
M?Z<LM*U"_>_U/RS:ZO>1:5<\[_\ 2?U>2S63TQ MVSRB- H!DD7[#%<//S"_
M)'R1^9NJP:MYG.K"0:1-H&IVFGZC<6,&H:3<SQ7,]C>+ RF2*1X5Y $<EJI/
M%B"57/\ SC]Y-N;36]-&L>9+;2-;UYO,_P"B(-4D2WM-7;5TUSZY:+QK$PO4
M]0"I45*\>)IB]]^0?D?5]1MM3URZUS7+E;:TM=86\U.<Q:LNG7,]WI[:E%&4
M2=K26X=HF(!'P@\@JT./RU_)?\NORC-^?(.A?H,:GI>BZ/>HLTDHDMO+]LUI
M8<O49JNL3D._VG/Q.2V^ $_(OR*=<UG7KT:EJUQKOFF/SC>65_>//:#58].D
MTD.D!'$1FRD$+1[H55:BHKBI_)#R)%^6GE7\I]/AU#2/*?DB32YO*GU.]E2[
MLI-&G2YL72Y8LY,4D:GXJUI0UPKT3_G'WR/Y:U+3M6\OZAYATJ^M+0V6I3)J
ML\S:K&^HW6K3-J37'JM</-=WL\DC$U;F1]F@!;9_\XS?EKIUC8VFG2Z_97.D
MW^FWVAZTNK7,E]8KHUK=6.G6MO-*7(M[:"]G1(R"/C8FK;YT7S'^7.B>:_+.
MD>6M:OM5N#H%U9ZAH_F*.\>+58+ZP:L-TMU'Q/J=0U1Q=6964JQ&0^P_YQY_
M*_2S926&DW=M=Z=J&BZK8:BE]<?68KW0A.EO<+,7Y%Y4NITN"2?76619.0<X
M9>;?R2\D^=O-D7F_7CJKWGH:3;:EI=MJ$]MI^H1:'>3ZAIR7MM$RB98;FX>0
M*3Q8T#AE%,)]*_YQV_+K3AH]I=IJ?F3R_P"7KV[U'0?*&NW9U#2;6ZO/K'J3
M):3*59E%U*$Y\N'+X:&E"R+_ )Q=_*>WTW5-"MK76;;RYK5I=VNH^6(=7O8]
M.E:[L'TIIS;)($,D=DX@C-**J1D+S16'6/+'D;R_Y/OO-%_H$,UF?-]^FJZQ
M9>L[6OUT0I!)/# 3PB>81JTI0#F]7:KLQ/.(/^<<_P MAI+:'J<&I^8=,?4O
M,6JM;:K?2W ,_FNWN;;6%/V:I<+>3-Q.RLY*TVPQ\H_D)^7/D:[\N:AY8L+W
M3K[RO->2Z==_7KAW>._L[>RN;>X+.?6AD2T@<H]1ZL:2#XUKBOF/\AORN\V7
MVN:MK_EJ*^UOS!J5IJE]Y@YM'J*264,-M%%;WB%9H(?2AXF.-E4\I#U=B3WR
M3^67E[R(NO2:==ZMJ^H^9C;_ *;UO6[^;4+V>.S@%M;1&:9B0L48( '4EF:K
M,22N]_)GR9<^3O(ODJU;5-%T_P#+6.VB\DZGI=_/:ZC8K:V4FG*$NT;FP>UE
M>)PU0P:I^( @AM_^<=OR]L;/S1H^F/K.E>5O.6F-I/F+R?::C*FF3V[:/%H7
M]T>3*XLX(U#*X/)0_P!JI.OO^<>O).KQZ>FN:MYEUMK"UGTR2:ZU:</=Z3=&
MW:?2[LQ>GZUJ[6L;%&WKRHU'<$&?^<8?RABU*37-+T2\T#7VEU6XB\P:5?W-
MK>Q7&LZO'K=U,DR/7E];B'$&JK'6'CZ1*9TKRE^7^B>2K/2M/T.ZU-;73/TE
M))'<WLUQ]<NM7NQ?7EW>&1B9IWGY.';[/-PM%-,G&;-FS9LV;-FS9LV;-FS9
MLV;-FS9LV;-FS9LV;-FS9Y;_ #[_ #P\P_E9YP_+WRMH]C:-!^8.F:Q$?,%_
M;S2V.BWT-_HME9ZCJ<L3H(K*'](OZM:<W,2"2(,SCD5_^>?YY6WE[\T_,,-S
M82Q>7O/"^2/*<:^4YI(.0\W6GEXW/UD:VAO9C#+(X@$< ]3;U*+\1OHWYR?G
MO<?FW:>04M8-?BT9?*A\S6 \G:A8-):ZW-<_I*^N-3&J7-GIC6<$0DCMY#,\
MQ%%^W\'7/S0\P?FUIGYK_E/Y7\F^;_+NB^6OS DU"VU"VU/R_/J5W ^E6<E]
M))'<1ZI:+295$84Q?!]JK?9SS@G_ #E5^:_F#\M?,/F+1],TORQK^C?EIY<\
MY076JZ3/<6EQ>ZEK-Y8W7HPI?Q,]LT-NOIGU%96/(\A\.=[B_,O\Q=)_./1_
M)OF6\TI/*5_?0:%8:K!I,SV^J7HT;Z[/QU"VOKD:?>?65?C9W< 5H "D[NPS
MG'YD_P#.0/YM>5/S4_,W2/+.C6OF'RK^6-IIE[J6@G0;_B]A<:7+J%]>W'F4
M72V5JUOPJENT+22#91\7)>=?F#_SE+^<7Y>>:+GR5J5UH6I7FEZ'+KTOFO2_
M+UU=:?,]S;:;)8VEVGZ35;.V2XNI(Y;QY^"H\+MPHY;M<?G'\_CYO_.+2[SS
M?Y1TZS\@>3;'S+I^D+Y;N;B6.ZUFWU1X;6:\&L(LR6<E@O)UB3U@3M%L<B4O
MY^?FWIGDC1O-]W=^6]4?0/)_D;S/YSTR'2KB"759/.^H3VOHV(^ORFT6SC12
MK,)O5<,#P'3HO_.,'Y[^8_SITAE\VZ98:)YJT'RMY:OO-^D6(DX1:GK(O;CU
M83([$VUS9QVUQ!6I"R$%F(VY5Y"_/;\Z_.%E#?7&HZ9I0\T><'\I: ]_Y0O+
M+3K0?I2_A%U;:E)J[)J;+:Z<R\$CB!ED0UXC@2C\M_\ G*;\U?./YIZ1Y(O=
M.TM>7F2'RU>6\>DW-OI]['9VMP^K7MKK$UYZ<4X^K-<P69CD=H3Q!:C3+W?\
MV?S5_,;R'YZL?*6D:/8:GI_G329M9\L:ZT;$:5!Y=7ZQYB2^B$H,S26[PBSX
M<:RR%9*(E6Y)!_SD9^;&E>9=)\MZVGEK6!K?D"7S]'K6FV5Q%;0?6=$OK^VT
MT5NYA)Z4]@[>KR!EB8? A4LPK\G?^<D/S&_,#\V-+\FZC;:>NG7LD[7]G^BI
M[&%=/M_+VFZC)=V&J37CI=SQWVH1PRVR0LR1RK(Q4(6<%^9W_.3/YD>4/S4_
M,WRAHEII]Q8^3EO&TFSO])N([6XMK+R='YAN9AK'UQ(WNH)Y%)M$A+O >0X@
M-*DR\I?F1^=?F"U\MZ#=^8- T3S1JWEO4O.=QK>N^6IM,M39V7Z-BCLULEUF
MY;TC)>NTMUZU54*HBJ>6<^\V?\Y-?FKH.F:!K=O#I&HV'YCW4A\MV6C:1<ZG
M?Z1;V/G#3?+TT1BCO!^D)Y[;40Z*HB*SHR\74T4)Y7_YR;_.+4X;WS?<R^3;
MOR9H9\HQ#39;2?3[G5[3S=K-[IEIJ?US](72:<Z1Q0S2VLD4QC_>H[JRT7TA
M^0OYA^=_.7^)])_,0VMIYIT&#2KN[T--*GTR>T74HIB:2?6KZTO;9I;>06]S
M;3L'"LKJK+5O1&;-G__5^_F;"CS!-KEOH.M3^6+*TU+S'#8W#Z!IU_.]M:SW
MBQL8(IYT25HXVDH&948@;A3TSRE_B_\ YSJ_\LE^4?\ X7&J_P#>"SL'Y9:Q
M^>^I:=YDD_-SR1Y0\J:I;"/_  K;>6]<N]6ANB4D,GUJ2XL+,PT<(!Q5Z@D]
MM^/CS?\ \YU4%?R2_*.O?_G>-5_[P6=7_*G6O^<@M4O]7C_.;R%Y,\GZ;%;Q
MMHEQY7U^\UB6:<L1(LR7.GV0C4+0@@M4]LYC>>;?^<WTO+M+#\E_RGGL4GD6
MRGF\ZZI'(\(8B-G0:&P5BM"0":')[^6&O?\ .2VI^8I[?\WORY\B>4_*ZV,C
MV^I^6O,E]JUXUX'C$<36]SIEF@C*%R6YU! '$UVB?F3S1_SF7;^8-;M_*OY0
M_E?JGEF&^G3R_J6H^<-2M;N>R60B"6X@CT658Y&2A95=@#L&/7#W\O/,7_.5
M.H>:["U_-#\L/R\\M>3)(YSJ.L>7_-%_J=_&ZQ,81':SZ5:HP:3B&)D%!4[T
MI@+SMYE_YRXLO-6L6OY??E5^6^O>3894&A:OK7FS4=/OYXS&A=I[:'2+A(R'
M+  2-L >],2\G>9O^<O;SS/HMMYZ_*?\M-$\H37''7]6TCS;J-]?00<3\<%M
M+H]NDC<J"AD7YX:_F-YA_P"<I-.\T7-K^5GY9_E]YG\GK!"UKJWF'S/?Z7?-
M,RUF5K:WTN[0*K;*1)N/#(UH?FK_ )S1GUO1X?,7Y/?E9I_E^:^MTUV_LO.6
MIW%S!9M(HN)8(7T6-9)$CJ54NH8T!8=<FWYI:[_SDAI>NV4'Y._EYY&\V^7'
ML5>_U#S/YBO=(NH[TR2!HHX;;3;Q6C$80ABX-21QVJ><P>;O^<Y&GA6X_)7\
MI8[<R*)Y$\[:JS*A(Y%5.A $@=!7.K?FOK/Y^Z5<Z*OY+^1?)WG"TFBG.OR^
M:=>N]&>"12GHB!;;3[T2!@6Y%BM*#K7.2'S?_P YU4-/R2_*.O;_ )WC5?\
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MZYY\NXX3YWT/6->N['3;)VM^4PLKR'3[B2<+-\*EXDJOQ;';.3_XO_YSJ_\
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M;S9QW_G(;1]8\P?D3^;^A>7K&YU/7-8\HZO9Z5IUF"UQ//-:2(D42KN68F@
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MK]=5 [2:E+:-"ESQ!9R0*D4SCFA_E?YEM_RN_*;0--_+?S%I?F.S_+?1=/\
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M-P_.'_?FE?\ "?\ -.;A^</^_-*_X3_FG-P_.'_?FE?\)_S3FX?G#_OS2O\
MA/\ FG-P_.'_ 'YI7_"?\TYN'YP_[\TK_A/^:<W#\X?]^:5_PG_-.;A^</\
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MT$L+/&]#W5B,[[G)?/?_ "F/Y=_\QI_Y.0YUK-FS_]#[^9L(_,__ "CFO_\
M;.N?^3383?EU_P H7H/_ !A?_DZ^37.(_F5^5L'FW\POR0\_V6EVDVN_EMYF
MN+F[U>X=A-;Z1=Z/J5I<16P-5Y2W$]N6H 2J[FBTSKFFW.H7*WAU'31IK0WD
M\-HHF6?UK=&I%.2H'#U!OP.Z]*YS3\ZO+'F#S5Y2TZT\M17,^IZ9YAT?5C%9
M7<5C=&&QO(YIOJ]Q.&C1^"FG(4/3(?YG\B?F'K=KK>H:!?2^6M?U3\N[;R_8
MWMU>+)?0:C'=23R+)<0J5Y,C<?60;,>0&V1SR;^6_P"9VD:KY&DUUK[6]-TU
M76%[GS+=12Z+&=0U">6.XAMU]+4/5LY[:!%<N(S%Q]0@"5A_DG\I?,/EWR)^
M7?E>&Q?1+_\ +SSBMX)XM8N9X[S3?K,K3S!B]66:&6GHS#8]AL<C<7Y/?FCJ
M@GLO,.LWJ:<U_+-J@@\QZ@&U*[73]:B&HJT3Q-;1RSW=C2U1@B&#EQ^%2W</
M,6@><-1_*NQT**Y>Z\UQ6>CC7%2^DLWOQ:RV\FIVR7T5'B:ZBCEB$@I0O6HZ
MB'^1_P KM?T[SAY$\Y^:93>:OY>\F:EH-W<'4;FY:)KO48;FUMVYLJW/HP!H
MVFD7D[*&.]"&?FQY \W>;O-=K^@]/LYM(UCR_P#H;4M:NKD1'3)(]5L[];E(
M>#O*ZI QBXTI(%Y,H^(-7\JO,-QK,5K>ZGJ$?E-O/&KZ]<VEKK=_!*UA>:<!
M;Q^I%,DG%+^LHB#\5V(%-L@5W^5WYR'7OS%U"XUN]UW1M<U6.X&A+KDME'J6
MF#57N4L[5H@)+)XK%A 6#HKE>#51C(I[+^5_GBVU7S-J^C69T_S%YN_+/2/+
MS^8SK]W<-9:II1N_4MVDF DD]=9XU2[5/4!5Y& <_&=>2ORT\WPZMI.I^9[W
M4;>RT?3+X^7M"7S!?S"PN+C4[F:T@N)%DI=&"SD2(O*)!U4<E4$G7Y ^4?/W
MDORSK&D^?+M[V=]3$VDSW5]+J%ZT7U:!)GN9WD>-B\Z.P,21!@>;0QR,XSNV
M;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS
M9LV;-FS9LV;-FS9LV;-FS9LV<E\]_P#*8_EW_P QI_Y.0YUK-FS_T?OYFPC\
MS_\ *.:__P!LZY_Y--A-^77_ "A>@_\ &%_^3KY-<V;-FS9LV;-FS9LV;-FS
M9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;
M-FS9LV;-FS9LV;-FS9LV;-FSDOGO_E,?R[_YC3_R<ASK6;-G_]+[^9L(_,__
M "CFO_\ ;.N?^3383?EU_P H7H/_ !A?_DZ^37-FSRK_ ,Y9:9^:&H^5ORYG
M_*(ZA_BS0?/$&MB"R]7T;F#3=(U6Y-E?&*E+>\D2.V8M\(:1.],\N:9^87_.
M76A^1M$T7R_HFM0:KI?D[RU90Z+?^5;J[DLK=]*T8MK$FISU6\OFO;BZMY[/
M=HUC,C(GIF23J'D;S3_SD=K]A^4'FSSOI-ZFN1-YUMO,>C#0)+)(I(M.N+C2
M;PH:R1%FXVRJQ*25!IZF^1RT_,[_ )S!LE\C6-]H\^HR7^L:>VKZS)Y8N8A,
M;[2?+U\=,GAM;><6T$4U]J,3W+&/@UN%>575ED3N/S:_YRX_Y5MYSUJ;0;NR
M\U:;YKT^VM-.MO*U_/<102I>F\L+2,V3+<0QRQVJI=*DL9$CAKA0?6A^C&GS
MW%S86-S=VSV5U<6\4ES9R<><,CH"T;<'D6JDT/%F'@3UP9FS9LV;-FS9LV;-
MFS9LV;-FS9LV;/E9IE]_SDS^6?Y?ZMY@L$\RG6O/'G_S]/)?OHVN>:]4@M],
MO-5;RQI\VFW=U<1VMMJ#K'&+BV@AB6#TN3*7$Z^Z/R0U'\T=9TGSAJWYIGZG
MJ,WFK5;7R]Y>%BMHNGZ79SM;VZK)5FN1+P,BS$T92O&H^)NUYX,_YR2UW\][
M?\X?R_US\L_*OFC5_(WY-QZ?KOG6#2+B2W@ULZWJ L;RR-IP/Z2-IIL,\PCC
MJ8I9(G(K09Y_M?\ G)#_ )REO=%_,JRL(]<USSIY>MO+5U'8V'DUT.D:QJ%G
MK]S?:/);QVU[-<VAN+&UMHKE5(8.KF>-7,N=5F\\_P#.4FDWMKJ&A:'=Z5H=
MMKM-4\M/Y:NKN&Z&N>;]>LI[R695ENEBLK&*UNV6#=E8-LKK69?\XZ^8OSW\
MP_F!Y:UC\T]7\U)I&M_EW<B?0;_038:4^N:?KMQ;37:.+&T>V]:V]*6WCNDB
MF>%_B0E&IZ+_ #]UGSIHOY0^=I?RYTB\UKS]JEDNC>3K.Q#^JFHZK*EC!<LZ
MJWI1VS3>O)(WPHB%FV&?._1M9_YR8\F:K^5]F='\\)YP\@VNM^2+E]2T>Z\T
MV_F*U/FC1)M,_2&L11B&,2:-,[27O-?WD$OQAE*-,M+_ ##_ .<H%6P\XZ]?
M>=[M[?RYYXTUM$TORC)'I]]JUK?:5^CM0MK:?3$NX81:S3R0"\@,K?5Y8T$[
M.!*86OG;_G*[5]"M-1L--U+RSYLU71[3]+^8V\KS2RSC3+7SO<1J;.[BB2)[
MF2PTQ3^Y0J;E1P4R(@^@7D'5M:U_R+Y*UWS)IDFB^8=:T'3;_7M&E1HY+2]N
M;6.6XMW1P&4QR,RD$ BF^2W-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-F
MS9LV;-FS9LV;-G)?/?\ RF/Y=_\ ,:?^3D.=:S9L_]/[^9L(_,__ "CFO_\
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M*\P>I^2UIY-@TJ!=3\QZAJ12*VMXHXEAMYF$:D-%ZKSSRSEPS,"K,<E?FO\
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MRM&F:;IE]IOEO3=2YZ7I^J^80NJ-(=.2Y_2K7$;P6UO-<R&)=,W].)F4/S=
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M_G(3\Q]4_*/\E_S#_,71+&VU+6O+.EF;1[2\+"V:ZFD2W@:;A1BB/*&8*02
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M;O.6B>2-+@U;7/KK07=Y!86=MI]E<ZA=37-P2(XXK:TCEE<FA.R[ 8O9>;-
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MRGYUE\VP7,%DD8'JZC<7;)$%H4<Q3"(L.H'AMG)/,O\ SCWJ*>2=6\O7NO\
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MI,VE7^M7'DO58+!;:NA-'+%<RWUXK:9&]MZ,'.2.DFK0*&*GD YX[('&Z?\
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MM>:!?>85T#R\8[?RVNK+HHU5_KT4Q\OIK;75RJQ.J6(>MN9E+$,5._3)4O\
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M?:Z-,U0Z)I]BMSK%XAU'E*9A<1@A'T^YK]9:-^C\2LJLTTT[S=^6WYB><OS
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M\A^9(?/GG>ZDL?+/F Z/K_F2:[0V\$MBMU>_45A=)Q#!$NISDK.G)6I(K )
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M "N_\M_^KIJ?_<"UC_LBS?\ *[_RW_ZNFI_]P+6/^R+-_P KO_+?_JZ:G_W
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MFS9LY+YP_P#)I_DY\_,/_4"F=:S9LV;-FS9LV;-FS9R7SW_RF/Y=_P#,:?\
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M#2[C6/+&HM!<7=G:7%S:7/J6<R7,+03VDD4Z.'C%.# G[/0D9\L_+7_./_\
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MJ_F%Y-\S_E?YVTBXT>.7RUJ?GKS%<^K%Y@"?HV6.XM]0,9]21C"ZFACD5J_
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MLS1L !\R<YQY#\Y>7;#RU8:9J6HQZ;?:;SAN(+BJ&O-FJ-O>GB#DQ_QUY/\
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M^S-_CKR?_P!3#9_\'_9F_P =>3_^IAL_^#_LS?XZ\G_]3#9_\'_9F_QUY/\
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M )::!/H.C>9[>YCN[^YU.]NI([.U,EQ<L"Q$%A;VMNBJJJJA(EV K4U)GO\
MCKR?_P!3#9_\'_9F_P =>3_^IAL_^#_LS?XZ\G_]3#9_\'_9F_QUY/\ ^IAL
M_P#@_P"S-_CKR?\ ]3#9_P#!_P!F;_'7D_\ ZF&S_P"#_LS?XZ\G_P#4PV?_
M  ?]F;_'7D__ *F&S_X/^S-_CKR?_P!3#9_\'_9F_P =>3_^IAL_^#_LS?XZ
M\G_]3#9_\'_9F_QUY/\ ^IAL_P#@_P"S-_CKR?\ ]3#9_P#!_P!F;_'7D_\
MZF&S_P"#_LS?XZ\G_P#4PV?_  ?]F;_'7D__ *F&S_X/^S-_CKR?_P!3#9_\
M'_9G/]9U:Q\U^>O)T&AS?7TTB5KF\N8P3&%#*YH33H$W/B0,[9FS9__1^_F;
M-A%=^5_+M]<275YHEG<7,IK+,\*EF/B33<X&_P &>4_^I>L/^1*_TS?X,\I_
M]2]8?\B5_IF_P9Y3_P"I>L/^1*_TS?X,\I_]2]8?\B5_IF_P9Y3_ .I>L/\
MD2O],W^#/*?_ %+UA_R)7^F;_!GE/_J7K#_D2O\ 3-_@SRG_ -2]8?\ (E?Z
M9O\ !GE/_J7K#_D2O],W^#/*?_4O6'_(E?Z9O\&>4_\ J7K#_D2O],W^#/*?
M_4O6'_(E?Z9O\&>4_P#J7K#_ )$K_3-_@SRG_P!2]8?\B5_IF_P9Y3_ZEZP_
MY$K_ $S?X,\I_P#4O6'_ ")7^F;_  9Y3_ZEZP_Y$K_3-_@SRG_U+UA_R)7^
MF;_!GE/_ *EZP_Y$K_3-_@SRG_U+UA_R)7^F;_!GE/\ ZEZP_P"1*_TS?X,\
MI_\ 4O6'_(E?Z9O\&>4_^I>L/^1*_P!,W^#/*?\ U+UA_P B5_IF_P &>4_^
MI>L/^1*_TS?X,\I_]2]8?\B5_IF_P9Y3_P"I>L/^1*_TS?X,\I_]2]8?\B5_
MIF_P9Y3_ .I>L/\ D2O],W^#/*?_ %+UA_R)7^F;_!GE/_J7K#_D2O\ 3-_@
MSRG_ -2]8?\ (E?Z9O\ !GE/_J7K#_D2O],W^#/*?_4O6'_(E?Z9O\&>4_\
MJ7K#_D2O],W^#/*?_4O6'_(E?Z9O\&>4_P#J7K#_ )$K_3-_@SRG_P!2]8?\
MB5_IF_P9Y3_ZEZP_Y$K_ $S?X,\I_P#4O6'_ ")7^F;_  9Y3_ZEZP_Y$K_3
M-_@SRG_U+UA_R)7^F;_!GE/_ *EZP_Y$K_3-_@SRG_U+UA_R)7^F;_!GE/\
MZEZP_P"1*_TS?X,\I_\ 4O6'_(E?Z9O\&>4_^I>L/^1*_P!,W^#/*?\ U+UA
M_P B5_IF_P &>4_^I>L/^1*_TS?X,\I_]2]8?\B5_IF_P9Y3_P"I>L/^1*_T
MS?X,\I_]2]8?\B5_IF_P9Y3_ .I>L/\ D2O],W^#/*?_ %+UA_R)7^F;_!GE
M/_J7K#_D2O\ 3-_@SRG_ -2]8?\ (E?Z9O\ !GE/_J7K#_D2O],W^#/*?_4O
M6'_(E?Z9O\&>4_\ J7K#_D2O],W^#/*?_4O6'_(E?Z9O\&>4_P#J7K#_ )$K
M_3-_@SRG_P!2]8?\B5_IF_P9Y3_ZEZP_Y$K_ $S?X,\I_P#4O6'_ ")7^F;_
M  9Y3_ZEZP_Y$K_3-_@SRG_U+UA_R)7^F;_!GE/_ *EZP_Y$K_3-_@SRG_U+
MUA_R)7^F;_!GE/\ ZEZP_P"1*_TS?X,\I_\ 4O6'_(E?Z9O\&>4_^I>L/^1*
M_P!,W^#/*?\ U+UA_P B5_IF_P &>4_^I>L/^1*_TS?X,\I_]2]8?\B5_IF_
MP9Y3_P"I>L/^1*_TS?X,\I_]2]8?\B5_IF_P9Y3_ .I>L/\ D2O],W^#/*?_
M %+UA_R)7^F;_!GE/_J7K#_D2O\ 3-_@SRG_ -2]8?\ (E?Z9O\ !GE/_J7K
M#_D2O],W^#/*?_4O6'_(E?Z9O\&>4_\ J7K#_D2O],W^#/*?_4O6'_(E?Z9O
M\&>4_P#J7K#_ )$K_3-_@SRG_P!2]8?\B5_IF_P9Y3_ZEZP_Y$K_ $S?X,\I
M_P#4O6'_ ")7^F;_  9Y3_ZEZP_Y$K_3#33]&TG21(-,TZWL1-0R^C&J%J=*
MD#?#+-FS_]+[^9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-
MFS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L
MV;-FS9__T_OYFS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;
M-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9
&LV;-G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>proxy_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy_02.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X0W717AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,C$Z,#0Z
M,C<@,3@Z-# Z-3<      Z !  ,    !  $  * "  0    !   #!: #  0
M   !   #Z          & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   RA
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M)*?_U?1V_P#+3_\ PLS_ ,^6)9V0ZFP#UA4"P\V5LUGZ6VZNSP2;_P M/_\
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M_)]/?M24_P#_V?_M$GI0:&]T;W-H;W @,RXP #A"24T$)0      $
M               X0DE- ^T      ! !+     $  0$L     0 !.$))300F
M       .             #^    X0DE-! T       0    >.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-! H       $  #A"
M24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      TT    &              /H   #!0    P < !R &\
M> !Y %\ 4 !A &< 90!? #(    !                          $
M         P4   /H                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   /H     %)G:'1L;VYG   #!0    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #Z
M  !29VAT;&]N9P   P4    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    !/_         X0DE-!!0       0    !
M.$))300,      R]     0   'P   "@   !=   Z(    RA !@  ?_8_^
M$$I&248  0(  $@ 2   _^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !
M_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.
M%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1" "@ 'P# 2(  A$! Q$!_]T !  (_\0!/P   04! 0$! 0$
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M&N;/J6&)&V?YI6/L?^3OL.__  /H^I'\GT]^U)3_ /_9 #A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
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MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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MN=&\V_E7I/YX^5_*-]H&JW]Y+YALK7S38Z/:11Z) &^KQQ037!G]-A24F:G
MJ695YX_Y[>>1IVLZ\NN:ZFFZ1^3O_.0FKW'E\>8-59;B_P#*_FH6EC<_6VN#
M<1R11(5A='#0*W&'@H Q5EGD;_G(O\_?*OFG\Z_-WFK4= U_\J/(NO\ Y76>
MMZ9.;][K0_+OF;2=.FN;ZVGDG/-K>._6>Y>4.SN)&J$"@*OK3RU_SD9JMQ_S
MCA^97_.2'F'RS'/Y=\O#S9KGD;1M*]1;C4O+6B3W,>FW$KREPLE[';>MS4<
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M^7-0O;V?2T\NZ?%J*V'F#U BRK+'.L9N(/359E:+AT;%6>?GU^9O_.0VA_\
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M)_Y9?DW^4NE-Y$\D^4O+WD33/.4UP&\OZ=#%:-J<PMR9R0M))F6!#4U)5!V
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MC_,C0[?RAYY\\V6B6U_J%YY8BA%J^FKZSQJA]!42.4\C'Q6BGB**O7O*UEY
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M2]2(WHO4A5XUYA_)O\P_*FKW^D>0];\T:SJ7EW\L_-_F'ROJB7,NF:5>^?\
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MO+92,\<D,C6S3'E,#(2PVT,$M5JLFHS8!DS2PZ;P_3AA'PQCK.#XN.6(3CD
M$HSB,HAMC].S7?#$ &A<KY]^W(WR^#Z5\Y?F?8R_E7Y!TG5?S#GOKW2;KRV/
MSMN]#G^IZQ<Z;);$WS6PL)Y)2QN!&;E;*5Y$C]4(U:5XCLSL&8[2U&3'IA&,
MAE_+"8XL<9B7HXO$B(UP<7AG-&,92X#(4Y,\HX ">ZZY_COIXYYM\Z:>]B\>
MG^=?/KVJ>4KL?D&%UN3Z]'YE_2=ZT)ULVTZ_!]7^I&#]*U46PD6?]_Z@/2=G
M=ES$[G@T]^-'\U^[' <'APOP>(<^/Q>/\MOXO"<?[OAJF<QT)Y>G?K?7[.?1
MD&HSVFN^:9M5U7\T=6MYM0_-M=+U*/3/-MW9V \IR:#&UTD$$-VD<=K)>)_?
M*HD5JA)$K3,/!">GTPQX]+ B.CXH\6",I_F!F/"92,23D&,_03PD;RB61()L
MR_B[^E?K?67_ #C]/=2_EI:P76JW>MQZ9KOF33M*U.^NWO[B73;/6[Z#3B]U
M(SO-2T2(+([,S+1BQ)KGG_M?"([1)C 0,L>*4A&/ !DEBA+)40 (_O#*X@
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M".WC6*(-Y<TQR%10J@LUN2: =2<C+VR[<D23KM1N;_O<G_%+^7Q?S1\@J?\
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M\X]_]Q?S5_WCL5>Q^:Y_^<AT_+GRU)Y(T[\O)_S;8V?^,+/7+S58O+J PO\
M7/J,UM;R734FXB/U(Q5*\J&@Q5X[]<_Y^#_]2]_SCW_W%_-7_>.Q5[%=S_\
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M"_Y45IOY=7]LT=Q_B8^>KS5K5UD!C^K_ %0:9;3A@1SY\Z4^&E=\5>/->_\
M/PGBW#R[_P X]<Z'C75_-5*]J_[CL5>Q_F-/_P Y$1^7?*S?E)IWY=W?FM^/
M^-8?-UYJUOIZ?N!R_1[V%O-*_P"^J!ZJK\'OMBKQWZY_S\'_ .I>_P"<>_\
MN+^:O^\=BKV+S//_ ,Y#K^6WER3R9IOY=S?F^QL_\76>M7FJQ^6T!B?ZY]1G
MM[=[MJ2\?3]2,56O*AIBKQ[ZY_S\'_ZE[_G'O_N+^:O^\=BKV*>?_G(?_E4M
MO+;:;^7A_/6J_6K&6\U4>4P/K9#<+@6YO?\ >6A%8O[S;[.^*O'?KG_/P?\
MZE[_ )Q[_P"XOYJ_[QV*O8-%G_YR);\K=:E\Q:;^74?YU W/^'K+3KS5G\KL
M R_5OK4\MLMXM5KSX1FAIQKBKQ_ZY_S\'_ZE[_G'O_N+^:O^\=BKV/R)/_SD
M-)Y,\U/^9FG?EY:_F$GUC_!%OY9O-5GT:2EL#;?I"6\MXKA*W%0_I(U(]Q5M
ML5>-B]_Y^$4'+R[_ ,X]\J;TU?S52O\ W#L5>Q_E5/\ \Y#RVWF/_E=VG?EY
M8W:B#_"(\D7FJW4;GC)Z_P!>.I6\!6C>GP],';E7MBKQSZ[_ ,_!_P#J7O\
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MQ_ZHXJ[ZG_S^4_ZNWY6_\#8_]4<5=]3_ .?RG_5V_*W_ (&Q_P"J.*N^I_\
M/Y3_ *NWY6_\#8_]4<5=]3_Y_*?]7;\K?^!L?^J.*N^I_P#/Y3_J[?E;_P #
M8_\ 5'%7?4_^?RG_ %=ORM_X&Q_ZHXJ[ZG_S^4_ZNWY6_P# V/\ U1Q5WU/_
M )_*?]7;\K?^!L?^J.*N^I_\_E/^KM^5O_ V/_5'%7?4_P#G\I_U=ORM_P"!
ML?\ JCBKOJ?_ #^4_P"KM^5O_ V/_5'%7?4_^?RG_5V_*W_@;'_JCBKOJ?\
MS^4_ZNWY6_\  V/_ %1Q5WU/_G\I_P!7;\K?^!L?^J.*N^I_\_E/^KM^5O\
MP-C_ -4<5=]3_P"?RG_5V_*W_@;'_JCBKOJ?_/Y3_J[?E;_P-C_U1Q5WU/\
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MQ_ZHXJ[ZG_S^4_ZNWY6_\#8_]4<5=]3_ .?RG_5V_*W_ (&Q_P"J.*N^I_\
M/Y3_ *NWY6_\#8_]4<5=]3_Y_*?]7;\K?^!L?^J.*N^I_P#/Y3_J[?E;_P #
M8_\ 5'%7?4_^?RG_ %=ORM_X&Q_ZHXJ[ZG_S^4_ZNWY6_P# V/\ U1Q5WU/_
M )_*?]7;\K?^!L?^J.*M?4_^?RG_ %=ORM_X&Q_ZHXJR3\G/^<N/^<G/R_\
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M8&M^26O)'6']V[<@#3=52_+_ /YP^UGR7YR_+R:[_-<:U^5GY/\ FGS+YO\
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M5V*NQ5V*NQ5V*NQ5^/O_ #\ _P#6S_\ GV__ .!Q)_W5M%Q5^P6*NQ5V*O\
M_]/[^8J[%7@W_.4__K,O_.0W_FMO-/\ W2;G%7C'_/MW_P!8D_(3_ME:C_W5
M[[%7W!BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?,_P#SE_\ F3K'Y7_\X^^?=8\JK<S>
M>_,4$/E3\NK.Q5GO)M>\P3)IUB+5$^)Y8WF]50-_@Q5\,?EE^??YJ^3/*6@?
MDCH^JZYIGG33_P ^-.\@P:M^:.G3WVOIY.\VZ=J&KZ9?W=O)=1O),CP21(S2
ME2(@#M50JAYO^<S/^<A=3\@V7F/2]1\J:5J/E[\G///YC>93-HLUS'J=]Y(\
MV/H"01)]>C^K1WL2<Y-W*$GABKTR?_G-'S;IOGMO*NKWFCVUY!^<5WH=UY5A
MLWGU<>2(O) \P0W<=JLHED9[RJ1RA0)0."[U(5>(>7/^<KOS0_.*7R=:7WF2
M,:;I7YX_DRVD:UHBQ:9<7VC^;H;NYN[#4(M-U'4("BO!P:(S,1O'./41@%7M
M?_.3?GW\Q?R^_P"<FKKS9Y5US69M&T#\K]'T:7R5;SW$EA-J?G+4M?TK2KUK
M-"8_535(;",R<>0C8BM,5>#^0/\ G(W\]_R@L?R^_*"QUK3O,":)=^88Y/.7
MG_4HS-YIN[3\P;_R_-I\>HZGJ%O(&@M(0R+ L\H>2+DBP@U51OYP?\Y:?\Y$
M:_Y7_P"<H]'T?4]&\B-Y-TWSG'96%C+:P^:=#A\M:K:6MI=QP+?O>LM]:R.T
MDTEM$J<XY+<LH8XJ]>MOST_-*'S_ *IY,\E>;M!GN/-GYT^7/(G^/9K.XU2U
MGTZ]_+Q-:DU"VLSJ/H(SSQ!XQ"ZQ4/Q*Y+,RKR/5/^<^?SL_Y5?8>=9=5\F^
M3-9LO(F@ZUIVC7^ESSGSCJFI^9KK0=1_1G*^B,*6$5LDKH@E*M)60B.F*OL/
M_G*O_G(#SY^4WF?3=!\O:UY=\@Z,/(7F3SE;>;O,]E)?6^N:UHC6XL_*]HJW
M-J%FNEE9SQ+3,H A0L&Q5C__ #CMY@\^>>_^<H_SV\V^<]2U;3K;2?R\_+B?
M2ORMN9;GT-"N/,>F2W]];K#ZZP&6.:W9'=H>;$CXE"T95\,Z7^;OG;1/+GYY
M6GEK\X/,OG/\Q;K\K//OF";SWI'F#4KXV=QI-V)X_P#$OD_5;97\KZC%"6M;
M4V<R1'<^FY"D*OJ*P_YRH_-+2O-WE7RM:>9O+?F>&PU'\M?+NC>5#9/)K'GO
M3?-=C:RZIYGTZ[CNV5(K-I936-)(E]"7UW!9>*KRO\P_^<G?S4\Z_D7YYUR3
M\PM$MO.D6L:'=-^2GEB"[TKS1Y:DM/S$LM'2PO=2^MLH%Y;KZ<BSI$SF3DJ^
MA48JC_-7_.0?YV:Q+Y#_ #2T#SG9^7?->@_DW^<'FOSGY,GL+B?2[75/*6IV
M?+0;FP%[$&N+)HC:&Z=BS#G*B*)5 5>M:)_SES^:>M_F;Y6TWTO+UI%K?G?R
MIY43\EQ9RR:[>:!Y@T&WU:[\W6]Y]9Y?5K:69Z?N#$(XF1W]8@A5\5R_\Y&_
MF[+_ ,XNZ9Y2N?S3/E&:R\D^6]:TG5M0ENI?,WG"[U7SQ=6E_P#H[5#>0S(N
MFV]JBR!$E/%SZG&.E%7TU??\YH_GK#_T,EJ'U+RGIR_EGH/GZ]TCRC=/:_I?
M2+CRK?Q6NE37-DFH->SPWD3<YFFMX%J\;0,T=<5>BZ]_SD?^<7Y?_G-^37Y>
M>=/.?E35-'\UVWER/79M!TB";5+K4O,-Y<+Z<VCRZS%?VUJL2HD-S:QW2HRM
M)<#B> 5?I3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\??^?@'_K9__/M__P #B3_N
MK:+BK]@L5=BKL5?_U/OYBKL5>#?\Y3_^LR_\Y#?^:V\T_P#=)N<5>,?\^W?_
M %B3\A/^V5J/_=7OL5?<&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ53DABE]/U8DE])Q)
M%S4-Q<=&%>A'CBJFUI:O*)WMHGG!4B8HI>J5XGE2NU33PKBJSZA8\2GU*#@4
M:(KZ:T*.>3+2G1CN1W.*KOJ5GZOK_5(?7^']]Z:\_@!"_%2OP@FGA7%7SG^7
M_P#SDI^1GG;R!IGYAG7-,\E:;=Z!/YKGTKS!):6=]8Z/9:E/IAU"YC2218X1
M=1LJN&(J>H)(Q5GEI^=7Y*ZIYNN_)-I^9/E6\\ZV1NX[[RXNHVK7T3:566Z2
M2(OR4VXJ[ [J*OTWQ5.O)/GO\M/S,L)M7\@>9]!\Z:=I%VT<]]I%Q!=I;7+*
M)#5HRW!G1PX/[2L&%0:XJ^=8_P#G,_\ )&_TO\R=>T;3M9UQ?*'F?1_(T$<.
MGQ6\_F35];A26PMM-%[+;AXW64TEN#%%P#2AC%1RJ^BORW\T:/\ F%Y)\M>=
M]-\L:EY7MM>MUNX-"U[3_P!'ZE9NG*$I<6YKP9>)4,K%66C(S(02J^"/S8_.
M+_G&GSWK?FFU_,[R1^9=AIODW1_TEIFB/)<Z9HWG:RTGS)!I<45KI,6H1K.3
MK,T4<8NX8#,&#5>$5"KV7S)_SFE^6^D>0=+\_7GY=^=]6L[>?7F\Z:+;Z7:2
MW7E-O*5XMAK,FKO)=K;1O:3N%5(9I))0>4*NM3BKU?2O^<@_RWUC\\G_ "*T
M1;^_\[?X:F\S:KJD=D\6G0V]J]D@MI+J7AZD_&_C?A&'X*:2%&(4JL>A_P"<
MF?RT/YSZI^3_ .A-5M;U-1GT"]\^RVMM'H4VNV>D#7)](,YG%PT\>GMZQ9H?
M2I5!(7^'%4NU_P#YRK_)SRYYS_+_ ,L:?:7GF;3_ #98Z%=6WY@:!!:7&A:/
M8^:[YM-T.2\NS/&Z1W]U&8XS"C@4Y/Q2C8JF?Y/?\Y(_EE^=OFSS3Y5\LZ'J
MFG7EC:MK.EZEJUG;PVWF/2K74KG2&U33GBFE>2&.\LWCK,L;CX&"\74XJBK?
M_G(;\M;G_G(6^_YQR31M07S=!IDMW+YB:T@_0\MVUM#?SZ4MQZGJ-=_4YDN7
M0QT],UY5VQ5Y._\ SG;^3$'D6[_,<^6/,:Q:9^8A_*O]$K9V?Z2^N EOK2+]
M:X_4N"&3GSK0?8KMBK[;.GV!2*-K*W*0AEA3TUH@?[044V![TZXJO:RLW:X=
M[2%WNU"73F-29578*YI\0'8'%6VM+5YH;EK:)KBW4K;SE%+QAMB%:E0#WIBJ
M(Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^/O_ #\ _P#6S_\ GV__ .!Q)_W5M%Q5
M^P6*NQ5V*O\ _]7[^8J[%7@W_.4__K,O_.0W_FMO-/\ W2;G%7C'_/MW_P!8
MD_(3_ME:C_W5[[%7W!BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKS+\UO+GYC>
M9/+UA%^5GGZV_+[S;I.KVFI17^H:<NJZ=?V\!83Z=?VPE@E,$ZMNT,T<BLJD
M/2H*KX-U_P#Y]ZZ[_@/2_(WD_P#-FQT^*Y_*.Y_*OSCJ&K:+)=O/'<:TVOM?
M6*0WL A9KJ22/A)Z@6,BA++4JLVUW_G!A_,KZQ;:G^8"P:9K_P"9'GWSOJ7U
M.Q*7*VOG7RQ-Y=^JQ2-*R^K;>KZOJ,I#4X\1UQ5[+_SC'_SCS>?D+IOF./6-
M7TG7]:U^#1;"?6-,AU:*2>TT&R^I6C71U75M4)?B318?3CC6D:J55:*O.?S*
M_P"<-/\ E8-]^<VK7'F/1KN[_,#\PO*/YA^6-(US1VU+2(+KRKIEMIWU'5[/
MZS#]=MKM(9!(H>.BOW*[JO5?R!_*KS[^2>D>3_RND\QV7F7\LO)ODN&TAU&6
MW:#4)?,,NI75Q<>B/7E$=E';R)'#"5_=*J*'DWXJO -6_P"<-_S2\Y:K^>^H
M^?/S;\O:M/\ FS<6-]Y;UN'0+HZGH<F@:O:ZKY>T\33:DT3Z=:/;'U+>**(S
M.[2M)SWQ5;YG_P"<.?S7U'R/Y1\I:)^;7ED!O/.O_F7^;NG:QY>N[K1/,WF'
M6=0;4H(WT^'4X76QLIGY);R32+(R1M+RXT*KZEN?REU"\_/KR7^=5SK\!'E?
MR#JWDZ]T1+9E-Q/JE]87INDE]0A%7ZF5X%23R^UMNJ\9O_\ G$5]4_YR='_.
M0^H>9-"E.D7,VJ^5K&#0$M=66^ET9M&2WU'4H+E$O+2%7>9 T G+%4>8QQHN
M*I9YI_YQ&\T>=/.ODWS;K?YBZ1:V\VG>2K7\X="T[0W@AU6;R)JTFM::VCM]
M=_W'QRW$I25&$O[L#@5;?%4^_P"<=?\ G$Z?\C/.NI>9[[SO%YJL-*\NW'DS
M\MM.BT]K*:PT&ZUR[U^5=0F-Q,MU<?6+H1B1$B7A&OP<F;%6%V'_ #A/KMGY
MZT[\VS^=6M2_F'!^;-Q^9=_IICC_ ,./#><M/GL(K*GUA'.C<;,3&X(JH;TZ
M?#BK';C_ )P$GFTRYLA^8MNKSZ5=6_I'3"8/TI/YKDUR/4ROK\O533Y6T_KN
M#RZ?#BK](L5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\??^?@'_ *V?_P ^
MW_\ P.)/^ZMHN*OV"Q5V*NQ5_];[^8J[%7@W_.4__K,O_.0W_FMO-/\ W2;G
M%7C'_/MW_P!8D_(3_ME:C_W5[[%7W!BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\R?,WE?5-&_YRK_ #BTRS_-
M#\Q_T)Y8_)K_ )65HOEV3SAK+Z=#KM[J6KV\A%H;KTC;K'!&$MROIIQ'%1BK
MR'R-_P Y(_G)9>0?R6\G^<M9L?-5SJ>A?D-YEM/-<3:M9:FUKYSULZ7?6^I7
M$6I%[Z;A;B5I&*1R,S++#(FV*OJG_G&/_G)?SG^;/YH_F'^7_GNY\M0:CH=I
M=ZOH6D>68H[^T_1L&KS:=%/'KMGJM_#<<E1!)%/;VLZR\Z1E!4*OG#5_^<\/
MS:TBW\]WULWD?S)=://^;UA;>3K"SNUU+1%_+V&ZN=-U35&_2$GJ6]WZ202*
M(HAR="DE24Q5FWG?_G+O\ZOR]6:#7)/)$^O>6/)GE+S>?+?Z.O;:Y\]3>;-4
MDMGTKRVKZB[QM80A(C(5G:2<J6CB1J!5D5Y_SD[^=&K_ )P?\Y&_E/Y)N?)6
MHW_Y7^7M;U7\K'ELKYG\R:M90V,[Z&&%RL#3Z496AO/2D+%IX&X1!) 56<^7
M/^<AO-'YI?\ .-?_ #DG^>FGV5M9>3M+TCS-/^3*H+NTNKFQT70^4UU=7,,\
M4M7U)+A$: Q,J(.+<OBQ5Y_^6?\ SE;YZO?SI_*[\L/,MUY;L/*7F[0O+T&A
MI9*=;U.\U"\\KPZS=1W]PNLO?:=.LC$I]:L)(Y(1R:XYL#BK+/S5_P"<I///
MY=?\Y*Z;^6DL?E]O(=X-)L])L["*+6=>U+5=2MKNX%C<P0:K!=Z8\I@1;:4V
M$\#_ !&21!2BKY>\[_\ .8/YK^=?R7\U_5_,.BP:EK/Y?^4/S!CU_P BFZL;
MSR=>:CYOT[3)_+6ISF[N"]PT$CCE2%VX3JT/&AQ5G^E_\Y8_F%IWF'S%Y37S
M1Y&_+73[+S'^9NI)YU_,!]5O=/U(>6_-\>CVVAVCRZD)(93!-ZS^B9 @X"&V
M1-L58YJW_.1OYM:+^?MW'IFM#_"OECS_ /G'9R^0 U]=-YCE\J^6-(U'3K%9
M;F\F,<DS73K##;QB)'JZP.QV53_R?_SFW^<6O^3?+.I:N?R^T1/.7G#R9HJ?
MF2TUG=Z5H%GYETJZU*\_2NG:?K]V\3126JVUNUQ=6YE]9"\<;JT959=^5?\
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M9'7P#$*L&;_G(S\JTA$YU+5J.[&&(:'JAEDMTCGE>]CC^J\FM56VF)G ]/\
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MJQC2?R/_ "QT6VEM;+R[(\<ZA)6N[^^NW9%_1X2,R7%Q(W%%TJT55K15B50
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MK$=%6%Z7_P Y1^2M72*2T\NZ^Z)>RVVKRHMA+%801'2:W<LL5XZ21,-9MB!
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MM^7OY?>>_,6C7SV_G:VT^6Y&GB(V^G&\LOKDDMU<7,L$<4,8!7F["IXCOBK
M%_YRK\N:7Y2N_,OFCRQJMC)8\[EH+9[%UN].$VI(M_9>I>(TL?'2YB4($IV(
MC*$-BJ>WO_.3?D^PU^WT"3ROYIN);F]NK9+RSL8[N,06VI2:0MXR03R2K%->
M0R1I5.8",[HJ48JLK\N_G?Y3\P_EQY@_,P6>H:9I7EA;@ZWHURL#:E;R6\23
M&"6W@FE].5ED6B2,K"HY #?%4!Y(_-W5/._YCZUY/C\G7GE[3/+&B"X\PSZG
M):-=0:O)>/"ME2TNIXV401^KS0NK<U')64J54KU'_G(S0+![CAY,\R7]LOZ6
MGTZ\MQIH6\L- DEAU:^B26_CD6.V>*G&54DDY+Z2/O15!S?\Y.>5(/K]T_E'
MS.="T\32-YB$5@;>2"*\O-/2=(_KOUCC-=63QH#$&W5V54)8*JD?_.2.D/?6
MVCO^7WFNWUW5+R33-!T:4:4);[4(!;2S6L<@U$Q1M'!=Q3%IG1.)*AC(I3%6
M2^0_ST\L?F%K=OH^BZ1K-M!>VLEQ8:S>Q6\=M/+!:Z?>7%LJI.\P>*/4HN1:
M,(6#A7;CNJPGS1_SE#Y=\M>9[WRW)Y3UF1M"U6[M?,EU,UG;O'I]CI][>SZE
M:VLEP+BXA5K0(&6,!N7PDFBLJF]W_P Y!VH7S-IUGY%UZ+S+Y/LIKCS;I=Z^
MFI'H\AB:2R%Y-'?.LJW5!Q^J&8J/MA3MBK*?+/YR^7?,?Y6V_P";:V=[;>5G
M423W$L:HZ6\<XM[F\:)W#Q0PGF[B4)(L:,6C#?#BKS>W_P"<J?*^J^8-'L=
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MNWBWQ'??%45I?DORCHFBWOES2/+.F:;H&I"4:CHUO:Q1VMP)T$4HEB"\7#(
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M6]EHEE))HL%O)?QWDMQ8_I&XTR)[FXB0Q^M$\=W.Z4]+AZ0Y,_[STU4AL/\
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M_@T^ZOM+CN9+BR]2H2YBNYZ$%3 (S5I&Y^FJ^Y,5=BKL5=BKL5?C[_S\ _\
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M-&T_2:>5+:[TRWL+S5)GO]0$=S=1>HOHS?5H+>L-8U_><F5">**L)\O>;?\
MG(+4?RD\_:GJ6C7.D^=[+5+7_!OUO30US)ITL=E)=<[:*,5>)WN8U*P2%0JL
M([B@,JK&]0\Y?\Y$:WHL6GW'E#7_ "W?02:=J5_J-G8P3S1VT=[Y>DX1&*:-
M)Y60ZBTD( JJ\'455&50]SYX_P"<J[==2$/E:74&N/+]M-I\_P"C8[463>O
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M?E[YHELEGMOJ/EK2)I;3ZC'$^E7!EN/3>/U/K'UX0B-FDXCN A?%6$1>5_\
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MY)^=[G\M/+_DRX\Z7\6HZ;J.LZC<3_IN^9HQ>6&H0Z?:I?VL-C--%:W5Q#*
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MS-J,'!7(+!MNF*HW3_SP_)S5M:3RYIGYH>6+[79;R\T^/28=4MGG:[TXTNX
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M6.^7?SJ_+?S+^6X_-VW\R6^F_ERYE,/FK4W2TMI(H[@VJS!I&V622BIRHQ)
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MW/%))#,L+FDL11^0ZE>2LJPR7_G$?RT==U+S%;_F+YOM]2-W+J?E:1GTR?\
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M@CT;5-;U;4;OR_JUHFG1:4UDKP7D5Q:QSPSSC4(&@C:.LHDCX5,L0=5-K?\
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MJZ+YDO/*U]JUNT]QY-U<:YH#K(Z"*]%I<V/-@I <>C=RKQ:HWKU Q5Y7K?\
MSC?^5GF#S+JWF;4]/U6:36[F?4=1\OKK&H)HKZI<V+:=)J8TM9Q:K=_5F*B4
M1U#?O!^\'/%6>^4/RY\J^1;W6+[RU9S6$FO6VF6^JP>O+)#*=)M196T_INQ4
M3?5TCC>0#DZQQAB>"T58OYL_(?\ +?SMY@F\S^8=*N;K5;J:VEOFCO;B&*XC
MMK"_TOZO-%&X1X9;74KB*2,CBX;?< A5(=%_YQD_*308-%@L]*U&8^7Y(Y=-
MGN]3O+B53!J5AJL(9Y)266.XTRVH#^RG'HS553'R_P#\X\?E;Y:\U>2O.6F:
M-<C7/R[T.+R]Y/GFO;B9;*QBLQ8!%5W-:VXXL"2I/[PKZGQXJJ>3_P B_+?D
M+6]1UORMYC\TVC:]YCG\S^9M/NM9NKVVO[VYAN8I1)%<O(%1C<*Q"T_NH5%%
MC48JJ6OY&^4],\XWGGK1=2U[2_,&H:@MW=R_I6ZN($MFNC?7>GVMO<2216UM
M>7)$L\<2J'8#I04562?D!^6=OY];\S_+?E^V\F>?;R1/TYYGT.*.TN=1@:_B
MU&ZANRB@2_6Y85$SL"[)5>6^*H/4/^<<?RKU3SEK'GN\TJ]DU_7;J*]OW^OW
M(@,\5SI=V'6+GQ7E+HUFQ V_=T  =PRJC!_SC5^5-KY@\K^9;73=2M=0\I7:
M7^FPPZK?):2W4-U?7D$UW:K,(KEH)=2N?3,JMP$A4;!:*IW/^2?E7_%U_P">
MM/U#7-,\S:A=07!NX]4NY8+6,75G=7T%E:32/!;)J/U&)+KTD'J*#W))54_,
MWY!_EGYNU3S-K&N:/<7-_P";H;RWUV5+RXC$L=_866F7 54<!>5OI\"CC2A4
ML-V)Q53\[?\ ./WY7_F%YFNO-OF;1KF;6=0T:70-6DM+^ZLX[RR>*X@1;B.W
ME0.T27<PC?[2\^NRT5231O\ G&/\K/+]Q8W6D1:[83VTES)?-;:YJ%NNI"ZE
M>X>+48X)HTNHEFE>5(Y%*(S-Q4*2N*LAM/R&_+:Q\IZ[Y+M=)N8-#\PKH_UY
M8[ZZ2XCE\OV=E8Z7/;W*R"6&6VCTZW9'1@>:!_M5.*L<_P"A7_RJ;5X-?GB\
MP7NMPZ:VF2:O>:]J5S=3*]C<Z<\TUQ-</*\K6]W(A<MWJ #BJ7:/_P XF?D[
MY8ETZ^\HZ9J'E;6M(M+ZWL-7T^_N(F]6]DNYQ<20JXA=X)[Z:6$< L;-15"A
M0%7H^L?E#Y-\PZOY;\P:_!>:MKOE>WTZWT_59KJ59'_1E_;ZG!),(RJ.WUJU
MCD8D?%N#\)IBK%]=_P"<;ORI\P^6_(7E34-)OAHWY:V;:?Y4@@U"YB:*U?T.
M44CK)62IM8C5JM\-*\6<,JA)?^<9/RP>WDM8)/-&G1IJ+:CHS6/F;6+5](]5
M)XYK726ANU-C;S)<RK)%!Q5@P_DCX*HFS_YQK_*>Q\PR^9H-(U!M1_2T6LZ;
M!/JU_/::==)J2ZQ+^C[66=HK5+B^07$Z1*JR.!R!  Q5C=[_ ,X@_DE?KJR7
M.DZPT6K/'6W_ $WJ)AM((CJ16TLHFG*6UN!J]V!'$ J^I5:,J%561W/_ #C5
M^5%U;B!M*OX)8FNIK'4;;4KR"[M+F[N-,NFNK:>*57BF2;2+5T=2"I0@;.P*
MJ;>5_P A?RY\G^<(//>BV>ICS+'IT6G7%_>:K?7GUHPVT=FMW=BYFD]>Y,$2
MQM-(2[*-S7?%4B7_ )Q>_):.]\TZC#Y3^KWWG*VUNT\P7,5S<(TT/F&^BU'4
M%4A_@YSPJ5XTX+55HI(Q5':1_P XY_E=HD]O/9Z9?N]G?VFHV7UC4;N<0R6.
MLW&O6T<?J2-2.*]NI'5.@4\/L@#%5^O?\X[_ )8>9==\W^8-8T_4+F\\\0WD
M.O0?I*[6V/Z0T^UTN[>&!9 D+S6ME C,@!/!3UWQ5--!_([\NO+6J^?=6T?2
MKBVF_,D78\S6AO+A[4_I"22:\-O TA2$W$LKR.4 JQJ*8J\]A_YQ#_*"/38;
M&63S9>7=E!9V.D>8YO-&L?I;3["QM[FUBL+*_2Z6:"V,-Y.CQ(P5Q(>52%*J
MISI/_.+?Y-:%K@U[2/+US87$=U97=I9QWUR+6W?3[VQU&W6&$R%55;C3H&X]
M*+P^P>.*IWY<_P"<?/RO\L7_ )UOM/T>[N(_/^FSZ+Y@TF_U"[O+ :9<W%W=
MRV5K:S2O%;0--?3L4B51\9'0 !54\A?D)^7/Y<:I::[Y=M-4GUZTBOK?].ZO
MJU]JM[+%?QZ?"\<T][-,\BQPZ7;11!C^[1*+]IBRJ21?\XR?E4M[J]Y<VVM:
MFNJ7]YJ5OIU_K-_<6>G7.HZFFKWKZ;:R3&*U-Q=(&<QJ"5JE>#,I5;F_YQ@_
M)JYO=&O;CRW/.VC:9=:-]5:^NO0N["ZENYVM[V+U>,Z))?W#(''P^H>U**H6
MZ_YQ=_+"_MM*AU"Y\V:A<:+!<V^G:O=>:-9FOXUGNK.]B9;M[HRJUI<:?;RV
MQ5AZ+)5?M-R53+_H6S\J5\N:IY6BTF^CTS6M,L-*U=FU"ZGFNX=/OK[4D>YD
MGDD-P\MUJ5S+,TO/U6?]YRH**LYB_*_R9;^2_*/Y?V^F20>5?(TNAS>6=.6X
MF+6[>7+BWNM-K*SM(XBDMHR>;'D!1J@G%7FTG_.+7Y1!];FL+#6="NM:U9]:
MBOM'UO4=.N-.NY_K7UDZ;-;3QO:+<?7K@2K$0&$C#H%XJHZ/_G&G\I8O,%UY
MD&DZE+?37\&J6EM/J^HSV=E>1ZC9ZO-/96LMP\5N]U>6$$URR*#,R_'7DW)5
M#C_G%[\G!HRZ - NOT8EL+-8?K]U7TAHD?EZG+U*_P"\$2QUKU^/[6^*H^Y_
MYQR_*FYUK0/,#:+=0ZKY=N]3N[.Y@O[J+UCJNI3ZQ<17(20":(7MQ),B/LA-
M!\)(*K']3_YQ-_)?5=*CT>71]5M+1+&UTJ1[#6=0LY9M.M-,M-)6RGE@G1I(
M'M[&W]2-B5=HU=@6Q55/_.*GY/B\U._AT_5[6\U758]8GGM]7O8F2XCGU*?C
M&5E!$;MK%XKI4AEE*&JJ@55?:_\ .*OY,6=]]>@T/40(XK-+/3GU:_>QM9;-
M[%_K-M:-.889Y_T;;":5$#2!#R/[R3FJBM4_YQF_*[4;OR]JD=GJ%AK'D^34
MKORCJ4-]/STZ_P!3GO;J6\A#.:2+-J$SBFQJJN&6- JJ>>9OR(\@^<==\H^:
M/,T6HZKYA\F6UE;:;JK7T\;3?4+F.]@>X2-E21A/&)">(Y$D-44 58AJO_.)
M?Y+:OI":)/H^JVED+"VTB5K#6=0LYIM-M=,M=(6QFE@G1Y('MK*W$D;$J[1J
M[ L,5>C^=OR<_+G\Q=<TCS#YR\M0ZWJ>B:3K&AV4DKR(AL-=@%K?PR)&RAP\
M554MNG)N!'(XJ\Z/_.)WY-2VC6M]I^N:PUU;:E::Q?ZGKVIWMYJ,6II8HXOK
MFXN'EG,(TRT-N6:L)AC,?$C=5--)_P"<9_RJT77_ "EYFLK/6!JODV2"XTYY
M-8OWAN;NV2\BAO+ZW,WI74Z)?SHKRJ2JMQ% J!54XN?R!_+*[U?4=<GT>X;4
MM5U$:K>S"\N &NAJMAK7(*'H!];TRW>@VHI7[+$%5+O,_P#SC=^5/G#S;K?G
M;7=)OKC7O,$7IW\T6HW4*+)]7M[9;B%8Y%]*5$M("CH04>-72CEBRJA+_P X
MT?E?=F7])+YCU>/4-&ET3S)!?^8]7G36H)8IX1+JRO=_Z9/&EU*(I9:M'5>!
M7TXN"JVS_P"<9/RFM-.U>P?3M6U*?7["ZL-;UW4=8U"\U2Z-U=6]XUU+?S3M
M.;B.:T@:*;ERC]- A4*!BJ41_P#.)'Y+QSV=RVF:Q=7-HMZ)+J[UJ_N9;F34
M)M3GN)KB2:9WDD=]8O"6)_W9O4I'Q59(/^<=/RQCUBPUZSM-6TK5;&[BNI+K
M3M8U"S-W'%;:?:BSO/0G3ZQ;,FE6Q:&2J,R$D?&X955T'_G'?\JO+?D3SI^6
MNEZ'<#R9Y]M9[#7-'GOKF=4LYH#;"VM6DD+01Q1L1&(R"G4&H!Q5*9_^<6_R
M7FT35/+L?EB2RTG5[G5KN\MK2]NH#Z^MZ6NCWCH\<@9";5%5:'X6'-:-OBK,
M_*_Y.>1?*.HMJVDV5V^I2V>JV-S>7=Y/<R31ZW?_ *3OS*9'/)YKGXRQW'0;
M8JPFT_YQ:_)JVT*V\MW&@7FKZ-:VEKIXM=2U&\NR]K9:5J&B6\,CR2EF6.QU
M.>):FH!4UY(I"J>?]"__ )=_X#TW\O0FLQZ1H^J'6M,U6+6+Z+5H+]O45YX]
M1CF6X1GCEDB;BP!C9DI0XJQRX_YQ1_)6YTG1M!G\O7<NC:'>:7?6>G/J-VT9
MFT>PT[3;)GY2$\HX-*M@'!#_  M\7[R3DJGVD?\ ..WY8:-]5CBL-4U&PTZ6
M];2-&U35[^_L;&WO[&739K&SM;F>2*"U^K3R(L,:A17ILM%6.Z9_SB=^3>D1
M6$-EINKB+3[9[*..76;^59+4WEE?10RJ\Q#K!+I\!BKNH4BOQ-55&:=_SBW^
M3NEO<R6VBZC*9FF2T6ZU?4+I;&TEL=2T_P#1]BL\[BVM(X=8N_3@BXHK2<@*
MJG%5/_,'Y ?EGYFO?)=_JNEWK2^1K.RTW38+?4KVVM[NQTZ>&ZM+34H(9DCO
M88;B!)52<..0/9G#*JNJ?D3^7FK>3_+GD:XL]0M] \JZI<:OHJ6FH75O/'<W
MB7D5R&GCD#NDT>H7$;HQ*E7(ITQ5(M1_YQC_ "?U-M+EN-"NX[G1[^&_L[RW
MU"[AF!BT[3M*,#/'*"T,EMI-JLD9V8QAOM$DJJ/F;_G&SR%YY_,;S+Y^\[?6
M_,EKYATG3M*;R=+<7$6E@6$&I6_K7%M%,(KB0QZG)Z;.G*(_$C5H0JB=._YQ
MJ_*W2]'NM%M;+5&AO=(ET2ZO)]4NY[F2SFO4OV1Y)9&Y?O8UV8$%!P8%"P*J
M2Z=_SB-^1ND1V=MIOEW4+/3;+2I=+CT./6-1&G,9;"XTLWKV7UCT&NUL[J6!
M)RG-$;BI 5.*J=:K_P XS_E'K5UI=UJ6AW5Q^B->MO,MK;F_N?2_25I#I\,$
MY7GLR+IEO0K0_"RDE7=65>^XJ[%78J[%78J_'W_GX!_ZV?\ \^W_ /P.)/\
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M:+BK]@L5=BKL5?_4^_F*NQ5X-_SE/_ZS+_SD-_YK;S3_ -TFYQ5XQ_S[=_\
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M^8JD/F?S+H7E#0[[S'YFOTTS1--$9O;UT>0)ZLBQ)\$:NQ+.Z@4!W.*OD?\
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M1?R4UK0X9M)U#3=%U%M/E?6]9 DOXKBXX.X^K *A"J >1*JO1/S$_P"<U/\
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M?SE=2:[>W.GZC-Y@T'R]H]U<K-<6J0M<:<ZRVYE5$9BR]7_8Q5Z__P XY?\
M.=WDO_G(3SY8>1;3R];^7KOS/Y=N?-/DQ[?7].UFX>QM+A8);;6+2R//3+WB
MZRBW<R QU/J<@5Q5]W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%7X^_\_ /_ %L__GV__P"!Q)_W5M%Q5^P6
M*NQ5V*O_UOOYBKL5>#?\Y3_^LR_\Y#?^:V\T_P#=)N<5>,?\^W?_ %B3\A/^
MV5J/_=7OL5?<&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5\2>:/^<%/RX\S:IYKMT\_>??+WY9>?]?\ \3>?
MOR2TC58;;RUJFI-*L\TC1_5FNH$GE19)8X9T5F Z4%%4\\_?\X8?ESY_\S^<
M]6NO-/FS0?*GYHW6E7OYN?ECI-Y;0Z'YEN-%$:VCW0DMI+F#DL2),+:>(3*H
MY[[E5=YT_P"<-?R^\[Z1^?6BZAYCU^RM?^<@?,'E[S#YF-H]HK6,_ELVAM8K
M'E;L%C?ZF@<2!S0GB1M15"ZO_P X7>1M5O?S'D/G7S3;:1^9/YB:+^:&H^7$
M>P:UM-?TB>&=Y+5VLS.$NC!&LB/(P '[OB=\53!/^<//(2:?9:<OF7S!Z=A^
M>;?GW#)SM>1UYKB2Y^I'_1Z?5.4A%*>I3_=F*L:/_."_D >:K76X_/\ YS7R
MSIOYG#\VM(_+9[BPET6W\PRNSWC?O+)KJ2*YY,"DD[! S>GQ+$XJG_D+_G#7
MR+Y#@OO+T?GGSIYB_+%]"UCRUHOY1:I?VQT&PTO7F=KVWX6]K#<7-/4986NI
MI6B4E4(Q5;^57_.'GEO\K//?D;S\OYH>>?.^H?EOY7O/)?DW3?,EW8SVEEH5
MPT)AM$6VLK=B;<0T61F+L" [,J(%52+\V/\ G!CR'^:_FW\RO--S^8/G'RM'
M^;+Z#=^=O+^DR:8UG=:AY95%TJZ#WEA<7*"'TU)A281.P#,A(&*LA\[_ /.&
M_D'SYIG_ #D+I>J^9O,%K'_SD?JOES5_-\UJ]JK6<_EH6OU9;'G;N%63ZJO/
MU.9W/$C;%4@\Z?\ .#/D+SAK_FO4(OS#\[>6?+/G+SGI_P"8>M?EUI5U8IHL
MGF>QFAE?4>$MG)/6X$(]6/U?3+'U./-4**O;?SB_(_1OSAO/RUU>[\S:UY0U
M_P#*KS*GF;RKKFB&T,JW @DMI8I8[VWNHGCDBE93\'(;%2,5>66W_.%WY;VW
MG&UUL>9_-4OD:P\\/^9>G?DS)=VQ\M0>:W8R?I!5^JB\X+*QF6W-R8%D)8)3
MX<59S^<W_..VD_G%YN_+'SZ?/7F;R!YO_*(:R_DO7/+4EFDD4^M0P032RI>V
MMU'*%C@X\&7@P9@P.U%7D4/_ #@7^6^C:;Y8C\C^?O/'Y?\ FG1-&U30-=_,
M'1[RQ;6=>L=<O6U+41J,UW8SIZTET[2QS0I')$3^[90  J^FO-?Y:6WFC\M)
M/RTA\W^:?+$'U"UL;7SCHNIR6VO0_4_3*3?76#EW?TQZOJ*RR L'!#'%7S=I
M7_."WY;Z?:PO<>;?,>H^8I?S.\N_FMKOF;T]*L7OM7\LAEL8#9:?I]K900%6
M/J"&!'<DL7J<5?.E[_SB'^;U]^=?DU=(TJ[\H_E%Y._.Y/S;6T?S79ZCY>I'
M<274YT_25TBWU&&YNW93Z<UR\%N6E](D/7%7U)I7_.%WY;Z9Y<_++RL^NZYJ
M6D_ECYYUKSW807;6CB^N==-[]:L[P"W :WXWSJ @5J 58[XJC/R[_P"</_)O
MD'3M4\KW'GWSIYU_+RY\JWODG1ORUUZ^MFT?3M#U!F,ULL=I:VTEPX5C&DUR
M\LB1_ K4Q5#_ )4_\X>^6_RL\^>2//Z_FAYZ\\:E^77E:\\E>3]/\R7=C/:V
M>A7#0M!:(MM96[$VXAHLC,78&CLP1 JJ9?FM_P XD>2_S3\U>:_-0\Y^;?(D
MWYE:%;>6/S<TORU=6D-MYHTBT+>C;WHNK2Y>)E1VB]6W>*0Q,T9:C8JDWF/_
M )PH_*_7]&_/[R]!J^MZ#HW_ #D#HWE30M:T[3WMA'I-EY/M$LM/CTWU8'*U
MBC4/ZIDKVIBKU[\UOR1\N?FYH/Y?^7]=U34M.M?RZ\W:!YQTF:P:%9)KSR])
MZMO%/ZL<@,;DT?B W@PQ5Y_JW_.*/EF\_,_6OS*T'\P?.GD>/S?K6E^8O/OD
MOR_>VUKIFM:GI$:Q6TT\C6KW<2R(H6>.">-)@/WBGKBK(['_ )QI_+RQ_/\
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M_P#8AO*/_24__-&*N_Z'U_YPY_\ 8AO*/_24_P#S1BKO^A]?^<.?_8AO*/\
MTE/_ ,T8J[_H?7_G#G_V(;RC_P!)3_\ -&*N_P"A]?\ G#G_ -B&\H_])3_\
MT8J[_H?7_G#G_P!B&\H_])3_ /-&*N_Z'U_YPY_]B&\H_P#24_\ S1BKO^A]
M?^<.?_8AO*/_ $E/_P T8J[_ *'U_P"<.?\ V(;RC_TE/_S1BKO^A]?^<.?_
M &(;RC_TE/\ \T8J[_H?7_G#G_V(;RC_ -)3_P#-&*N_Z'U_YPY_]B&\H_\
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M_P#8AO*/_24__-&*N_Z'U_YPY_\ 8AO*/_24_P#S1BKO^A]?^<.?_8AO*/\
MTE/_ ,T8J[_H?7_G#G_V(;RC_P!)3_\ -&*N_P"A]?\ G#G_ -B&\H_])3_\
MT8J[_H?7_G#G_P!B&\H_])3_ /-&*N_Z'U_YPY_]B&\H_P#24_\ S1BKO^A]
M?^<.?_8AO*/_ $E/_P T8J[_ *'U_P"<.?\ V(;RC_TE/_S1BKO^A]?^<.?_
M &(;RC_TE/\ \T8J[_H?7_G#G_V(;RC_ -)3_P#-&*N_Z'U_YPY_]B&\H_\
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MYQ%_]AS\A?\ <&MO^:<5=_T))_SB+_[#GY"_[@UM_P TXJ[_ *$D_P"<1?\
MV'/R%_W!K;_FG%7?]"2?\XB_^PY^0O\ N#6W_-.*N_Z$D_YQ%_\ 8<_(7_<&
MMO\ FG%7?]"2?\XB_P#L.?D+_N#6W_-.*N_Z$D_YQ%_]AS\A?]P:V_YIQ5W_
M $))_P XB_\ L.?D+_N#6W_-.*N_Z$D_YQ%_]AS\A?\ <&MO^:<5=_T))_SB
M+_[#GY"_[@UM_P TXJ[_ *$D_P"<1?\ V'/R%_W!K;_FG%7?]"2?\XB_^PY^
M0O\ N#6W_-.*N_Z$D_YQ%_\ 8<_(7_<&MO\ FG%7?]"2?\XB_P#L.?D+_N#6
MW_-.*N_Z$D_YQ%_]AS\A?]P:V_YIQ5W_ $))_P XB_\ L.?D+_N#6W_-.*N_
MZ$D_YQ%_]AS\A?\ <&MO^:<5=_T))_SB+_[#GY"_[@UM_P TXJ[_ *$D_P"<
M1?\ V'/R%_W!K;_FG%7?]"2?\XB_^PY^0O\ N#6W_-.*N_Z$D_YQ%_\ 8<_(
M7_<&MO\ FG%7?]"2?\XB_P#L.?D+_N#6W_-.*N_Z$D_YQ%_]AS\A?]P:V_YI
MQ5W_ $))_P XB_\ L.?D+_N#6W_-.*N_Z$D_YQ%_]AS\A?\ <&MO^:<5=_T)
M)_SB+_[#GY"_[@UM_P TXJ[_ *$D_P"<1?\ V'/R%_W!K;_FG%7?]"2?\XB_
M^PY^0O\ N#6W_-.*N_Z$D_YQ%_\ 8<_(7_<&MO\ FG%7?]"2?\XB_P#L.?D+
M_N#6W_-.*N_Z$D_YQ%_]AS\A?]P:V_YIQ5W_ $))_P XB_\ L.?D+_N#6W_-
M.*N_Z$D_YQ%_]AS\A?\ <&MO^:<5=_T))_SB+_[#GY"_[@UM_P TXJ[_ *$D
M_P"<1?\ V'/R%_W!K;_FG%7?]"2?\XB_^PY^0O\ N#6W_-.*N_Z$D_YQ%_\
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MAS\A?]P:V_YIQ5W_ $))_P XB_\ L.?D+_N#6W_-.*N_Z$D_YQ%_]AS\A?\
M<&MO^:<5=_T))_SB+_[#GY"_[@UM_P TXJ[_ *$D_P"<1?\ V'/R%_W!K;_F
MG%7?]"2?\XB_^PY^0O\ N#6W_-.*N_Z$D_YQ%_\ 8<_(7_<&MO\ FG%7?]"2
M?\XB_P#L.?D+_N#6W_-.*N_Z$D_YQ%_]AS\A?]P:V_YIQ5W_ $))_P XB_\
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,V*NQ5V*NQ5V*O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>richard.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 richard.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#S?Q%;YM3]
M*Y*QLPV[UKL=8D\RSR>M<B7,.2.F:_.H2/>DM2GJ>^Q7S(^M.\*^(7U&X>)^
MH.*IZU=9MR",5!X"@,FIR-C S70I:,@Z_5[!UC$BFF:98WE[*D,"-)(>BK74
M26:W42(S>6G5F] /ZUI:)YES(MC80^3$3@[?O/[L>]8^S=1<S=D>AAZ+JNR,
MVQ\-:C9W"E[F"%\_=,W/Z5[Y\*)KW36A6YD;#=&1MR'Z&N2;X?7,=GYCQE9/
M0T_0=1O?"]X(MQ5,CCM6E.G3F^52:9Z%3"NE'G6J/I35+B"336/F,[[>AKY#
M^,=U'+JQBA!,O.[':OH-?$1UKP_*Z*!*@VM@^W!KPK6M!>\U2:>8;F)YKSL9
M4G1FX2W1DHPG%.)XU<V\ZJ2 :KZ?',+]&.:]6NO#<>#\HKFM8T<6.9 H&!7'
M3Q$G))D^Q10\1:T+/2A@\]*\@M[A=0\2%I/F^?J:Z3Q-JC7$+19/W\5RFCPL
M-> /]ZO;IZ1;.2M[LDCV33"(K?"\#%%)8J?*_"BLXR!E_4D_T4#'-<O+#DD8
MKK=0_P!17.LG+5C%LP>YS6M6^83Q4'@60KJCJ.F:T=;8+;G-9'@5F;7&QZUM
M%Z,R:U/6GP843."S ?6NB\#ZYHVC^(H8;^^CLYLA@) 3@>K8' ^M9<FCRQ6E
MC>.P5992B@ ]!C#$^O7\J[8^!_&.E6=Q)X8U2RTHWBHP,UJ',R_Q?.<\^@X%
M:QY7RQ;L?1X>,Z5*\5=L]Z9K/6+*TD_M&TO;:10!<0.N.F0/?I7B7CS4M!TZ
M^>)]=M([F-BK1,_(/;/I6G;6FHZ)X-UI;G[/+J?D[BT*_(K@DA@.QQUQWJ*+
M0]>U+PQID>E6VB26%TK_ &U)XO-G9MORMG&6)/7TJ(2C*HY/2QW5%4A3LM;F
MMX-ED_LRYC20/NBWAE.5([$'O7+:Q<>3.Z\EB:OZA]J^'O@&XE'DV%_N%O%
M.44GG8,]C@X],UGR0MJ4$%U(GER2QK(R?W20#BN?-K2E":ZH\>G&44].IS>H
M:@T,H7I4%U;KJEJ1C)Q6IK>G*R@]ZK:7&%1P?>O'@EHT#E*YXKXL\.-!*Q"X
M&^N8TVQV^(!QT:O6?%T:2*XS_%7G.E[7\3F/.?F'%?1P3Y#SJDN:1Z+8P?+C
M%%7XT%K)@C@BBN57-&R"^.Z&L"3[QQ6Q=,?+YK(;YGXHBC![F!KD!DB(ZUG>
M$(S:ZT!C&372SVWVA@N.:@CTO[)J4,J\<\U<--R'N>J2:U%)X/M[%I<W$-VL
MBPLO#+GLWX\BNV_X6TMOH.D65^D6G6Z3B.:Z"YF?LL,?H6(Z]@*\CFO$6W#
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M7'_$X* \I&!_6N)M;T"[N$SQN#C\1_B*_7LGA[+!4H^7YGQV+DY5I,TI(R[
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,[N,G8^IP?O44V?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>thompson.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 thompson.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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3<DT45+$2PL96R.%]:***8S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>vogt.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vogt.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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M*9"/,#%,MZ[1G';-?K)8LOE@'!R.1ZU^;_[5VC?\(+^U%:3;0EE<117%LO.
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B\)7 .T1ZK;$GV,BC^M%%%?)9Q%2J0;['TN5R<822[G__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
